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Abstract 
 
In Europe, Health Technology Assessment (HTA) bodies produce coverage decisions 
that guide public funding of pharmaceuticals.  This thesis examines and weights those 
factors that drive HTA coverage decisions, focusing on the National Institute for Health 
and Clinical Excellence (NICE) in England and Wales, the Scottish Medicines 
Consortium (SMC), the Dutch College voor Zorgverzekeringen (CVZ), and the French 
Haute Autorité de Sante (HAS).  To address the research question, a dataset of 
approximately 1000 HTA coverage decisions by NICE, SMC, CVZ and HAS from the 
period 2004-2009 was created, containing more than 30 clinical, economic, process and 
socio-economic factors extracted from published HTA reports.  A three-category 
outcome variable was used, defined as the decision to ‘recommend’, ‘restrict’ or ‘not 
recommend’ a technology.  Multivariate analyses were conducted to assess the relative 
contribution of the explanatory variables on coverage decisions both within and 
between HTA bodies.   
 
Results demonstrate that different combinations of clinical/economic evidence, process 
and socio-economic factors drive HTA coverage decisions by NICE, SMC, CVZ and 
HAS.  In addition, the same factor may behave differently according to the nature of the 
coverage decision.  The analysis further suggests there is a significant difference 
between HTA bodies in the probability of reaching a ‘restrict’ or ‘not recommend’ 
decision outcome relative to a ‘recommend’ outcome, adjusted for evidence, process 
and context factors.   This thesis contributes to the understanding of factors driving 
HTA coverage decisions by examining multiple European HTA bodies, enhancing the 
comprehensiveness of the factors examined through descriptive and multivariate 
analyses and by identifying and weighting the key drivers of the coverage decisions 
made by the four HTA bodies between 2004 and 2009.  This research further provides 
relevant insights to variation among HTA bodies in the determination of patient access 
to pharmaceuticals, and implications for collaboration between European HTA bodies.  
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1 Introduction 
 
 
“Our job is to make sure taxpayers’ money is only spent on 
healthcare that works and is good value” (NICE statement on 
BBC Breakfast News, 13th May 2008)  
 
“It's a system of blocking. They're [NICE] not looking at patients 
and saying "how can we fund it?", they are saying, "how can we 
not fund it?"…[Cancer] medicines are licensed and working yet 
we in Britain aren't allowed to access them. While we wait for 
Nice to decide, patients are dying.”  (Kate Spall1 on BBC 
Breakfast News 13th May 2008) 
 
The quotations above juxtapose different perspectives on the public funding of 
pharmaceutical technologies within the healthcare system, raising interesting questions 
about how funding decisions are made, and the impact this may have on patients, as 
well as on providers, manufacturers and health policy makers.  In the heavily regulated 
European pharmaceutical market (Maynard and Bloor 2003; Mossialos et al. 2004), one 
of the areas under considerable regulation is the public funding of pharmaceutical 
technologies.  Health Technology Assessment (HTA) is a process that exists in several 
European Union (EU) Member States to advise healthcare systems on the appropriate 
use of a new technology and whether it should be recommended for public funding.  
Examples of HTA agencies include the National Institute for Health and Clinical 
Excellence (NICE) in England and Wales, the Scottish Medicines Consortium (SMC), 
the Commissie voor Zorgverze (CVZ) in the Netherlands and the Haute Autorité de 
Sante (HAS) in France.   
 
This chapter aims to set the scene for this thesis by presenting the context and rationale 
for the research question, and by setting out how the thesis is structured. Firstly, the 
extent and nature of the regulation of the pharmaceutical market in EU Member States 
is analysed and the concept of HTA is introduced. Coverage decisions and their 
implications for patients, providers and manufacturers are highlighted in the third 
                                                 
1 Kate Spall is a member of the public who has been involved in helping more than 50 patients across 
England and Wales to receive funding from local Primary Care Trusts ( PCTs) for new cancer drugs that 
had not yet been reviewed by NICE.   
13 
 
 
 
section of this chapter, and finally the research question is outlined, along with an 
outline of the chapters that lie ahead.  
 
1.1 Overview: Regulation of the Pharmaceutical Market in EU Member States 
The pharmaceutical market in the EU is heavily regulated for several reasons.  Firstly, 
the presence of regulatory mechanisms to control the level of drug utilisation reflects 
the oligopoly structure of the pharmaceutical industry and its tendency for monopoly-
like power, as well as the characteristics of health system users and its various providers 
(physicians etc) (McGuire et al. 2004).  Secondly, regulation of pharmaceuticals is 
necessary due to the fact that patients lack complete information about treatment 
options, and that both patients and providers (due to their ‘third party’ status) are 
seldom in a position to bear the full cost of utilisation of pharmaceuticals (Mossialos et 
al. 2004; Vogel 2004).   In addition, other factors have led to the increased involvement 
of national governments and supra-national governing bodies (i.e. the European 
Commission) in the regulation of access to healthcare.  These include the existence of 
complex stakeholder relationships, i.e. the provider/payer/patient ‘triangle’ that 
characterizes healthcare systems (Reinhardt 1990), the ‘imperfect’ nature of the 
healthcare market (Abel-Smith and Grandjeat 1978; Jacobzone 2000; Barr 2001; Dukes 
2003; McGuire et al. 2004), and the shift towards a greater use of market forces in the 
distribution of healthcare (Rice et al. 2000).    
 
Such regulation impacts on the entire ‘life-cycle’ of pharmaceuticals along their path 
from discovery in the laboratory to patient use.  There are a series of key requirements 
which must be satisfied, both before and after marketing authorisation has been granted.  
Such requirements can be categorised into pre- and post-marketing authorisation 
requirements and are designed to impact on patients, providers, payers and the industry 
(either individually, or in combination).  Pre-marketing authorisation requirements mark 
key milestones in the discovery and development process of a compound – a process in 
which, for example, one out of every 10,000 potential medicines investigated by 
research-based pharmaceutical companies makes it through the research and 
development pipeline and is approved for patient use by the United States Food and 
Drug Administration (PhRMA  2007), amounting to an average of 15 years of research 
14 
 
 
 
and costing US$800 million (or around €552-€690 million)2 (European Commission 
2009).  Pre-marketing authorisation requirements cover various stages of the discovery 
and development phase, and consist of nine key decision points.  These decision points 
are accurately illustrated by Garret et al. (2003), who provide an analysis of the process 
with which an anti-tumour target is identified, validated and selected, developed into a 
clinical candidate, and finally, developed into a registered medication for cancer therapy 
(Figure 1.1).  
 
Figure 1.1 Drug discovery and development process 
 
Source: Adapted from Garret et al. 2003.    
Note: DP - decision point 
 
In contrast to the relative homogeneity of the pre-marketing authorisation requirements 
across products and geographies, Member States differ in the types of requirements that 
they have put in place to manage patient access to medications once marketing 
authorisation is granted.  After marketing authorisation, a series of nationally-led payer, 
provider and patient-related requirements determine patient use and access to 
pharmaceuticals.  In response to specific welfare and healthcare systems, Member 
                                                 
2 While there is some debate as to the magnitude of the cost of drug development (Permanand 2006; EU 
Commission 2009), the literature is in agreement on the fact that the ‘entry’ costs into the market for the 
pharmaceutical companies are high.   
DP 6
DP 7
DP 8
DP 5
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DP 4
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States have adopted distinctive combinations of payer-led requirements (Pricing and 
Reimbursement (P&R), budget allocation, Heath Technology Assessment), tools aimed 
at providers (clinical guidelines, gate-keeping mechanisms) and tools aimed at patients 
(co-payments for medications, doctor’s visits to obtain prescription).  The next section 
focuses on payer-led funding requirements in EU Member States to regulate the funding 
of pharmaceuticals, with a particular focus on Health Technology Assessment (HTA). 
 
1.2 Funding requirements in Europe and the role of HTA 
 
“The [Dutch] government policy aimed at reducing drug 
expenditure appears to bear fruit.  Total drug expenditure 
increased this year by 2.6 percent to 5.2 million [euros] per year.  
In 2007 the increase was three times as high.”  (NOS 2008, p1) 
 
The EU, with its 27 Member States, spends €138 billion annually on pharmaceuticals 
(EU Commission 2009).  Regulations to control and optimise public spending on 
pharmaceuticals exist in all Member States, initiated and implemented by those entities 
within the healthcare system that manage pharmaceutical budgets and expenditure, 
often referred to as payers.  Prior to examining the use of such mechanisms and the 
variation between Member States in their use, the concepts of ‘payers’ and ‘funding 
requirements’ are outlined.  
 
Payers represent the actors within the healthcare system that are responsible for budget 
allocation and management, either directly, by being accountable for a budget, or 
indirectly by providing guidance on the allocation of  budgets to pharmaceuticals3.  The 
term ‘payers’ represents a heterogeneous pool of actors within the healthcare system.  
Payers can exist at each level of the healthcare system, whether national, regional or 
local.  National-level payers are those entities, such as Ministries of Health, that hold a 
budget for pharmaceutical expenditure at the national level. Reimbursement committees 
(e.g. the INAMI in Belgium) are also examples of national-level payers – while not 
necessarily having direct accountability for the pharmaceutical budget, they issue 
guidance on which pharmaceuticals should be covered by the healthcare system.   A 
further example, in Italy, is the authority for evaluation of pharmaceutical products at 
                                                 
3 While noting that requirements for patient copayment for medication exist in several Member States, for 
the purposes of this research, patients are not considered as payers. 
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the national level (AIFA), which grants price approval, determines reimbursement 
criteria, and is responsible for liaising with the Ministry of Health to publish the price 
and reimbursement criteria in the national ‘Gazzetta’.  Regional level payers are those 
that hold budgets or have responsibilities for pharmaceuticals at a sub-national level.  
For example, in Italy, which is comprised of 20 regions, each region has independent 
responsibility for its own pharmaceutical budget and expenditure.  Finally, there are 
local level payers such as hospital formulary committees, hospital pharmacists, or 
hospital budget holders that hold responsibility for funding and providing access to 
pharmaceuticals within their local jurisdiction.  To continue the Italian example, the 
hospitals within each region (assuming a technology is a compound destined for use in a 
hospital setting), has its own individual procedures for budget allocation and formulary 
decisions.  The combined pool of payers within the healthcare system is collectively 
responsible for the purchasing of pharmaceutical technologies, aided by the use of 
funding regulations.   
 
Regulations on public funding of pharmaceuticals, depending on the perspective 
adopted, can be labelled differently.  From a manufacturer perspective, regulations 
linked to the funding of compounds have been defined as ‘4th hurdles’ in the literature 
(Maynard and Bloor 2003; Taylor et al. 2004).  From the perspective of the health care 
system, these regulations are not perceived as ‘hurdles’ but as ‘tools’ to aid the 
achievement of system objectives, including assurance of the quality of services 
provided, and the efficiency of drug utilisation (Saltman et al. 1998; Mrazek 2002; 
Maynard and Bloor 2003; Mossialos et al. 2004).  Whether labelled from a 
manufacturer or health care system perspective, the attributes of these regulations 
remain the same.   
 
In an effort to adopt a ‘neutral’ label for regulations that aim to control and guide public 
funding of pharmaceuticals, for the purposes of this thesis, these regulations can be 
considered to be ‘funding requirements’.  These represent conditions/regulations that 
must be met for coverage to be provided, and include activities such as the requirement 
for health technology assessment to be undertaken in order to obtain public funding, 
price setting, reimbursement processes and inclusion of the technology in formulary 
lists as a requirement for funding.  Such funding requirements exist in all EU member 
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states, although within the context of the ‘subsidiarity principle’4, health care systems 
differ to some extent in the mechanisms that have been set up to guide public funding of 
pharmaceuticals (Permanand 2006).   
 
In Europe, the implementation of the subsidiarity principle means that the use and 
characteristics of funding requirements, as well as their management and 
implementation, fall largely, if not totally under member state competency (rather than 
centralized EU competency).  This allows for variations in the nature of funding 
requirements and funding decisions between Member States (G10 Medicines Group 
2002).  Such variation can be attributed in part to the fact that industrial policy, public 
health, and health policy objectives influence the nature of pharmaceutical regulation 
(Permanand 2006).  Industrial policy objectives focus on ensuring the productivity of 
the pharmaceutical industry in Europe, as well as the realisation of a single European 
market, which is the remit of the EU Commission.  In Europe, the pharmaceutical sector 
employs more than 600,000 people (Kanavos et al. 2011).  In contrast, public health 
objectives related to pharmaceutical regulation focus on ensuring public health by 
providing patients with access to efficacious, safe and high-quality medicines.  The 
European Medicines Agency’s (EMA) ‘registrational requirement’ acts as a safeguard 
for patient health in this respect and addresses public health objectives.  Finally, health 
policy objectives aim to balance equity and efficiency of distribution of effective 
therapies for the patient population (Mossialos et al. 2004; Vogel 2004).  Indeed, from a 
theoretical perspective, effective healthcare provision requires a balance between two 
potentially conflicting objectives – on the one hand i) an increase in efficiency in the 
production process, through the minimisation of government intervention, freely 
competitive markets allowing free pricing and no regulatory intervention by 
government bodies; and on the other hand ii) the search for an equitable distribution in 
society of the benefits derived from health care inputs through government intervention, 
such as price controls (Vogel, 2004).   
 
How the balance is struck between industrial policy, public health and health policy 
objectives varies between countries, in part due to differences in welfare systems which 
                                                 
4 The notion of subsidiarity can be defined as “the principle that a central authority should have a 
subsidiary function, performing only those tasks which cannot be performed effectively at a more 
immediate or local level”.  (Oxford English Dictionary 2011). 
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reflect societal preferences.  Wiktorowicz (2003) analysed the approach to 
pharmaceutical regulation adopted by the USA, Canada, Britain and France by 
considering five features for analysis – representation, process, stance, institutional 
power, and resources.  This was coupled with an institutional framework approach to 
help clarify the patterns observed in the selected countries.  The results of this analysis 
highlighted important differences in the approaches adopted towards pharmaceutical 
regulation, reflecting differences in how countries aim to balance objectives of 
timeliness of the decision-making processes along with the demanding regulatory 
requirements.   
 
Figure 1.2 aims to summarise the key forces mediating the regulatory mechanisms that 
govern healthcare access in a particular healthcare system, and to highlight the focus of 
this research within the overall context.  The diagram starts with the three key 
healthcare objectives as described above (Phase 1).  The welfare system, depicted as an 
‘osmotic’ barrier (Phase 2), favours specific types of objectives over others – thus, 
healthcare objectives that more closely fit into the welfare system type filter more 
quickly through the preference system.  For example, in a member state where the 
pharmaceutical industry is a significant contributor to the country’s gross domestic 
product (GDP), industrial policy objectives may carry more weight and align more 
closely with the welfare system.  In Phase 3, regulatory mechanisms are implemented 
that reflect the trade-off resulting from Phases 1 and 2 (i.e. where healthcare objectives 
meet welfare preferences).  The presence of the various types of regulatory mechanisms 
thus reflects the healthcare system’s trade-off between objectives, within the context of 
the welfare system.  These regulatory mechanisms then impact on the ‘target’ actor of 
the healthcare ‘triangle’ – be it the provider, payer or patient (or a combination of 
these).  In this thesis, the focus will be exclusively on the payer and in particular, on 
how HTA bodies implement regulations and make decisions within the context of 
national healthcare and welfare systems – which in turn influence healthcare system 
outcomes (Phase 5).  These outcomes are expected to either reinforce the welfare 
system and health care objective trade-off, or challenge it to change (Phase 6).  This 
sixth phase, while useful to acknowledge as a key part of the context within which 
payers operate, is not the focus of this thesis.   
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Figure 1.2 Context for analysis:  the healthcare system and the influence of healthcare objectives and the 
welfare system on regulatory mechanisms 
 
 
Pricing and reimbursement requirements are present in most EU Member States, 
although their nature varies (Mossialos et al. 2004; Kanavos et al. 2011).  For example, 
in Belgium, as in Austria, Greece, Portugal, Spain and Switzerland, price and 
reimbursement submissions occur as parallel but separate processes, while in the United 
Kingdom price approval is required, but there is currently no required reimbursement 
submission (Mossialos et al. 2004).  In Finland, France, Italy, the Netherlands and 
Sweden a combined pricing and reimbursement procedure exists.   Four distinct 
approaches to the regulation of pricing of pharmaceuticals have been identified (Mrazek 
2002) – fixed pricing, cost-effectiveness pricing, profit controls and reference pricing.  
These approaches can be combined, and EU Member States differ in the approaches 
adopted (Kanavos et al. 2011).  Beuscart et al. (2010) show that in France the final 
coverage decision actually represents a series of processes lasting several years, 
designed to ensure public funding is spent on technologies that bring an added benefit 
and that are safe and of high quality.  The steps include obtaining the European 
marketing authorisation, control of quality by the Agence française de sécurité sanitaire 
des produits de santé (Afssaps), submission to the Haute Autorité de santé (HAS) for 
reimbursement assessment, and final negotiation with the Comite economique des 
produits de santé  (CEPS) to finalise the reimbursed price (Beuscart et al. 2010).   
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Health Technology Assessment (HTA) is an important requirement which exists in 
several EU member states.  HTA can be defined as a: 
 
The systematic evaluation of the properties, effects, and/or other 
impacts of health care technology (HTAi  2010)  
 
The assessment of the evidence and the subsequent appraisal of the evidence represent 
two distinct stages within HTA (Sorenson 2010), and successful implementation of 
HTA requires multi-disciplinary assessment of the range of social, economic, clinical 
and healthcare system organisational consequences stemming from the introduction of a 
new technology relative to the existing standards of care (EUnetHTA 2010; Velasco-
Garrido and Busse 2005; Henshall et al. 1997; HTAI 2007).   
 
The nature of HTA has evolved over time - since its debut in the 1970s as a tool for 
controlling the use of expensive medical equipment (Jonsson and Banta 1999), HTA’s 
remit is now broader in scope and includes pharmaceutical technologies in its 
assessment programme.  While originating in the USA, HTA is now established in 
many EU Member States (Jonsson 2002; Banta and Oortwijn 2000a, 2000b; Gulacsi 
2001; Oliver et al. 2004; Velasco-Garrido and Busse 2005; Sorenson 2010). Economic 
evaluations are becoming an increasingly wide-spread requirement across European 
countries (Kanavos et al. 2000;Nuijten et al. 2001; Drummond 2003; Nuijten and Kosa 
2004, Kanavos et al. 2011).  The nature of HTA varies between European countries 
both in terms of the assessment of the evidence and the appraisal of the evidence, as 
well as in the role of HTA within each healthcare system (Jonsson 2002; Banta and 
Oortwijn 2000; Gulacsi 2001; Oliver et al. 2004; Velasco-Garrido and Busse 2005; 
Sorenson 2010).  
 
The National Institute for Health and Clinical Excellence (NICE) in England and Wales, 
the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekeringen 
(CVZ), and the French Haute Autorité de Sante (HAS) are examples of HTA bodies in 
Europe and have been chosen as the focus of this research.  The implications of HTA 
decisions are further explored in the section that follows.   
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1.3 Implications of HTA decisions for patients, providers, manufacturers and 
health policy makers 
 
“[In France] Between 1990 and 2009, public prices of reimbursed 
medicines decreased by 20.6%, although in the same time period, 
inflation increased by 38.4%”5 (Les Entreprises du Medicament 
2010 p1)  
 
“Scottish cancer patients should be able to access the same 
standards of cancer care as their English counterparts.” (RCF 
Chief Executive Andrew Wilson in Herald Scotland 2010 p1)  
 
This thesis distinguishes between coverage of pharmaceuticals – which reflects the 
willingness to fund a particular technology that is deemed to be of value – and 
reimbursement of pharmaceuticals, which is the implementation of the coverage 
decision in regulatory mechanisms that allows for their inclusion/exclusion from a 
reimbursement list and from use within a healthcare system.  HTA bodies vary in the 
nature of recommendations they make, the evidence and processes they use to make 
such recommendations, and whether their recommendations have an advisory or 
regulatory role (Sorenson 2010, Sorenson et al 2008).  For example, the CVZ will 
concurrently examine the degree of value of intervention and whether it should be 
funded by the healthcare system (i.e. coverage), but also the price of the intervention 
and whether the technology should be clustered, independently priced, or placed on an 
‘expensive drug’ list (i.e. reimbursement).  In France, on the other hand, the HAS, and 
specifically the Comitee de Transparence, issues advice on the value of the technology 
for a particular population (ASMR) and advises on the patient population eligible for 
treatment (i.e. coverage), while the CEPS negotiates price and volume agreements with 
manufacturers on the basis of the ASMR rating provided by the HAS (i.e. 
reimbursement) (Sorenson 2010)6.     Technologies with an ASMR rating of V are those 
that represent no incremental value and can only be considered for reimbursement if its 
cost is below that of its comparator7, highlighting that there is no willingness to fund 
                                                 
5 Original quotation: “Entre 1990 et 2009, les prix publics des médicaments remboursables ont diminué 
de 20,6% alors que dans le même temps, l'inflation augmentait de 38,4%” 
6    For technologies with an ASMR I-III rating the healthcare system is willing to pay more (premium) 
over standard of care as they are associated with significant incremental benefit, while technologies with 
an ASMR IV rating can expect to receive the same level of funding as that obtained by their comparator 
technology. 
7   It is unclear however, to what extent manufacturers in France who receive an ASMR V rating opt for a 
reduction in price to obtain reimbursement or if they withdraw from the healthcare system.   
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such technologies without cost savings.   The decision output by the HAS diverges from 
NICE, SMC and the CVZ which consider both coverage and reimbursement in their 
decision-making, and in which non-recommendations preclude the inclusion on 
reimbursement lists, or highly discourage the use of the technology.  With the 
considerable intricacies and heterogeneity in the reimbursement mechanisms and 
pharmaceutical pricing policies in place, this thesis aims to focus on assessing the 
factors driving the willingness to fund a particular technology, rather than the 
reimbursement mechanisms and negotiations that follow.   
 
Coverage decisions represent a key point within the complex decision-making process 
that governs funding and access for pharmaceuticals.  Coverage decisions are of interest 
because of their implications for patients, providers, manufacturers and health policy 
makers.   
 
There is particular interest from multiple stakeholders in HTA because of the 
implications that coverage decisions can have on access to pharmaceuticals, and on 
health outcomes.  From an efficiency-driven approach, access to health care can be 
justified from an economic perspective because of its presumed benefits in improving 
the health of the population (both from a clinical point of view but also from a 
productivity point of view) (Gulliford and Morgan 2003).  However, such an approach 
may disregard the needs of vulnerable populations (e.g. the elderly, those with mental 
health problems, prisoners etc.).  An assessment of the level of access to healthcare 
necessitates consideration of various components including the comprehensiveness of 
the services offered, when and to whom these are offered, and how such services impact 
on health outcomes (Gulliford and Morgan 2003).  Two facets of ‘access’ become 
apparent in the literature and are of relevance in any analysis of access.  From one 
perspective, access can be defined as equal utilisation of healthcare resources 
(Donabedian 1972 in Gulliford and Morgan 2003).  Alternatively, access can be defined 
as the availability of a service, where access is about equal opportunity, not equal 
utilisation (Mooney 1983).  National HTA bodies fit within the latter definition of 
access, in that they have the ability to define the availability of a therapy, by 
determining whether or not a pharmaceutical technology will be publicly funded, and if 
so, to what degree.  
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The implications of coverage decisions for patients and providers are more visible when 
HTA bodies decide not to reimburse a product for a particular patient population, as 
highlighted in the following excerpt:  “…[Cancer] medicines are licensed and working 
yet we in Britain aren't allowed to access them. While we wait for NICE to decide, 
patients are dying” (Kate Spall on BBC Breakfast News, May 13th 2008).  Thus, non-
recommendations from HTA bodies can be perceived as decisions that reduce treatment 
options for particular patient groups.  The excerpt also highlights the potential 
implications linked with coverage decisions for health outcomes, in this example, death.   
 
While recognising the role of broader medical and non-medical factors on health 
outcomes such as the life expectancy of the population, the literature does provide 
evidence that links access to pharmaceuticals with better health outcomes.  There are 
several studies reported in the literature that assess the impact of pharmaceutical access, 
as measured by levels of pharmaceutical expenditures, on life expectancy.   Within 
OECD countries, Miller and Frech (2000) calculated the ratio of money spent on 
pharmaceuticals versus the life expectancy gain and concluded that pharmaceutical 
consumption was associated with a statistically significant positive effect on life 
expectancy.  In a further study by Frech et al. (2004), the authors confirmed that a 
strong statistical effect was observed between pharmaceutical consumption and life 
expectancy at both 40 and 60 years.   
 
In addition, they also examined the impact of pharmaceutical consumption on quality of 
life, using disability adjusted life expectancy (DALE) as the measure of quality of life.  
In their analysis they found that pharmaceutical use was associated with an even larger 
effect than that observed on life expectancy:  positive statistically significant effects of 
pharmaceutical utilisation on DALE were observed both at birth and at 60 years.  In 
examining the relationship between pharmaceutical expenditure and life expectancy, 
Caliskan (2009) took the methodology one step further by adjusting for other factors 
known to have an impact on life expectancy, including socio-economic status, lifestyle 
factors and demographic factors.  The results suggest that pharmaceutical expenditure 
impacts positively on life expectancy, and further note that this effect varies by age and 
gender.  A similar study examining the relationship between pharmaceutical 
expenditure and life expectancy in Canada also showed that the association between 
pharmaceutical expenditure and health outcomes was statistically significant (Cremieux 
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et al. 2005).  In addition, the authors examined variations in pharmaceutical expenditure 
among the Canadian provinces and demonstrated that provinces with higher 
pharmaceutical spending were those provinces with better health outcomes (as 
measured by infant mortality and life expectancy, among other endpoints).  The authors 
estimated that if all provinces were to increase pharmaceutical spending to the level of 
the ‘high spending’ provinces, this could lead to an additional 6 months of life 
expectancy at birth and an estimated 584 fewer infant deaths annually and (Cremieux et 
al. 2005).    
 
In parallel to studies on the impact of pharmaceutical access on life expectancy and 
infant mortality, a study in Germany examined the role of pharmaceutical interventions 
on the decline in cardiovascular-related deaths (Häussler et al. 2007).  The analysis 
involved examining specific types of pharmaceutical interventions, alongside other 
medical interventions, to assess to what degree the introduction of pharmaceutical 
interventions impacted on mortality from cardiovascular causes.  The results of the 
regression analysis found that the different types of pharmaceutical interventions tested 
(from use of ACE inhibitors and channel blockers, to the use of diuretics and beta-
blockers) had individually and collectively statistically significant effects on the decline 
of mortality.   
 
Coverage decisions not only have implications for patients and providers but also for 
the pharmaceutical market and health-policy makers.  Within the European internal 
market, pharmaceuticals are categorised like any other good, meaning that free 
movement and access to the market is advocated and required as a condition for 
participation in the market.  Thus, the availability of pharmaceuticals and the time taken 
for them to be available within the market is not only a concern for patients and health 
care providers, but also for national and supra-national government entities such as the 
European Commission.  To this end, the EU Transparency Directive 89/105/EEC(The 
Council of the European Communities 1989) adopted in 1989  requires EU Member 
States to implement “objective and verifiable criteria”  in determining the price for 
novel pharmaceutical compounds and in determining whether such a compound should 
be funded/reimbursed (The Council of the European Communities, 1989 p. 67).  In 
addition, the EU Directive sets a time limit of 180 days for the completion of the 
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coverage decision-making process, which Member States are requested to implement 
(unless a ‘clock-stop’ is required due to the need for further data/clarification) 8.      
 
Despite the existence of the above directive for more than 20 years, and the presence of 
a centralised procedure for granting marketing authorisation since 1993 (EEC No. 
2309/93 (The Council of the European Communities 1993), variation between EU 
Member States in the availability of medications continues to be documented in the 
literature (Anis et al. 2001; Wilking and Jonsson 2005; IMS 2007; Jonsson and Wilking 
2007).  Wilking and Jonsson (2005), and Jonsson and Wilking (2007) provide evidence 
of variation in the diffusion of new medications for cancer illnesses in Europe, which 
suggests that access to new cancer therapies is to a large extent dependent on a patient’s 
country of residence.  Specifically, the authors venture to suggest (but not test) 
processes that augment variation in access to care, including the drug approval process, 
the role of health economics in decision making, and budgetary issues.  In Jonsson and 
Wilking (2007), these factors are re-examined over a larger sample size (both in terms 
of drugs and countries), but data on the impact of factors such as reimbursement 
processes and cost-effectiveness requirements is still lacking.   
 
As documented by IMS data collected between 2002 and 2006, there appears to be 
variation between EU Member States in the number of novel medications accessible to 
patients, and also variation in the time taken by the decision-making authorities to grant 
access to medications (Figure 1.3).  In the majority of cases, the time between 
marketing authorisation and a final coverage decision was often higher than the 180 
days stipulated in the EU Transparency Directive.  This analysis was recently repeated 
and confirmed earlier results, highlighting that significant variation remains between 
EU Member States in the percentage of licensed pharmaceuticals available for 
prescription (39% to 86%), and in the time taken to complete pricing and 
reimbursement processes (88 to 392 days) (EFPIA 2010).   
 
                                                 
8 It should be noted that the European Commission has recently launched a consultation on the EU 
Transparency Directive, with the aim to modernize the directive to reflect the changes in the EU 
pharmaceutical market over the past 20 years.  
http://europa.eu/rapid/pressReleasesAction.do?reference=IP/11/370&format=HTML&aged=0&language
=EN&guiLanguage=en 
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Figure 1.3 Range of time (days) between EMA marketing authorisation and market access (hospital and 
retail combined)  
Source: IMS 2007.   
Note:  In this IMS analysis, time to market access refers to the time from marketing authorisation to the 
availability of the technology funded by the particular healthcare system.  For the UK, while technologies 
can be prescribed within the NHS shortly after marketing authorisation,   the market access of the 
technology is limited until it has completed HTA procedures within the UK.   
 
Variation in the availability of medications and the average time to access them could 
be influenced by a number of factors, including the nature of the decision-making 
procedures, but also the manufacturer’s submission strategies (for example, launching 
in free-pricing countries first), product characteristics (therapeutic value), country GDP, 
and the objectives of the welfare and health care systems.  The need for Member States 
to work harder to adhere to the Transparency Directive is highlighted in 2002 in the 
G10 Report, which recommends that “… Member States should examine the scope for 
improving time taken between the granting of a marketing authorisation and pricing and 
reimbursement decisions in full consistency with Community Legislation” (G10 
Medicines Group 2002 p. 13).   
 
Thus, coverage decisions are of interest because of their far reaching consequences for 
patients, health care providers, manufacturers and health policy makers.  HTA bodies 
face distinct pressures from each of these stakeholders when making their decisions.  
Therefore, it is important to understand what factors are in fact driving patterns of 
coverage decisions within and between HTA agencies.  
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1.4 Research Question 
This introductory chapter has aimed to provide the context and rationale for the research 
question of this thesis.  Across EU Member States, the pharmaceutical market is heavily 
regulated, and public funding of pharmaceuticals is guided by specific processes and 
regulations, which vary across countries.  Such variation across EU Member States is in 
large part due to diverse approaches reflecting differences in national healthcare and 
welfare objectives.  This is accompanied by an observable variation in the level of 
access to medication between EU Member States.  European Member States implement 
regulations aiming to control the cost of supplying medications to the healthcare system 
by deciding what technology should or should not be publicly funded, and if it is, under 
what conditions (its price, who should have access to it, and who should prescribe it).  
HTA is a specific type of assessment required in many European countries to obtain 
public coverage of pharmaceutical technologies.  Within this context, HTA bodies have 
a role in defining whether public funding should be allocated to the technology.  The 
interest in analysing such coverage decisions is heightened by the fact that ultimately 
the decisions may not only impact on medication price and volume, but are also likely 
to impact on patients’ access to medications, as well as on the behaviour of prescribers, 
manufacturers and policy makers.  Moreover, the need for difficult decision-making 
with regard to healthcare spending and allocation of resources is amplified as demand 
for healthcare increases while at the same time governments and healthcare providers 
struggle to manage healthcare expenditure, giving rise to tensions between HTA 
agencies, the public, healthcare providers, manufacturers and health policy makers.  In 
this context of difficult decision-making, there is a recognised need for the transparent 
communication of the processes and criteria adopted by HTA bodies in making 
decisions about public funding and granting (or not) of access to pharmaceuticals.  This 
thesis analyses the factors that drive HTA coverage decisions and public funding of 
pharmaceuticals in a selection of European countries, namely UK, France, and the 
Netherlands.   
 
Specifically, this thesis aims to:  
• Describe the range of factors taken into account by NICE, SMC, CVZ and HAS in their 
decision making, including the clinical/economic evidence considered, the process 
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through which technologies were appraised and the socio-economic context in which 
the appraisals took place.  
• Explore the impact of such factors on coverage decisions.  Given the multidisciplinary 
nature of HTA decision-making and the high degree of stakeholder involvement in and 
around HTA decision-making, it is hypothesised that HTA coverage decisions are 
influenced not only by the evidence supporting the technology, but also by the 
assessment processes used and the context in which they operate.  This will be tested by 
identifying, for each HTA body, the set of explanatory variables that significantly 
impact on its decision outcomes, while adjusting for the presence of other confounding 
factors.  Decision outcomes will be defined as the log odds of restriction versus 
recommendation or non-recommendation versus recommendation.   
• Assess whether HTA bodies (NICE, SMC, CVZ, HAS) differ in terms of the coverage 
decisions they make.  This hypothesis will be tested in a pooled analysis in which the 
HTA effect will be assessed while adjusting for a range of confounders.   
 
In order to address the research question, the thesis is structured into nine chapters.  
Following this introductory chapter, the second chapter identifies gaps in the literature 
that this thesis seeks to address, and provides the analytical framework for the research.  
The methods chapter (Chapter 3) identifies the sets of factors that, through the literature 
review, have been identified as potential determinants of coverage decisions, and the 
methods by which these factors will be considered in single HTA and pooled analyses.  
Chapters 4 to 7 present the quantitative analyses performed to assess the factors driving 
coverage decisions individually within each of the four HTA bodies included in the 
research.  Chapter 8 examines the factors driving coverage decisions across the pooled 
sample of appraisals from the four HTA bodies and Chapter 9 presents the conclusions 
and key policy implications. 
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2 Framing the Research Question 
 
 
In order to frame the research question, an introductory example  is presented, which 
summarises the coverage decisions by two HTA agencies, the Scottish Medicines 
Consortium (SMC) in Scotland and the Transparency Commission of the Haute 
Autorité de Santé  (HAS) in France.  In 2007, both the HAS and the SMC reviewed a 
request for reimbursement of dasatinib, a new therapy for the treatment of chronic and 
advanced phases of chronic myeloid leukaemia (CML).  The excerpts below summarise 
the advice given by both HTA bodies: 
 
Scottish Medicines Consortium (SMC) Drug advice on dasatinib: 
“dasatinib [...] is accepted for restricted use within NHS Scotland 
for the treatment of adults with chronic myeloid leukaemia 
(CML) with resistance or intolerance to prior therapy including 
imatinib mesylate. 
It should be restricted to use in patients who are in the chronic 
phase of the disease. The manufacturer’s justification of the 
treatment’s cost in relation to its health benefits for the 
accelerated or blast phases was not sufficient to gain acceptance 
by SMC” (SMC 370/07 2007 p.1)  
 
Commission de la Transparence (Haute Autorité de Santé) advice on 
dasatinib12: 
“In chronic phase chronic myeloid leukemia (CML), after 
resistance or intolerance to previous therapy including imatinib, 
Sprycel brings an ASMR of level II (important) compared to 
current treatment.    In accelerated or blast phase chronic myeloid 
leukemia after resistance or intolerance to imatinib and in acute 
Ph+ lymphoblastic leukemia after resistance or intolerance to 
previous therapy, Sprycel brings and ASMR of level I (major) 
compared to current treatment”  (Commission de la Transparence 
2007 p. 11) 
 
                                                 
1 “Dans la LMC en phase chronique, après résistance ou intolérance à une thérapie antérieure incluant 
imatinib, Sprycel apporte une ASMR de niveau II (importante) par rapport à la prise en charge 
thérapeutique actuelle.  Dans la LMC en phase accélérée ou blastique après résistance ou intolérance à 
l’imatinib et dans la leucémie aiguë lymphoblastique Ph+ après résistance ou intolérance à une thérapie 
antérieure, Sprycel apporte une ASMR de niveau I (majeure) par rapport à la prise en charge 
thérapeutique actuelle.”.   
2 Note: Sprycel© is the tradename for dasatinib.   
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As highlighted by the quoted excerpts, both HTA agencies come to a similar decision 
with regard to the public funding of dasatinib for chronic phase CML, but not for 
advanced stages of CML.  The SMC and HAS recommended dasatinib for the treatment 
of chronic phase CML.  The SMC states that dasatinib is “accepted for restricted use” 
while the Transparency Commission grants it an ASMR of level II.  The “amélioration 
du service médical rendu” (ASMR) is a rating which aims to capture the extent to which 
a medication can improve the outcomes for patients and address significant unmet 
medical need.  A rating of ‘I’ is given to those medicines considered to bring a 
significant medical improvement, versus a rating of ‘V’ for those medicines considered 
to provide no improvement.  Thus, by giving an ASMR rating of ‘II’, the Transparency 
Commission recognises that dasatinib brings an important medical improvement versus 
the standard of care (imatinib) in the treatment of chronic phase CML.  However, 
opposing decisions were made with regard to the recommendation of dasatinib for 
treatment in the advanced phases of the disease.  In Scotland, the SMC did not 
recommend use of dasatinib in advanced phases of CML.  In contrast, the French 
Transparency Commission awarded dasatinib an ASMR rating ‘level I’ for treatment of 
advanced phase CML for providing a major medical improvement to patients.   
 
Within this particular case-study, what are the factors that can explain the coverage 
decisions made in France and in Scotland with regard to dasatinib?  Was the same 
evidence (clinical and economic) considered by both HTA bodies?  Are the decision-
making processes different and could that explain their recommendations?  Perhaps the 
healthcare system, welfare system and societal context influenced the HTA agencies’ 
decision?  Is a difference in recommendations made by these two bodies consistently 
observed, or is this a one-off difference?  This example sets the scene for the focus of 
this research project – that is, the in-depth analysis of what factors drive HTA coverage 
decisions. 
 
This chapter aims to frame the research question by combining theoretical and empirical 
elements to develop an analytical framework that can be used to analyse coverage 
decisions and the factors driving these decisions.  The chapter is divided into four 
sections. The first section provides an overview of theoretical approaches to 
understanding HTA decision-making.  The literature relevant to the research question is 
then presented and analysed, focusing on the evidence, process and context factors that 
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have been associated with coverage decisions.  The third section highlights the gaps and 
limitations of the currently available literature, and identifies those gaps which the 
thesis will attempt to address.  The final section brings together the theoretical concepts 
and empirical data to propose an analytical framework that will help shape the methods 
adopted to address the research question.   
 
2.1 Theoretical models for understanding coverage decision-making 
The need to prioritise resources in a healthcare system is linked to two phenomena: 
firstly, the demand for health and healthcare by the population and secondly, the 
recognition that the resources available to meet those demands (i.e. healthcare) are 
limited.  This has put pressure on healthcare systems to develop ways to prioritise the 
use of healthcare resources.  Indeed, from a theoretical perspective, priority-setting 
within the healthcare system requires an equilibrium between two potentially 
conflicting objectives – on the one hand (i) the objective of  increasing the efficiency of 
the production of health gains for the population, through freely competitive markets 
allowing free pricing and no regulatory intervention by government bodies; and on the 
other hand (ii) the objective of achieving an equitable distribution in society of the 
benefits derived from health care resources through government intervention (Vogel, 
2004). HTA decision-making on whether to recommend a new medication for public 
funding is a specific example of prioritisation of resources within a healthcare system. 
Figure 2.1 (below) outlines how coverage decisions fit within the concept of priority 
setting. The complexity around evaluating priority-setting decisions and their success is 
linked to the fact that various criteria can be used in prioritizing healthcare resources, 
such as: ethical considerations, efficiency considerations and effectiveness 
considerations (Sibbald 2009; Al et al. 2004; Permanand 2006).  If a healthcare system 
objective is to strive for effectiveness over efficiency, the prioritisation exercise would 
yield different results as supposed to a healthcare system that aims to sacrifice some 
efficiency gains to give more weight to ethical considerations, for example.   
 
In Europe, when making funding decisions, HTA bodies can be influenced by 
potentially conflicting objectives: public health objectives, health policy objectives and 
industrial policy objectives (Permanand 2006).  Industrial policy objectives focus on 
ensuring the productivity of the pharmaceutical industry in Europe, as well as the 
realisation of a single European market, which is the scope of the EU Commission 
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(Directorate General for Enterprise).  Public health objectives related to pharmaceutical 
regulation focus on ensuring public health by providing patients with access to 
efficacious, safe and high quality medicines.  The European Medicines Agency’s 
(EMA) ‘registrational requirement’ acts as a safeguard for patient health in this respect 
and addresses Public Health objectives.  Finally, health policy objectives aim to balance 
equity and the efficiency of distribution of effective therapies for the patient population 
(Mossialos et al. 2004; Vogel 2004).   
 
Figure 2.1 HTA Coverage Decisions as a mechanism of prioritisation of resources within the healthcare system 
 
 
Due to the complexity surrounding priority-setting decisions, a number of different 
suggestions have been made regarding how to make decision-making more systematic.  
An important development recorded in the literature over the last few decades is the 
move towards evidence-based policy and evidence-based medicine as a means of 
making prioritisation decisions more rational, systematic, justifiable and transparent 
(Daniels and Sabin 1997; Drummond, Schwartz et al. 2008).  Within the sphere of 
coverage decision-making, the HTA movement can be linked to this phenomenon, 
developed as a means of systematically evaluating evidence to come to a conclusion 
about the utilisation and funding of a new health technology.  
 
Theoretical models have been developed to characterise how evidence has or can be 
used in policy-making.  In social policy, several theoretical models have been proposed 
to explain how and to what extent evidence is incorporated in policy-making (Weiss 
1979).   For this research question, two particular models proposed by Weiss are 
Coverage
Decisions
Pharmaceutical 
regulation
Resource prioritisation across
Healthcare system
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relevant:  (i) the ‘problem-solving model’ because it represents what evidence-based 
funding strives for, and (ii) the ‘interactive model’ which represents the situation where 
decisions are influenced by diverse factors, many of which are not evidence-based.    
 
The premise of the ‘problem-solving model’ is that evidence, especially developed to 
answer a specific policy problem, is directly applied to solve the policy decision 
problem, in this case, coverage decisions.  As outlined by Weiss (1979), the ‘problem-
solving model’ suggests that evidence is integrated in decision-making through the 
following steps:  “… definition of pending decision → identification of missing 
knowledge → acquisition of social science research → interpretation of the research for 
the decision context → policy choice” (Weiss 1979 p. 428).  Thus, in this model, the 
evidence is tailor-made to answer a specific policy-maker’s question and assumes that 
evidence is the primary influencer of the decision.  It also assumes that, by directly 
influencing the decision, the evidence will also lead to a rationalization of resource use 
in accordance with the evidence.  Furthermore, one of the key conditions of this model 
is that there is alignment between the researcher and decision-maker in terms of the 
problem definition and objectives.    
 
While this model was originally developed by Weiss (1979) to characterize the use of 
social research evidence, it aptly describes the ideal world of evidence-based policy 
making, where relevant, high-quality evidence reduces uncertainty in HTA decision-
making about the introduction of a new therapy in the healthcare system, and is thus the 
key driver of the decision.  Clinical and economic evidence are key drivers of HTA 
coverage decision-making, as they are a distinct and important part of the assessment 
and appraisal process.  In addition, in England, NICE commissions specific third-party 
assessments of economic evidence specifically for the scope of the appraisal being 
undertaken (Williams and Bryan, 2007).    The CVZ in the Netherlands, with its 
‘conditional reimbursement scheme’, provides another example of a ‘problem-solving 
model’; i.e. reimbursement status is granted over a three-year period, on the condition 
that effectiveness and cost-effectiveness data are collected, as per a mutually agreed 
protocol, to confirm the reimbursement status of the medication with real-life data at a 
defined time point in the future.   
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There are several challenges however, when it comes to the implementation of the 
‘problem-solving model’ in HTA decision-making.  First of all, the model assumes that 
all evidence consistently supports a specific decision which is preferable to all other 
possible decisions (Weiss 1979). However, in reality, different sources of evidence can 
conflict with each other, and the need to combine different sources of evidence involves 
subjective value judgments about which aspects of the evidence are of greater or lesser 
relevance to the decision-problem.   
“The problem that remains is: priority setting involves the 
adjudication between many relevant values and that people (and 
disciplines) will disagree about which values should dominate in 
any specific priority setting context and there is no agreed upon 
normative approach for resolving the disagreement” (Sibbald et 
al. 2009 p. 10).   
This suggests it is important to distinguish between accessibility to high-quality, 
relevant evidence which this model emphasizes, and the second step which involves the 
acceptability of the evidence, which is linked to the value judgements that surround the 
decision-problem, as highlighted by Sibbald et al. (2009) and Williams and Bryan 
(2007).   
 
Another implementation challenge associated with the ‘problem-solving model’ is that 
it assumes that there are only two stakeholders, namely the decision-maker and the 
researcher.  However, in reality, in many circumstances this is not the case.  For 
example, NICE implements a broad and complex consultation programme for each of 
its appraisals to ensure that a variety of stakeholders are consulted and involved in the 
appraisal process.  Stakeholders in the NICE process include clinicians, patient groups, 
carer groups, manufacturers.  Stakeholders involved in the SMC process are equally 
varied.  One of the key stakeholders for the HAS is the CEPs, the committee which uses 
HAS output to negotiate a reimbursed price.  The ‘problem-solving’ model does not 
factor in the role of these additional stakeholders in the coverage decision-making 
process.   
 
An additional hurdle for the applicability of this model to coverage decisions includes 
the fact that the model assumes that evidence reduces the level of uncertainty around a 
decision-problem.  However, the degree of uncertainty remaining around the decision to 
fund new medication is often high, despite the evidence available.  For example, the 
appraisal of adalimumab for the treatment of ankylosing spondylitis by NICE (2008), 
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included the assessment of five different cost-utility models that pointed to different 
base case incremental cost-effectiveness results.  Thus, despite a significant volume of 
economic evidence, the uncertainty for the Appraisal Committee remained – to the 
extent that the final appraisal allocated a range cost-effectiveness ratio for adalimumab, 
rather than a specific number, due to the lack of consensus.   
 
A final challenge to the implementation of the ‘problem-solving’ model is that it 
assumes aligned objectives between the evidence provider and the decision-maker.  
However, there are empirical examples where objectives are not shared by both parties, 
and where objectives are unclear.  For example, Al et al. (2004) describe four HTA 
decision-makers working at different decision-nodes within the system that had 
different objectives when making prioritisation decisions (i.e. equity considerations, 
efficiency considerations etc.).  The authors stress the need to clarify objectives between 
HTA and the evidence provider so that the evidence is helpful in solving the decision-
problem.  The authors also show that there are implicit HTA preferences that influence 
their objectives, which correlates well with qualitiative findings from other research 
done on HTA preferences (Anell and Persson 2005; Haslé-Pham et al. 2005; Sinclair et 
al. 2008; Vuorenkoski et al. 2008).  Thus, the objectives of HTA decision-making are 
not always transparent and known to the researcher or healthcare system.   
 
As an alternative to the ‘problem-solving model’ and in recognition of the complex web 
of factors (both explicit and implicit) that influence coverage decisions, the ‘interactive 
model’ is presented here as a model that aims to capture the situation in which the 
evidence used by the decision-maker is taken from a multitude of sources (Weiss 1979).  
As Weiss (1979 p. 429) explains, “In this model, the use of research is only one part of 
a complicated process that also uses experience, political insight, pressure, social 
technologies, and judgment”. Important components of decision-making within this 
particular model include the need for negotiation between different perspectives and 
objectives, the need to align various points of view and a need to come to a solution.  
While evidence does play a role, it is not the key influencer of the decision.  In this 
model, the responsibility is placed is on the decision-maker to gather what evidence 
there is from numerous sources – there is no specific evidence commissioned to address 
a specific decision-problem.   
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When we consider this model and its applicability to HTA decision-making, evidence 
from the literature does suggest that, apart from the evidence provided by clinical and 
economic evaluations, HTA agencies consider several other factors when making their 
decisions (Ross 1995; OECD 2005; Drummond, Brown et al. 2003; Brouselle and 
Lessard 2011; Iversen and Vondeling 2007; Al et al. 2004).  This model would also 
reflect the fact that HTA agencies must juggle between addressing healthcare policy, 
public health, and industrial policy objectives (Permanand 2006).  This model, however, 
goes against the principle that policy-making, and in particular HTA, should be 
primarily evidence-based.  In addition, the ‘interactive model’ assumes that no bespoke 
research is done to address decision-maker evidence needs.  In reality, HTA bodies can 
commission specific research, and manufacturers themselves commission specific 
research to address the HTA body’s questions as specified within their methodology 
guidelines.  For example, NICE’s Multi Technology Appraisal process includes the 
commissioning of specific research for the appraisal.  Thus, the ‘interactive model’ also 
faces implementation challenges and represents, to some extent, an opposing view of 
decision-making to that encapsulated in the ‘problem-solving model’.   
 
The premise of this thesis is that these two models define the extremes of a continuum 
along which coverage decisions can be classified.  In the analysis that follows, 
quantitative and qualitative methods will be deployed to assess where, along this 
continuum, different HTA bodies lie, and how this impacts on the HTA decision.  To 
optimise and focus this research, a review of the literature was performed to identify the 
state of knowledge around the factors impacting on HTA funding decisions for 
pharmaceuticals.   
 
2.2 Literature Review 
In line with the theoretical models presented, the literature was examined to shed light 
on evidence, process, and context factors that impact on coverage decisions.  The goal 
of the literature review was four-fold: (i) to critically examine the analyses performed of 
EU HTA bodies, (ii) to inform the selection of independent variables for analysis, the 
literature was examined to identify which evidence, process or context factors had been 
shown to impact on coverage decisions, (iii) to critically review the methods used to 
assess the relationship between evidence, process or context factors and coverage 
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decisions ; and (iv) to set the scene for the development of the analytical framework that 
will shape the methodology and analyses of this research.    
 
2.2.1 Impact of evidence on HTA decision-making 
In the literature, both quantitative and qualitative analyses have been performed to 
understand how evidence is used in decisions to fund new pharmaceuticals.  The 
literature agrees in its findings that evidence is usually a key component of the decision-
making process, but that its impact is dependent upon the generalisability and quality of 
the evidence.  Qualitative studies have looked at the issue of generalisability and quality 
of the evidence for decision-making, and how this can impact on the use of evidence in 
decision-making.  In addition, qualitative and quantitative studies have looked at the 
relative impact of evidence on decision-making, in the face of competing factors and 
objectives.   
 
The literature suggests that the degree of usefulness or accessibility of the data for 
decision-making is influenced by several factors.  Accessibility of the data refers to the 
degree to which it is generalisable and of high quality and therefore useful to the 
decision-maker (Williams and Bryan 2007).  The accessibility of the evidence is a 
necessary pre-requisite for evidence to have an impact on coverage decisions.  
Moreover, the availability of high quality data has been identified as a key factor for 
facilitating the use of evidence in the decision making process.  Of similar importance is 
the need for HTA agencies to have access to data which are generalisable to their 
population.  Thus, whether HTA expectations are met in terms of the quality and 
relevance of the data package submitted will depend on the quality and generalisability 
of clinical trial results, cost-effectiveness results and other factors such as whether or 
not the comparison of clinical efficacy is made with regard to the current standard of 
care.   A recent development is the creation of an HTA adaptation toolkit and published 
in the literature, that assists in identifying the degree of relevance, generalisability, and 
quality of the submitted material to facilitate adaptation of HTA assessments between 
bodies (Turner et al. 2009; Chase et al. 2009).   
 
One key characteristic of accessible evidence for decision-making is that it is relevant.  
Studies suggest that an evidence package which does not provide information that is 
relevant to HTA agencies will be less likely to obtain a positive funding decision 
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compared to a data package that meets the decision-maker’s expectations.  For example, 
in the USA, the FDA registrational file supporting gabapentin (for depression) was 
perceived to fulfil the quality expectations of the Federal Drug Administration (FDA) 
decision-makers and thus generated a positive recommendation from the FDA.  
However, when the evidence package supporting gabapentin was presented to state 
HTA decision-makers for inclusion in state formularies, a sub-set of regional HTA 
agencies did not accept the drug on their respective formulary list (Bloom, 2004).  This 
divergence between the FDA and regional HTA decision-makers was, in part, attributed 
to the difference in objectives of the two decision-makers (one focused on public health 
objectives, the other on healthcare policy objectives), and differences in the data needed 
for them to make a decision.  This example from the literature highlights the need for 
the evidence to be of relevance to its payer-audience, and suggests that the evidence that 
may be of relevance for regulatory/ registration purposes may not be relevant for HTA 
processes and vice versa.   
 
Economic evaluation, and its accessibility, has been a recurrent theme in the literature.  
Several authors have discussed the barriers to the use of economic evaluations as part of 
HTA decision-making (Ross 1995; Williams and Bryan 2007; Bryan et al. 2007; 
Hoffman et al. 2000; Drummond et al. 1999; Bloom 2004).  Lack of management of 
uncertainty around key parameters in the cost-effectiveness model was identified as a 
key factor that made evidence unhelpful to HTA agencies. Sculpher and Claxton (2005) 
highlight the need for managing the degree of uncertainty around key parameters of 
relevance for HTA decision-making – including the healthcare system objectives in 
which the HTA operates; how the product’s incremental cost-effectiveness ratio (ICER) 
compares with the HTA agencies’ threshold of willingness to pay; how the product 
compares to all relevant alternatives; and how and what costs are considered.  McGuire 
et al. (2000) highlight the importance of understanding the objectives underlying 
economic evaluations, and in particular the objectives driving economic guideline 
development.  In parallel, studies carried out in Europe and Australia identified similar 
barriers to the use of economic evaluation:  the perception that the data was too 
complex; lack of generalisability; bias in the data; and untimely availability of data 
(Hoffman et al. 2000; Ross 1995; Bryan et al. 2007; Drummond, Schwartz et al. 2008). 
Thus, the literature suggests that the utility of economic evidence to the HTA decision-
maker is influenced by several factors.  It is further implied, but not directly assessed, 
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that lack of relevance and quality leads to non-use or reduced use of evidence from 
economic evaluations.  Potentially, this could be extended to suggest that evidence 
which is not tailored to be useful to payer bodies will be less likely to influence the 
decision.  Currently, the literature does not comment on barriers to accessibility for 
evidence other than economic evidence. 
 
The use of cost-effectiveness evidence as part of HTA decision-making has been 
examined in several studies.  Hoffman et al. (2000) conducted a European survey on the 
use of economic evaluations and found at the time that, on average, evidence from 
economic evaluations was considered by 30% of respondents.  This is likely to have 
increased over time.  Similar findings have been reported by Drummond et al. (1997) 
where use of economic evaluation was modest.  More recently, in a qualitative study, 
Klarenbach et al. (2010) examined the role of economic evaluation in health technology 
assessments on anti-hypertensive therapy published by several HTA agencies, and noted 
that while economic evaluation was recognised as a factor in both HTA reports, the 
impact on the decision-making varied, as the reports differed in the conclusion of the 
technology that was regarded as ‘most’ cost-effective, and that this was driven 
principally by differences in the costs of the technology and its comparators.   
 
Aside from cost-effectiveness considerations, the clinical and epidemiological evidence 
and the characteristics of the disease area for which it is indicated are important 
determinants of coverage decisions to grant or deny access.  Greenhalgh et al. (2004) 
argues that the attributes of the innovation itself have a clear impact on its probability of 
diffusion – attributes include the relative advantage of the innovation vs. other existing 
products, compatibility, low complexity, and the nature of the knowledge required to 
implement the innovation.  In countries where drug listings and formularies exist, a key 
criterion for inclusion in the list/formulary is the level of therapeutic value of the drug 
under consideration – lists are a means of excluding drugs perceived to have a low 
therapeutic value (Le Pen 1996; Fattore and Jommi 1998).   The use of the ASMR 
rating system in France is an example of a system which bases the degree of funding 
awarded on the incremental therapeutic value demonstrated relative to standard of care.   
 
Linked to the demonstration of added value is whether surrogate outcomes or hard 
endpoints are used.  The demonstration of effectiveness through modification of 
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surrogate outcomes (e.g. blood pressure) are considered to be less convincing than the 
demonstration of effectiveness through modification of the frequency of 
outcomes/events (e.g. hypertension).  Velasco Garrido et al. (2009) examined to what 
degree HTA recommendations utilised surrogate endpoints in their assessments.  When 
examining the methodological guidelines from various HTA agencies, there were 
differences in the suggested use and appropriateness of surrogate outcomes in the 
appraisal process.  Subsequently, in a sample of 140 HTA reports, 62% had utilised 
surrogate endpoints to support decision-making, although only 3% of recommendations 
were based exclusively on surrogate endpoints (Velasco Garrido et al. 2009).  However, 
the authors did not examine to what degree the use of surrogate or hard endpoints 
impacted on the coverage decision.  Nevertheless, their analysis highlights that the 
clinical and epidemiological evidence and the characteristics of the disease area for 
which it is indicated are key parts of the evidence used in making coverage decisions.   
 
In addition to the nature of the endpoints within clinical trials, the nature of the disease 
itself, and particularly its severity, has been highlighted as a potentially important factor 
considered in coverage decisions (Drummond and Mason 2009; Bredesen 2003; 
Carlsson 2004; Clement et al. 2009).  Both Norway and Sweden consider disease 
severity as an explicit factor in their decision-making processes (Bredesen 2003; 
Carlsson 2004).  In addition, other healthcare systems have set up specific committees 
dedicated to specific disease areas, such as cancer, which are considered to be severe 
diseases.  The Joint Oncology Drug Review committee in Canada is such an example 
(Mason and Drummond 2009).  Furthermore, NICE has recently appended to its 
methodology guidelines specific advice to the appraisal committee on considerations to 
be taken into account when appraising so called ‘end-of-life’ technologies that may be 
life-extending (NICE 2009).  Thus, aside from the nature of the clinical trial evidence, 
additional considerations linked to the disease characteristics are formal factors that are 
taken into account in coverage decisions.    
 
The role of the evidence, relative to the role of other factors, has been examined in the 
literature. It is clear that HTA agencies/ payers have to consider a number of different, 
and often conflicting, factors when making decisions.  Both qualitative and quantitative 
analyses have been performed that assess the relative impact of evidence in relation to 
other factors that may impact on the decision (Ross 1995; OECD 2005; Klarenbach et 
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al. 2010).  Qualitative analyses have assessed the key factors that HTA agencies 
perceive to have an impact on their decisions.  For example, in Ross (1995), 34 
decision-makers within the funding process were interviewed.  When asked which 
factors were important in decision-making, 44% cited economic appraisal or efficiency 
concerns; and 38% stressed the availability of relevant information and expert advice as 
having an impact on their decision.  Similarly, in a survey of decision-makers within 
HTA systems across several countries, the OECD (2005) concluded that the evidence of 
efficacy/effectiveness (86%) and quality/safety (91%) were considered to be very 
important for funding decisions.  In both studies, however, there were at least six other 
factors (such as equity or political considerations) which were ranked as important by 
the decision-makers.  Thus, the available qualitative literature suggests that HTA 
agencies have to consider a number of different, and potentially conflicting, factors 
when making decisions.  Therefore, it is necessary to consider an approach that attempts 
to analyse a set of factors simultaneously, rather than examines factors individually, as 
non-adjustment for the presence of other factors may lead to misinterpretation of the 
role of specific factors in decision-making. 
 
Such qualitative analyses highlight two aspects of HTA decision-making:  firstly, that 
while evidence is considered an important influential factor in decision-making by HTA 
agencies, decision-making is not 100% driven by evidence; secondly, that other factors, 
including process-related factors, efficiency and disease characteristics are also of 
concern for HTA agencies, within their decision-making process.  From a quantitative 
point of view, international studies have examined the relative impact of evidence, in 
particular clinical and cost-effectiveness evidence, on decision-making (George et al. 
2001; Clement et al. 2009; Lexchin and Mintzes 2008; Mason and Drummond 2009; 
Devlin and Parkin 2004; Dakin et al. 2006; Tappenden et al. 2007).  George et al. 
(2001) examined, through development of a league table of reimbursed drugs by the 
Australian Pharmaceutical Benefits Advisory Committee (PBAC), whether PBAC 
decisions are consistent with the principle of maximum economic efficiency.  Through 
the examination of 355 submissions made between 1991-1996, the authors report a 
statistically significant difference between the cost per life-year gained for drugs 
recommended for listing compared to those not recommended, through which it was 
inferred that the PBAC applies the criteria of economic efficiency in its decision 
making, and that the economic evaluation had an impact on the decisions made, 
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although other factors also influenced the decision (e.g. therapeutic value/need for the 
compound).  However, the authors did not examine the impact of economic evaluation 
by adjusting for other factors.  Thus, the relative importance of economic evaluation 
relative to the effect of other factors was not tested in this particular analysis.    
 
In Europe, both agency-specific and cross-agency comparisons have been performed in 
the literature.  With regard to single agency analyses, the literature has mostly focused 
on NICE, and on untangling, among various factors, those which appear to impact most 
on NICE decisions (Devlin and Parkin 2004; Dakin et al. 2006; Tappenden et al 2007; 
Mason and Drummond 2009).   Devlin and Parkin (2004) use a binary choice analysis 
to identify the determinants of NICE recommendations, and consider a selection of 
explanatory variables including the cost per life year or per Quality Adjusted Life Year 
(QALY) gained; uncertainty regarding cost effectiveness result; budget impact from the 
NHS’s perspective; the disease burden; and the availability (or not) of alternative 
treatments.  The authors show that cost effectiveness, coupled with uncertainty and the 
burden of disease, explain NICE decisions better than cost effectiveness alone. 
Similarly, Tappenden et al. (2007), explore what factors NICE takes into account when 
making decisions through a stated preference binary choice experiment.  Factors 
evaluated included preferences for incremental cost effectiveness, the degree of 
uncertainty surrounding incremental costs and health outcomes, the age of beneficiaries, 
baseline health-related quality of life (HR-QOL) and the availability of alternative 
therapies. Results suggest that a negative recommendation was more likely if the 
product under evaluation was associated with increases in the Incremental Cost 
Effectiveness Ratio (ICER), higher economic uncertainty, and the availability of 
alternative therapies (p < 0.01), suggesting that coverage decisions take multiple types 
of evidence into account.   
 
To better reflect the reality of NICE decisions, Dakin et al. (2006) and Mason and 
Drummond (2009) depart from a binary modelling approach.   Instead of assuming that 
NICE operates with a binary choice system, both studies categorise NICE coverage 
decisions into three coverage levels:  recommendation for use, recommendation for 
restricted use and no recommendation for use in the National Health Service (NHS).  In 
Dakin et al.’s (2006) analysis, the NICE appraisal process was modelled as a single 
decision between the three categories. Multinomial logistic regression techniques were 
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used to evaluate the impact of: quantity/quality of clinical evidence; cost-effectiveness; 
existence of alternative treatments; budget impact and technology type. Results 
indicated that evidence was an important driver of NICE decisions:  interventions 
supported by a greater number of randomised trials and those with more systematic 
reviews were less likely to be rejected.  Furthermore, interventions with ‘higher’ cost-
effectiveness ratios were more likely to be rejected rather than recommended for 
restricted use.     
 
The literature comparing coverage decisions and factors driving variation in coverage 
decisions across agencies has generally included NICE and/or SMC, as well as the 
Canadian and Australian HTA agencies (Clement et al. 2009; Lexchin and Mintzes 
2008; Barbieri et al. 2009).  Two studies (Barbieri et al. 2009; Lexchin and Mintzes 
2008),  attempt to examine factors explaining coverage decision patterns within their 
sample, but neither applied methods to assess the contribution of the variables of 
interest while adjusting for potential confounding factors.  Barbieri et al. (2009), in their 
comparison of NICE and the SMC coverage decisions, attempted to explain differences 
in coverage decisions through the fact that NICE uses third party assessment, while 
SMC does not.  However, the lack of sample size impeded the authors from, firstly, 
demonstrating the presence of statistically significant differences in coverage decisions 
between the two bodies, and secondly, from demonstrating if these differences were 
driven by third party technology assessment processes, rather than other factors (e.g. use 
of clinical/economic evidence, agency’s mission, other process elements e.g. inclusion 
of patient groups etc).  The coverage decisions of the SMC were also compared with the 
Australian Pharmaceutical Benefits Advisory Committee (PBAC) and the Canadian 
Common Drug Review (CDR) in a study by Lexchin and Mintzes (2009).  The authors 
found statistically significant differences in coverage decision patterns between the 
bodies; however, the analysis of the factors driving such differences was limited to 
qualitative assessment of a subset of individual technology appraisals to identify 
potential factors driving the observed discrepancy in coverage decisions.  Possibly due 
to limited data and small sample size, Lexchin and Mintzes (2009) did not test in a 
quantitative and comprehensive fashion the degree to which different factors could be 
contributing to diverging patterns of coverage decisions between the agencies.   
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Of the available studies in the literature, Clement et al. (2009) provide the only analysis 
that aimed to explain differences in coverage decisions between NICE, PBAC and CDR 
through the systematic collection of data on a range of factors, and their analysis 
through quantitative techniques.  For each appraisal, data was collected on a range of 
clinical, economic and process factors.  Clinical variables included the level of clinical 
uncertainty, weight of the clinical evidence, the study endpoint of the clinical trial, the 
goal of the treatment (quality of life enhancement, life extension, or both).  Economic 
criteria that were considered were the type of cost-effectiveness evidence provided and 
the level of economic uncertainty.  Through descriptive statistics, each of the variables 
was compared across the three agencies. This analysis suggested that there were 
statistically significant differences between the agencies in the types of technologies 
appraised (a higher percentage of technologies appraised by CDR were aimed at 
improving both quality of life and life expectancy compared to the other agencies), 
while NICE appeared to appraise technologies with a higher proportion of clinical end 
points in their clinical trials (as opposed to surrogate endpoints).  There were also 
significant differences in the type of economic evidence considered by the three 
agencies – with NICE most likely to consider cost utility analyses, and PBAC and CDR 
more likely than NICE to consider cost minimization analyses (p<.001).  There did not 
appear to be statistically significant differences in the level of economic uncertainty of 
the technologies appraised by the three agencies.   
 
The results of the Clement et al. (2009) analysis suggest that there are statistically 
significant differences in the nature of the coverage decisions made by NICE, PBAC 
and CDR.  And additionally, the results show that there are differences in the 
characteristics of the technologies appraised by the agencies, and the evidence that 
supports them.  However, the study is not able to clarify the relative importance of each 
of the examined factors relative to the other, as a regression model was not attempted to 
allow for the adjustment of the effect of individual factors towards one another.  Nor 
was the study able to provide direct evidence of the impact of variation in a specific 
variable leading to variation in coverage decisions.   
 
In summary, the literature on the impact of evidence on coverage decisions described 
above focuses on the degree to which evidence related to the medicine under review 
(whether clinical, economic or otherwise) can impact on HTA coverage decisions.  The 
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literature suggests that, while evidence is an important component that influences the 
decision outcome, it is necessary to look beyond the evidence base and to consider other 
non-evidence based factors that impact on decisions – in particular, the processes that 
guide decision-making, as well as the socio-economic-political context in which these 
decisions are made.   
 
2.2.2 Process-related factors that impact on the payor decision 
 
“. . . it doesn’t matter what your decision is when you come to the 
end. It’s the process that’s got to have been absolutely rigorous.” 
(Pharmaceutical advisor, interview 4 in Wirtz et al. 2005 p. 335) 
 
The literature examining the HTA appraisal process is primarily qualitative in nature.  It 
provides insights into a number of process-related factors that can potentially influence 
coverage decisions including: (i) the approach to decision-making and criteria 
considered as part of the decision-making process; (ii) composition of the decision-
making committee; and (iii) key components that make up the decision-making process. 
  
It can be hypothesised that the approach to HTA decision-making, or, in other words, 
the objective that the appraisal process strives for, shapes the HTA process and 
subsequent decisions.  In practice, most decision-making processes are attempting to 
address numerous objectives simultaneously, with HTA being an approach that 
endeavours to consider several different components in one assessment, including costs 
and effectiveness but also clinical data, epidemiological data and disease characteristics, 
equity, social considerations, patient perspective, industrial policy objectives and so 
forth.  Evidence of the impact of different HTA approaches/ objectives on coverage 
decisions is limited.  Al et al. (2004) aimed to assess the underlying objectives that HTA 
agencies were striving for when making their decisions.  This was done through semi-
structured interviews with four stakeholders within the Dutch decision-making system.  
Several HTA objectives were tested:  to maximize health gain for a fixed budget 
(efficiency); to maximize net health benefit with and without weighted health effects; 
decreasing marginal value with/without weighted health effects; equity considerations 
by age or socio-economic status . These seven goals were presented to the interviewees 
within seven potential budgetary constraints.  Interviewees were asked to rank the goals 
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in terms of which they would prioritise first, and across the four interviewees there was 
wide variation.   
 
While the sample size in Al et al. (2004) is too small to allow generalisability, it 
suggests that HTA agencies do have formalized objectives through which they make 
their decisions and that therefore, understanding the objectives may help to better 
understand coverage decisions.   For example, George et al. (2001) examined whether 
PBAC decisions are consistent with the principle of maximum economic efficiency, and 
report a statistically significant difference between the cost per life-year gained for 
drugs recommended versus those not recommended, through which it is inferred that the 
PBAC applies the criteria of economic efficiency in their decision making.  Menon et 
al. (2005) in Canada, evaluated spatial variation in the availability of cancer drugs 
across ten Canadian provinces, and assessed inter-provincial variations in the processes 
that govern those decisions.  The authors reported that only 7 of 115 cancer drugs 
evaluated were available in all ten provinces, and indirectly link this variation in access 
to the decision-making process adopted, and as a result, the variation in the relative 
importance of different components in their decision-making.    
 
How and by whom the objective or approach towards decision-making is implemented 
can be supposed, at least theoretically, to have an impact on decision outcomes.  Indeed, 
studies suggest that the composition of the decision-making committee can impact on 
the HTA decision.  HTA decision-making bodies tend to be composed of a mix of 
individuals from different roles and backgrounds.  In a review of decision-making 
processes Vuorenkoski et al. (2008) concluded that experts such as pharmacists or 
physicians were key stakeholder groups with considerable influence on the HTA 
decision-making process.  Menon et al. (2005) analysed the variation in availability of 
oncology therapies across provinces in Canada and found that there were significant 
differences between HTA bodies in the frequency of meetings, composition of the 
committee in terms of absolute size and characteristics of the members (i.e. clincians, 
staff of HTA agencies, pharmacists, health economists etc).  Similarly, the OECD 
(2005) surveyed the types of participants involved in decision-making across several 
countries:  in general, government officials (67%), health-care managers (76%) and 
academics/technical experts (67%) were most commonly involved in HTA decision-
making.  Patients/consumer groups, politicians and industry representatives were the 
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least involved (<25%).   Both studies show that variation exists in the composition of 
HTA decision-making bodies and their operational characteristics. However, neither 
study attempted to directly link the differences in the composition of the decision-
bodies used by different HTA agencies to differences in coverage decisions across 
provinces/HTA bodies.   
 
Iversen and Vondeling (2007), on the other hand, do consider the impact of actors 
within the reimbursement process in Denmark on HTA decision making and diffusion 
of technologies.  In a case-study on the reimbursement of glitazones in Denmark, 
Iversen and Vondeling (2007) provide a detailed analysis of the different actors 
involved in the reimbursement process including the ministry of health, the Danish 
Medicines Agency, the counties and non-governmental organizations, including the 
industry and patient groups.  They assess, for this particular case study, how the 
reimbursement decision came about as a result of the interaction between the actors 
identified in the process.  The analysis highlights the importance of considering the 
extent of involvement of various stakeholders and how this impacts on the HTA 
decision.  However, as the analysis was based on a single case study in Denmark, its 
generalisability is limited.   
 
The components of the appraisal process, as distinct from the participants within the 
process, have been examined in the literature and their potential impact on coverage 
decisions has been highlighted (Dakin et al. 2006; Barbieri et al. 2009; Vuorenkoski et 
al. 2008).  The components of the appraisal process refer to the different elements which 
are evaluated as part of the appraisal process.  Thus, for instance, whether economic 
evaluation is included, and whether patient submissions are allowed are two 
components which may or may not be part of an appraisal process.   
 
Research to assess how variation in the presence or absence of these components can 
impact on coverage decisions is largely limited to qualitative analyses that describe 
variation in use of specific components within HTA appraisals, but are not able to 
demonstrate a link between such variation and differences in coverage decisions.   
In a qualitative review, severity of disease and past decisions made by the agency 
appeared to be important components of decision-making (Vuorenkoski et al. 2008), 
although evidence of direct impact on coverage decision was lacking.  Barbieri et al. 
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(2009) assessed to what degree the use of third party technology assessment (by 
external academic groups) could impact on coverage decisions.  This involved 
comparison of NICE and the SMC – in the former, third party evidence is used, while 
this is not the case in the SMC appraisal process.   Case studies and examples where 
third party assessment appeared to be important in explaining differences in 
recommendations between NICE and SMC were highlighted.  However, sample size 
limitations meant that the impact of third party assessment on NICE and SMC coverage 
decisions could not be examined more formally.   
 
Additional research across other European and non-European HTA bodies confirm that 
the elements included as part of the HTA process vary by country and by type of 
intervention.  The OECD (2005) provides an overview of the different types of evidence 
considered in Health Technology Assessments for 5 different types of interventions 
(PET, Hepatitis C genotyping, Telemedicine, Prostrate cancer screening and stroke 
technologies).  While none of these interventions is a pharmaceutical, the results of this 
study give a flavour of the types of evidence considered by HTA agencies in these 
HTAs.  Evidence considered includes information on efficacy/effectiveness, 
quality/safety, cost-effectiveness, and burden of disease in population.  In addition to 
the evidence base varying by type of intervention, it also appears to vary by country 
(OECD 2005).  For example, in the HTA of PET, a survey of HTA agencies across 
eight countries revealed that evidence on effectiveness and safety was consistently used 
across countries, while evidence of cost-effectiveness and total cost burden was 
considered by approximately half of the countries.  No two countries were alike in the 
type of evidence considered.  Similarly, Draborg et al. (2005) reviewed 11 HTA bodies 
in 2002, and identified differences in the scope and nature of the country-specific HTA 
processes.  The clinical component of the HTA assessment was most consistently 
considered, while economic, patient and organisation-level impact was less consistently 
analysed.  In about half of the HTA bodies evaluated, HTA processes included an 
economic evaluation, often in the form of a cost-effectiveness analysis.  Since 2002, 
more HTA bodies and pricing and reimbursement (P&R) processes have adopted 
economic evaluations of new pharmaceutical compounds. Neither study assessed to 
what extent differences in the data used between countries could explain differences in 
coverage decision.   
 
53 
 
 
 
In an assessment of NICE guidance, interventions supported by patient group 
submissions increased the probability of a recommendation for routine rather than 
restricted use (Dakin et al. 2006).  This represents the only identified analysis in which 
the absence or presence of a component of the appraisal process was linked to coverage 
decisions.  It was not, however, able to comment on to what degree variability in the use 
of this component could help explain variability in coverage decisions between HTA 
agencies.   
 
Related to the review of the characteristics of HTA assessments across HTA bodies in 
Europe, a body of literature is available that focuses specifically on the analysis of the 
extent to which economic evaluations are part of the HTA decision-making process.  
Bloom (2004) examined the use of formal benefit/cost evaluations by health care 
decision makers (n=104) in the USA, UK, France and Sweden.  42.1% of respondents 
reported using formal economic analyses in their funding decisions.   Kanavos et al. 
(2000) consider the place of cost-effectiveness evaluation in the decision-making 
process, and document the variations observed in Portugal, Netherlands, Finland and the 
UK in how the cost-effectiveness component is applied within the appraisal process. 
 
In addition to assessing the presence or absence of economic evaluations within HTA, 
studies have examined the components within the economic component – i.e. the 
methodologies used for economic evaluations.  Methodologies for economic evaluation 
have different components within them, and the incremental cost-effectiveness ratio 
(ICER) produced by an economic evaluation is dependent in part on the outcomes 
included and in part on the methodology with which it is derived – i.e. perspective, time 
horizon, discount rate, costs to be included, choice of comparator, patient population etc 
(Kanavos et al. 2000; Hjelmgren et al. 2001; Drummond 2003; Sculpher and 
Drummond 2006).    Hjelmgren et al. (2001) show that, across countries, the level of 
methodological agreement between Health Economic guidelines ranged from 40-100%.  
Sculpher and Drummond (2006) examine variation in 27 guidelines for economic 
evaluation across countries, highlighting considerable variation in the methods 
recommended on choice of comparator, approach sensitivity analysis, identification of 
relevant evidence, etc. Barbieri et al. (2005) examined 46 inter-country drug 
comparisons of cost-effectiveness studies, to assess the variability of the cost-
effectiveness results and note that the variability observed was not systematic, thus 
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highlighting the importance of the country-specific cost-effectiveness threshold as a key 
determinant of the outcome of the decision.  Despite identifying variability in the results 
of cost-effectiveness analyses for the same technology, the authors do not explore how 
this may explain variability in HTA recommendations.  It is of interest to examine 
further how differences in the use and methodology of economic evaluation may be 
partly accountable for differences in HTA recommendations between 
countries/assessment bodies.   
 
2.2.3 Healthcare and welfare context – impact on HTA coverage decision 
The literature has shown that coverage decisions are influenced by macro factors, such 
as healthcare spending per capita, societal willingness to pay, the structure of the 
healthcare system, as well as ethical and social considerations (Packer et al. 2006; 
Owens 1998; Buxton 2005; Bryan et al. 2007; Ross 1995).  This section focuses on the 
acceptability of evidence within the context of the decision-making process (Williams 
and Bryan 2007). Thus, the notion of acceptability from a macro point of view can be 
analysed by considering two distinct types of acceptability:  structural/ institutional 
acceptability and ethical/political acceptability (Williams and Bryan 2007).   
 
Packer et al. (2006) consider the impact of specific factors on  the differential diffusion 
of six innovations in ten countries.  Results of the analysis showed that there were some 
systematic country trends:  i.e. a tendency for a selection of countries to have a high up-
take, including Sweden, Switzerland, Canada and Norway, and other countries to have a 
tendency for low up-take, including UK, Spain and Denmark.  Of the variables 
considered, macro economic factors measured in terms of health spending per capita 
appeared to be associated with an increased diffusion of the health technology, while an 
above average funding from taxation appeared to be linked to a reduced rate of diffusion 
of two health technologies (verteporfin and interferon beta).  While the analysis did not 
focus on the impact of socio-economic factors on HTA coverage decisions, the analysis 
of different patterns of diffusion suggests that such factors could be of relevance when 
attempting to explain patterns of coverage decisions.     
 
Differences in societal willingness to pay for a healthcare benefit (such as an additional 
QALY) will impact on the cost-effectiveness threshold used in decision-making and 
thus may also impact on coverage decisions.  There is considerable literature illustrating 
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the variation of the cost-effectiveness threshold across time and geography, and the aim 
here is not to provide a comprehensive overview of this set of literature, but to highlight 
that the cost-effectiveness threshold does vary between HTA bodies (both within and 
between countries and across time) and the existence of such a threshold can have an 
impact on the final HTA decision to recommend or reject a pharmaceutical for public 
funding. Owens (1998) considers factors that influence the interpretability of cost-
effectiveness analyses, and raises the question of how to determine the cut-off point at 
which an ICER should be considered cost-effective or not.  Buxton (2005), in his 
discussion of the ‘implicit’ cost utility thresholds in the first 39 NICE appraisals, 
discusses the principles that may be used to determine the appropriate and explicit cost-
effectiveness threshold.  The GDP of a country is considered as a potential method of 
deriving a societal value for an added quality-adjusted-life-year, within the economic 
constraints of that society.  Ultimately, differences in the use of cost-effectiveness 
thresholds are expected to impact on the outcome of HTA coverage decisions, although 
currently the literature available has not explored this particular dimension. Therefore, it 
is of interest to consider differences between European Member States in how the cost-
effectiveness threshold is determined and applied to coverage decisions about the public 
funding of pharmaceuticals.   
 
Several authors have discussed the acceptability barriers, particularly with reference to 
the use of economic evaluations as part of HTA decision-making (Ross 1995; Bloom 
2004; Williams and Bryan 2007; Bryan et al. 2007; Hoffman et al. 2000; Drummond et 
al. 1999; Kanavos et al. 2000; Sculpher and Claxton 2005).  One of the barriers 
highlighted in the literature is the perceived difficulty by HTA agencies in converting a 
theoretical economic benefit into reality within their healthcare system, and secondly, 
scepticism about whether projected savings could actually be realized (Ross 1995; 
Hoffman et al. 2000).   
 
The HTA decision and the extent to which it is purely evidence-based is also influenced 
by how it marries with other key considerations in decision-making, such as political, 
social or ethical considerations (Bryan et al. 2007; Ross 1995).  For example, in a 
qualitative study examining the factors impacting on the use of cost-effectiveness 
analyses in the NICE decision-making process, the difficulty of reconciling CEA 
analysis with equity considerations, such as disease severity, was raised (Bryan et al. 
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2007).  Diverging views were expressed from NICE committee members with different 
backgrounds and expertise.  Some criticized CEA from a methodological standpoint, 
pointing out their belief that currently no methodological approach was available to take 
equity into consideration within CEA analyses.  Others highlighted the inconsistent 
approach with which equity principles are applied.  Situations were described when 
disease severity may carry more weight in the decision-making process and override or 
neutralize the evidence:   
“The fact that it is an important disease that causes death focuses 
the mind a little more than perhaps some other technologies 
we’ve looked at where there may be good randomised clinical 
trials but sometimes it’s difficult to judge the relative merits of 
the technology” (Bryan et al. 2007 p. 189).   
Thus, disease severity/equity considerations can influence the HTA decision by 
impacting on the evidence used in the process, and impact on the decision itself.   
 
2.3 Gaps in the literature and implications for this research  
The literature was examined and analysed to (i) to critically examine the analyses 
performed of EU HTA bodies, (ii) to inform the selection of independent variables for 
analysis, the literature was examined to identify which evidence, process or context 
factors had been shown to impact on coverage decisions, (iii) to critically review the 
methods used to assess the relationship between evidence, process or context factors 
and coverage decisions ; and (iv) to set the scene for the development of the analytical 
framework that will shape the methodology and analyses of this research.    In 
summary, the review of the literature suggests there are limitations in terms of their 
scope of EU HTA bodies analysed, analytical methodology adopted to examine HTA 
coverage decisions and comprehensiveness of the variables considered in analyses of 
HTA coverage decisions.  These limitations and the implications for this research are 
examined further below.  
 
A key limitation identified in the literature is the focus on NICE as an example of HTA 
in Europe, despite the fact that in recent years there has been a growth in the use of 
HTA across EU Member States (OECD, 2005).  The scope of the available literature 
has either focused on agency-specific analyses (primarily NICE-related), and any cross 
agency analyses have included Anglophone agencies, namely NICE and SMC, 
alongside CDR in Canada and PBAC in Australia.   Multiple European HTA agencies 
have been compared and contrasted in literature examining the characteristics and 
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differences in processes between HTA bodies, but without linking such differences in 
characteristics and processes to explaining variation in coverage decisions (Sorenson 
2008; Hutton et al. 2006).  For example, a comparative assessment of the characteristics 
of different HTA agencies was provided and proposed by Hutton et al. (2006).  While 
the framework proposed represents a useful starting point for developing an analytical 
framework and for identifying variables of relevance for a comparative analysis, it is not 
designed to analyse to what extent the use of HTA (i.e. the characteristics of the 
technology under evaluation and the process by which it is evaluated) impacts on the 
HTA decision to grant, restrict or deny public funding for new technologies.  In 
response to this current gap in the literature, this thesis aims to contribute by broadening 
the scope of the available literature by analyzing the factors influencing HTA decision-
making in a selection of European HTA agencies.   
 
A second limitation observed in the literature on coverage decisions by HTA agencies is 
the consideration of a limited range of variables/factors.  The literature examining 
factors driving decision-making has to a large extent focused on specific types of factors 
(e.g. papers focusing on economic factors, others on process factors etc.).  Few have 
combined factors (e.g. Clement et al. 2009), and there are no studies which have 
combined clinical, economic, process, disease and socio-economic context variables 
into a single analysis, extracted directly from HTA reports. While process and context- 
related factors have been identified as potentially important factors influencing coverage 
decisions, and differences in these factors between HTA bodies have been described, 
few authors have in fact made a link between differences in process and context factors, 
and coverage decisions.  Several surveys and qualitative analyses have shown that HTA 
agencies consider a wide range of evidence and that there is variation in the components 
of the decision-making process.  However, little research has been performed to assess 
how variation in the presence or absence of these components can impact on coverage 
decisions.  With regard to the impact of process-related factors, such as the composition 
of decision-making committees, while the literature shows that variation exists in the 
composition of HTA decision-making bodies and their operational characteristics, there 
is no attempt to directly link the differences in composition used by different HTA 
bodies to differences in coverage decisions across provinces/HTA bodies.  This thesis 
aims to contribute by considering a broad range of clinical, economic, process and 
context variables in the analysis of factors driving coverage decisions.   
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Another important gap observed in the literature is related to the analytical methodology 
adopted to assess coverage decisions and relevant factors.  In general, the analyses 
adopted have been primarily qualitative or have adopted descriptive quantitative 
methodologies.  The study comparing NICE, PBAC and CDR was descriptive in nature 
(Clement et al. 2009).  Such descriptive analytical techniques make it difficult to 
interpret the relative contribution of each factor, given the absence of adjustment for 
other factors in the analysis.   Models of NICE decision-making have been developed 
for NICE, but not for other European HTA agencies, neither as single agency analyses 
nor as comparative analyses across several European HTA bodies.  This thesis aims to 
address this gap by creating a bespoke dataset of HTA coverage decisions from four 
different HTA bodies in Europe over a five-year period and utilising statistical methods 
of analysis to assess the relative contribution of a comprehensive range of factors on 
coverage decisions both within each HTA body and across HTA bodies.    
 
Based on the literature review presented, and on the identified gaps in the literature, the 
section that follows will aim to present the analytical framework that will shape the 
methodology, structure and analyses performed as part of this thesis.   
 
2.4 Analytical Framework 
The literature suggests that while clinical and economic evidence is an important 
component that can influence HTA coverage decisions, an analytical framework would 
need to look beyond the evidence base and also consider other non-evidence based 
factors that can impact decisions – in particular the processes that guide decision-
making, as well as the socio-economic-political context in which these decisions are 
made.  An analytical approach has been developed to assess and compare HTA 
decision-making across healthcare systems, and to identify those factors that can explain 
HTA decision-making patterns observed within and between HTA bodies across EU 
Member States. The principles upon which the framework is based are derived from the 
theoretical concepts and empirical evidence identified from the review of the literature 
presented earlier.   
 
From a theoretical perspective, the movement of evidence-based medicine in the realm 
of policy making has meant that evidence-based policy-making has become an 
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important movement.  Payers, like other policy decision-makers have moved towards 
incorporating the elements of evidence-based policy making into their decision-making.  
Weiss (1979) introduced two models that can help understand how evidence is 
incorporated in decision-making:  the ‘problem-solving model’ and the ‘interactive’ 
model, the former being an evidence-driven model while the latter is driven by 
interactions between different stakeholders and factors within the decision-making 
process, of which evidence is only one component.  When thinking about the 
transferability of these theoretical models to the analysis of HTA decision-making in 
real-life healthcare systems, it is necessary to analyse the extent to which evidence is 
used in HTA decision-making, and to what extent process and context factors influence 
coverage decisions.  
 
In alignment with the theoretical concepts identified above, three “streams” of research 
become apparent from the literature.  Firstly, research on the impact of evidence on the 
HTA decision.  Secondly, research on the decision-making process itself, rather than on 
the technology (e.g. whether economic evaluation is a component of the decision-
making process or not).  Thirdly, reference in the literature is made to the impact of the 
overall healthcare and welfare characteristics on HTA decision-making (e.g. the impact 
of healthcare expenditure levels and the health policy priorities being reinforced by the 
Ministry of Health at the time of HTA decision-making).  Given these themes observed 
in the literature, the analytical framework is based on a three-pronged approach and 
employs three components of analysis (Fig 2.2): 
• Component 1:  Technology evidence-base characteristics:  assessment of the 
technology’s supporting evidence  
• Component 2:  Process characteristics – examines the process with which 
technologies are evaluated  
• Component 3:  Socio-economic characteristics, which examines the socio-
economic and political context for decision-making    
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igure 2.2 Three-component framework for evaluating outcomes of the HTA appraisal process 
 
 
 
Component 1 focuses on analyzing the availability and quality of the data inputs related 
to the technology and the disease area that go into specific health technology appraisals.  
The second component focuses on capturing the characteristics of the decision-making 
process itself, not specific to any one technology assessment.  The third component 
takes a macro approach and aims to assess overall systemic factors, including social, 
economic and political factors that could influence HTA decision making.   
 
Ultimately, the approach employed in this thesis aims to examine empirically to what 
extent different factors play a role in HTA decision making, and where coverage 
decisions lie within the spectrum moving from a tailored, systematic evidence-driven 
approach to a multi-factorial approach to decision-making on coverage.  The three-
component analytical framework will be used to structure thinking around the 
appropriate methodology to address the research question, in particular regarding the 
research methods, variables for consideration, data sources and consideration of 
limitations.   
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3 Methods 
 
 
The objective of this thesis is to assess the factors that drive HTA coverage decisions to 
recommend, restrict or not recommend technologies for public funding.  Through the 
analysis of the literature (Chapter 2), it became evident that in order to increase our 
understanding of the factors driving HTA coverage decisions in Europe, the following 
strategies would be required: i) increasing the scope of analysis to multiple EU HTA 
bodies; ii) enhancing the comprehensiveness of the factors that are assessed; and iii) 
using alternative methods of analysis that would better capture those factors that are 
able to explain variation in coverage decisions within and between HTA bodies.    
 
The analytical framework, described in the previous chapter, was used to guide the 
methods applied in this thesis.  The premise of this framework is that examining 
characteristics of the technology, the decision process and the socio-economic context 
of coverage decisions will provide a comprehensive view of HTA decision-making and 
a platform from which to examine factors driving HTA outcomes.  In line with the 
analytical framework, this chapter discusses the methods that were used to address the 
research question.   In particular, this chapter presents the criteria for selecting the HTA 
bodies for analysis, the process of identification of variables for inclusion, the methods 
used to create a bespoke dataset for the analysis, and the methods of statistical analysis.  
Finally, the potential limitations of the proposed methods are discussed.   
 
3.1 HTA decision-making: hypothesised drivers 
As discussed in Chapter 2, upon examination of the literature, three “streams” of 
research on factors impacting on HTA decision-making became apparent.  Firstly, 
research on the impact of evidence on the HTA decision, which focuses on the degree to 
which evidence related to the medicine under review (whether clinical, economic or 
otherwise) can impact on HTA coverage decisions (including Clement et al. 2009, 
Dakin et al 2006, Devlin and Parkin 2004, Mason and Drummond 2009).  Secondly, 
research on the decision-making process itself, rather than on the technology (e.g. 
whether economic evaluation is a component of the decision-making process or not).  
The literature examining the HTA appraisal process provides insights into a number of 
process-related factors that can potentially influence coverage decisions (including Al et 
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al. 2004, Menon et al. 2005, Vuorenkoski et al. 2008, OECD 2005).  Thirdly, reference 
in the literature is made to the impact of the overall healthcare and welfare 
characteristics on HTA decision-making (e.g. the impact of healthcare expenditure 
levels and the health policy priorities being reinforced by the Ministry of Health at the 
time of HTA decision-making). The literature has shown that coverage decisions are 
influenced by macro factors, such as healthcare spending per capita, societal willingness 
to pay, the structure of the healthcare system, as well as ethical and social 
considerations (including Packer et al. 2006; Owens 1998; Buxton 2005; Bryan et al. 
2007; Ross 1995).   Given these themes in the literature, it was hypothesised that HTA 
decisions were driven by the HTA decision-making process, the evidence considered 
within that process, and by the socio-economic and political context in which the 
decision was made (Fig. 3.1)  
 
Figure 3.1.   HTA decision-making: hypothesised drivers 
 
 
 
Multinomial logistic regressions were used to assess the hypothesized influence of 
evidence, process and contextual variables on the different coverage outcomes from the 
HTA bodies (recommended, restricted or not recommended). The underlying 
relationship between the HTA outcomes and the 3 set of influential variables was thus 
modeled as: 
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Which results in: 
ܲሺܻ ൌ ݆|ܧ௅, ெܲ, ܥேሻ ൌ
݁௑ೕ
1 ൅ ݁௑ೕ
 
 
With ௝ܺ ൌ ߙ௝ ൅ ∑ ߝ௝௟ܧ௟ ൅ ∑ ߨ௝௠ ௠ܲ ൅ ∑ ߛ௝௡ܥ௡ே௡ୀଵெ௠ୀଵ௅௟ୀଵ  
And where: 
 
ܲሺܻ ൌ ݆|ܧ௅, ெܲ, ܥேሻ is the probability of belonging to group j given ܧ௅, ெܲ, ܥே 
ܧଵ, … , ܧ௅  is the vector E of L explanatory EVIDENCE variables, 
ଵܲ, … , ெܲ  is the vector P of M explanatory PROCESS variables, 
ܥଵ, … , ܥே  is the vector C of N explanatory CONTEXT variables, 
ߝ௝ଵ, … , ߝ௝௅  is the vector ߝ of the L coefficients corresponding to the L 
explanatory EVIDENCE variables 
ߨ௝ଵ, … , ߨ௝ெ  is the vector ߨ of the M coefficients corresponding to M 
explanatory PROCESS variables 
ߛ௝ଵ, … , ߛ௝ே  is the vector ߛ of the N coefficients corresponding to N 
explanatory CONTEXT variables, 
ߙ௝   is the constant. 
 
Significant efforts were made to create a dataset that was consistent and comprehensive, 
and able to address the research questions.  It was a specific objective of this research to 
ensure that a comprehensive set of common variables was collected across the HTA 
bodies to avoid model misspecification.  From the general framework characterized by 
the equations presented above, overall research objectives and HTA-specific objectives 
were derived to reflect the understanding of the context and healthcare system within 
which each HTA body operates.  A common set of variables, complemented by HTA–
specific variables where pertinent for the research objectives, were subsequently 
selected to enable the measurement of the role of evidence, process and context in HTA 
decision-making, illustrated by EL , PM and CN above.  The literature that supports the 
selection of the underlying variables is presented in Chapter 2.  The variables included 
in the analyses are described in Section 3.2 and in Chapters 4-8.     
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3.2 Creating the Dataset – a new and unique platform for analysis 
It is recognized in the literature that HTA guidance to grant or deny funding for new 
technologies is influenced by different types of factors related to the evidence and 
disease characteristics, the process by which the decision is made, the healthcare and 
welfare systems, societal context and the economic environment.  Based on the 
understanding that multiple factors are involved in coverage decision-making, from a 
methods point of view it was desirable to be able to explore a broad range of factors to 
capture as much as possible the reality of this decision-making.  A need was therefore 
identified to develop a database of coverage decisions that captured the relevant 
information.  A data set of information pertaining to NICE, SMC, CVZ and HAS 
appraisals was created, collecting information on variables relating to (i) the clinical and 
economic characteristics of the technology under appraisal, as well as (ii) the processes 
used to come to coverage decisions, and (iii) the socio-economic context in which these 
decisions were made. 
 
To create this database, several steps were implemented (Figure 3.1).  Inclusion and 
exclusion criteria were established to define the sample of appraisals for inclusion in the 
analysis.  The variables for inclusion were defined in accordance with the analytical 
framework.  Publicly available sources of data containing information on the variables 
of interest were identified for each HTA body.  A data extraction form was developed 
and used to extract relevant data from the identified sources in a way that was 
transparent, reproducible and as consistent as possible between the appraisals and HTA 
bodies.  Finally, the resulting extracted data was coded and prepared for analysis.  
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Figure 3.2 Process for the development of a dataset of coverage decisions made by NICE, SMC, CVZ and HAS 
between 2004-2009 
 
3.2.1 Defining the sample for analysis 
The choice of HTA body included in the analysis aimed to maximize the chance of 
obtaining useful data to address the research question, provide a comprehensive 
platform for analysis of the research question rather than the examination of a particular 
factor in isolation, and to allow for the exploration of variation in the implementation 
and drivers of HTA decision-making.  To gather information on variables related to the 
coverage decision for specific technologies, data were required from HTA bodies that 
published their appraisal decisions and rationale for those decisions in a comprehensive 
format that was accessible to the public.  The following HTA bodies in Europe that 
fulfill these data requirements were identified:   
• Scottish Medicines Consortium (SMC), Scotland (UK) National Institute for 
Health and Clinical Excellence (NICE), England and Wales (UK);  
• College voor Zorgverzekeringen (CVZ), the Netherlands ; and  
• Haute Autorité de Sante (HAS – French Health Authority), France.   
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The drug technology appraisals performed by NICE, SMC, CVZ and HAS formed the 
basis for the sample included in this analysis.  The composition of the sample was 
determined through the following inclusion and exclusion criteria. The sample included 
all drug technology appraisals (as opposed to medical devices or other interventions) 
made in 2004-June  2009, indicated for an adult population (≥18 years).  To capture a 
sufficient number of appraisals for both individual and aggregate analyses, a five-year 
time horizon was implemented.  Technology appraisals were excluded from the analysis 
for any of the following reasons:  if they focused on a non-adult population; if they 
appraised non-drug interventions; if marketing authorisation was withdrawn; if the 
ASMR was not reported (HAS only); if an abbreviated or Independent Review Panel 
(IRP) guidance was issued (SMC only); or if the full guidance was not available. 
 
With regard to the HAS, additional inclusion criteria were employed.  The French Haute 
Autorité de Sante (HAS), has numerous responsibilities, one of which is the provision 
of advice on new technologies available for patients.  In total, the Commission issued 
more than 2,600 recommendations between 2004 and 2009.  Given the resource 
constraints available, it was not possible to review all 2,600 recommendations to 
identify those of relevance for this research (i.e. not all recommendations provide an 
ASMR, some recommendations are related to a new mode of administration, new safety 
information or a re-review of technologies licensed prior to 2004 etc).  In order to 
extract a relevant sample for this research, a list of technologies that had been included 
in the SMC and NICE reviews was created and available HAS recommendations linked 
to these technologies were extracted for review.  While understanding that this approach 
may lead to selection bias, the benefit of this approach was that it increased the 
opportunity for comparability across agencies by collecting information on a common 
list of compounds, streamlining data extraction to those appraisals that were relevant for 
the research question.   
  
3.2.2 Determining the explanatory variables for inclusion in the dataset 
In alignment with the framework set out in section 3.1, three sets of explanatory 
variables were considered, corresponding to the three components of analysis:  (i) 
variables characterizing the evidence base and disease for which the technology is 
indicated (Component 1) (ii) factors relating to the appraisal process (Component 2) and 
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(iii) socio-economic variables reflecting the healthcare system and welfare system 
context in which coverage decisions are made (Component 3).   
  
Explanatory variables related to evidence and disease characteristics - Component 1 
The first set of explanatory variables was related to the evidence and disease 
characteristics considered by the decision-makers in the appraisal. The quality and 
quantity of data inputs, as well as the context pertaining to the disease and respective 
population, are hypothesized to be key variables that impact on HTA coverage 
decisions.  A significant proportion of studies examining the factors that drive coverage 
decisions have considered the clinical and economic characteristics of the technology to 
be key drivers of decision-making (Devlin and Parkin, 2004; Dakin et al., 2006; 
Sculpher and Drummond, 2006; Tappenden et al. 2007; George et al. 2001; Clement et 
al. 2009).   In addition, as recognised in the literature, the degree of uncertainty 
underlining the key characteristics of a technology under evaluation and its use in 
clinical practice can influence the probability of obtaining a positive or negative 
recommendation (Devlin and Parkin, 2004; Clement et al. 2009).  To reflect the nature 
of the evidence supporting the technology, and the degree of uncertainty around the 
evidence, data on the quantity and quality of the clinical and economic characteristics of 
the technology was extracted.  Clinical variables included the characteristics of the 
randomized clinical trials, use of non-randomised data, and the disease characteristics 
that the technology is licensed to treat.  Several types of economic variables were 
considered in the analysis – the use of cost-utility analysis (CUA) was documented, and 
for those appraisals that included CUA, the incremental cost-effectiveness ratio (ICER) 
was recorded, along with measures of uncertainty around the ICER (both probabilistic 
and univariate measures of uncertainty).  A previous analysis of NICE decision-making 
by Dakin et al. (2006) did not consider the impact of the degree of uncertainty around 
the ICER, although Devlin and Parkin (2004) and Clement et al. (2009) did include 
economic uncertainty as a variable in their analyses.  To capture as much as possible the 
clinical and economic evidence supporting the technology, as well as the disease 
characteristics of relevance for the technology, the following variables were extracted 
for analysis for each appraisal:   
• Characteristics of randomized clinical data 
o Number of RCTs included in the submission 
o Size of the population included in RCT(s) 
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o Statistically significant results reported in RCT(s) 
o Length/extent of follow-up in the RCT (weeks) 
o Use of active or placebo comparator in RCT(s) 
• Other non-randomised clinical data on efficacy/effectiveness 
o Number of observational studies included in the submission 
• Disease-area / treatment paradigm 
o Prevalence of the disease/clinical condition for which technology is 
indicated 
o Availability of alternative pharmaceutical therapies in the current 
treatment setting 
o Disease area category (as per British National Formulary categories) 
o Orphan designation status  
• Economic Evaluations 
o Inclusion of Cost Effectiveness Analysis in the submission 
o ICER of technology vs. comparator 
o Reporting of multiple ICERs  
o Uncertainty around the ICER reported in the submission (univariate and 
probabilistic) 
o Anticipated incremental pharmaceutical budgetary impact of introducing 
the new technology into the health care system 
o Use of societal perspective  
 
Explanatory variables related to decision-making process - Component 2 
Explanatory variables related to the decision-making process were also be extracted for 
analysis.  This included a range of variables that captured key aspects of the appraisal 
process.  Of particular interest was the impact of specific components of the decision-
making process on the decision outcome – namely, the presence of a cost-effectiveness 
evaluation and/or a budget impact assessment (Packer et al. 2006; Devlin and Parkin 
2004; Tappenden et al. 2007; Clement et al. 2009; George et al. 2001).  Hutton et al. 
(2006) also highlight the relevance of considering the characteristics of the decision-
makers, how many are involved in the decision-making and whether the HTA body is 
independent of the Department for Health or part of it.  It was hypothesized that in the 
HTA appraisal process where patient group submissions are permissible, the use of such 
submissions may increase the probability of a recommendation (Dakin et al. 2006).   
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Within NICE decision-making, the use of an MTA or STA process has been 
hypothesised to impact on decision-making (Barbieri et al. 2009)1.  Finally, whether the 
HTA decision-maker is aware of the price of the technology prior to the appraisal may 
also impact on the coverage decision, as opposed to a body that appraises a technology 
without knowledge of its price.  The process-related factors that were included in the 
analytical framework include:   
• Components of the decision-making process 
o Inclusion of patient submissions 
o Cost-effectiveness evaluation component within the process 
o Budget impact as a component of the decision-making process 
• Price of the technology known at the time of appraisal 
• Number of accountable decision-makers 
• Accountability for the drug budget by the agency 
• Independence of the decision-making agency 
• Number of technologies appraised simultaneously 
 
Explanatory variables related to the socio-economic context of decision-making - 
Component 3 
Finally, macro-economic, societal and healthcare system-related variables were 
included to reflect the context in which coverage decisions are made, and to assess their 
degree of impact on HTA decision-making.  There is less variation between appraisals 
with regard to these indicators because they are defined at the country level rather than 
at the appraisal level.  For example, it was hypothesized that the percentage of GDP 
spent on healthcare, and the percentage allocated to the drug budget, may impact on the 
rate of reimbursement of new technologies (OECD 2005; Packer et al. 2006).  It was 
also envisaged that government prioritization of specific disease areas may help spur 
reimbursement for technologies emerging in those priority disease areas, potentially at 
the expense of other technologies indicated for ‘less-priority’ diseases.  With regard to 
the year of appraisal, HTA appraisal processes can/have changed over time and this may 
impact on the coverage decision.  Population size, in terms of the population under the 
                                                 
1 Multi technology assessments (MTA) and Single technology assessments (STA) are two appraisal 
processes used by NICE to issue guidance on technologies.  The MTA process includes a third-party 
review and analysis of the clinical and economic evidence, while the STA process relies on manufacturer 
provided information (Barbieri et al. 2009). 
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agency’s remit, was considered relevant, as it can have implications for the budgetary 
impact of new technologies, absolute levels of funding that are available, and absolute 
levels of demand.  The extent to which decisions for funding are made exclusively at the 
national level, or whether the agency in question operates at a regional or local level 
were also considered as pertinent factors to record.  Finally, given that healthcare policy 
is influenced by the political context in which it is made, it was thought relevant to 
capture whether decisions were being made in an election year.  To this end, the 
following variables were captured: 
• Date of submission 
• Population size – agency coverage 
• GDP-healthcare expenditure (as percentage of GDP spent on healthcare) 
• Healthcare expenditure on pharmaceuticals per patient per annum 
• Drug funding process within the healthcare system – whether centralized or 
decentralized 
• Election year at the time of the decision 
• If technology was indicated for a priority disease area 
 
3.2.3 Data sources 
Data sources for the analyses of coverage decisions were organized by the three 
components of analysis.  Data sources related to the clinical and economic evidence as 
well as the disease relevant to the technology (Component 1 of the analytical 
framework) were derived from the reports of coverage decisions by NICE, SMC, CVZ 
and HAS.  Data sources related to HTA appraisal processes (Component 2) were 
derived from the agencies themselves, as well as from national Department of Health 
sources and the literature. Finally, data sources to capture macro variables related to the 
healthcare system, as well as societal and welfare system characteristics, were captured 
from ministry of health documents, national statistics publications, and published 
literature.   
 
To gather information on variables related to the characteristics of the technology under 
appraisal (Component 1), data were obtained directly from each of the HTA web 
portals.  For NICE, information on appraisals was collected from several types of 
sources available on the NICE website.  The Final Appraisal Determination (FAD) was 
used as the key source of data for extraction.  In addition, Assessment group, Expert 
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Review Group reports, as well as stakeholder submissions and manufacturer reports 
were also accessed to extract needed information.  For the SMC, the appraisal report for 
each technology was accessed.  For the CVZ, a series of documents were used as 
sources of data for the creation of the dataset.  This included the official letter from the 
CVZ to the Ministry of Health, providing information on the final recommendation of 
the CVZ.  Additional sources include the CVZ report, and in addition the cost 
consequence report, where applicable.  For technologies applying for inclusion in the 
‘expensive drug list’ the particular document created by the CVZ which documents the 
available information and intended analyses to be performed in the future was utilised.  
Finally, to ascertain the coverage decisions, the following documents were accessed:  
the official ‘expensive drug list’, the Medicijn Kosten web-portal (which documents all 
medicines available in the Netherlands and gives information on whether there is a co-
payment for the patient, a restriction on use etc); and the Farmaceutisch Kompas which 
lists all of the technologies reimbursed in the medicine reimbursement system 
(Geneesmiddelen Vergoedings Systeem, GVS) under either List 1A, 1B or List 2 (See 
Section 6.2).     To gather information on the clinical and disease characteristics of the 
technologies appraised by HAS, the Transparency Committee’s reports were accessed.  
 
With regard to data on payer decision-making processes (Component 2), a range of data 
sources were examined to extract information about the characteristics of the appraisal 
process. HTA guidelines for manufacturers and the methodology guidelines were 
accessed from the NICE and SMC websites.  For the SMC, the minutes of the 
Committee meeting in which the appraisal was discussed was also accessed from the 
SMC website, to ascertain the members that were involved in the decision-making 
process as well as to collect any insight on other factors or rationales taken into account 
that were reflected in the minutes.      Legal documents outlining the appraisal process 
were utilised for both the CVZ and HAS.    In addition, information about the appraisal 
process was extracted from the literature for each of the HTA bodies (e.g. Mason and 
Drummond 2009; Sorenson et al. 2008; Clement et al. 2009; Schäfer et al. 2010; 
Sandier et al. 2004).  
 
Finally, with regard to data related to the context in which payer decisions are made 
(Component 3), multiple sources were utilised.  Information about expenditure on 
healthcare for each for the British, French and Dutch healthcare systems were extracted 
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from the OECD database and from Ministry of Health figures.  The European Statistics 
and Population database, as well as specific population statistics from the respective 
jurisdictions were utilised to estimate total national population and the population 
within the remit of the agency.  Government and media publications were accessed to 
identify years when national elections took place, and what the priority disease areas 
were for the respective healthcare systems.     
 
The detailed sources of data used for each HTA body and variables are provided in the 
description of the dataset in the empirical chapters that follow (Chapters 4-7).   
 
3.2.4 Data extraction 
To encourage consistency and rigour in the data extraction process, a data extraction 
protocol was developed. This ensured, to as great a degree as possible, that the relevant 
data was extracted from the identified sources in a way that was transparent, 
reproducible and as consistent as possible among the different appraisals and HTA 
bodies.   
 
The data extraction form was organized into three segments, relating to the three 
components of analysis that are integral to this research.  The first segment was 
designed to allow for extraction of information relating to the decision itself – the nature 
of the clinical evidence available, whether cost-effectiveness evidence was put forward, 
and if so, the characteristics of that evidence.  The second segment captured information 
relating to the process by which the recommendation was issued – for example, within 
NICE appraisals, there is the possibility to appraise via a Multi Technology Appraisal 
(MTA) or a Single Technology Appraisal (STA).    Finally, the third segment of the 
data extraction form captured information on the context in which the guidance was 
issued (healthcare system, economic and social context).  
 
3.3 Statistical Analysis 
Having set the scene by providing both the list of dependent and explanatory variables 
for analysis, as well as the HTA agencies which were analysed, this section outlines the 
statistical methods that were employed to analyse the data set and to examine the 
importance of a range of diverse factors on coverage decisions made by NICE, SMC, 
CVZ and HAS from 2004 to 2009. 
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3.3.1 Descriptive statistics 
Descriptive statistics were calculated for each HTA body for each extracted variable, 
stratified by outcome group (recommended, restricted, or not recommended).  This 
included the mean, standard deviation, median, minimum-maximum range observed, 
and confidence interval. For categorical variables the chi-squared test was performed 
across the three outcomes to ascertain if a statistically significant difference of the 
means between recommended and restricted technologies as well as between 
recommended and non-recommended technologies was present, at a level of 
significance of 0.05.   
 
With regard to non-categorical variables, to determine the relevant statistical tests to use 
in assessing the significance of differences observed between means (at 0.05 level), it 
was necessary to assess whether the normality assumption was valid for the variables 
under consideration.  For all variables, the sample is >30.  It has been suggested that 
when analysing sample sizes of >30, even when the normality assumption is violated, 
parametric tests may still be performed (Pallant 2007).  Prior to making a decision on 
which statistical tests to apply to specific variables, the distribution for each variable 
was further examined.   
 
To test the normality assumption the following was performed for each non-categorical 
variable: i) skewness and Kurtosis was calculated, and ii) the standardised normal 
probability plot (P-P plot) was graphed.  The results of the above-described tests for 
each HTA body are presented in Appendices A, B, C, D for NICE, SMC, CFH and 
HAS respectively. Given the results of the tests, it was considered appropriate to run 
both a range of statistical tests to ascertain the presence of a statistically significant 
difference between the observed means for recommended versus restricted technologies 
as well as between recommended and non recommended technologies.  Two parametric 
tests were performed: i) Student’s T-test and ii) one-way ANOVA.  For the t-test, first 
the means of recommended versus restricted interventions were compared, then 
restricted versus not recommended were compared via a Student’s unpaired T-test.   
Bartlett’s test was performed to ascertain if the t-tests should assume equal or unequal 
variance.  The Kruskal-Wallis test was also implemented. Statistical analyses were 
conducted using Intercooled (IC) STATA (Version 10.1 2009). 
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3.3.2 Multivariate analysis – considerations 
A number of considerations were taken into account in selecting the statistical model 
that would be most appropriate for the analysis, including the definition of the outcome 
variable,  the ordinality of the data.  Methods for characterising and handling of missing 
data were also considered.  In developing and performing multivariate analysis, the 
objective was to identify the individual effect of each of the factors considered, 
controlling for their potential association with the rest of the factors in the model, and to 
assess which combination of factors best explains the pattern of coverage decisions 
observed within each HTA body, as well as across HTA bodies.  Multivariate analyses 
of each HTA agency were undertaken to understand the specificities of each HTA 
agency in the factors that drove coverage decisions within the appraisal process.   
Pooled analyses of the data in the four HTA bodies were then conducted to better 
understand the sources of variation in coverage decisions between HTA agencies and 
jurisdictions.  Thus, the combination of single and pooled analyses was used to address 
the research question in order to explore single agency decision-making, and to test for  
differences on the impact of factors on cross-agency variation in coverage decisions.  
The face validity of the multivariate analysis results was assessed by conducting 
interviews with representatives of NICE, SMC and CVZ in which the model results and 
interpretation of results was discussed and assessed.  A representative of the HAS as not 
available for comment.  Interview summaries are provided in Appendix E.      
 
Categorisation of the outcome variable and implications for analysis 
Econometric analyses of coverage decisions have adopted both binary and multi-
category outcome variables as the basis for their analysis (e.g. Dakin et al. 2006; Devlin 
and Parkin 2004; George et al. 2001; Clement et al. 2009).    For example, Devlin and 
Parkin (2004) adopted a binary outcome variable, thus modelling the impact of five 
explanatory variables on the odds of a recommendation or a non-recommendation by 
NICE.  Similarly, George et al. (2001) adopted a list/not list binary outcome variable in 
their analysis of Pharmaceutical Benefits Advisory Board (PBAC) coverage decisions 
in Australia.  In contrast, both Dakin et al. (2006) and Clement et al. (2009) adopted a 
three-category explanatory variable.  Dakin et al. (2006) adopted a three-category 
outcome variable, examining the impact of explanatory variables on the decision 
between recommendation, restriction and non-recommendation by NICE.  Similarly, 
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Clement et al. (2009) considered ‘list’, ‘list with conditions’, and ‘do not list’ categories 
in their analysis of PBAC, Canadian Drug Review (CDR) and NICE coverage 
decisions, although they did not perform a regression analysis of their dataset, but 
focused on a descriptive analysis of the data by examining the role of each variable 
separately from the other.    Therefore, there are examples from the literature of the use 
of both binary and three-category outcome variables to analyse coverage decisions. 
 
In parallel to a review of outcome variables used in the literature on coverage decisions, 
an assessment was also made of how each HTA body operates in terms of its decision-
making.  All four agencies appear to consider more than two types of coverage options 
when making their final recommendation.  HAS uses a five point scale known as the 
ASMR rating, that classifies the technology according to the level of incremental 
medical service rendered, with the highest level - I - being high incremental medical 
service and V denoting no additional medical benefit. Subsequent pricing and volume 
negotiations are based on these ratings.  Thus, a binary approach would not fit the way 
in which HAS approaches coverage decisions.  Similarly, the CVZ has several possible 
coverage options in its armamentarium.  According to whether the technology is for 
inpatient or outpatient use, it can cover a technology under a special ‘expensive drug 
list’, in List 1A, where price is clustered to the lowest price in the cluster, List 1B for 
those technologies that cannot be clustered or include a technology in List 2, which is 
for those technologies (either in 1A or 1B) that have additional conditions attached to 
them: e.g. use in a specific patient group etc).  Thus, more than two coverage options 
are also available to the CVZ committee.  The SMC utilises the three-category 
approach:  accepted for use, accepted for restricted use and not accepted for use in NHS 
Scotland, therefore clearly not operating in a binary-type coverage decision system.  
Similar to the SMC, NICE either recommends, recommends with conditions or does not 
recommend technologies for NHS coverage in England and Wales.  In all four HTA 
bodies therefore, coverage decisions are based on more than a binary decision-process.  
This was therefore a key motivation for justifying a non-binary modelling approach.  
The outcome variable for this analysis was categorised into three possible outcomes, 
where the new technology can be   
• recommended for routine use 
• recommended for restricted use 
or 
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• not recommended 
 
The choice of a three-category outcome variable was selected to best reflect the way in 
which HTA bodies consider their coverage options.  This choice was done with full 
knowledge of the complications associated with using a three-category dependent 
variable from a statistical modelling point of view, but more importantly due to 
complications arising from the heterogeneity in the types of coverage decisions/types 
possible – particularly with regards to the ‘restricted’ category.  This heterogeneity has 
been recognised both by Raftery (2006) as well as O’Neill and Devlin  (2010).  Raftery 
(2006) identified various forms of restrictions made by NICE in its appraisals, which 
were categorized into ‘major’ and ‘minor’ restrictions.  Major restrictions included, for 
instance, the recommendation of the technology for a specific sub-population of the 
licensed indication, or recommendation of the technology for use in second or third line 
use.  Minor restrictions included the requirement to monitor as a condition for using the 
technology or prescription being restricted to a specialist.  A more quantitative 
assessment of the heterogeneity of restrictions made by NICE was performed by 
O’Neill et al. (2010).  In this assessment, restriction was evaluated by calculating ‘M’ or 
the proportion of patients for whom the technology was recommended, relative to the 
population that would be eligible for the technology as per the license:   
M = (p/P)*100 
where M is the level of patient access (0=0%, 1 = 100%), P is the total eligible 
population and p is the recommended population within the coverage decision (O’Neill 
and Devlin 2010).   
 
The results of this quantitative analysis of NICE restrictions (n=34)  showed that the 
degree of restriction varied between technologies/appraisals:  71% of technologies had 
an M of 50 or less, 32% had an M of 10 or less, while approximately 30% had an M of 
50 or more.  As a more precise measure of the impact of coverage decisions on patient 
volume, the ‘M’ concept usefully illustrated the variability in the level of access 
associated with a restriction.  However, the use of ‘M’ as an outcome variable for the 
analysis of coverage decisions is limited by (i) non-availability of the data to run this 
calculation; (ii) its focus on a specific type of restriction; and (iii) by its assumption that 
NICE is aware of the impact of its restriction on the size of patient access prior to its 
recommendation.  In approximately half of the appraisals considered by O’Neill and 
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Devlin (2010) it was not possible to calculate M, due to poor information on the total 
population eligible and the estimate of the population to which the technology was 
recommended.  While M calculates the impact of a restriction on patient volume, it does 
not take into consideration other types of restrictions that can be issued by NICE, such 
as restrictions on specific types of prescribers, with specific monitoring (Raftery 2006).  
Finally, the analysis is also limited by its assumption that NICE, when making its 
restriction, takes into account the impact of that restriction on patient volume.  
However, there is no evidence to suggest that this is the case:  usually, target population 
size is calculated as part of costing templates, and these templates are produced as a 
result of the NICE appraisal conclusions, rather than as a factor influencing the outcome 
of the appraisal.  While there are differences in the approach to analyzing ‘restricted’ 
technologies, both Raftery (2006) and O’Neill and Devlin (2010) suggest that the 
impact of the restriction can vary and that the use of restrictions is heterogeneous.   
While this variability in the ‘restricted’ category has implications for the interpretation 
of the results of multivariate analyses, the notion of removing this restricted category 
and considering a binary approach does not provide a ready solution, as it would simply 
lead to a category in which recommended and restricted coverage decisions are 
combined, increasing the heterogeneity of the category even further and reducing the 
ability of the analysis to reflect the way HTA bodies perceive what the coverage options 
available to them are.  
 
In summary, given that this thesis aims to analyse the factors that drive HTA coverage 
decisions, the analysis was designed to consider coverage decisions in the way that 
HTA bodies define them (i.e. in multiple options rather than a binary (yes/no) option).  
From this perspective, a multinomial logistic approach was deemed attractive as it is an 
appropriate method for handling outcome variables with multiple non-ordinal 
categories.    Using a three-category outcome variable reduced the need to collapse the 
multiple variable categories into binary categories, and thus better reflected the multiple 
coverage options available to HTA bodies.   However, to ascertain the impact of model 
characteristics and assumptions on understanding HTA decision-making, the results of 
the base case models for both single HTA body analyses as well as pooled analyses, 
were compared with models specified with binary outcome categories (see below).      
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Ordinality of the outcome variable 
In addition to defining the number of categories for inclusion in the outcome variable, 
an important consideration from a methodological standpoint is whether ordinality 
should be assumed, as this has implications for the statistical methods that should be 
applied.  A categorical variable can be considered ordinal if there is a ‘natural’ ordering 
in the outcome that can be identified.  Dakin et al. (2006), in their econometric analysis 
of NICE decision-making, used a three-category approach, and argued that an 
assumption of ordinality was not appropriate as there was no consensus on the 
‘direction’ of the ordering.  In other words, depending on whether the aim of the 
appraisal decision was to define volume (i.e. number of patients that can access the 
therapy), total drug cost for the technology (budget impact) or maximization of 
patient/healthcare system outcome can lead to different ordering and consideration of 
appraisal decisions.  For example, if the main objective of the coverage decision was to 
control cost, then it could be expected that those decisions which restrict or not 
recommend access may be considered as preferable to a recommendation. The opposite 
is true if we consider patient access to medications as the main objective of coverage 
decisions:  in this case, a coverage decision that covers 100% of the eligible population, 
less than 100% or 0% could be considered.  In the base case analysis, multinomial logit 
regression was assumed to be appropriate, although sensitivity analyses in which 
ordinality was assumed were run for each HTA body and for the pooled data set to 
examine the impact of that assumption on model results (see below).   
 
Missing data and imputation 
While every effort was made during the data extraction process to identify the 
information relevant to the variables of interest, a proportion of data was missing.  
Missing data can impact on the results of the analysis if conclusions are drawn from 
biased parameter estimates, due to reliance on the complete observations within the 
dataset or to biases arising in the imputation of missing explanatory variables.  To 
generate robust multivariate analyses of HTA decision-making, it was important to 
identifying the most suitable means of handling missing entries in this data set.  
 
To assess the extent to which imputation of missing data would be appropriate, the rate 
and pattern of missing data for each HTA body was first examined, alongside an 
assessment of the process by which data was missing and whether an assumption of 
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“missing at random” (MAR) was justified (Rubin 1976, Lu and Copas 2004).  The 
proportion of missing entries for each HTA body within the dataset was relatively small 
and ranged from 5% to 10% (Table 3.1).  On average, for each appraisal, no more than 
three indicators were missing, of the 30+ collected variables.   The extent of missing 
information across the outcome categories was also examined and showed that the 
proportion of missing values were similarly distributed across the outcome variable, 
suggesting that the impact of any biased imputation would not fall disproportionately on 
a particular outcome category (Table 3.1).    
 
With the exception of the HAS, economic-related variables capturing information on the 
uncertainty estimates around the ICER suffered from the highest proportion of missing 
entries, driven from lack of reporting of this information in the public domain (Table 
3.1).  Missing values for these variables were imputed using information from other 
variables, particularly the ICER itself, and a set of clinical trial related variables.  
However, the imputed uncertainty variables were finally excluded from the models due 
to the extent of missing data and because of the high collinearity with the ICER 
explanatory variable.   
 
Table 3.1 Description of missing data, by HTA body 
 NICE SMC CVZ HAS 
Proportion of 
incomplete 
entries (%) 
8% 10% 9% 
 
5% 
Missing entries 
by outcome 
variable 
Recommended: 5% 
Restricted: 9% 
Not recommended: 
9% 
Recommended: 
10% 
Restricted: 9% 
Not recommended: 
10% 
Recommended: 
9% 
Restricted: 8% 
Not 
recommended: 
9% 
ASMR 1-2: 7% 
ASMR 3-4: 4% 
ASMR 5: 4% 
List variables 
with missing 
values (top three 
variables) 
Univariate 
uncertainty 
estimates around 
ICER 
Probabilistic 
sensitivity analysis 
Univariate 
uncertainty 
estimates around 
ICER 
Probabilistic 
sensitivity analysis 
ICER 
ICER –related 
sensitivity 
analysis 
Size of RCT 
Duration of RCT 
Demonstration of 
clinical 
superiority 
Missing entries 
per appraisal 
(mean and range) 
3  (range: 0-9) 3 (0-10) 3 (range: 0-8) 1 (range: 0-8) 
 
  A relatively low proportion of missing values were noted for other variables 
(Appendix A-D Figures A.1, B.1, C.1, D.1, provide data on the distribution of missing 
entries per variable for each HTA body).  Within the HAS appraisals, clinical variables 
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including the size, duration and statistical significance of the results were variables with 
the highest number of missing entries.  The likelihood of missingness for these 
indicators was mostly linked to the reason for appraisal and the nature of the 
technology.  Specifically, amongst the appraisals with missing RCT-related variables, 
56% were re-appraisals of previous HAS decisions and 17% were orphan designated 
medicines.   The mean ASMR among appraisals with missing RCT-related entries was 
3.5 compared with 3.9 for those appraisals with complete RCT-related entries.   To 
consider these variables in the model, the imputation process utilized the comprehensive 
range of variables collected within the data extraction process.  For example, in the 
instance that a particular clinical variable was missing, such as RCT sample size, the 
size the eligible population for treatment and therapeutic area (BNF category), coupled 
with additional clinical variables (use of active comparator, number of clinical trials) 
were identified as variables that could be utilized in the imputation process.  A more 
detailed description of the imputation approach taken is provided below.  
 
To maximize the number of observations and sample size for both the individual and 
pooled analyses, imputation techniques were used to estimate entries for those 
observations that were lacking.  In order to determine the method most adapted to the 
analyses, several approaches to imputation were tested including (i) imputation by 
replacing missing values with the overall mean of the variable, (ii) generating regression 
estimates of the missing value, and (iii) multiple imputation techniques that take random 
variation into account.  This exercise was performed on one of the HTA datasets (SMC 
dataset) to test which imputation method would be most useful to extrapolate to the 
remaining HTA multivariate analyses.  The results of this exercise are summarised in 
Appendix F.  The results suggest that the various imputation techniques provided 
similar pseudo R-squared results across the models and similar pattern of size, direction 
and significance of effect.  It was therefore felt to be appropriate, for the remainder of 
the multivariate analyses to impute missing values by using regression estimates of the 
missing value (option ii, performed using the ‘impute’ command in STATA data 
analysis software (Intercooled (IC) Stata version 10.1).  For each imputed dataset, 
imputation output was checked for coherence.  In addition, dummy variables were 
created for those factors that had observations with incomplete entries, so as to be able 
to ascertain, through regression analysis, whether the lack of data was significantly 
associated with the outcome variable.  Sensitivity analyses were conducted in which 
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those observations with missing entries were removed from the models so as to allow 
for an assessment of the impact of imputation (or no imputation) on the model results.  
This sensitivity analysis was implemented with the knowledge that removing those 
observations with missing data could lead to selection bias in the analysis due to the fact 
that appraisals with incomplete observations may be different than appraisals with 
complete observations.  However, what this sensitivity analysis wished to assess was 
the implications of making a trade-off between including in the analysis only those 
observations with data, therefore avoiding imputation but potentially increasing bias in 
the analysis, or maximising sample size and validity of the model output by utilising 
imputation techniques.   
 
3.3.3 Multivariate analyses  
Model specification 
As indicated in Chapter 3, a large number of interrelated factors could be hypothesised 
to influence the coverage decisions taken by HTA bodies. The analysis has collected 
data relating to many of these factors (see Chapter 3, section 3.1.2). In terms of the 
statistical modeling of the coverage decisions, however, a process needed to be 
developed in order to select the set of explanatory variables that appeared in the final 
specification of each of the models estimated. This selection process involved the 
following steps: 
1. The referent outcome variable was defined.  The base outcome utilised for all 
four multinomial regression models was the ‘recommended’ outcome.  Thus, 
recommended technologies were compared with restricted and non-
recommended technologies each in turn.   
2. The results of the descriptive analyses of the dataset were reviewed 
3. The full set of variables extracted for each HTA body was considered in the 
model specification process.  This was done by examining the impact of 
potential explanatory variables in ‘mini’ bi-variate regression models.  In 
addition, dummy variables were created for incomplete observations, to be able 
to explore their impact in the model. 
4. Those variables with a p value of ≤0.25 were included in the preliminary model.  
Subsequently, the coefficients and significance of the variables in the 
preliminary model were compared with the coefficients and significance 
observed in the bi-variate models and any evidence of interaction was noted. 
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5. Using the preliminary model as a basis, the model was reduced by removing 
those variables that were significantly above the 0.10 threshold.  The 
coefficients and significance of the variables remaining in this ‘reduced’ model 
were compared with the coefficients and significance levels observed in the 
preliminary and bi-variate models to seek evidence of interaction effects.  
6. To examine the stability of the model, re-estimation of the ‘reduced’ model was 
performed by sequentially removing one variable at a time and observing the 
effect on the coefficient and significance level of the remaining variables to the 
original ‘reduced’ model.  If the variables remained stable in their effect size and 
significance, this was considered the base case model.  
7. This base-case model was subsequently tested through alternative model 
specifications (further described below).  
8. As a final step, the base-case model results were presented to representatives of 
the HTA body to which the analysis pertained to seek feedback on the variables 
identified within the base case model, the coefficient and level of significance to 
assess the validity of the model. 
 
By selecting only the subset of indicators with the strongest effect on the coverage 
decision, the systematic application of steps 1 to 8 facilitated the interpretation of the 
results of the models, whilst allowing for the testing of the potential impact of the wide 
range of indicators collected in the study.  
 
In the first instance, multivariate analyses were conducted separately for each HTA 
body, to maximise the use of available data, and to allow for each analysis to be 
conducted specifically to match as closely as possible the characteristics of their 
decision-making process in terms of the process adopted, as well as to accommodate 
differences in the outcome and independent variables considered.  For instance, HAS 
synthesizes its analysis of the clinical value of a technology by awarding a rating 
(ASMR rating) – this is a particular characteristic of the HAS system that is not 
observed in NICE, SMC or CVZ appraisal processes.  For each HTA body, the 
characteristics of the sample, the protocols for method extraction and the data sources 
are described in the chapters that follow (4-7).   In addition to modelling coverage 
decision-making for each agency separately, a pooled analysis of all coverage decisions 
across HTA bodies was identified as an important additional analysis of direct relevance 
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to the research question.  The analysis was performed using the STATA data analysis 
software (Intercooled (IC) Stata version 10.1). 
 
Alternative model specifications - sensitivity analyses  
To examine the robustness of the base case model, alternative model specifications were 
tested in sensitivity analyses (Figure 3.2).  The general aim of these sensitivity analyses 
was to assess to what degree the base case model results changed if model specifications 
for particular assumptions were altered.  A sensitivity analysis was conducted 
examining the impact of a binary rather than a three-category outcome variable.  As 
indicated above, the rationale for this analysis was linked to the fact that previous 
analyses published in the literature on NICE and SMC decision making used a binary 
approach in the regression analyses (Devlin and Parkin 2004; Clement et al. 2009).   
This was done by considering a ‘covered’ and ‘not covered’ approach:  the 
recommended and restricted categories were grouped together, and the not 
recommended category was kept as in the base case analysis.  Logistic regression was 
performed examining the log likelihood and the odds of coverage versus no coverage. 
Related to this, a specific sensitivity analysis was performed for the HAS sample, 
testing the impact of an alternative classification of HAS coverage decisions using 
different ASMR categories.    
 
To test the impact of imputation on the model results, a sensitivity analysis was 
conducted restricting the base case analysis to complete observations only (thus 
excluding observations with imputed values).  This sensitivity analysis was 
implemented with the knowledge that removing those observations with missing data 
could lead to selection bias in the analysis due to the fact that appraisals with 
incomplete observations may be different than appraisals with complete observations.  
However, what this sensitivity analysis wished to assess was the implications of making 
a trade-off between including in the analysis only those observations with data, 
therefore avoiding imputation but potentially increasing bias in the analysis, or 
maximising sample size and validity of the model output by utilising imputation 
techniques.   
 
To examine the impact of assuming a non-ordinal outcome variable, a sensitivity 
analysis was conducted assuming the outcome variable was ordinal.  The proportional 
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odds model, and when the assumption of proportional odds was violated, the 
generalized ordered logistic model were used.  Further description of the methods 
considered for this sensitivity analysis are summarised in Appendix G.  
 
In the base case analysis, all technologies were included in the analysis, and the disease 
areas to which they were related (defined by BNF criteria) was used to adjust for 
differences in technologies assessed between HTA bodies.  In addition, the analysis was 
repeated using a sub-set of technologies reviewed by all four agencies, albeit at the cost 
of reducing the sample size, to standardise the baseline sample used in the multivariate 
analysis.  Furthermore, the analysis was performed in which the sample was restricted 
to cancer therapies, as an alternative means of standardising the type of technologies 
assessed by each HTA body.   
 
 
3.4  Discussion  
The methods proposed for this thesis involved the creation of a specific dataset 
containing detailed information on the characteristics of coverage decisions by four 
European HTA bodies, and the quantitative analysis of this dataset using multivariate 
techniques.   The methods were selected in the belief that they would provide 
informative and helpful analyses and observations to address the research question.  At 
the same time, it is recognised that such an approach faces a number of important 
limitations which need to be identified and if possible, addressed. 
 
The selection of HTA agencies included in the analysis was in part limited by data 
availability.  In particular, only those HTA agencies that published their decision-
making process and reports in the public domain were considered for analysis.  
Therefore, generalisation of results, even within the respective agencies, must be 
attempted cautiously.  HTA agencies are continuously evolving and factors that may 
have driven their decision-making during 2004-2009 may not be the same or remain 
constant over time.  Within the United Kingdom, the new Conservative-Liberal 
Democrat government elected in May 2010 has indicated that they will change NICE's 
role such that its reimbursement recommendations will only have advisory status.  
While this change in NICE’s role may or may not impact on the factors driving its 
decision-making, these changes would appear to impact most significantly on the 
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implementation of NICE guidance by the health services in England and Wales (further 
discussed in Chapter 4 and 9, section 9.5.2).   
 
While every effort was made to create a dataset and analysis that was comprehensive in 
its inclusion of explanatory variables, invariably it was not feasible to capture all 
variables presumed to have a potential impact on coverage decisions.  Although the 
analysis captured information on the ICER and the uncertainty around it, these 
indicators do not provide information on the nature of the economic model, the design, 
comparators and subtleties of the analysis submitted to the HTA body.  Moreover, the 
use of surrogate outcomes was not captured as a specific variable in the dataset - there is 
increasing interest in understanding better the use of surrogate endpoints in decision-
making. As the literature does suggest that most clinical trials utilise surrogate 
endpoints, it was considered not practical to include this as a variable due to potential 
lack of variability between technologies, and other variables linked to the clinical 
characteristics of the technology were prioritised instead (e.g. use of active comparator 
in trial, demonstration of superiority in clinical trial etc).   
 
The speed of the appraisal process was also not factored in the analysis.  The fact that 
the SMC takes 3 months and NICE takes 12 months to complete an appraisal could 
have an impact on the nature of the evidence considered and the impact of the process 
on outcomes.  The analysis is also limited in that it cannot systematically examine time-
to-coverage decisions as a specific outcome of analysis.  Finally, the data base excludes 
those appraisals for which no documentation was available.  This includes situations 
where manufacturers did not make a submission, and therefore no appraisal was 
conducted.  This could be considered as a source of bias in the sample in that it may not 
consider the characteristics of those technologies that were not appraised.  The 
proportion of such cases excluded due to non-submission were recorded and reported.   
 
Socio-economic indicators, and particularly GDP, are correlated with many different 
factors.  Indeed, such indicators act as a surrogate for many characteristics of the 
country it applies to.  In addition, such indicators that vary at the HTA body level, rather 
than the technology appraisal level, are unlikely to have a very strong effect, due to the 
limited number of HTA bodies in this analysis.  Therefore, the interpretation of the 
impact of such broad indicators, such as the percentage of GDP spent on healthcare, will 
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need to take into consideration the risk that variations observed in such indicators across 
HTA bodies may be correlated with other factors.   
 
Finally, it is important to consider the research findings within the context of the 
respective origins and objectives of NICE, SMC, CVZ and HAS.  The evolution of the 
HTA bodies, their origins and their role within pharmaceutical regulation and coverage 
decisions vary.  In particular, their role within their respective healthcare systems is 
very much driven by the context and characteristics of the healthcare system, and each 
HTA agency has peculiarities about their role that are linked directly to that system.  
HTA bodies, both within and outside of Europe, vary in their objectives, and in the 
approach and methods used to implement HTA within their jurisdictions (Neumann et 
al. 2010).  The scope of this thesis was limited to national level HTA bodies.  In 
addition, the analysis of factors influencing coverage decisions were performed on 
decisions made within HTA processes.  However, within a healthcare system, where 
funding/reimbursement decisions are confirmed at a national level, regional and local 
payers may re-assess whether funding/reimbursement should be provided.   Due to time 
constraints, the nature of factors influencing regional/local funding/reimbursement 
decisions was not assessed. 
 
Before embarking on a pooled analysis of coverage decisions across HTA bodies, the 
pros and cons of such an analysis were assessed.  Several considerations favoured a 
pooled analysis: firstly, it could provide data to help explain variation in coverage 
decisions across HTA bodies, which is of direct relevance to the research question.  
Secondly, the pooling together of appraisals from four HTA agencies could 
significantly increase the sample size, creating one of the largest single sets of data on 
HTA coverage decisions and accompanying appraisal characteristics.  Pooling across 
HTA bodies was felt to be feasible due to the fact that the data set was created 
specifically for this research question, and all data were extracted by the same 
researcher with a specific data extraction protocol.    Challenges identified in 
performing a pooled analysis across HTA bodies were: i) HTA bodies do not formulate 
coverage decisions in the same way; ii) heterogeneity in the nature of technologies 
assessed by the different HTA bodies used in the analysis; and iii) heterogeneity in the 
information available for extraction.   The need to address as much as possible these 
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limitations was a key driver in how the sample was pooled, the analyses performed, and 
in the choice of sensitivity analyses that were run.    
 
In summary, the methods used to address the research question focused on three 
elements:  i) increasing the scope of analysis to multiple EU HTA bodies; ii) enhancing 
the comprehensiveness of the factors assessed; and iii) using analysis methods that 
capture better variations in coverage decisions within and between HTA bodies.    
Multivariate analyses were conducted separately for each HTA body are presented in 
Chapters 4-7.  A pooled analysis of coverage decisions across HTA bodies is presented 
in Chapter 8.      
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4 Empirical analysis of NICE coverage decisions 
 
 
Adalimumab was reviewed by NICE, SMC, CVZ and HAS for the treatment of 
ankylosing spondylitis1.  NICE provided the following guidance:  
 
1.1 Adalimumab or etanercept are recommended as treatment 
options for adults with severe active ankylosing spondylitis only 
if all of the following criteria are fulfilled. 
 
The patient’s disease satisfies the modified New York criteria for 
diagnosis of ankylosing spondylitis. 
 
There is confirmation of sustained active spinal disease (...) 
 
Conventional treatment with two or more non-steroidal anti-
inflammatory pharmaceuticals taken sequentially at maximum 
tolerated or recommended dosage for 4 weeks has failed to 
control symptoms. (...) 
 
1.3 It is recommended that the response to adalimumab or 
etanercept treatment should be assessed 12 weeks after treatment 
is initiated, and that treatment should be only continued in the 
presence of an adequate response as defined in section 1.4.”  
(NICE 2008a section 1.1.-1.3) 
 
This extract summarises NICE’s guidance on adalimumab in which its use is restricted 
to the sub-set of the eligible population that have failed to respond to at least two 
conventional therapies.  The restriction on patient population is also accompanied by a  
so called ‘stopping rule’,  in which clinical assessment should be made every 12 weeks 
to decide whether to continue with treatment or stop, based on the level of response to 
adalimumab.  It also shows that adalimumab was appraised side by side as part of a 
multi technology appraisal with etanercept.  This extract raises a key question for this 
research:  what are the factors that drive NICE coverage decisions?   
 
This chapter provides empirical analyses of coverage decisions made by NICE during 
2004-2009.  First, an overview of the objectives of NICE and its appraisal process is 
provided.  The methods for the analysis are outlined, building upon the methodological 
framework discussed in Chapter 3.  The results of descriptive and multivariate analyses 
                                                 
1 Adalimumab (Humira©) is an anti-inflammatory medicine and is indicated, among other diseases, for 
the treatment of  adults with severe active ankylosing spondylitis (a disease causing inflammation and 
pain in the joints of the spine) who have not responded adequately to other treatments (European 
Medicines Agency, 2009, EPAR Adalimumab) 
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on NICE coverage decisions are then reported and explored, and limitations considered.  
The chapter concludes with a brief discussion about the empirical analyses performed 
for NICE. 
 
4.1 NICE appraisal process 
Established in 1999, NICE is responsible for providing guidance to the NHS in England 
and Wales on the funding of new technologies and their use (Chalkidou 2009).  One of 
the key rationales for setting up NICE was to help tackle the geographic inequality in 
access to technology or the phenomenon more frequently referred to as ‘postcode 
prescribing’ (Summerhayes and Catchpole 2006).  Since 2002 NICE's recommendations 
have been mandatory and NHS organizations have had to comply, usually within three 
months2.  NICE “is an independent organisation responsible for providing national 
guidance on promoting good health and preventing and treating ill health” (NICE 2011 
p.1).  The NICE work programme includes not only health technology assessments of 
new technologies, but also of existing technologies. Its scope of work covers non-
pharmaceutical technologies (e.g. medical devices) and the issuing of clinical guidelines 
(in addition to guidance) that provide information on how to best utilise the technology 
(Summerhayes and Catchpole 2006).  NICE is a large organisation and combined with 
the network of academic assessment groups, there are over 2000 individuals 
contributing to NICE’s guidance generation at any one time (Littlejohns et al. 2009).   
   
Within NICE, the Centre for Health Technology Evaluation focuses on issuing guidance 
on the appropriate use and funding of technologies.  Overall, there is a central concern 
for evidence-based and transparent decision-making.  The NICE HTA process is 
characterised by involving a panel of clinical, academic, and industry stakeholders and 
the general public.  The NICE appraisal process is governed by the use of established 
standard methodology for the evaluation of clinical and economic characteristics of the 
technology under appraisal (Littlejohns et al. 2009).  The composition of the NICE 
Appraisal Committee includes members with health economic, statistical, clinical and 
academic expertise (Cairns 2006).  In addition to the appraisal committee members, 
there are additional stakeholders that are involved in the appraisal processes, including 
clinical experts, patient groups, and physician/carer groups.  For example, the NICE 
Citizens Council is a committee made up of 30 members from the general public, 
                                                 
2 However, the new Conservative-Liberal Democrat government elected in May 2010 have indicated that 
they will change NICE's role and its coverage recommendations may only have advisory status. 
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aiming to provide insights into NICE decision-making through its broader public and 
socio-economic perspective.  The technologies for appraisal by NICE - which form their 
work programme - are selected by the Department of Health (DH) in England and the 
Welsh Assembly government, although NICE is involved in specific stages of the 
selection and uses a series of criteria to shortlist those technologies for consideration by 
the DH and Welsh government (Sorenson 2008).  These criteria include considerations 
such as the burden of disease, if the disease is a government priority, and whether there 
is evidence of considerable inequality in access across the UK (NICE 2008b, Sorenson 
2008).   
 
The NICE HTA process starts with a scoping exercise in which the context of the 
appraisal is clarified amongst the stakeholders and confirmed.  This includes agreement 
on the technologies included in the appraisal, the comparators, the indication, and the 
type of clinical and economic outcomes that will be examined.  Once the scoping 
document is confirmed, the formal appraisal process commences, and manufacturers are 
asked to make their submissions.  Once the submissions are made, if the process 
followed is a Multiple Technology Appraisal (MTA), the Assessment group is involved 
in the reviewing of the manufacturer submission(s) and the creation of their own 
independent report.  This information is passed on to the Appraisal Committee.  If the 
process followed is a Single Technology Appraisal (STA), manufacturer submissions 
are the main source of evidence considered by the Appraisal Committee.  A meeting is 
held to produce the Appraisal Consultation Document (ACD) which represents the draft 
NICE guidance.  The ACD is provided to the public for consultation and comments by 
stakeholders, including patient groups, clinicians, and manufacturers.  Following the 
receipt of comments on the ACD and the processing of these comments, a second 
Appraisal Committee meeting is held to create the Final Appraisal Determination 
(FAD), which represents the final guidance issued.  There is also the possibility for 
stakeholders to appeal the FAD.   
 
There are a range of clinical criteria evaluated during a NICE appraisal, but the main 
focus is on evaluating the effectiveness of the technology based on the best quality 
evidence.  Information on the pivotal RCTs is considered of primary importance in the 
appraisal, and significant care is made to assess the uncertainty and generalisability of 
this clinical evidence.  Where necessary, a formal indirect comparison using Baysian 
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Box 4.1 In light of the discussion in Chapter 2, the NICE-specific 
research hypotheses this analysis wishes to test are: 
• Whether non recommendations and restrictions are 
increasing over time relative to recommendations.  
• Whether the ICER remains a highly significant explanatory 
variable of NICE decision-making; specifically whether an 
increase in the ICER decreases the odds of 
recommendation.  
• Whether technologies for cancer therapies will increase the 
odds of recommendation relative to non-recommendation. 
• Whether the use of an MTA process will increase the odds 
of restriction relative to recommendation, compared with 
the STA process.   
• To compare the results of NICE model with previously 
published models of NICE decision-making (Devlin and 
Parkin 2004; Dakin et al. 2006) with regards to the factors 
identified as having a significant impact on NICE decisions  
 
techniques is implemented to be able to facilitate as robust as possible a comparison 
between the relevant comparators.    
 
The submission of cost-utility evidence is an integral part of the NICE process, 
irrespective of whether an MTA or STA process is followed. This includes providing 
information on the cost-utility model structure, rationale, key assumptions, data inputs, 
main results, and sensitivity analyses surrounding the results.  Detailed instructions 
regarding the methodology adopted for cost-utility modelling forms the basis for 
manufacturer submissions.  Budget impact criteria are also considered – specifically to 
assess the incremental pharmaceutical budget implications associated with the 
implementation of NICE guidance.   
 
In addition to economic and clinical criteria, the patients’ perspective and patient 
evidence, as well as the perspective of carers and other members of the NHS are taken 
into consideration via the consultation and stakeholder submission process.  Equity 
concerns are also a key factor in NICE decision making – particularly the reduction in 
health inequalities, and the concept of ‘fairness’ (NICE 2008c).  To take social values 
into account, NICE operates through a framework that encapsulates the circumstances 
and the process through which social values should be incorporated in decision-making 
(Littlejohns et al. 2009).  These eight principles include taking into account the “need to 
distribute health resources in the fairest way within society as a whole” (Littlejohns et 
al. 2009 p. 421).     
 
4.2 Methods 
The overall objective 
was to examine the 
impact of evidence, 
process and context 
factors on decisions 
made by NICE to 
recommend, restrict or 
not recommend new 
technologies for use in 
England and Wales.  In 
addition to the general 
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analysis aims described in Chapter 1, the set of particular hypotheses relevant for the 
modeling of coverage decisions taken by NICE are highlighted in Box 4.1.  Building on 
from the methods described in Chapter 3, this section describes the methods used to 
select the sample for analysis, the outcome variable and explanatory variables 
considered, and the statistical techniques adopted. 
 
4.2.1 Sample  
The pharmaceutical technology appraisals performed by NICE formed the basis for the 
sample included in this analysis.  The composition of the sample was determined 
through the following inclusion and exclusion criteria. The sample included all 
pharmaceutical technology appraisals (as opposed to medical devices or other 
interventions) conducted in the period 2004-2009 indicated for an adult population (≥18 
years).  To capture a sufficient number of appraisals for both individual and aggregate 
analyses, a five-year time horizon was implemented.  Technology appraisals were 
excluded from the analysis for any of the following reasons:  i) they focused on a non-
adult population (aged <18 years); ii) the appraised technologies were non-
pharmaceutical interventions; iii) marketing authorisation was withdrawn, or iv) the full 
guidance was not available. 
 
4.2.2 Outcome variable 
To address the research question, HTA decisions were analysed by considering HTA 
outcomes in three categories, where the new technology can be:   
• recommended for routine use 
• recommended for restricted use 
or 
• not recommended 
 
NICE guidance (summarised in section 1 of each guidance) indicates whether an 
intervention should be recommended or not for use in the NHS.  A medication was 
considered as not recommended for use by NICE guidance if the words ‘not 
recommended’ were stated in section 1 of the guidance.   With regards to distinguishing 
between recommended and restricted interventions, decision rules were developed to 
help classify which of the recommendations issued from NICE guidance were for 
routine use, and those that were for restricted use.  Specifically, the Raftery (2006) 
classification was utilised to distinguish between restriction and recommendation.  
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Where a recommendation was made for a technology to be used in a population 
identical to its licensed indication, it was considered to be ‘recommended’.  Where a 
recommendation contained one of the following provisos in relation to the technology it 
was considered to be ‘restricted’: i) it should be used in a sub-population of its licensed 
indication; ii) it should be used in a second line or higher line of therapy; iii) it required 
monitoring; iv) it should be employed at the lowest acquisition cost; or v) it required 
prescription by a specialist (Raftery 2006).  
 
4.2.3 Explanatory variables 
In line with the hypothesised drivers of HTA decision-making highlighted in Chapter 3, 
the NICE dataset includes 34 variables including variables relating to (i) the clinical and 
economic characteristics of the technology under appraisal, as well as (ii) the processes 
used to come to a coverage decision, and (iii) the socio-economic context in which these 
decisions were made.  
 
In addition to the common set of variables, there are certain particularities related to the 
appraisal process utilised by NICE.  For instance, the budget impact estimates provided 
in NICE appraisals reflect the budgetary impact of the implementation of NICE 
guidance.  In other words, the budget impact estimates that are reported do not always 
provide information on the maximum potential budget impact if the full population 
meeting the license criteria is eligible for treatment.  To make sure that the full potential 
budget impact was extracted for analysis, the budget impact estimated in the Technical 
Appraisal Report (TAR) was used, rather than the budget impact estimated in the NICE 
guidance.  If it was not reported in the TAR, the manufacturer’s submission (where 
available) was used to estimate maximum potential budget impact.  If that was not 
available, then the NICE costing template was modified to estimate what the maximum 
budget impact would be.  Other ‘NICE-specific’ variables that were collected through 
the data extraction process included whether the appraisal was a Multiple Technology 
Appraisal (MTA) or a Single Technology Appraisal (STA).    
 
4.2.4 Data extraction form 
The data extraction form contained the definitions and decision rules used when 
extracting the data from the guidance documents issued by NICE, as well as from 
minutes of meetings available to the public via the NICE website, and other data 
sources. The data extraction form was organized into three segments, relating to the 
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three components of analysis that are integral to this research.  The data was extracted 
following the protocols outlined in Chapter 3, section 3.1.3.  Table 4.1 provides the list 
of variables extracted to create the NICE dataset, as well as the accompanying decision 
rules, definitions and data sources. 
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Table 4.1  NICE dataset:  Included Variables, Definitions, Data Extraction Rules and Data Sources 
# Variable Descriptor Unit measure Definition Data Sources 
1 Number of RCTs considered 
in decision 
Count The number of distinct Randomised Controlled Trials (RCTs) that provide data 
related to the therapeutic indication under evaluation. 
 
Excluded:  studies that are single arm, that have no randomization, or that are non-
interventional.  
Technical Appraisal 
Report (TAR) 
2 Size of population included in 
RCTs 
Numeric Mean number of patients per RCT.   TAR section 2 
3 Length/extent of follow-up in 
RCT 
Numeric Mean number of weeks that data is collected on patients that entered the RCTs (see 
variable no. 1).  
TAR section 2 
4 Statistically Significant results Categorical 
(yes/no/inconsiste
nt) 
Presence of statistically significant superiority of technology vs. comparator for 
primary endpoint(s). 
 
If more than one RCT was considered, and the technology showed statistically 
significant superiority in one trial, but not in another, the results were considered to 
be ‘inconsistent’ and classified as such.  RCTs designed as ‘non-inferiority’ studies 
were classified as not showing any statistically significant superiority (i.e. ‘no’).    
TAR section 4 
5 Use of active comparator in 
RCTs 
Numeric Percentage of RCTs where an active comparator was used.   TAR section 4 
6 Number of observational 
studies considered in the 
guidance 
Count Number of observational studies providing information to support the study 
pharmaceutical.  Observational studies in this circumstance are defined as studies 
that are non interventional (i.e. do not explicitly request the patient to take 
particular medication or the physician to follow a particular protocol).   
TAR section 4 
7 Priority disease area Categorical – 
yes/no 
This variable aims to capture the health policy context in which the coverage 
decision is made, by capturing whether the pharmaceutical in question is linked to a 
disease area that is prioritized by the Department of Health.   Priority disease areas 
were identified by examining government plans/health documents that highlight 
national health care system focus. 
Department of Health 
(DH) (2002),   DH 
(2006a), DH (2006b) 
DH (2007) 
8 Orphan Status Categorical – 
yes/no 
This variable captured information on whether  or not the technology was 
recognized by the European Medicines Agency (EMA) as an orphan designated 
medicine.   
European Medicines 
Agency (accessed 2010).   
9 Disease area category Categorical – 13 
categories 
The British National Formulary (BNF) categories were used to classify each 
technology into the corresponding therapeutic area.   
British National Formulary 
(2010) 
10 Prevalence of disease/clinical Numeric Reported number of patients eligible for treatment, defined by patient population TAR section 2 and/or 5; 
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# Variable Descriptor Unit measure Definition Data Sources 
condition for which the technology is indicated.   European Medicines 
Agency 
11 Availability of alternative 
therapies in current treatment 
setting. 
Categorical – 
yes/no  
An alternative was considered to be available if comparators were clearly defined 
in the review by the HTA agency.  An alternative was considered NOT to be 
available if it was stated as such in the appraisal, or if ‘best supportive care’ or 
‘palliative care’ was specified as the comparator. 
TAR section 2 
12 Consideration of Cost Utility 
Analysis in guidance 
Categorical – 
yes/no 
Presence or absence of a cost-utility analysis.   TAR section 4 
13 Incremental Cost-utility ratio 
of technology vs. comparator 
in base case 
Numeric ICER (Cost per QALY) reported in the HTA dossier for base case as accepted by 
the Appraisal Committee.  This is defined as the ICER that is related to the 
recommendation.   
If more than one ICER is presented due to the recommendation covering more than 
one population, then the ICER pertaining to the larger of the populations was 
reported.   
In NICE appraisals, if no ICER was reported by the Appraisal Committee, then the 
ICER reported by the Assessment Group was used.  The ICER reported in the 
manufacturer submission was used if it was not stated in the guidance or the 
assessment group report.   
If the technology is reported as dominant or dominated, it was recorded  as such in 
the data extraction sheet.   
TAR section 4 
14 Multiple CUA/CEA models 
reported 
Categorical - 
yes/no 
Whether more than one cost-utility or cost-effectiveness model was considered 
during the appraisal 
TAR section 4 
15 Multiple economic models 
resulting in a range of ICERs 
reported’ 
Numeric If yes, report range of base case ICERs presented between the different models 
reported. The difference between the lowest and highest ICER will be calculated. 
 
16 Uncertainty around the base 
case ICER reported in 
submission (probabilistic) 
Numeric  This should be reported as the percentage probability of acceptance at the threshold 
used by the agency.  The probability of medication to be cost-effective at a 30,000 
GBP threshold was reported. 
TAR section 4/ 5 
17 Uncertainty around base case 
ICER reported in submission 
(univariate) 
Numeric This should be reported as the range of ICERs (min-max) resulting from univariate 
sensitivity on the base case.     
TAR section 4/ 5 
18 Non-cost per QALY cost-
effectiveness analyses 
submitted 
Categorical - 
yes/no 
Indicates if non-cost per QALY economic analyses were submitted and reviewed.   TAR section 4 
19 Anticipated budgetary impact Numeric Estimated annual incremental budgetary impact of introducing new medication into TAR section 5 
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# Variable Descriptor Unit measure Definition Data Sources 
of introduction of new 
technology in health care 
system 
the current treatment setting, if the pharmaceutical were to be introduced without 
any restriction.  Pharmaceutical cost only (per year). 
This is the potential budget impact were a recommendation for use in the total 
indicated population to be granted.    
20 Inclusion of patient 
submission 
Categorical – 
yes/no 
A patient submission was considered to have been included as part of the appraisal 
process if a submission from a patient group was posted on the webpage pertaining 
to the guidance.  
NICE (2011) section 
describing the history of 
the appraisal 
21 Number of Decision Makers 
Accountable 
Numeric Captures the number of decision-makers accountable for guidance issued, as 
reported.   
TAR Appendix B of each 
guidance 
22 Cost-effectiveness evaluation 
component in process 
Categorical – 
yes/no 
Captures whether cost-effectiveness is a component of the decision-making process 
or not. If cost-effectiveness analysis is a formal part of the appraisal process, this 
variable was marked as ‘yes’.  
TAR / NICE (2008b) 
23 Budget impact as a component 
of decision-making process 
Categorical – 
yes/no 
Captures whether budget impact considerations are part of decision-making process TAR / NICE (2008b)  
24 Pricing known during 
appraisal process 
Categorical – 
yes/no 
Captures whether the price of the technology under appraisal was known during the 
assessment.     
TAR section 3 
25 Multiple technologies or a 
Single technology is appraised 
Categorical – 
MTA/STA 
Data specifically extracted for NICE.  Records whether guidance was issued after 
the appraisal of an individual technology following the STA or MTA process.  As 
the STA process was introduced in 2006, those technologies appraised prior to this 
year were automatically considered as having been appraised via an MTA.  
TAR Cover Page 
26 Number of technologies 
appraised simultaneously 
Count This variable captures the number of technologies appraised simultaneously in the 
appraisal.   
TAR cover page / section 
3 
27 Accountability of 
pharmaceutical budget 
Categorical – 
yes/no 
The HTA agency was examined to assess whether the agency making the funding 
decisions is also accountable for the pharmaceutical budget or not.  
Sorenson (2008);  NICE 
(2011) 
28 Independence of decision-
making agency 
Categorical – 
yes/no 
This pertains to whether the HTA body is independent of the Department of Health 
or part of it. 
Sorenson (2008); Hutton 
(2006);  NICE (2011) 
 
29 Date guidance was issued Numeric Year when coverage decision was issued TAR cover page 
30 Population size – Agency 
coverage 
Numeric Estimate of population size within remit of the agency performing the evaluation. National Office of 
Statistics (2009)    
31 GDP-healthcare expenditure Numeric (%) Percentage of GDP spent on healthcare, during year of decision OECD (2009) 
32 Healthcare expenditure on 
pharmaceuticals per patient 
per year 
 
Numeric (£) Healthcare budget spent on pharmaceuticals per patient per year, during the same 
year in which the appraisal was published.  
Association of the British 
Pharmaceutical Industry 
(2010) 
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# Variable Descriptor Unit measure Definition Data Sources 
33 Pharmaceutical funding 
process within healthcare 
system – whether centralised 
or decentralised 
Categorical – 
centralized, 
decentralized 
States whether pharmaceutical funding process within the healthcare system  is 
centralized at a national level or whether funding decisions are decentralized to the 
regional level 
Sorenson (2008), Hutton 
(2006) 
34 Election year at time of 
decision 
Categorical – 
yes/no 
This variable captures whether the coverage decision was made within an election 
year.  An election year was defined as a year in which either national government 
or regional elections took place.     
BBC 2005 
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4.2.5 Statistics 
The methods for the descriptive statistics and multivariate analyses were described in 
Chapter 3.  Descriptive statistics were calculated for each extracted variable, stratified 
by outcome group (recommended, restricted or not recommended).  Following a 
descriptive analysis of the dataset, a multinomial logit regression was modelled.  The 
objective of this analysis was to obtain a parsimonious model that best reflected the 
main drivers of NICE decision-making.    
 
4.3 Results 
4.3.1 Sample characteristics  
Table 4.2  Coverage decisions issued by NICE, 2004-2009 
NICE guidance  Number of coverage decisions Percentage  
Recommended 32 27% 
Restricted 69 58% 
Not recommended 17 14% 
Total 118 100% 
 
A total of 99 technology appraisals issued between January 2004 and June 2009 were 
retrieved from the NICE website.  Of these, 65 were included in the analysis and are 
listed in Appendix A. Thirty-four (34) technology appraisals were excluded from the 
analysis for the following reasons:  i) they focused on a non-adult population (n=5); 
they appraised non-pharmaceutical interventions (n=23); iii) marketing authorisation 
was withdrawn (n=2); or iv) full guidance was not available (n=4).  The 65 technology 
appraisals that were included in the analysis covered a total of 118 technologies.  Table 
4.2 shows NICE guidance issued between 2004- June 2009, and the proportion of 
recommendations, restrictions and non recommendations made.  The majority of NICE 
coverage decisions restricted funding for the appraised technology (58% of technologies 
were restricted), while the least common coverage decision was a non recommendation 
(14% of technologies were not recommended by NICE for NHS funding).   
 
In the NICE sample, incomplete observations were found to occur more frequently in 
those variables related to the economic characteristics of the technology.  The 
distribution of incomplete observations was concentrated in a small selection of 
variables linked to the economic profile of the technology.  Based on this, dummy 
variables were inserted into the model to analyse the impact of incomplete data.  A more 
detailed description of missing data within the NICE sample is provided in Appendix A.  
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4.3.2 Descriptive statistics 
Clinical Evidence 
Descriptive statistics for the NICE sample are summarized in Table 4.3.  Six variables 
related to the clinical evidence supporting the technology under evaluation by NICE 
were evaluated by decision outcome.  The first three variables described the nature of 
the randomised clinical trial data available in terms of the number of trials, sample size 
and trial duration.   Interventions recommended for use or for restricted use had a 
similar number of randomised controlled trials (RCTs) reported as part of the appraisal 
process (mean of 7 and 8 trials, respectively).  Interventions not recommended for use 
had a lower number of RCTs considered in the appraisal process (mean 3 trials).  The 
differences observed between means were statistically significant.  The mean size of the 
patient sample included in RCTs was higher for those interventions recommended by 
NICE (mean = 1765 patients), compared to those interventions restricted or not 
recommended by NICE (1044 and 1154 patients, respectively, p<0.05).  The mean trial 
duration across the three outcome groups was 96, 66 and 82 weeks respectively for 
recommended, restricted and not recommended interventions.  The difference in mean 
duration between the recommended and restricted interventions was statistically 
significant. 
 
Aside from the size, number and duration of RCTs, the results of the RCTs were also 
captured.  In particular, information was collected on whether the RCTs demonstrated 
the technology to be statistically significantly superior in its primary endpoint relative to 
the comparator.    59% of recommended interventions demonstrated statistically 
significant superiority, as opposed to approximately 29% of restricted and 35% of not 
recommended interventions (p<0.05).  The comparator used within the clinical trial 
programme was assessed – in particular, the percentage of comparisons made to ‘active’ 
comparators as opposed to placebo was recorded.  The interventions recommended were 
more likely to compare to active comparators (63%) than interventions that were 
restricted or not recommended (40%, 44% of RCTs with active comparators, 
respectively. p=0.05).   
 
Consideration of non-randomised observational data was also recorded.   Overall, very 
little observational data was referred to in NICE appraisals (the mean across appraisals 
was 0.6 observational studies).   
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Disease characteristics 
The prevalence of the clinical condition related to the technology under appraisal 
averaged at 2.2 million patients across all decisions.  This ranged from 0.392 million for 
recommended interventions to 3.194 and 2.270 million in the restricted and not 
recommended interventions.  The differences between outcome groups were statistically 
significant. The availability of alternative therapies was assessed to ascertain if it 
differed between recommended and restricted or not recommended interventions.  In the 
majority of technologies appraised, an alternative was available (in 89% of cases, all 
decisions considered) (p=NS).  It was hypothesised that there may be diseases for which 
technologies were more likely to be recommended rather than restricted, such as cancer 
therapies.  In this particular sample, across the majority of disease areas there were no 
statistically significant differences between outcome groups.   Technologies for the 
management of central nervous system disorders represent the exception to this rule:  
22% of restricted technologies were indicated for central nervous system disorders as 
opposed to 6% of the recommended and not recommended technologies (p<0.10).     
  
 
110 
Table 4.3  NICE Coverage Decisions 2004-2009:  Descriptive statistics for extracted variables, by coverage decision (recommended, restricted, not recommended) 
  NICE Total (n=118) Recommended  (n=32) Restricted  (n=69) Not Recommended  (n=17) P value 
Test  
   mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI     
Number of RCTs 
considered in 
decision 
6.7 5.2 8.3 6.8 2.1 11.4 7.6 5.9 9.2 3.4 2.1 4.8 <0.05 3 
Size of 
population 
included in 
RCTs 
1249 807 1691 1765 804 2727 1044 442 1645 1154 464 1844 <0.05 3 
Length/extent of 
follow-up in 
RCT 
76.2 63.5 88.9 95.9 65.9 125.8 65.8 51.5 80.2 81.9 41.5 122.3 NS 1 
Statistically 
Significant 
results -                  
yes 
38% 29% 47% 59% 41% 77% 29% 18% 40% 35% 10% 61% <0.05 2 
no 15% 9% 22% 6% -3% 15% 17% 8% 27% 24% 1% 46% NS 2 
inconsistent 43% 34% 52% 31% 14% 48% 51% 39% 63% 35% 10% 61% NS 2 
Relevance of 
RCT to payor 
decision 
47% 39% 55% 63% 46% 80% 40% 30% 50% 44% 18% 69% <0.10 3 
Number of 
observational 
studies 
considered in 
guidance 
0.6 0.1 1.1 1.5 -0.4 3.4 0.3 0.1 0.5 0.0 0.0 0.0 NS 1 
Consideration of 
Cost Utility 
Analysis in 
guidance 
95% 91% 99% 100% 100% 100% 94% 89% 100% 88% 71% 105% NS 2 
Incremental 
Cost-
effectiveness 
£31,910 £20,945 £42,874 £17,782 £11,066 £24,498 £24,867 £21,002 £28,731 £99,239 £11,882 £186,597 <0.01 3 
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  NICE Total (n=118) Recommended  (n=32) Restricted  (n=69) Not Recommended  (n=17) P value 
Test  
   mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI     
ratio of 
technology vs. 
comparator in 
base case 
 
 
More than one 
CUA submitted 65% 56% 74% 69% 52% 86% 63% 51% 75% 67% 40% 94% NS 2 
If more than one 
CUA submitted - 
low range 
£13,318 £10,511 £16,125 £8,607 £4,551 £12,664 £13,417 £10,119 £16,714 £21,441 £9,663 £33,220 <0.01 3 
If more than one 
CUA submitted - 
high range 
£107,421 £66,886 £147,956 £83,666 -£12,619 £179,951 £129,690 £85,202 £174,179 £83,242 £33,511 £132,974 <0.01 3 
Uncertainty 
around base case 
ICER reported in 
submission 
(univariate)  
Low 
£25,417 £6,412 £44,422 £7,881 £5,234 £10,527 £19,747 £4,460 £35,035 £92,379 -£58,911 £243,668 <0.01 1 
Uncertainty 
around base case 
ICER reported in 
submission 
(univariate) High 
£167,389 £56,865 £277,913 £113,286 £1,293 £225,279 £57,146 £29,962 £84,329 £731,151 -£83,313 £1,545,615 <0.05 3 
Uncertainty 
around the base 
case ICER 
reported in 
submission 
(probabilistic) 
43% 34% 52% 61% 45% 77% 41% 29% 53% 8% -1% 17% <0.01 3 
Non-CUA 
analyses 22% 14% 30% 22% 7% 37% 28% 17% 38% 0% 0% 0% <0.10 2 
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  NICE Total (n=118) Recommended  (n=32) Restricted  (n=69) Not Recommended  (n=17) P value 
Test  
   mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI     
submitted 
Anticipated 
budgetary impact 
of introduction 
of new 
technology in 
health care 
system 
 
 
£708 £182 £1,235 £36 £18 £54 £828 £51 £1,606 £1,632 -£610 £3,874 <0.10 3 
Prevalence of 
disease/clinical 
condition 
     
2,288,409  
     
1,189,422  
     
3,387,396 
    
392,063  
      
82,017  
    
702,109  
     
3,194,243  
     
1,419,388 
     
4,969,097 
     
2,270,955 
-   
290,109 
     
4,832,019  <0.01 3 
Societal 
Perspective 
adopted 
3% 0% 5% 3% -3% 9% 3% -1% 7% 0% 0% 0% NS 2 
Availability of 
alternative 
therapies in 
current treatment 
setting. 
89% 83% 95% 88% 75% 100% 90% 83% 97% 88% 71% 105% NS 2 
Inclusion of 
patient 
submission 
87% 81% 93% 91% 80% 101% 84% 75% 93% 94% 82% 107% NS 2 
Number of 
Decision Makers 
Accountable 
30 28 32 28 25 31 31 29 34 28 23 33 NS 1 
Cost-
effectiveness 
evaluation 
component in 
process 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% n/a n/a 
Budget impact as 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% n/a n/a 
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  NICE Total (n=118) Recommended  (n=32) Restricted  (n=69) Not Recommended  (n=17) P value 
Test  
   mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI     
a component of 
decision-making 
process 
Price of 
technology 
known during 
appraisal 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a n/a 
Use of STA 
process 25% 17% 32% 34% 17% 52% 16% 7% 25% 41% 15% 67% <0.05 2 
Number of drugs 
appraised in 
same appraisal 
2.8 2.5 3.2 2.0 1.5 2.5 3.4 2.9 3.9 2.1 1.5 2.7 <0.01 3 
Accountability 
of drug budget 
 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a n/a 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% n/a n/a 
Date guidance 
was issued 2007 2006 2007 2006 2006 2007 2007 2006 2007 2007 2007 2008 <0.05 1 
Population size – 
Agency coverage 
            
53.90  
            
53.80  
            
54.00  
        
53.80  
        
53.70  
        
54.00  
            
53.90  
            
53.80  
            
54.10  
            
54.20  
         
54.00  
            
54.40  <0.05 1 
GDP-healthcare 
expenditure 8% 8% 8% 8% 8% 8% 8% 8% 8% 8% 8% 8% <0.05 3 
Healthcare 
expenditure on 
pharmaceuticals 
£175 £173 £176 £173 £171 £175 £174 £173 £176 £178 £175 £180 <0.05 1 
Election year at 
time of decision 7% 2% 11% 6% -3% 15% 7% 1% 14% 6% -7% 18% NS 2 
Priority disease 
area 56% 47% 65% 59% 41% 77% 57% 45% 69% 47% 21% 74% NS 2 
Orphan 
Designated 3% 0% 5% 3% -3% 9% 3% -1% 7% 0% 0% 0% NS 2 
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  NICE Total (n=118) Recommended  (n=32) Restricted  (n=69) Not Recommended  (n=17) P value 
Test  
   mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI     
Cardiovascular 
system 10% 5% 16% 13% 0% 25% 12% 4% 19% 0% 0% 0% NS 2 
Central nervous 
system 15% 9% 22% 6% -3% 15% 22% 12% 32% 6% -7% 18% <0.10 2 
Ear, nose and 
oropharynx 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% NS 2 
Endocrine 
system 1% -1% 3% 0% 0% 0% 1% -1% 4% 0% 0% 0% NS 2 
eye 2% -1% 4% 3% -3% 9% 0% 0% 0% 6% -7% 18% NS 2 
Gastro-intestinal 
system 2% -1% 4% 0% 0% 0% 1% -1% 4% 6% -7% 18% NS 2 
infections 12% 6% 18% 19% 4% 33% 7% 1% 14% 18% -3% 38% NS 2 
Malignant 
disease and 
immunosuppress
ion 
 
31% 22% 39% 41% 23% 59% 23% 13% 33% 41% 15% 67% NS 2 
Musculoskeletal 
and joint 
diseases 
19% 12% 27% 16% 2% 29% 22% 12% 32% 18% -3% 38% NS 2 
Nutrition and 
blood 3% 0% 5% 0% 0% 0% 4% -1% 9% 0% 0% 0% NS 2 
Obstetrics, 
gynaecology, 
and urinary-tract 
disorders 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% NS 2 
Respiratory 
system 1% -1% 3% 0% 0% 0% 1% -1% 4% 0% 0% 0% NS 2 
Skin 5% 1% 9% 3% -3% 9% 6% 0% 11% 6% -7% 18% NS 2 
Notes:   Test 1. Both ANOVA and Kruskal-Wallis test indicate similar level of statistical significance.   
Test 2. Chi-squared test used, as categorical variable.   
Test 3 Either ANOVA or Kruskal-Wallis test indicate statistical significance.   
NS = not significant.  /  N/A = not applicable   
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Economic Evidence      
In addition to the clinical variables, a range of economic-related variables were included 
for analysis.  The majority of NICE decisions were backed by use of the cost utility 
analyses (CUA) (95%).  In 65% of decisions, multiple economic models were 
considered in the appraisal process and the use of multiple models was consistent across 
outcome categories.  For the interventions supported by a CUA, the incremental cost-
effectiveness ratio (ICER) was significantly different (p<0.001) between the 
recommended interventions (mean ICER of £17,782), compared to the restricted 
interventions (mean ICER of £24,498), and the interventions not recommended for use 
(mean ICER of £99,239).  The pattern of base-case ICERs issued by NICE along with 
the corresponding coverage decision is presented in Figure 4.1.   In general, 
technologies that were recommended or restricted (green and orange bars) were found 
in the lower ICER ranges, while not recommended technologies (red bars) were located 
in the upper ICER range.  However, the figure also shows that, while the ICER is an 
important variable in NICE decision-making, there are exceptions to its usefulness as a 
predictor of coverage decisions.  There are recommended technologies with very high 
ICERs, as there are technologies with lower ICERs that are not recommended.  This 
suggests the need to examine the role of a combination of factors to explain NICE 
decision-making.  For the interventions supported by multiple economic models, the 
range of ICERs reported by these models was recorded, namely the lowest and highest 
base-case ICERs reported across the models considered by the appraisal committee.  
The base-case ICERs across different models varied significantly between 
recommended, restricted and non-recommended interventions.   
 
Considerable effort was made to capture information on the uncertainty around base-
case ICER estimates.  This was done by recording the results of probabilistic sensitivity 
analyses (the probability of ICER remaining below a set threshold), and by recording 
univariate sensitivity analyses (lowest ICER, highest ICER).    The probability of the 
ICER remaining below £30,000 was 61% for recommended interventions, 41% for 
restricted interventions and 8% for interventions not recommended for use.  These 
differences were statistically significant.  With regard to univariate sensitivity analyses, 
the range of uncertainty was smallest for those interventions that were restricted for use 
(£19,747 –£ 57,146), the widest range of uncertainty was observed for interventions not 
recommended for use (£92,379-£731,151).  These differences were statistically 
significant.    
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Aside from examining the results of the CUA considered by the appraisal committee, 
information was also captured on whether alternative cost-effectiveness models using 
outcomes other than cost per QALY (cost per life year gained) were considered in the 
decision-making process.  The results varied: 22% of recommended and 28% of 
restricted interventions were supported by non-CUA models; however non 
recommended technologies were not supported by non-CUA models. 
 
The potential budget impact of a positive recommendation was analysed - the mean 
estimated maximum yearly incremental budget impact across all decisions was in the 
order of £708 million.  This ranged from £36 million for the recommended 
interventions to £828 and £1606 million for the restricted and not recommended 
interventions, respectively.  While the T-test suggested a statistically significant 
difference between the recommended and restricted interventions (p<0.10), the rest of 
the statistical tests suggested the differences were not statistically significant. 
 
NICE assessment process characteristics 
A series of variables related to the NICE appraisal process were recorded.  A societal 
perspective was formally referred to in the appraisal process in only 3% of decisions.  In 
87% of decisions, patient-group submissions were formally considered in the appraisal.  
On average, the appraisal committee comprised of 30 members.  In all of the decisions 
there was a cost-effectiveness evaluation component as well as a budget impact 
component, and the pricing of technologies was known during the NICE appraisal 
process.  None of these variables differed significantly between outcome groups.   
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Figure 4.1  NICE:  Base-case ICER reported in NICE appraisals, by coverage decision (n=90) 
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Two NICE appraisal processes co-exist:  the MTA process for appraising multiple 
technologies simultaneously and the STA process (introduced in 2006) for appraising 
single technologies.  On average, 25% of decisions followed the STA process – 
although this varied across outcomes:  41% of interventions that were not recommended 
for NHS funding followed the STA process, as opposed to 16% of restricted 
interventions and 34% of recommended interventions. This difference was statistically 
significant (p=0.031).    The number of technologies reviewed per appraisal was also 
statistically significantly different between outcome groups:  restricted interventions 
were simultaneously appraised together with an average of 3.4 technologies compared 
to recommended and not recommended interventions (2 technologies appraised 
simultaneously on average).  Statistical tests suggested the differences were statistically 
significant. 
 
Socio-economic context of NICE decision-making 
To complete the description of NICE decision-making in 2004-2009, the socio-
economic context in which this decision-making took place was assessed.  In particular, 
information was recorded on the year of the appraisal, size of the population under 
NICE’s remit (approximately 53.9 million), the percentage of GDP spent on healthcare 
(8% on average across groups), whether appraisal coincided with a general election year 
and whether the technology under appraisal was linked to a disease considered a 
‘priority’ by the Department of Health (56% of technologies appraised were directly 
linked to a priority disease area).  There was a strong correlation between the year of 
appraisal and the other socio-economic factors.  Across the outcome groups, the year of 
appraisal, population size, health care expenditure as percentage of GDP, and average 
health care expenditure per patient per year varied significantly.      
 
Summary of descriptive analysis  
In summary, the descriptive analysis of the NICE data set suggests that of the range of 
variables examined, a subset of these were found to have statistically significant 
differences between recommended, restricted and not recommended technologies.  Of 
the 34 explanatory variables examined, descriptive analysis suggested that a subset of 
19 variables may play an important contributing role in determining NICE decision-
making. These are listed in Table 4.4.  
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Table 4.4  NICE descriptive statistics: statistically significant variables (p≤ 0.05) 
Evidence factors Variables 
Clinical Package No. of RCTs 
Size of RCT population 
Duration of RCT 
Statististically Significant Superiority demonstrated in 
RCT 
Active comparator used 
Consideration of observational data 
Economic Package ICER 
Range of ICERs 
Uncertainty around ICER: probabilistic, univariate 
Use of non-CUA economic  models 
Maximum budget impact 
Disease characteristics Prevalence of disease 
Technologies for treatment of CNS disorders 
Process factors Use of STA vs. MTA process 
No. of technologies reviewed simultaneously 
Socio-economic context factors Date of appraisal 
National population size 
Percent GDP spent on healthcare 
Pharmaceutical expenditure per patient per annum (GBP) 
Note:  variables in bold text were statistically significant at the p ≤ 0.01 level 
 
4.3.3 Multivariate analysis results 
Following the model specification process described in Chapter 3 which included the 
development of a preliminary model (Appendix A), the base case NICE regression 
model was developed which included four variables:  (i) whether statistical superiority 
of the primary endpoint in the RCT was demonstrated, (ii) the ICER, (iii) the number of 
pharmaceuticals appraised, and (iv) the year of the appraisal (Table 4.5).  When the 
coverage decisions were regressed with these four variables, the resulting pseudo R 
squared was 0.26, suggesting that the four variables explained approximately 26% of 
the variability in NICE coverage decisions.  The model suggests that a combination of 
clinical, economic and process variables best explain NICE decision-making.  
Demonstration by the technology under appraisal of statistically significant superior 
efficacy decreased the log odds of a restriction or non recommendation (p=0.006 and 
p=0.016).   A unit increase in the ICER increased the log odds of moving from a 
recommended to a restricted decision (p= 0.009) versus recommendation and a not 
recommended decision versus recommendation (p<0.0001).  The number of 
technologies reviewed simultaneously within the same appraisal had a statistically 
significant impact on the decision between recommendation and restriction but not 
between recommendation and non recommendation.  The presence of an additional 
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technology in the appraisal process increased the log odds of restriction (p=0.005) and 
the log odds of non recommendation (NS).  The year of appraisal also impacted 
significantly on the coverage decision.  For every additional year, this increased the 
odds of a restriction (vs. recommendation) (p=0.072) and the odds of a non-
recommendation (vs. recommendation) (p=0.028).   
   
Table 4.5  Multivariate analysis of NICE coverage decisions 2004-2009:  base case model results (n=118) 
Restricted Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.568 0.006 -2.679 -0.457 
ICER 0.000048 0.009000 0.000012 0.000085 
Number of technologies appraised simultaneously 0.489 0.005 0.144 0.834 
Year of Appraisal 0.358 0.072 -0.032 0.748 
Constant -718.973 0.071 -1500.761 62.815 
Not Recommended Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -2.01 0.02 -3.64 -0.38 
ICER 0.000087 <0.001 0.000042 0.000131 
Number of technologies appraised simultaneously 0.12 0.65 -0.39 0.63 
Year of Appraisal 0.67 0.03 0.07 1.27 
Constant -1351.14 0.03 -2552.90 -149.38 
Note:  Recommended technologies are the reference case. Multinomial logistic regression, pseudo R-
squared: 0.26.   
 
Impact of alternative model specifications – sensitivity analyses 
A series of sensitivity analyses were performed on the base case NICE regression model 
to help evaluate the robustness of the results, as outlined in Chapter 3.  The general aim 
of these sensitivity analyses was to assess to what degree the base case model results 
changed if model specifications for particular assumptions were altered.  The sensitivity 
analyses included: i) examining the impact of a binary rather than a three-category 
outcome variable; ii) restricting the base case analysis to complete observations, thus 
excluding observations with imputed values; and iii) examining the impact of assuming 
that the outcome variable is ordinal.   
 
The first sensitivity analysis assessed whether the impact of the explanatory variables 
on NICE decision-making varied if a binary outcome variable was utilised instead of the 
base case three-category outcome variable (Table 4.6).  In order to create this binary 
variable, the recommended and restricted technologies were collapsed into one category 
(covered), and the not recommended category was used as in the base case (not 
covered).  The logistic regression results using a binary outcome variable no longer 
showed a predictive value for demonstration of clinical superiority (p=0.657).  
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However, in other aspects the results are similar to the base case analysis in that they 
confirm the impact of the ICER, number of pharmaceuticals appraised and the year of 
appraisal on NICE coverage decisions.  Specifically, a unit increase in the ICER 
increased the likelihood of no coverage (p=0.005).    A unit increase in the number of 
pharmaceuticals appraised within the same appraisal increased the odds of coverage 
(p=0.063).    An increase in the year of appraisal appeared to increase the odds of no 
coverage (p=0.046).  
 
Table 4.6  Sensitivity Analysis 1.  Multivariate analysis of NICE coverage decisions 2004-2009:  alternative 
model using a binary outcome variable (n=118) 
  Log Odds of 
Listing 
P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT 0.33 0.66 -1.13 1.79 
ICER -0.000043 0.005 -0.000074 -0.000013 
Number of technologies appraised simultaneously 0.46 0.06 -0.03 0.94 
Year of Appraisal -0.53 0.05 -1.04 -0.01 
Constant 1056.81 0.05 20.65 2092.97 
 
In the second sensitivity analysis (Table 4.7), the regression analysis was run for a 
subset of complete observations (n=98 /118).    This sensitivity analysis was 
implemented with the knowledge that removing incomplete observations from the 
analysis could bias the analysis.  The pseudo R-squared for this model was 0.32, 
suggesting that this set of variables explain approximately 32% of the variability 
observed in NICE decision-making, as opposed to 26% in the base case model.  In this 
sensitivity analysis, the impact of the ICER and the year of appraisal remained similar 
to that observed in the base case analysis, a unit increase in both parameters leading to a 
statistically significant increase in the log odds of a restriction or non-recommendation. 
However, unlike the base case model, the impact of the demonstration of statistical 
superiority as well as the number of technologies appraised simultaneously was weaker 
in this sensitivity analysis as a statistically significant effect on the odds of non-
recommendation was no longer observed.     
 
In the third sensitivity analysis, ordinality of the outcome variable was assumed.  This is 
in contrast with the base case analysis, where ordinality was not assumed and 
multinomial logistic regression was used.  In this sensitivity analysis ordinal logistic 
regression was used.  The detailed results of this analysis are provided in Appendix G, 
and show very similar results to the base case analyses run using a multinomial logistic 
regression model.  
  
 
122
 
 
Table 4.7 Sensitivity Analysis 2.  Multivariate analysis of NICE coveage decisions 2004-2009: alternative model 
in which incomplete observations are excluded (n=98) 
Restricted Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.51 0.01 -2.67 -0.35 
ICER 0.000045 0.02 0.000007 0.000084 
Number of technologies appraised simultaneously 0.53 0.01 0.16 0.90 
Year of Appraisal 0.51 0.02 0.07 0.95 
Constant -1030.32 0.02 -1909.69 -150.95 
Not Recommended Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.59 0.12 -3.60 0.42 
ICER 0.00011 <0.001 0.000050 0.00017 
Number of technologies appraised simultaneously 0.08 0.83 -0.65 0.82 
Year of Appraisal 1.19 0.03 0.11 2.28 
Constant -2397.84 0.03 -4573.51 -222.17 
 
 
4.4   Discussion 
The overall objective of this chapter was to examine the factors that influence decisions 
made by NICE to recommend, restrict or not recommend pharmaceutical technologies 
for use in the National Health Services of England and Wales. In line with the 
hypothesised drivers of HTA decision-making highlighted in Chapter 3, and in light of 
evidence review presented in Chapter 2, a wide range of explanatory variables were 
included in the analysis, reflecting clinical and economic characteristics of the 
technology under appraisal, the appraisal process itself and the socio-economic context 
in which NICE operates.  In addition to the general aims of the research, specific 
hypotheses relevant for NICE decision-making were explored and are discussed below.  
 
The relationship between explanatory variables and the outcome variable (coverage 
decision) was assessed and suggested that the variation in NICE coverage decisions can 
be explained by four variables:  whether statistical superiority of the primary endpoint 
in the RCT was demonstrated, the ICER, the number of pharmaceuticals appraised 
within the same appraisal, and the year of appraisal.  The internal validity of the results 
obtained in this analysis was examined in two ways.  Firstly, by comparing the results 
with published analyses of NICE decision-making, and secondly by sharing the base-
case model results for review with a member of NICE (Interview with Professor Peter 
  
 
123
Littlejohns)1.   The aim of this interaction was to ascertain if the NICE characteristics 
were accurately captured in the sample used for analysis, if the approach to the analysis 
was clear and in particular, the reaction to the model results and potential for 
suggestions or additional analyses.   
 
4.4.1 Pattern of NICE decision-making 
The resulting model of NICE coverage decisions provided useful glimpses into the 
factors driving its decision-making.  The analysis of NICE coverage decisions involved 
the review of 118 technology appraisals performed during 2004-2009.  The majority of 
NICE coverage decisions restricted funding to the appraised technology (58% of 
technologies were restricted), while the least common coverage decision was non 
recommendation (14% of technologies were not recommended by NICE for NHS 
funding).  This pattern is not dissimilar to that reported in Kanavos et al. (2010) which 
examined NICE coverage decisions in 2007-2009:  that analysis revealed that of the 
technologies appraised, 19% were recommended, 63% were restricted and 18% were 
not recommended.  Clement et al. (2009) examined NICE coverage decisions between 
2001- 2008 and reported 87% of technologies as listed (recommended or restricted), 
leaving 13% of technologies as not recommended.  In the analysis of NICE decision-
making during 2000-2003 produced by Dakin et al. (2006) it was reported that 21% of 
technologies were recommended for routine use, 66% for restricted use and 13% were 
not recommended.   Devlin and Parkin (2004) reported NICE outcomes using a binary 
outcome variable, and during the period 2000-2002 reported that 71% of appraisals 
recommended use of the technology and 29% of appraisals did not recommend use of 
the technology. Therefore, the pattern observed within the data set used in this thesis 
seems similar to that observed in other reports, suggesting that the method of 
classification and data extraction used was robust.   
 
4.4.2 Impact of clinical evidence and disease characteristics on NICE decision-
making 
It was hypothesised that clinical variables, which were found to be significant 
explanatory variables in previous NICE analyses, would maintain their significance in 
this analysis.  In the analysis of NICE decision-making presented here, demonstration 
                                                 
1 Littlejohns, Peter. Professor, Clinical and Public Health Director National Institute for Health and 
Clinical Excellence.  Interviewee: Karin Cerri.  Interviewed by telephone, on February 2nd 2011.  Meeting 
minutes are provided in Appendix E.    
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by the technology under appraisal of statistically significant superiority in its primary 
endpoint increased the odds of recommendation.  Technologies recommended by NICE 
demonstrated statistically significant superior efficacy over the comparator in 59% of 
appraisals, compared with 29%-35% of technologies that were restricted or not 
recommended.  This result can be seen to reflect the role of evidence-based medicine in 
coverage decisions and the fact that NICE defines the value of the compound in terms 
of the ability of the technology to demonstrate, with greater certainty, its incremental 
clinical value through superiority designed trials that provide stronger data to support a 
funding decision than technologies not able to provide evidence of superior efficacy.  
Comparing this result with those previously published in the literature (Dakin et al. 
2006; Devlin and Parkin 2004), it is noteworthy that Devlin and Parkin (2004) did not 
measure the demonstration of clinical superiority while in Dakin et al. (2006), this 
variable was measured but was not found to have a statistically significant impact, 
although the sample size was smaller than that used within the analyses presented here, 
and pertained to NICE appraisals made in 2000-2003.   
 
Other clinical variables which were tested in the present analysis included information 
on the characteristics of RCTs used in the appraisal (number, size, duration).  Within 
descriptive analyses, these variables were found to differ statistically significantly 
between coverage decisions.  However, they were not key drivers within the 
multivariate analyses.  This is not to say that the characteristics of RCTs are not 
important or not considered within the NICE appraisal process, but that within the 
multivariate analysis the demonstration of superiority and the contribution of other 
factors, such as the ICER, had a more significant impact.  This result is not dissimilar to 
that observed in an analysis of NICE decisions by Dakin et al. (2006), in which RCT 
size was not found to have statistically significant effects on the odds of a restriction or 
non recommendation relative to a recommendation within their multivariate analysis.  
The number of RCTs, however, did have a statistically significant impact in Dakin et 
al.’s (2006) model, which was not observed in the analyses presented here.  This could 
be due to differences in the samples analysed:  Dakin et al.’s analysis was smaller (n=60 
vs. n=118 in this analysis) and the analysis included NICE appraisals published in a 
different time period (2000-2003), as opposed to this analyses which included 
appraisals from 2004-2009.  The analyses by Dakin et al. (2006) also show that the use 
of systematic literature reviews within the NICE appraisal process appears to decrease 
the odds of non recommendation and restriction relative to a recommendation at 
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statistically significant levels.    This variable was not examined in this analysis because 
it was noted in a review of appraisals that the majority of appraisals post 2004 included 
systematic reviews the clinical and economic literature as part of the process.   
 
It was hypothesised that technologies for diseases characterised by high unmet medical 
need may increase the log odds of recommendation relative to non-recommendation – 
with particular focus on cancer therapies.   Through the model specification process, the 
effect of cancer therapies on the log odds of non-recommendaiton was not observed and 
thus the final base-case model does not include this particular variable.  The hypothesis 
was also not supported by descriptive evidence generated in this chapter.  There was no 
statistically significant difference detected across outcome variables in the proportion of 
cancer therapies - of recommended techonologies, 41% were cancer therapies compared 
with 23% and 41% for restricted and not recommended technologies respectively.  
 
4.4.3 Economic evidence and its impact on NICE decision-making 
Consistent with previously published analysis of NICE coverage decision-making 
(Dakin et al. 2006; Devlin and Parkin 2004), the ICER had a significant impact on 
NICE decision-making, and confirmed the hypothesis as stated in Box 4.1.  An increase 
in the ICER increased the odds of a restriction versus recommendation or non 
recommendation versus recommendation, and this effect was highly statistically 
significant.  The mean ICER for technologies recommended by NICE was £17,782, 
compared with mean ICERs of £24,867 and £99,239 for restricted technologies or 
technologies not recommended by NICE.  The effect of the ICER was observed 
consistently throughout all of the sensitivity analyses conducted.  This would suggest 
that, in addition to the strength of the clinical data, the incremental costs and benefits 
associated with the technology, and the resulting ICER, play a significant role in 
coverage decisions by NICE, and represent the agency’s focus on maximization of 
efficiency.   This interpretation of the multivariate model results is reinforced by a 
descriptive assessment of the mean ICER reported for technologies which demonstrated 
clinical superiority compared with those technologies that did not, suggesting that the 
ICER is a product of the clinical value demonstrated(Figure 4.2). 
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Figure 4.2 NICE decision-making:  mean ICER stratified by demonstration of clinical superiority in RCT 
  
 
When examining the relationship between the ICER and coverage decision in a 
descriptive fashion (Figure 4.1), the analysis confirms the multivariate results in two 
ways.  Firstly, it suggests that the concept of  ‘value for money’ is applied with some 
consistency in NICE decision-making such that restricted and recommended 
technologies tended to appear more frequently at lower ICER levels  while non 
recommended technologies tend to appear at the upper end of the observed range of 
ICERs.  However, the descriptive analysis also confirms the multivariate analysis by 
highlighting the presence of exceptions to this application of ‘value for money’ by 
NICE.  There are recommended technologies with ICERs significantly above the 
commonly accepted threshold of £20,000 to £30,000, as there are restricted or non-
recommended technologies with ICERs within commonly accepted thresholds.  In part, 
these ‘discrepancies’ can be attributed to the heterogeneity of the ‘restricted’ category 
which incorporates both major and minor restrictions.  This would suggest that other 
factors, aside from the ICER, are also driving NICE decision-making, reflecting the 
results of the multivariate analysis which suggests that a combination of clinical, 
economic, process and context factors play a role in explaining NICE decision-making.   
 
4.4.4 Number of technologies appraised simultaneously impacts on NICE decision-
making 
The resulting multivariate model of NICE decision-making also suggests that there are 
process factors, beyond evidence considerations, which explain NICE coverage 
decisions. When considering appraisal process-related factors, the results of the model 
suggests that an increase in the number of technologies reviewed simultaneously within 
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the same appraisal increased the odds of a restriction relative to a recommendation.  
Technologies that were restricted were part of appraisals that on average appraised 3 
technologies simultaneously, compared with recommended and not recommended 
technologies which were appraised with an average of 2 technologies.  It was 
hypothesised that this may reflect the fact that NICE assessment processes differ 
according to the number of technologies under appraisal.   Single technologies are 
evaluated using the STA process while multiple technologies are evaluated using the 
MTA process.  The latter involves the use of third party assessments to provide bespoke 
research to support NICE assessment, while the STA process relies on manufacturer 
submissions similar to the process undertaken by the SMC in Scotland.   However, 
when the model specification was altered to include a variable capturing the use of 
MTA or STA processes, the effect of this variable on coverage decisions was not 
statistically significant.  Thus, the effect on coverage decisions arising from the 
appraisal of multiple technologies simultaneously could not be entirely explained by the 
use of MTA or STA alone.  It was suggested by Professor P. Littlejohns2, that the 
increased odds of restriction associated with higher number of technologies appraised 
simultaneously may reflect an approach in which a ‘winner’ is picked among the 
technologies, with the remainder recommended for restricted use or non-
recommendation.  To further examine Professor P. Littlejohns suggestion, a descriptive 
analysis was conducted of NICE decision-outcome stratified by number of technologies 
appraised (Figure 4.3).  It suggests that that proportion of restrictions increases as the 
number of technologies appraised increases, and that non-recommendation appears to 
occur most frequently in appraisals with fewer technologies appraised simultaneously.  
Unfortunately, none of the published multivariate analyses of NICE decision-making 
examined the role of process factors, and thus a comparison with previous analyses is 
not possible.   
 
 
 
 
 
 
 
                                                 
2 Littlejohns, Peter. Professor, Clinical and Public Health Director National Institute for Health and 
Clinical Excellence.  Interviewee: Karin Cerri.  Interviewed by telephone, on February 2nd 2011.  Meeting 
minutes are provided in Appendix E.    
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Figure 4.3 NICE decision-outcome stratified by number of technologies appraised 
 
4.4.5 Year of appraisal impacts on NICE decision-making 
In terms of the socio-economic context of NICE decision-making, it was hypothesised 
that non-recommendations and restrictions are increasing over time relative to 
recommendations.  The results of the model show that the year of appraisal impacted 
significantly on the coverage decision – moving from 2004 to 2009 increased the odds 
of a restriction versus recommendation and non-recommendation versus 
recommendation (Figure 4.4).  The year of appraisal may reflect multiple socio-
economic factors, including the political climate, a change in key staff of the HTA 
body, a change in societal preferences or the overall economic context.  It should be 
noted that this analysis was conducted prior to the implementation of changes in 
methods of NICE appraisal process, including criteria for consideration in the appraisal 
of rare diseases, cancer therapies.  The analysis does however cover the period where 
other key changes took place in NICE appraisal process including the introduction of 
the Single Technology Appraisal process as well as the 2008 up-date to the methods 
guide.  By way of comparison, Dakin et al. (2006) included this variable in their 
analyses, and also found a statistically significant effect of the time of appraisal on 
outcome.  In particular, an increase in the time of appraisal (i.e. as the appraisals came 
closer to the present), increased the odds of a non recommendation.  However, Dakin et 
al. (2006) did not observe the effect of appraisal date on the odds of a restriction relative 
to a recommendation. 
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Figure 4.4NICE coverage decisions between 2004-2009 (n=118) 
 
 
4.4.6 Limitations 
The analysis of NICE decision-making presented in this chapter was limited by several 
factors including:  i) the dependence on publicly available information for the creation 
of the dataset; ii) challenges in data extraction, and iii) heterogeneity in the definition of 
‘restricted’ technologies.    
 
The database constructed for these analyses, incorporating information on appraisals 
conducted by NICE from 2004-2009, was dependent on publicly available information.  
Thus, it is possible that subtle concepts or rationales discussed by the appraisal 
committee orally were not captured in the documentation of the appraisal.  In addition, 
the dependence on public information meant that in the situation where the information 
available was incomplete, it was not possible to ascertain if this was because the 
information was never considered in the appraisal or if it was considered but not 
recorded in the documentation.  The presence of non-reporting reflects a lack of 
transparency associated with the documentation of the appraisal process. This was noted 
particularly with regard to the non-reporting of uncertainty information around the cost-
utility/effectiveness results.  Incomplete observations were taken into account in the 
regression models by creating dummy variables to examine whether the presence or 
absence of information on that variable had any explanatory value.  None of these 
dummy variables appeared to have a significant effect on the odds of NICE coverage 
decisions.  A sensitivity analysis was also conducted in which incomplete observations 
were removed from the sample for analysis.  The results of this sensitivity analysis were 
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similar to those observed in the base case analysis, suggesting that the factors identified 
in the base case model are robust to alternative model specifications.  
 
Challenges were faced in the creation of the dataset of NICE decision-making due to the 
dispersal of information between various documents, and the potential for inconsistency 
between NICE guidance drafts, manufacturer reports and Assessment Group reports, 
leading to a reduction in the transparency of the information that was considered by 
NICE.  This challenge was managed by creating a specific data extraction protocol with 
specific rules about the nature of the data that should be extracted and how to select the 
data of most relevance.  For example, it was not uncommon for multiple models to be 
submitted and considered.  In these instances, the model that provided the ICER which 
drove the decision-making was selected and included in the dataset.   
 
There was heterogeneity in the means through which technologies were restricted 
within NICE coverage decisions.  The notion of restriction within NICE coverage 
decisions ranged from major restrictions, including restriction for use within a sub-set of 
the licensed indication, to minor restrictions such as the need for monitoring along with 
the use of the technologies.  The notion of major and minor restrictions was suggested 
in research by Raftery (2006) on NICE guidance in which various sub-types of 
restrictions were presented.  O’Neill and Devlin (2010) also highlighted the variation in 
the degree of restriction related to NICE decision-making.  It is a limitation for this 
analysis to have such heterogeneity in the degree of restriction within a single category.  
However, in its actual decision-making, NICE has more than two coverage options at its 
disposal and thus, the use of a third coverage category within the analysis was felt to 
better reflect real-life HTA decision-making.  To test the impact of using a binary 
outcome variable on the base case model results, a sensitivity analysis was performed 
using a binary outcome variable, which confirmed the role of the factors identified in 
the base case analysis.   
 
In summary, the overall objective of this chapter was to examine the factors that 
influence decisions made by NICE to recommend, restrict or not recommend 
pharmaceutical technologies for use in its respective healthcare systems, with a focus on 
research hypotheses specific to NICE decision-making. The analysis provided a rich 
source of data from which to examine the role of each factor on NICE coverage 
decisions, and more importantly the contribution of each factor while adjusting for the 
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effect of confounding variables. The results suggest that the variability in coverage 
decisions observed can be explained by a combination of clinical, economic, process, 
and socio-economic factors.   The analysis showed that the proportion of restrictions 
and non-recommendations issued by NICE are increasing over time relative to 
recommendations.  The analysis also confirmed that the demonstration of clinical and 
economic value is central to NICE coverage decisions.  While the NICE appraisal 
process was also shown to impact on coverage decision-making, the anticipated effect 
of the use of STA or MTA processes was not observed – rather an effect was observed 
of the number of technologies appraised simultaneously.  In comparison with previously 
published models of NICE decision-making, there is consistency observed in the effect 
of clinical and economic variables, while providing new insights into the effect of 
variables that have not been previously studied.   
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5 Empirical analysis of SMC coverage decisions 
 
 
Adalimumab is indicated for the treatment of ankylosing spondylitis1, and was reviewed 
by NICE, SMC, CVZ and HAS to assess whether it should be funded by the healthcare 
system.  The SMC provided the following guidance:  
“Adalimumab (Humira©) is accepted for restricted use within 
NHS Scotland for the treatment of adults with severe active 
ankylosing spondylitis who have an inadequate response to 
conventional therapy. It is restricted to use in accordance with the 
British Society for Rheumatology (BSR) guidelines of July 2004. 
 
Adalimumab improves signs, symptoms, physical function and 
quality of life in patients with severe active ankylosing 
spondylitis. It reduces spinal inflammation, but there is no 
radiological evidence that it decreases joint damage. An 
economic evaluation demonstrated that it is a cost-effective 
treatment option when used in tumour necrosis factor (TNF)-
antagonist naïve patients in accordance with the BSR guidelines 
and where clear and rigorous stopping rules are applied.” 
(SMC 2006 p. 1) 
 
The guidance issued by the SMC on adalimumab is not dissimilar to that issued by 
NICE (see Chapter 4), in which its use is restricted to a sub-set of the eligible 
population that have failed at least two conventional therapies.  While arriving at an 
apparently similar coverage decision to that of NICE, the SMC assessment differed 
from the NICE assessment in the evidence, process and context within which it made its 
decision.  For example, the SMC considered one economic model, while NICE 
considered five models (NICE 2008); the SMC analysed adalimumab alone, while 
NICE analysed adalimumab within the context of a Multi Technology Appraisal (MTA) 
process.    What is the impact of evidence, process and context factors on SMC 
decisions?  Do the factors that drive NICE decisions, as highlighted in Chapter 4, play a 
role in SMC coverage decisions?  Or is SMC decision-making best explained by a 
different mix of evidence, process and socio-economic context factors? 
 
This chapter provides an empirical analysis of coverage decisions made by SMC during 
the period 2004-2009.  First, an overview of SMC, its objectives and appraisal process 
                                                 
1 Adalimumab (Humira©) is an anti-inflammatory medicine and is indicated, among other diseases, for 
the treatment of  adults with severe active ankylosing spondylitis (a disease causing inflammation and 
pain in the joints of the spine) who have not responded adequately to other treatments (European 
Medicines Agency, 2009, EPAR Adalimumab) 
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is provided.  The methods for the analysis are then outlined, building upon the methods 
discussed in Chapter 3.  Next, the results of descriptive and multivariate analyses of 
SMC coverage decisions are reported and explored, and limitations considered.  The 
chapter concludes with a brief discussion on the empirical analyses performed for SMC. 
 
5.1 SMC Appraisal Process 
Established in 2001, the Scottish Medicines Consortium advises NHS Scotland on the 
use of newly licensed technologies or newly licensed indications for existing 
technologies. The purpose of the SMC is “to avoid duplication of new medicines 
assessment by individual ADTCs [NHS Board Area Drugs and Therapeutics 
Committees], to avoid geographical inequity in decision making and to make the best 
use of expertise available across Scotland” (SMC 2010a p. 4).  The SMC is made up of 
a consortium of 14 Health Boards.  The advice of the SMC is made available to the 
health boards, which then make a recommendation as to the use of technologies within 
their area of remit. Individual clinicians make the final prescribing decision in relation 
to their patients.   In addition to the evaluation of new technologies and indications, the 
SMC also has a role in horizon scanning – that is, the identification of new technologies 
in development and the communication of such technologies to the Scottish NHS 
Health Boards to facilitate financial and service planning for future years.    
 
The SMC provides guidance to NHS Scotland based on a rapid review soon after the 
marketing authorisation is obtained for the technology (Cairns 2006; SMC 2010a). The 
assessment of the SMC is based on evidence submitted by the manufacturer, and there 
is no third party assessment within its appraisal process (Drummond and Mason 2009).  
The New Drugs Committee (NDC) is a sub-group of the SMC that provides an 
assessment of the clinical and economic evidence and formulates a draft advice for 
consideration by the SMC.  The SMC issues the final advice after consultation with its 
members and stakeholders.  The composition of the Consortium and the NDC that 
advises the SMC on new technologies includes clinicians, pharmacists and health 
economists, in addition to stakeholders from manufacturers, patient groups and the 
government.  The appraisal process and key stakeholders are highlighted in Figure 5.1.   
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Figure 5.1 SMC appraisal process   
 
Source: SMC 2010a. 
 
A series of clinical criteria are taken into account in the SMC’s assessment of 
pharmaceutical technologies (SMC 2010b).  This includes information on the evidence 
demonstrating the efficacy of the technology, with a particular focus on randomised 
controlled studies (RCTs).  The importance of evidence from active-controlled studies, 
as opposed to placebo-controlled studies, is stressed.  The process however, also allows 
for the submission of non-randomised studies, although the rationale for doing so needs 
to be provided.  In addition to efficacy data, safety information is also assessed.  
Clinical effectiveness, relative to a comparator, is a key part of the SMC appraisal, 
which aims to assess the relevance of the efficacy and safety outcomes of the clinical 
studies to treatment practice and patients in Scotland.   
 
A range of economic criteria are included in the SMC appraisal process. The 
pharmacoeconomic assessment examines the economic model and results submitted by 
the manufacturer, including its relevance and robustness.  Sensitivity analysis around 
the economic model results is an important component of the evaluation.  In addition to 
pharmacoeconomic assessments, resource implications associated with the introduction 
of the technology are also assessed by the SMC.  The assessment is primarily focused 
on estimating the size of the target population and the incremental drug budget 
Submission of new product assessment 
form to SMC
Assessment review (clinical and 
economic streams)
New Drugs Committee
Final SMC detailed advice 
document
Applicant company
Patient interest group submission
Scottish Medicines ConsortiumNDC detailed advice
Assessment & draft detailed advice 
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Company comments to SMC
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associated with the introduction of the technology.  In addition to clinical and economic 
criteria, submissions by patient groups are a formal part of the appraisal process.  
Patient groups have the option to provide information via a specific submission form, 
which is then considered by the SMC during its appraisal.  Having outlined the role and 
appraisal process of the SMC, the next section summarises the methods used to analyse 
the factors driving SMC coverage decisions. 
 
5.2 Methods 
The overall objective was to 
examine the factors that drive 
decisions made by SMC to accept 
for use, accept for restricted or not 
recommend.   In addition to the 
general analysis aims described in 
Chapter 1, the particular 
hypotheses relevant for the 
analysis of coverage decisions by 
SMC are highlighted in Box 5.1.      
Building on from the methods 
described in Chapter 3, this 
section describes the methods 
used to select the sample for 
analysis, the outcome variable and 
explanatory variables considered, and the statistical techniques adopted. 
 
5.2.1 Sample  
Pharmaceutical technology assessments performed by the SMC formed the basis of the 
sample included in this analysis.  The composition of the sample was determined 
through the following inclusion and exclusion criteria. The sample included all drug 
technology appraisals (as opposed to medical devices or other interventions) completed 
in 2004-2009 and indicated for an adult population (≥18 years).  Technology 
assessments were excluded from the analysis for any of the following reasons:  i) they 
focused on a non-adult population; ii) they appraised non-drug interventions; iii) 
marketing authorisation was withdrawn; iv) an abbreviated or IRP guidance was issued;  
or v) the full advice report was not available. 
Box. 5.1 In light of the discussions presented in Chapter 
2, SMC-specific research objectives were to test 
whether: 
• The odds of SMC recommendation is 
impacted upon by the type of submission 
(first-time submission or resubmission)  
• The pattern of coverage decision-making by 
SMC is changing over time – such that the 
proportion of non-recommendation and 
restrictions were increasing over time relative 
to recommendations 
• The ICER is a key explanatory variable of 
SMC decision-making and increasing ICERs 
are hypothesised to be associated with an 
increased log odds of restriction or non-
recommendation relative to recommendation  
• Pharmaceutical budget impact estimates 
significantly impact on SMC outcomes – 
increasing budgetary impact is hypothesised to 
increase the log-odds of non-recommendation 
or restriction relative to recommendation 
• The odds of non-recommendation decrease for 
technologies indicated for conditions with no 
alternative treatment options 
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5.2.2 Outcome variable 
To address the research question, SMC decisions were analysed by considering SMC 
decision outcomes in three categories:   
• accepted for routine use 
• accepted for restricted use 
• not recommended for use 
 
The SMC is the only one of the four HTA bodies examined in this thesis that explicitly 
uses these three categories to express the outcome of its decision-making and these 
correspond closely with the categories needed for the analyses.  Thus, no additional 
algorithm or decision rule was used to translate coverage decisions made by the SMC 
into the three categories used for descriptive and multivariate analysis.  
 
5.2.3 Explanatory variables 
In line with the hypothesised drivers of HTA decision-making highlighted in Chapter 3, 
the SMC dataset includes 36 explanatory variables, including variables collecting 
information on i) the clinical, disease and economic characteristics of the technology 
under appraisal, as well as ii) the process used to come to a coverage decision, and iii) 
the socio-economic context in which these decisions were made.   
 
5.2.4 Data extraction form 
Similar to the form utilised to extract data from NICE guidance (see Chapter 4), the 
SMC form contained the definitions and decision rules used when extracting the data 
from the guidance documents issued by SMC, as well as from minutes of meetings 
available to the public via the SMC website, and other data sources. The data extraction 
form was organized into three segments, relating to the three components of analysis 
that are integral to this research.  The data was extracted following the protocols 
outlined in Chapter 3 (Section 3.1.3).   Table 5.1 provides the list of variables extracted 
to create the SMC dataset, as well as the accompanying decision rules and definitions. 
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Table 5.1  SMC dataset:  Included Variables, Definitions, Data Extraction Rule and Data Sources 
# Variable Descriptor Unit measure Definition Data Sources 
1 Number of RCTs 
considered in decision 
Count The number of distinct RCTs that provide data related to the 
therapeutic indication under evaluation. 
 
Excluded:  studies that are single arm, that have no randomization, or 
that are non-interventional.  
SMC Advice, “Summary of evidence 
on comparative efficacy” section 
2 Size of population included 
in RCTs 
Numeric Mean number of patients per RCT.   SMC Advice, “Summary of evidence 
on comparative efficacy” section 
3 Length/extent of follow-up 
in RCT 
Numeric Mean number of weeks that data is collected on patients that entered 
the RCTs (see variable no. 1).  
SMC Advice, “Summary of evidence 
on comparative efficacy” section 
4 Statistically Significant 
results 
Categorical 
(yes/no/inconsistent
) 
Presence of statistically significant superiority of technology vs. 
comparator for primary endpoint(s). 
 
If more than one RCT was considered, and the technology showed 
statistically significant superiority in one trial, but not in another, the 
results were considered to be ‘inconsistent’ and classified as such.  
RCTs designed as ‘non-inferiority’ studies were classified as not 
showing any statistically significant superiority (i.e. ‘no’).    
SMC Advice, “Summary of evidence 
on comparative efficacy” section 
5 Use of active comparator in 
RCT 
Numeric Percentage of RCTs where active comparator was used.   SMC Advice, “Summary of evidence 
on comparative efficacy” section and “ 
Summary of clinical effectiveness 
issues” section 
6 Number of observational 
studies considered in 
guidance 
Count Number of observational studies providing information to support 
study drug.   
 
Observational studies in this circumstance are defined as studies that 
are non interventional (i.e. do not explicitly request the patient to take 
particular medication or the physician to follow particular protocol).   
SMC Advice, “Summary of evidence 
on comparative efficacy” section, and “ 
Summary of evidence on comparative 
safety” section 
7 Priority disease area Categorical – yes/no This variable aims to capture the health policy context in which payer 
decision is made, by capturing whether the pharmaceutical in question 
is linked to a disease area that is prioritized by the Department of 
Health.   Priority disease areas were identified by examining 
government plans/health documents that highlight national health care 
system focus. 
NHS Health Scotland (2004, 2005, 
2006, 2007, 2008) 
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# Variable Descriptor Unit measure Definition Data Sources 
8 Orphan Status Categorical – yes/no This variable captured information on whether or not the technology 
was recognized by the European Medicines Agency (EMA) as an 
orphan designated medicine.   
European Medicines Agency (accessed 
2010) 
9 Therapeutic Area Categorical – 13 
categories 
The British National Formulary (BNF) categories were used to classify 
each technology into the corresponding therapeutic area.   
British National Formulary (2010) 
10 Prevalence of 
disease/clinical condition 
Numeric Reported number of patients eligible for treatment, as per the Summary 
Product Characteristics and indication of the medication under 
evaluation.   
SMC Advice,  “ Additional 
information: budget impact” section 
11 Availability of alternative 
therapies in current 
treatment setting. 
Categorical – yes/no An alternative was considered to be available if comparators were 
clearly defined in the review by the HTA agency.  An alternative was 
considered NOT to be available if it was stated as such in the appraisal, 
or if ‘best supportive care’ or ‘palliative care’ was specified as the 
comparator. 
SMC Advice “ Additional information: 
comparators” section 
12 Consideration of Cost 
Utility Analysis in guidance 
Categorical – CUA 
performed or no 
CUA 
Presence or absence of a cost-utility analysis.   SMC Advice “ Summary of 
comparative health economic 
evidence” section 
13 Incremental Cost-utility 
ratio of technology vs. 
comparator in base case 
Numeric ICER (Cost per QALY) reported in the HTA dossier for base case as 
accepted by the Appraisal Committee.  This is defined as the ICER that 
is related to the recommendation.   
 
If more than one ICER is presented as the recommendation covers 
more than one population, than the ICER pertaining to the larger of the 
populations was reported.   
 
If technology is reported as dominant or dominated, it was recorded as 
such in data extraction sheet.   
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
14 Multiple CUA/CEA models 
reported 
Categorical - 
Yes/No 
Whether more than one cost-utility or cost-effectiveness model was 
considered during the appraisal 
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
 15  Multiple economic models 
resulting in a range of 
ICERs reported 
Numeric If yes, report range of base case ICERs presented between the different 
models reported. The difference between the lowest and highest ICER 
will be calculated. 
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
16 Uncertainty around the base 
case ICER reported in 
submission (probabilistic) 
Numeric  This should be reported as the percentage probability of acceptance at 
the threshold used by the agency.  The probability of medication to be 
cost-effective at a 30,000 GBP threshold was reported. 
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
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# Variable Descriptor Unit measure Definition Data Sources 
17 Uncertainty around base 
case ICER reported in 
submission (univariate) 
Numeric This should be reported as the range of ICERs (min-max) resulting 
from univariate sensitivity on the base case.     
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
18 Non-cost per QALY cost-
effectiveness analyses 
submitted 
Categorical - 
Yes/No 
Indicates if non-cost per QALY economic analyses were submitted and 
reviewed.   
SMC Advice “ Summary of 
comparative health economic 
evidence” section 
19 Anticipated budgetary 
impact of introduction of 
new technology in health 
care system 
Numeric Estimated annual budgetary impact of introducing new medication into 
the current treatment setting, if the pharmaceutical were to be 
introduced without any restriction.  Drug cost only (per year).   This is 
the potential budget impact were a recommendation for use in the total 
indicated population is granted.   
SMC Advice,  “ Additional 
information: budget impact” section 
20 Availability of alternative 
therapies in current 
treatment setting. 
Categorical – yes/no An alternative was considered to be available if comparators were 
clearly defined in the review by the HTA agency.  An alternative was 
considered NOT to be available if it was stated as such in the appraisal, 
or if ‘best supportive care’ or ‘palliative care’ was specified as the 
comparator. 
SMC Advice “ Additional information: 
comparators” section 
21 Inclusion of patient 
submission 
Categorical – yes/no A patient submission was considered to have been included as part of 
the appraisal process if a submission from a patient group was 
acknowledged to have been included in the relevant section of the 
SMC Advice.   
SMC Advice, “ Summary of patient 
and public involvement” section 
22 Number of decision makers 
accountable 
Numeric Captures the number of decision-makers accountable for guidance 
issued, as reported in meeting minutes in which the technology was 
discussed.   
SMC Meeting Minutes,  
http://www.scottishmedicines.org.uk/A
bout_SMC/Minutes/Minutes 
23 Cost-effectiveness 
evaluation component in 
process 
Categorical – yes/no Captures whether cost-effectiveness is a component of the decision-
making process or not. If cost-effectiveness analysis is a formal part of 
the appraisal process, this variable was marked as ‘yes’.  
SMC Advice, SMC (2010b)  
24 Budget impact as a 
component of decision-
making process 
Categorical – yes/no Captures whether budget impact considerations are part of decision-
making process 
SMC Advice,  SMC (2010b)  
25 Pricing known during 
appraisal process 
Categorical – yes/no Captures whether the price of the technology under appraisal was 
known during the assessment.     
SMC Advice,  SMC (2010b)  
26 Number of technologies 
appraised simultaneously 
Count This variable captures the number of technologies appraised 
simultaneously in the appraisal.   
SMC Advice,  SMC (2010b)  
27 Different process for 
medications destined for 
Categorical – yes/no Records whether funding decisions for medications follow different 
processes depending on whether they are destined for hospital or retail 
SMC Advice,  SMC (2010b)  
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# Variable Descriptor Unit measure Definition Data Sources 
hospital or retail use prescription.  
28 Accountability of drug 
budget 
Categorical – yes/no The HTA agency was examined to assess whether the agency making 
the funding decisions is also accountable for the drug budget or not.  
SMC (2010a)  
29 Independence of decision-
making agency 
Categorical – yes/no This pertains to whether the HTA body is independent of Department 
of Health or part of it. 
SMC (2010a) 
30 Date guidance was issued Numeric Year when coverage decision was issued SMC Advice 
31 Population size – Agency 
coverage 
Numeric Estimate of population size within remit of the agency performing the 
evaluation. 
National Office of Statistics (2009)    
32 GDP-healthcare expenditure Numeric (%) Percentage of GDP spent on healthcare, during year of decision OECD (2009) 
33 Healthcare expenditure on 
pharmaceuticals per patient 
per year 
Numeric (£) Healthcare budget spent on pharmaceuticals per patient per year, 
during the same year in which the appraisal was published.  
ISD (2009)  
34 Drug funding process 
within healthcare system – 
whether centralised or 
decentralised 
Categorical – 
centralised, 
decentralised 
States whether drug funding process within the healthcare system  is 
centralized at a national level or whether funding decisions are 
decentralized to the regional level 
SMC (2010a) 
35 Election year at time of 
decision 
Categorical – yes/no This variable captures whether payer decision was made within an 
election year.  An election year was defined as a year in which either 
national government or regional elections took place.     
BBC 2005, BBC 2007 
36 Submission type Categorical – first 
or re-submission 
Collected for the SMC – this provides information on whether the 
submission under analysis is a first full submission or re-submission. 
This data was extracted directly from the appraisal summary 
document.  
SMC Advice cover page 
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5.2.5 Statistics 
The methods for the descriptive statistics and multivariate analyses were described in 
Chapter 3.  Descriptive statistics were calculated for each extracted variable, stratified 
by outcome group (recommended, restricted or not recommended).  Following a 
descriptive analysis of the dataset, a multinomial logit regression was modelled.  The 
objective of this analysis was to obtain a parsimonious model that best reflected the 
main drivers of SMC decision-making.    
 
5.3 Results 
5.3.1 Sample characteristics  
Table 5.2  Outcome of SMC Guidance issued between 2004-June 2009 
SMC guidance  Number of coverage decisions Percentage 
Recommended 54 19% 
Restricted 102 35% 
Not recommended 132 46% 
Total 288 100% 
 
A total of 531 drug reviews issued between January 2004 and June 2009 were retrieved 
from the SMC website.  Of these, 288 full submissions and resubmissions were 
included for analysis. A total of 243 technology appraisals were excluded from the 
analysis for the following reasons:  i) due to an abbreviated/IRP or non submission 
(n=169) ii) full guidance was not available (n=58); iii) they focused on a non-adult 
population (n=11); and iv) marketing authorisation was withdrawn (n=5).  Prior to 
January 2005, full guidance was not reported, therefore this analysis focused on SMC 
coverage decisions made between 2005-2009.  The 288 drug reviews that were included 
in the analysis covered a total of 184 medications.  The most common coverage 
decision by the SMC was to not recommend funding for the new technology (46%), 
followed by restriction of funding (35% of technologies), and technologies 
recommended for funding (19%) (Table 5.2).   
 
 
In the SMC sample (n=288), there were about 15% of variable entries for which data 
was lacking.  The variables with the highest number of incomplete entries were for 
those variables related to the economic characteristics of the technology.  More than 
half of submissions where cost-utility models were presented did not report uncertainty 
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estimates around the base case ICER. A more detailed description of incomplete data 
within the SMC sample is provided in Appendix B.   
 
5.3.2 Descriptive statistics  
Clinical Evidence 
Descriptive statistics for the SMC sample are summarised in Table 5.3.   Six variables 
related to the clinical evidence supporting the technology under evaluation by SMC 
were evaluated by decision outcome.  The first three variables described the nature of 
the randomised clinical trial data available in terms of the number of trials, sample size 
and trial duration. On average SMC took into consideration 2 RCTs in their review 
process. This did not differ between interventions that were recommended, restricted or 
not recommended.   The mean size of the patient sample included in RCTs was higher 
for those interventions recommended by SMC (mean = 1532 patients), compared to 
those interventions restricted or not recommended by SMC (1360 and 484 patients, 
respectively) (p<0.01).  The mean trial duration across the three outcome groups was 
60, 50 and 35 weeks respectively for recommended, restricted and not recommended 
interventions (p<0.05).   
 
The impact of the RCT design and outcomes was also assessed.  In particular, 
information was collected as to whether the RCTs demonstrated the technology to be 
statistically significantly superior in its primary endpoint to the comparator.    
Unexpectedly, a higher proportion of RCTs demonstrating superiority of efficacy were 
not recommended.  48% of recommended interventions demonstrated statistically 
significant superiority, as opposed to approximately 52% of restricted and 58% not 
recommended interventions (NS).  The interventions recommended for use had a higher 
chance of comparison to active comparators (67%) than interventions that were 
restricted or not recommended (53%, 43% of RCTs with active comparators, 
respectively) (p<0.05).   
 
Consideration of non-randomised observational data was also recorded.   On average, 
SMC appraisals considered 1.3 observational studies.  Recommended and restricted 
interventions did not consider any observational data, compared to not recommended 
interventions supported by 2.7 studies.  However, these differences between outcome 
groups were not statistically significant.   
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Disease characteristics 
Disease characteristics, including the disease category, size of the population eligible 
for treatment, the availability of alternative therapies, and orphan designation status 
were recorded.  The average size of the eligible population for treatment by the 
technology under review was 11,229 patients across all decisions.  This ranged from 
36,122 patients for recommended interventions to 6,584 and 4,000 patients in the 
restricted and not recommended interventions (p<0.05).   
 
The availability of alternative therapies was assessed to ascertain if this differed 
between recommended and restricted or not recommended interventions.  In the 
majority of technologies appraised, an alternative was available (in 83% of cases, all 
decisions considered).  Unexpectedly, the availability of alternative therapies was higher 
in the recommended group (93%), than in the not recommended group (77%).  It had 
been hypothesised that therapies indicated for treatment of diseases for which there was 
no alternative would be more likely to be recommended due to higher unmet need.  This 
did not appear to be the case, based on the descriptive analyses presented.  The 
differences between outcomes were statistically significant (p= 0.031).  Of the 
technologies assessed by the SMC, 13% had an orphan designation.  A lower proportion 
of orphan technologies were in the recommended group (6%) relative to the restricted 
(9%) and not recommended group (18%).  These differences were statistically 
significant between the groups, suggesting that a higher proportion of orphan designated 
technologies were not recommended.  A higher proportion of technologies indicated for 
infectious diseases were in the non recommended group (5%) compared with the 
recommended (17%) and restricted groups (16%) (p<0.05).   
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Table 5.3  SMC Coverage Decisions:  Descriptive statistics for extracted variables, by coverage decision (recommended, restricted, not recommended)  
 Total SMC sample (n=288) SMC Recommended Technologies 
(n=54) 
SMC Restricted Technologies 
(n=102 
SMC Not Recommended 
Technologies (n=132) 
Variable Mean 95% CI  Mean 95% CI  Mean 95% CI  Mean 95% CI  
Number of RCTs  2.2 1.9 2.5 2.3 1.7 2.9 2.3 1.7 2.8 2.1 1.8 2.4 
Size of population 
included in RCTs 
999 693 1305 1532 572 2492 1360 691 2028 484 377 592 
Length/extent of 
follow-up in RCT 
(weeks) 
45 39 52 60 42 78 50 38 63 35 28 42 
Statistically 
Significant results -   
yes  
54% 48% 60% 48% 34% 62% 52% 42% 62% 58% 49% 66% 
no 21% 16% 26% 22% 11% 34% 23% 14% 31% 20% 13% 27% 
inconsistent 18% 13% 22% 24% 12% 36% 22% 13% 30% 12% 6% 18% 
Use of Active 
Comparator in RCT 
51% 45% 57% 67% 55% 79% 53% 44% 62% 43% 34% 51% 
Number of 
observational 
studies considered 
in guidance 
1.3 -0.4 3.0 0.0 0.0 0.0 0.1 0.0 0.2 2.7 -1.0 6.4 
Consideration of 
Cost Utility 
Analysis in 
guidance 
74% 69% 79% 67% 54% 80% 77% 69% 86% 75% 68% 82% 
Incremental Cost-
effectiveness ratio 
of technology vs. 
comparator in base 
case 
£34,013 £21,661 £46,364 £11,893 £8,645 £15,140 £26,316 £13,265 £39,367 £46,679 £23,373 £69,985 
More than one 
CUA submitted 
1% 0% 2% 0% 0% 0% 1% -1% 3% 2% -1% 4% 
If more than one 
CUA submitted - 
low range 
£10,399 -£9,782 £30,580 . . . £3,194 . . £14,002 -£52,096 £80,100 
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 Total SMC sample (n=288) SMC Recommended Technologies 
(n=54) 
SMC Restricted Technologies 
(n=102 
SMC Not Recommended 
Technologies (n=132) 
Variable Mean 95% CI  Mean 95% CI  Mean 95% CI  Mean 95% CI  
If More than one 
CUA submitted - 
high range 
£18,207 -£2,672 £39,086 . . . £10,920 . . £21,851 -£48,681 £92,383 
Uncertainty around 
the base case ICER 
(probabilistic) 
58% 43% 72% 72% -164% 307% 71% 53% 90% 37% 13% 61% 
Uncertainty around 
base case ICER 
(univariate)  Low 
£33,277 £8,916 £57,637 £11,251 £5,017 £17,486 £8,963 £5,794 £12,132 £63,494 £8,516 £118,471 
Uncertainty around 
base case ICER 
(univariate) High 
£77,071 £27,230 £126,912 £31,647 £19,847 £43,448 £27,112 £20,849 £33,375 £147,174 £26,746 £267,601 
Non-CUA analyses 
submitted 
30% 25% 36% 39% 25% 52% 25% 16% 33% 31% 23% 39% 
Potential budgetary 
impact  (million) 
£1.190 £0.928 £1.451 £1.816 £0.923 £2.708 £1.205 £0.743 £1.668 £0.907 £0.661 £1.153 
Prevalence of 
disease/clinical 
condition 
11229 1640 20819 36122 -12168 84412 6584 1612 11557 4000 1694 6307 
Societal 
Perspective adopted 
0% 0% 1% 0% 0% 0% 1% -1% 3% 0% 0% 0% 
Availability of 
alternative 
therapies in current 
treatment setting. 
83% 79% 87% 93% 85% 100% 85% 78% 92% 77% 70% 85% 
Inclusion of patient 
submission 
41% 35% 48% 27% 14% 41% 45% 34% 56% 44% 35% 54% 
Number of 
Decision Makers 
Accountable 
25 24 25 25 24 26 25 24 25 25 24 26 
Cost-effectiveness 
evaluation 
component in 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
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 Total SMC sample (n=288) SMC Recommended Technologies 
(n=54) 
SMC Restricted Technologies 
(n=102 
SMC Not Recommended 
Technologies (n=132) 
Variable Mean 95% CI  Mean 95% CI  Mean 95% CI  Mean 95% CI  
process 
Budget impact as a 
component of 
decision-making 
process 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Price of technology  
known during 
appraisal 
100% 100% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Accountability of 
drug budget 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Date guidance was 
issued 
2007 2007 2007 2007 2006 2007 2007 2006 2007 2007 2007 2007 
Population size – 
Agency coverage 
(millions) 5137 5133 5140 5138 5129 5147 5135 5129 5141 5138 5133 5143 
GDP-healthcare 
expenditure 
8% 8% 8% 8% 8% 8% 8% 8% 8% 8% 8% 8% 
Healthcare 
expenditure on 
pharmaceuticals 
£191 £191 £192 £191 £190 £193 £191 £190 £192 £192 £191 £193 
Election year at 
time of decision 
47% 41% 53% 48% 34% 62% 48% 38% 58% 45% 37% 54% 
Priority disease 
area 
66% 61% 72% 67% 54% 80% 69% 59% 78% 64% 56% 73% 
Orphan Designated 13% 9% 16% 6% -1% 12% 9% 3% 14% 18% 12% 25% 
Proportion of 
Advice following 
Full submission 
78% 73% 83% 81% 71% 92% 80% 73% 88% 75% 68% 82% 
BNF1 
cardiovascular 
10% 7% 14% 17% 6% 27% 9% 3% 14% 8% 4% 13% 
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 Total SMC sample (n=288) SMC Recommended Technologies 
(n=54) 
SMC Restricted Technologies 
(n=102 
SMC Not Recommended 
Technologies (n=132) 
Variable Mean 95% CI  Mean 95% CI  Mean 95% CI  Mean 95% CI  
system 
BNF2 central 
nervous system 
21% 16% 26% 15% 5% 25% 19% 11% 26% 26% 18% 33% 
BNF3 ear, nose and 
oropharynx 
0% 0% 1% 2% -2% 6% 0% 0% 0% 0% 0% 0% 
BNF4 endocrine 
system 
8% 5% 12% 9% 1% 17% 10% 4% 16% 7% 2% 11% 
BNF5 eye 1% 0% 2% 4% -1% 9% 1% -1% 3% 0% 0% 0% 
BNF6 gastro-
intestinal system 
4% 2% 6% 2% -2% 6% 1% -1% 3% 8% 3% 12% 
BNF7 infections 11% 7% 14% 17% 6% 27% 16% 9% 23% 5% 1% 8% 
BNF8 malignant 
disease and 
immunosuppression 
25% 20% 30% 20% 9% 31% 26% 18% 35% 26% 18% 33% 
BNF9 
musculoskeletal 
and joint diseases 
3% 1% 6% 0% 0% 0% 5% 1% 9% 4% 0% 7% 
BNF10 nutrition 
and blood 
6% 3% 9% 6% -1% 12% 3% 0% 6% 9% 4% 14% 
BNF11 obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
2% 0% 3% 0% 0% 0% 3% 0% 6% 2% -1% 4% 
BNF12 respiratory 
system 
4% 2% 6% 2% -2% 6% 3% 0% 6% 5% 1% 9% 
BNF13 skin 4% 2% 6% 7% 0% 15% 5% 1% 9% 2% -1% 4% 
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Economic Evidence      
A range of economic related variables were included for analysis.  74% of SMC 
decisions were backed by use of CUA.  The difference between recommended, 
restricted or not recommended interventions in the availability of non-CUA was not 
statistically significant (p=0.359).  In almost all cases a single CUA, rather than 
multiple CUA, was reviewed.   
 
For the interventions supported by a CUA, the ICER was significantly different between 
the recommended interventions (mean ICER of £11,893), compared to the restricted 
interventions (mean ICER of £26,316), and the interventions not recommended for use 
(mean ICER of £46,679) (p=0.0001).  A descriptive analysis of the ICER within SMC 
advice is displayed in Figure 5.2.  The appraisals are ranked by the size of the ICER, 
and the bars are coloured in accordance with the coverage decision made.  In general, 
technologies that were recommended or restricted (green and orange bars) were found 
in the lower ICER ranges, while not recommended technologies (red bars) were located 
in the upper ICER range.  However, the figure also shows that, while the ICER is an 
important variable in SMC decision-making, there are exceptions in its usefulness as a 
predictor of coverage decisions.  There are recommended technologies with very high 
ICERs, as there are technologies with lower ICERs that are not recommended.  This 
suggests the need to examine the role of a combination of factors to explain SMC 
decision-making.   
 
Considerable effort was made to capture information on the uncertainty around base-
case ICER estimates.  This was done by recording results of probabilistic sensitivity 
analyses (the probability of ICER remaining below a set threshold), and by recording 
univariate sensitivity analyses (lowest ICER, highest ICER).    The probability of the 
ICER remaining below £30,000 was 72% for recommended interventions, 71% for 
restricted interventions and 37% for interventions not recommended for use.  The 
differences between restricted and not recommended interventions were statistically 
significant (p=0.018), and differences between all three coverage outcomes was 
statistically significant at the p<0.10 level.   
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Figure 5.2  SMC:  Base-case ICER reported in SMC appraisals, by coverage decision (n=169) 
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With regard to univariate sensitivity analyses, the uncertainty around the base case 
ICER was measured by capturing information on the lowest ICER generated by the 
model and the highest ICER.  The difference between these two provided useful 
information on the range of uncertainty around a base case ICER.  The range of 
uncertainty was similar for those interventions that were recommended (£11,251-
£31,647) or restricted for use (£8,963-£27,112), while the widest range of uncertainty 
was observed for interventions not recommended for use (£63,493-£147,174).   
 
Aside from examining the results of CUA considered by the SMC review committee, 
information was also captured on whether alternative cost-effectiveness models (non-
CUA) were considered in the decision-making process.  30% of interventions were 
supported by non-CUA models.   Modest differences between decision outcome groups 
in the use of non-CUA models were not statistically significant (p=0.198). 
 
The potential budget impact of a positive recommendation was analysed - the mean 
estimated maximum yearly budget impact across all decisions was in the order of £1.9 
million.  This ranged from £1.82 million for the recommended interventions to £1.21 
and £0.90 million for the restricted and not recommended interventions, respectively.  
These differences observed between groups were not statistically significant. 
 
SMC assessment process characteristics 
A series of variables related to the decision-making process were recorded.  Less than 
1% of decisions formally considered a social perspective in the review process.  In 41% 
of decisions, patient-group submissions were formally considered in the appraisal.  On 
average the appraisal committee comprised of 25 members.  In all of the decisions there 
was a cost-effectiveness evaluation component as well as a budget impact component.  
The Drug review process considers only one compound at a time. In terms of the 
submission process, 78% of submissions were “full submissions”, and 22% were 
“resubmissions”.  None of the above variables differed significantly between outcome 
groups.   
 
Socio-economic context of SMC decision-making 
A series of variables were recorded to capture the socio-economic context in which 
SMC decisions were made.  In particular, information was recorded on the year of the 
appraisal (mean 2007), size of population under SMC remit (approx. 5.14 million), 
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percentage of GDP spent on healthcare (8% on average across groups), whether 
appraisal coincided with an election year and whether the technology under appraisal 
was linked to a disease considered to be a ‘priority’ by Department of Health (66% of 
technologies appraised were directly linked to a priority disease area).  There was strong 
correlation between the year of appraisal and the other socio-economic factors.  The 
year of appraisal, population size, percentage of GDP spent on healthcare and mean 
healthcare expenditure per patient per year did not vary significantly between outcome 
groups.   
 
Summary of descriptive analysis 
Of the 36 explanatory variables explored within the SMC sample, descriptive analysis 
suggests that nine factors may play an important contributing factor in determining 
SMC decision-making (Table 5.4).  For these variables, statistically significant 
differences were observed between interventions that were recommended, restricted and 
not recommended (p ≤ 0.05).   Highly statistically significant differences (p ≤ 0.01) 
were observed for variables highlighted in bold in Table 5.4.   
 
Table 5.4  SMC descriptive statistics: statistically significant variables (p≤ 0.05) 
Evidence factors Variables 
Clinical Package Size of RCT population 
Duration of RCT 
Active comparator used 
Statistically significant superiority not demonstrated in 
RCT 
Economic Package ICER 
Uncertainty around ICER: probabilistic, univariate 
 
Disease characteristics Prevalence of disease 
Alternative 
Orphan designated status 
BNF categories:  eye disorders, gastro-intestinal system, 
infections 
Process factors -  
Socio-economic context factors - 
Note:  variables in bold text were statistically significant at the p ≤ 0.01 level 
 
5.3.3 Multivariate Analysis 
Following the model specification process described in Chapter 3 which included the 
development of a preliminary model (Appendix B), the base case SMC regression 
model was developed which included seven variables (Table 5.5):  the size and duration 
of the RCT, the ICER, if the technology was indicated for use in infections or skin 
diseases, number of patients eligible for treatment, and the availability of alternative 
therapies within NHS Scotland.  When the coverage decisions were regressed with these 
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seven variables, the resulting pseudo R-squared was 0.10, suggesting that these seven 
variables explained approximately 10% of the variability in SMC coverage decisions.  
The ICER and number of patients eligible for treatment were the only variables that had 
statistically significant impact on coverage decisions whether between a 
recommendation and a restriction or recommendation and a non-recommendation.  A 
unit increase in the ICER increased the probability of a decision to restrict or not 
recommend – which was statistically significant in both arms of the model (p=0.33 and 
p=0.018, respectively).  A unit increase in the number of patients eligible for treatment 
statistically significantly decreased the odds of both a restriction and recommendation.   
 
Table 5.5  Multivariate analysis of SMC coverage decisions 2005-2009:  base case model results   
Restricted Technologies Log Odds P value 95%  Conf. Interval 
RCT size 0.000056 0.42 -0.00008 0.00019 
RCT duration of follow-up -0.0039 0.19 -0.0098 0.0019 
ICER 0.000025 0.033 0.000002 0.0000472 
Infectious Diseases -0.16 0.74 -1.10 0.78 
Skin Diseases -0.32 0.66 -1.74 1.10 
No. of patients eligible for treatment -0.000016 0.083 -0.0000337 2.08E-06 
Presence of alternative therapy -0.53 0.39 -1.73 0.67 
Constant 0.97 0.15 -0.35 2.29 
Not Recommended Technologies Log Odds P value 95%  Conf. Interval 
RCT size -0.00029 0.067 -0.00060 0.00002 
RCT duration of follow-up -0.0096 0.008 -0.017 -0.0025 
ICER 0.000027 0.018 0.0000048 0.000050 
Infectious Diseases -1.67 0.004 -2.81 -0.53 
Skin Diseases -1.72 0.061 -3.52 0.08 
No. of patients eligible for treatment -0.00002 0.087 -0.00003 0.00000 
Presence of alternative therapy -0.98 0.106 -2.16 0.21 
Constant 2.18 0.001 0.87 3.49 
Note:  Recommended technologies are the reference case.  Multinomial logistic regression, pseudo R-
squared: 0.10.   
 
The impact of the remaining variables varied according to the nature of the decision.  
When the decision was between a recommendation and a non-recommendation, several 
clinical and disease variables were found to be significant.  The size and duration of the 
RCT, if the technology was indicated for the treatment of infections or skin diseases, 
and the presence of an alternative therapeutic option, all had a statistically significant 
impact on the probability of a recommendation versus a non-recommendation.  A unit 
increase in the number of patients enrolled in the RCTs included for review within the 
appraisal process decreased the log odds of a non-recommendation relative to a 
recommendation (p=0.067).  Similarly, the duration of follow-up within RCTs reviewed 
by the SMC appeared to have an impact on coverage decisions – a unit increase in 
duration increased the probability of a decision recommendation (p=0.008).   The nature 
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of the disease for which the technology was indicated, particularly if it was indicated for 
treatment of infectious or skin diseases, appeared to decrease the odds of a non-
recommendation (p=0.004, p=0.061 respectively).  Perhaps counter-intuitively, the 
presence of a pre-existing alternative therapy available within the Scottish NHS 
increased the odds of a recommendation.   
 
Impact of alternative model specifications- sensitivity analyses 
Sensitivity analyses were conducted on the SMC regression model, as described in 
Chapter 3.  This included i) examining the impact of a binary rather than three-category 
outcome variable; ii) restricting the base case analysis to complete observations, thus 
excluding observations with imputed values, and (iii) examining the impact of assuming 
ordinality of the outcome variable.     
 
A first sensitivity analysis was conducted on the SMC regression model by collapsing 
the three category outcome variable into a binary outcome variable.  A logistic 
regression was performed examining the log likelihood and the odds of coverage versus 
non coverage.  In this binary model, strong interaction was observed between the ICER 
and the variable signalling the presence of an alternative therapy.  When the latter 
variable was removed from this model the remaining variables, as shown in Table 5.6, 
maintained a similar direction of effect and statistical significance of these effects.  An 
increase in the sample size of the RCT was associated with an increase in the odds of a 
recommendation, as was a unit increase in the duration of the clinical trial.  The ICER 
continued to have a statistically significant effect, as observed in the base case analysis.  
Technologies indicated for the management of infectious or skin diseases appeared to 
have increased odds of being covered.  Finally, a unit increase in the prevalence of the 
disease also increased the odds of coverage. Overall, this sensitivity analysis 
demonstrated that, through the use of a binary outcome variable as opposed to a three-
category outcome variable, the variables that were associated with a statistically 
significant impact on SMC coverage decisions in the base case analysis had a similar 
effect in this alternative binary outcome model.  However, it should be noted that one 
variable had to be dropped due to the interaction observed which had not been found in 
the base case analysis.  In addition, the use of a binary modelling approach was not able 
to reflect how the role of each factor varies according to the decision being made:  i.e. 
the impact of a single variable on the decision to recommend or not recommend may be 
different than its impact on the decision to recommend or to restrict. This was clearly 
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shown to be the case in the base case model where many of the factors had a statistically 
significant impact when the decision was between recommendation and non-
recommendation, but not between recommendation and restriction.    
 
Table 5.6  Sensitivity Analysis 1.  Multivariate analysis of SMC coverage decisions 2005-2009:  sensivitiy 
analysis using binary outcome variable (covered vs. not covered) 
  Log Odds P value 95%  Conf. Interval 
RCT size 0.000355 0.049 1.94E-06 0.000708 
RCT duration of follow-up 8.06E-03 0.013 0.001688 1.44E-02 
ICER -7.84E-06 0.076 -1.7E-05 8.35E-07 
Infectious Diseases 1.608167 0.005 0.475342 2.740993 
Skin Diseases 1.587428 0.049 0.00466 3.170196 
Disease prevalence 7.38E-06 0.104 -1.51E-06 1.63E-05 
Constant -0.49728 0.02 -0.91499 -0.07957 
 
A second sensitivity analysis was performed in which the sample of analysis excluded 
incomplete observations.  This led to a reduction in sample size from 287 to 143 
observations.  The results of the analysis are provided below, and show that the number 
of variables that have a statistically significant impact on SMC coverage decisions is 
reduced to five variables:  duration of RCT follow-up, ICER, if the technology is 
indicated for the treatment of infectious diseases, and disease prevalence (Table 5.7).  
The pseudo R-squared value was 0.14, thus this model explained a higher proportion of 
the variability observed in SMC coverage decisions compared to the base case model 
(pseudo R-squared of 0.10).  However, the results of the model show that the exclusion 
of appraisals with missing data alters three of the seven variables that demonstrated 
significance in the base-case model:  the impact of sample size of the RCT and of 
technologies treating skin diseases was no longer observed, nor was the impact of the 
presence of alternative therapies observed in this sensitivity analysis. The remaining 
variables in the model appear to maintain a similar direction of effect as that observed in 
the base case analysis.  However, of note is the fact that infectious diseases technologies 
and disease prevalence appear to have a statistically significant impact on both the log 
odds of restriction and non-recommendation, while in the base case analysis, a 
statistically significant impact was only observed in the latter instance.  Thus, the 
exclusion of incomplete observations in this sub-analysis does not change the 
importance of the ICER, the duration of the RCT, the prevalence of the disease and the 
nature of the disease (i.e. if indicated for infectious disease) on SMC coverage 
decisions.  These four variables that were found to be important in the base case 
analysis remain as such.  However, three variables which had significant impact in the 
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base-case analysis no longer show such an effect in this sub analysis.  This may reflect 
the bias created in the sample by the removal of incomplete observations. 
 
Table 5.7  Sensitivity Analysis 3. Multivariate analysis of SMC coverage decisions 2005-2009:  sensivitiy 
analysis excluding incomplete observations from the sample  
 Log Odds P value 95%  Conf. Interval 
Restricted technologies 
RCT duration of follow-up -0.0011 0.0042 -0.27 0.79 
ICER 0.000052 0.000025 2.10 0.036 
Infectious Diseases -1.97 0.83 -2.39 0.017 
Disease prevalence -0.000031 0.000017 -1.82 0.069 
Constant 0.60 0.51 1.17 0.243 
Not Recommended Technologies 
RCT duration of follow-up -0.01 0.01 -2.66 0.008 
ICER 0.000056 0.000 2.30 0.021 
Infectious Diseases -1.69 0.76 -2.21 0.027 
Disease prevalence -0.000073 0.000039 -1.87 0.062 
Constant 1.45 0.51 2.82 0.005 
Note:  Recommended technologies are the reference case.  Multinomial logistic regression, pseudo R-
squared = 0.14 
 
In the third sensitivity analysis, ordinality of the outcome variable was assumed.  This is 
in contrast with the base case analysis, where ordinality was not assumed and 
multinomial logistic regression was used.  In this sensitivity analysis ordinal logistic 
regression was used.  The detailed results of this analysis are provided in Appendix B, 
provide generally very similar results to the base case analyses run using a multinomial 
logistic regression model. 
 
5.4 Discussion 
The overall objective of this chapter was to examine the evidence, process and context 
factors that influence decisions made by SMC to accept for routine use, accept for 
restricted use or not recommend new technologies for use in NHS Scotland. In line with 
the hypothesised drivers of HTA decision-making highlighted in Chapter 3, and in light 
of evidence review presented in Chapter 2,  A wide range of explanatory variables were 
included in the analysis, reflecting clinical and economic characteristics of the 
technology under appraisal, the appraisal process itself and the socio-economic context 
in which the SMC operates. In addition to the general aims of the research, specific 
hypotheses relevant for SMC decision-making were explored and are discussed below.  
 
To help evaluate the internal validity of the multivariate analyses performed, the base 
case model results were shared for review with a member of the SMC (Interview with 
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Dr. A. Walker1).  The aim of this interaction was to ascertain if the SMC characteristics 
were accurately captured in the sample used for the analysis, if the approach to the 
analysis was clear and, in particular, the reaction to the model results and potential for 
suggestions or additional analyses. 
 
5.4.1 Pattern of SMC coverage decisions 
The analysis of SMC decisions involved the review of 288 technology appraisals.  The 
most common coverage decision by the SMC was to not recommend funding for the 
new technology (46%), followed by restriction of funding (35% of technologies), and 
technologies recommended for funding (19%).  Multivariate analysis of SMC coverage 
decisions suggest that seven variables appear to have a significant effect on coverage 
decisions: the sample size and duration of the RCT(s); the incremental cost-
effectiveness ratio (ICER); if the technology was indicated for use in infections or skin 
diseases, the prevalence of the disease in question, as well as whether there was an 
alternative therapy available within NHS Scotland.  Other analyses of coverage 
decisions made by the SMC provide different proportions of coverage types, although 
this appears to be due to differences in time horizon.  For example, the SMC Annual 
Report (SMC 2008) summarises coverage decisions for 2008:  31% accepted for use, 
36% of technologies accepted for restricted use, and 33% technologies not 
recommended for use.  In a similar exercise but looking at decisions in the period 2007-
2009, Kanavos et al. (2010) find that the SMC recommended 28% of technologies, 
restricted 40% of them and did not recommend 32% of technologies.  Thus, the period 
used within the analyses produced in this thesis, spanning 2005-2009, has a higher 
proportion of non-recommendations in its sample than observed in other publications 
reporting SMC decision-making.  Dr. A. Walker1 suggested that such differences can be 
attributed to the use of different time horizons (2005-2009 vs. 2007-2009 or single 
years) and also to the fact that publications report SMC coverage decisions across all 
types of submissions, whether full submissions, resubmissions, abbreviated submissions 
or IRPs.  Within the SMC sample used for this thesis, only full or re-submissions were 
included. 
 
                                                 
1 Walker, Andrew. Senior Lecturer in Health Economics, University of Glasgow and member of the New 
Drugs Committee at the Scottish Medicines Consortium.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on December 20th 2010.  Meeting minutes are provided in Appendix E.    
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5.4.2 The role of clinical evidence factors in SMC decision-making 
The duration and size of the RCTs supporting the technology had a significant impact 
on coverage decision.  Specifically, increasing trial duration and trial sample size was 
associated with decreased log odds of a non-recommendation versus recommendation, 
and a decreased log odds of restriction relative to recommendation.  Technologies 
recommended by the SMC tended to be supported by on average larger trials of longer 
duration (sample of 1,532 patients, with trial duration of 60 weeks), compared with 
technologies that were restricted (mean sample of 1360 patients, with trial duration of 
50 weeks) or not recommended (mean sample of 484 patients, with mean trial duration 
of 35 weeks) by SMC.    
 
Disease characteristics were also found to play an important role in SMC coverage 
decisions.  The nature of the disease and the size of eligible patient population were 
found to have a statistically significant effect.  Perhaps unexpectedly, an increasing size 
of eligible population of the disease targeted by the technology was found to decrease 
the odds of non recommendation relative to recommendation.  This result is contrary to 
the hypothesis that there would be a relationship between budgetary impact of new 
technologies, which are in part driven by the anticipated volume of up-take of a new 
technology, and SMC decision-making, specifically that an increase in budgetary 
impact would be associated with a decrease in the log odds of recommendation relative 
to restriction and non-recommendation.  This data however suggests that an increase in 
patient volume, which would tend to increase budgetary impact, is not associated with 
decreased log odds of recommendation – but rather the contrary.  The mechanism for 
this was suggested to be related to the characteristics of those technologies that have 
low number of patients eligible for treatment (Dr. A. Walker).   When appraisals were 
grouped by the size of the eligible population for which the technology was indicated 
(500 patients or less per year “low eligible population”, vs. >500 patients per year), the 
mean ICER in the low eligible population group was more than twice that of the 
technologies with larger eligible population (£48,480 vs. £19,945).  The technologies 
for which there are an estimated <=500 eligible population appeared to be supported by 
lower quality set of supportive clinical evidence relative to the >500 eligible population 
group (Table 5.8) 
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Table 5.8 SMC coverage decisions – comparison of characteristics of evidence supporting technologies, by size 
of eligible population 
Size of eligible 
population 
ICER No. Of RCTs RCT sample size RCT duration 
(Weeks) 
<= 500 eligible 
patients per year) 
£48,480 1.5 423 46 
>500 eligible 
patients per year 
£19,945 2.7 1,753 42 
 
Technologies indicated for the management of infectious diseases increased the odds of 
a recommendation relative to a non-recommendation.   Among the set of technologies 
for infectious diseases (n=28), 35% were for the treatment of HIV infection, while the 
majority (54%) of these technologies were antibiotic or anti-fungal agents (n=15).  
Among this set of technologies (n=15), none of the appraisals reported ICERs, and the 
clinical data supporting these studies was lower than the average for the entire SMC 
sample.  Specifically, antibiotic/anti-fungal agents were supported by 1.4 studies (vs. 
mean of 2.2) and approximately half of the mean sample size (999 patients in total SMC 
sample vs. mean 513 patients in this subsample).  Despite the relatively low quality 
supporting evidence, 80% of the antibiotic/anti-fungal agents were restricted (12 of 15) 
and only 2 were not recommended.  A plausible explanation for the impact of infectious 
diseases on coverage decisions could be the fact that antibiotics are included within this 
BNF category, and that on the one hand, the quality of data for antibiotic therapy is not 
very high, but on the other hand the concern over developing resistance to antibiotics 
suggests that there is a need to allow for new antibiotics to be available for use 
(Interview with Andrew Walker, 2010).  This may explain the result obtained in the 
model with effects which are significant when there is a trade-off between 
recommendation and non-recommendation, but not statistically significant when the 
trade off between restriction and non-recommendation.   
 
5.4.3 The role of economic evidence in SMC decision-making 
The ICER was found to have a significant positive effect on the odds of a restriction and 
non-recommendation relative to a recommendation.  This can be seen to reflect the 
SMC’s objective to identify those technologies that represent value for money.  As 
shown in Figure 5.2, technologies that were recommended or restricted were found in 
the lower ICER ranges, while not recommended technologies were located in the upper 
ICER range.  However, the figure also shows that, while the ICER is an important 
variable in SMC decision-making, there are exceptions in its usefulness as a predictor of 
coverage decisions.  There are recommended technologies with very high ICERs, as 
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there are technologies with lower ICERs that are not recommended.  The role of 
uncertainty around the ICER was challenging to assess due to poor reporting of 
information. Of the 288 observations, uncertainty information (whether univariate or 
probabilistic) was missing in more than 200 observations.   
 
The results also suggest that in its decision-making the role of the ICER has a prominent 
impact, relative to other factors such as degree of unmet medical need.  The presence of 
an alternative therapy indicated in the same population to the technology under 
evaluation appears to impact significantly on SMC coverage decisions, although 
perhaps not in the direction that had been hypothesised based on the literature.  The 
analysis suggests that the presence of an alternative therapy decreases the odds of a non-
recommendation (p=0.106).  In other words, those technologies where no alternative 
was present had increased odds of non-recommendation, relative to those technologies 
where an alternative was already available in NHS Scotland, all other things being 
equal.  It is noteworthy that about 40% of those technologies with no alternatives were 
orphan-designated technologies.  Moreover, those technologies where no alternative 
was available also had higher mean ICERs compared to those technologies where 
alternatives were available – almost three times as high (£62,021 vs. £20,679 
respectively, Fig. 5.3).  This provides an example of the various clinical, disease and 
economic factors intertwined within an HTA process.  In addition, these results raise 
questions about the extent to which the SMC encourages innovation in the 
pharmaceutical industry.   
 
Figure 5.3 SMC: mean ICER for technologies where alternative therapy is present or absent 
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5.4.4 No clear impact of process or socio-economic context variables on SMC 
decision-making 
It was hypothesised that SMC decision-making would be impacted by the process 
through which the technology was appraised.  In particular it was hypothesised that the 
type of submission (whether first-time submission or re-submission) would impact on 
decision outcomes.   However, this was not found to be the case – across the outcome 
categories, there were no statistically significant differences in the proportion of 
technologies appraised under first or re-submissions.  Indeed, none of the variables 
collected to assess impact of process on decision-making (including use of economic 
evidence as part of process, size of committee) were associated with significant impact 
on the outcome variable.   With regards to the socio-economic context variables – none 
were found to have a statistically significant and stable effect in the multivariate 
analyses nor in the descriptive analyses.  This evidence therefore is not in support of the 
hypothesised change in decision-making outcomes over time.   
  
5.4.5 Limitations 
When examining the results of the multivariate analyses, there are several limitations 
that need to be taken into account.  The first is that the SMC, compared with other 
agencies like NICE, provides relatively limited information in the public domain on the 
evidence reviewed and considered in their decision-making process.  In general, the 
SMC Advice reports that are publicly available provide concise summaries of key 
issues but do not document details on the various clinical considerations or economic 
arguments to which they were exposed; primarily they highlight those considerations 
that were found to be drivers of their decision.  On the one hand, this helps the data 
extraction process by providing the key data that was felt, by the agency, to drive their 
decision-making.  On the other hand, the aim of this thesis and analysis was to collect as 
much objective evidence as possible on factors driving decision-making.  The lack of 
detail in reporting led to higher rates of incomplete observations, particularly with 
regard to information on the uncertainty around incremental cost-utility/effectiveness 
ratios, compared to agencies like NICE where a larger quantity of information is 
publicly available, including manufacturer submissions (depending on the appraisal 
process used).  The lack of data linked to this reporting style was managed by using 
imputation techniques in the multivariate analysis.  The implications of using such 
techniques, versus restricting the analysis to complete observations were assessed in a 
sensitivity analysis conducted on the sample of coverage decisions for which the data 
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was complete.    The results of these sensitivity analysis showed that limiting the 
analysis to complete observations, and thereby removing 130 decisions from the 288 
SMC advice reports, may lead to bias in the sample for analysis.  Despite this bias, four 
of the seven variables significant in the base-case analysis remain significant in this sub-
analysis, thus confirming their important role in SMC coverage decisions.   
 
An important factor to take into account when examining SMC coverage decisions is its 
reliance on manufacturers’ submissions to formulate its advice.  There is no third party 
or significant additional new analysis performed on the evidence submitted by the 
manufacturer. The focus of the SMC is to critically review the submitted evidence in 
order to reach a conclusion about the degree of certainty or uncertainty around the 
effects and value for money of the technology under appraisal.  Given the lack of 
accessibility to manufacturer submissions in the public domain, it was not possible to 
take into account in the analyses to what degree the SMC advice was driven by the 
manufacturer submission strategy relative to SMC decision-making criteria 
(Conversation with Andrew Walker, 2010).  For example, for a technology that was 
accepted for restricted use, it was not possible to ascertain if this restriction was 
proposed and implemented by the SMC, or whether the restriction was proposed by the 
manufacturer in their submission.  Nevertheless, while there was lack of complete 
information on the evidence and manufacturer strategy used within SMC assessments, it 
can be argued that whether a particular coverage decision is proposed by the 
manufacturer or by the SMC does not hamper the ability to identify the effect and 
significance of the clinical, economic and disease characteristics of the technologies 
assessed by the SMC on its coverage decisions.   
 
It is noteworthy that none of the appraisal process characteristics or socio-economic 
factors appeared to have a significant effect on coverage decisions.  This suggests the 
general stability of the appraisal process and socio-economic context of decision-
making, and therefore the lack of significant variation within the period for which 
coverage decisions were extracted.  In addition, it should be noted that socio-economic 
factors varied at the agency level, rather than at the decision-level:  thus the degree of 
variability was substantially reduced to annual changes in socio-economic factors.  The 
relative importance of socio-economic and process factors will be examined further in 
the pooled analysis of coverage decisions from all four HTA bodies, presented in 
Chapter 8.   
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In summary, the overall objective of this chapter was to examine the factors that 
influence decisions made by SMC to recommend, restrict or not recommend 
pharmaceutical technologies for use in its respective healthcare systems, with a focus on 
research hypotheses specific to SMC decision-making. The results suggest that the 
variability in coverage decisions observed can be explained by a combination of 
clinical, disease and economic factors.   It is noteworthy that the role and effect of the 
majority of variables differed according to the nature of the decision.  This suggests that 
the use of a multinomial outcome variable facilitates the ability to identify potential 
differences in the impact of the same factor on different coverage decisions, which 
would not have been possible with a binary outcome category.  The analyses did not 
support the hypothesis that process factors impact on SMC decision-making, nor that 
socio-economic factors, measured by time, significantly impact on SMC decision-
making.   The analysis confirmed the important role of the ICER in SMC decision-
making in which increases in the ICER are associated with decreasing log odds of 
recommendation relative to restriction or non-recommendation.  The results also 
suggest that the ICER may take a central role in decision-making over and above other 
considerations such as unmet medical need.  This was observed in a closer examination 
of technologies for which there were no alternative regimens available – lack of 
alternative tended to increase rather than decrease the odds of non-recommendation 
contrary to the hypothesised effect.  Contrary to expectations, budgetary impact was not 
found to play a significant role in SMC decision-making, based on the multivariate 
model generated.   
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6 Empirical analysis of CVZ coverage decisions 
 
 
Adalimumab was reviewed by NICE, SMC, CVZ and HAS for the treatment of 
ankylosing spondilitis.  The CVZ provided the following guidance:   
“...[adalimumab is] indicated for an insured member of eighteen 
years of age or older (...) with severe active ankylosing 
spondylitis where there is evidence of insufficient response to at 
least two non-steroidal anti-inflammatory drugs at maximum 
dose and other conventional therapy”.  (CVZ 2006 section 7a)1. 
 
Based on its assessment of adalimumab, the CVZ restricted its use to those patients that 
had experienced ‘insufficient’ response to at least two previous therapies.  This decision 
is similar to that made by both NICE and the SMC, despite the fact that the Dutch 
reimbursement system and CVZ assessment process differ from the pharmaceutical 
funding mechanisms within the NHS structures in Scotland and England and the 
methods by which NICE and SMC appraise technologies.   To what extent do evidence, 
process and context factors play a role in CVZ decision-making?  And are the factors 
that were found to impact significantly on NICE and SMC decision-making also 
reflected within CVZ coverage decisions?    
 
This chapter provides an empirical analysis of coverage decisions made by CVZ in 
2004-2009.  First, an overview of the CVZ, its objectives and appraisal process is 
provided.  The methods for the analysis are then outlined, building upon the methods 
discussed in Chapter 3.  Following this, the results of the descriptive and multivariate 
analyses of the CVZ coverage decisions are reported and explored, and limitations 
considered.  The chapter concludes with a brief discussion on the empirical analyses 
performed for the CVZ. 
 
6.1 CVZ Appraisal Process 
In the Netherlands, the College Voor Zorgverzekeringen (CVZ) has an important role in 
supporting and maintaining the quality, accessibility and affordability of health care in 
the Netherlands.  It has both an advisory and implementation role for two social health 
insurance funds: the Zorgverzekeringswet (Zvw) and the Algemene Wet Bijzondere 
                                                 
1 Original CVZ statement:  “uitsluitend voor een verzekerde van achttien jaar of ouder (...) met ernstige 
actieve spondylitis  ankylopoëtica waarbij er sprake is van onvoldoende respons op ten minste twee 
prostaglandinesynthetaseremmers in maximale doseringen en andere conventionele behandeling.” CVZ 
2006 section 7a.   
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Ziektekosten (AWBZ).    The Commissie Farmaceutische Hulp (CFH) is a part of the 
CVZ.  It is tasked with the assessment of the therapeutic value of new technologies for 
inclusion in the Medicine’s Reimbursement System (Geneesmiddelen Vergoedings 
Systeem – GVS), or inclusion in the various reimbursement policies of the Dutch 
Health Authority (Nederlandse Zorgautoriteit - NZa).   
 
The CFH is composed of 20 external members, with a maximum eight-year length of 
service that meets on a monthly basis to review applications for reimbursement (CFH 
2011).  Unlike NICE and its MTA appraisal process, there is no third party evaluation 
system utilised by the CFH.  Collectively, the role of the CFH and CVZ is to advise the 
Minister of Health on whether to include the technology for reimbursement and if so, on 
what basis.  Thus, the Ministry of Health has the final decision-making authority with 
regard to the reimbursement of new technologies.   
 
The GVS includes the list of medicines that are reimbursed under the conditions of the 
Zorgverzekeringswet (Zvw).  The technologies included in the GVS list are reimbursed 
by all the sickness funds.  Those that are included on the special policy lists (e.g. 
expensive drug list) are reimbursed by the Ministry of Health, Welfare and Sports (CVZ 
2010a).  There are two lists within the GVS:  the 1A and 1B list (CFH 2010a; Sorenson 
et al. 2008; Stolk and Rutten 2005).  Figure 6.1 summarises the coverage options 
available within the Dutch health care system. List 1A is for technologies used to treat a 
similar patient population with comparable therapeutic value and mode of 
administration.  Technologies in List 1A are ‘clustered’ around one reference price for 
each ‘basket’ of technologies.   List 1B includes medicines that are not clustered and 
thus do not fall within the reference pricing system.  In addition, there is a List 2 which 
includes medicines for which there are restrictions on use (CVZ 2010a).   Unlike 
technologies on List 1A which have a reimbursement limit calculated based on the 
prices of other technologies within the cluster, technologies on 1B and 2 do not have a 
pre-specified limit.  For those technologies in List 1A where the acquisition costs are 
higher than the limit, the patient is asked for a co-payment by the health insurers to be 
able to access the medications.   
 
 
 
 
  
 
169
Figure 6.1 Pharmaceutical Reimbursement System in the Netherlands 
  
 
In its review of the reimbursement request by the manufacturer, the CVZ aims to 
provide advice to the Ministry of Health on two aspects: firstly, the positioning of the 
technology under appraisal vis a vis existing technologies; and secondly, under which 
reimbursement list should the technology be funded – the GVS 1A or 1B list, or specific 
reimbursement policies (e.g. the expensive drug list, List ‘2’).  The lists differ in the 
appraisal process and criteria used.  For inclusion on the GVS 1B list, since 2005 
pharmacoeconomic evaluation is a mandatory requirement (Stolk and Rutten 2005).  
For inclusion in the expensive drug list, pharmacoeconomic evaluation and a protocol 
for future pharmacoeconomic evaluation based on real-life effectiveness evidence is 
needed.  Specific types of technologies are exempt from pharmacoeconomic evaluation, 
including orphan designated technologies, technologies for which the total budgetary 
impact of the introduction of the technology after a five year period is lower than EUR 
€500,000, or technologies for which there is equivalence in both effectiveness profile 
and price.   
 
In assessing the positioning of the technology, the therapeutic value of the technology 
plays an important role in the CVZ recommendation.  The CVZ considers three levels 
of therapeutic value in comparison to a standard of care already reimbursed:  i) lower 
therapeutic value (e.g. worse safety profile, lower efficacy), ii) comparable therapeutic 
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benefit (e.g. no relevant differences in favour or against the technology have been 
identified); or iii) added therapeutic benefit (where there are relevant advantages in 
either efficacy, safety or both) (CVZ 2010b).   
 
In order to assess into which therapeutic benefit category the technology should be 
placed, the CVZ takes into account several factors, including the disease for which the 
technology is indicated and whether or not there is a standard of care already 
reimbursed for that system with the same indication, based on clinical guidelines and 
clinical criteria.  The review then considers various aspects of the technology to 
determine whether an incremental therapeutic benefit exists.  This includes the review 
of efficacy and safety, based on randomised clinical control trials (RCTs) and safety 
registries, as well as information about the experience with the technology - such as 
time on the market - to assess the risk of unknown side effects occurring over time and 
to increase the certainty around the therapeutic benefit of the technology.    The CVZ 
evaluates the suitability of the technology – that is, if there are contra-indications for 
specific subgroups of the population e.g. the elderly or for paediatric use.  The CVZ 
also reviews the ‘ease of use’ of the technology – including aspects such as dose 
frequency, whether it is intravenous or oral, how it is packaged and any other aspect that 
could influence the ease of use for patients or carers administering the technology.  The 
financial implications or cost-consequences of adoption of the technology are also 
assessed, similar to budget impact estimation.  
 
Once all of the above aspects have been considered for each individual technology, the 
importance of each factor is weighted and technologies are compared, to come to a 
decision on the category of therapeutic benefit that should be applied (lower benefit, 
comparable benefit or higher benefit).  The CVZ states that in this weighting process, 
several factors are taken into account, including the severity of the disease, whether the 
disease is chronic, and whether alternative therapies are available (CFH 2010b).  Once 
the CVZ has provided its advice to the Ministry of Health, and the Ministry of Health 
gives its formal approval, the reimbursement decision for extramural2 medicines is 
published on the Pharmaco-therapeutic Compass (Farmaco-therapeutisch Kompas) 
(CFH 2010a).   
 
                                                 
2 Extramural medicines are those medicines prescribed outside of a hospital inpatient setting.  
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A special process exists for so called ‘expensive intramural medicines’ (Beleidsregel 
dure geneesmiddelen) which are restricted for use in inpatient hospital conditions 
(College Tarieven Gezondsheidszorg ZorgAutoriteit 2006).  A technology can be 
considered for inclusion in this list if all of the following conditions are met: i) the total 
costs for the technology are equal to or higher than 0.5% of the total hospital 
pharmaceutical budget at national level; ii) if the technology appears to have a 
therapeutic benefit that is of value to the healthcare system; and iii) if there is an 
agreement in place on the data and research that will be carried out after reimbursement 
to establish the true effectiveness of the technology in real-life.  
Three years after inclusion in the expensive drug list, the CVZ re-appraises the 
technology and evaluates its true demonstrated effectiveness, providing advice to the 
NZa on whether to maintain or remove the technology from the list.  This process, in 
fact, represents a type of conditional coverage mechanism, where the technology is 
introduced, observed and re-evaluated in a defined period of time according to a defined 
process.  This system was put in place in 2006.   
 
The CVZ also has a particular role, perhaps less common in other HTA bodies, of 
reviewing technologies for unlicensed indications, upon the request of the health 
insurance bodies.  In this situation, the CVZ is asked to establish if the unlicensed 
indication is rare (less than 1:150,000 population), if there is a scientific basis for the 
efficacy of the technology in this unlicensed indication and if there is no other 
alternative therapy available in the Netherlands for the condition under review.   
 
6.2 Methods 
The overall objective was to 
examine the factors that drive 
decisions made by CVZ to 
recommend, restrict or not 
recommend new technologies for 
use in the Dutch healthcare 
system. In addition to the general 
analysis aims described in 
Chapter 1, the particular 
hypotheses relevant for the 
modeling of coverage decisions 
Box. 6.1 In light of the discussions presented in Chapter 
2, CVZ-specific research objectives were to test whether: 
• Pharmaceutical budget impact estimates 
significantly impact on CVZ outcomes: 
increasing budgetary impact is hypothesised to 
increase the log-odds of non-recommendation 
or restriction relative to recommendation 
• The use of cost-effectiveness analysis 
introduced in 2006 plays a role in CVZ 
decision-making  - increasing ICERs are 
hypothesised to be associated with an increased 
log odds of restriction or non-recommendation 
relative to recommendation 
• ‘me-too’ technologies negatively impact on 
odds of recommendation versus restriction or 
versus non-recommendation 
• Therapeutic areas differ in their impact on the 
odds of recommendation versus restriction or 
versus non-recommendation 
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by CVZ are highlighted in Box 6.1.  Building on from the methods described in Chapter 
3, this section describes the methods used to select the sample for analysis, the outcome 
variable and explanatory variables considered, and the statistical techniques adopted.    
 
6.2.1  Sample  
The pharmaceutical technology reviews performed by CVZ formed the basis for the 
sample included in this analysis.  The composition of the sample was determined 
through the following inclusion and exclusion criteria. The sample included all drug 
technology appraisals (as opposed to medical devices or other interventions) made 
during the period 2004-2009 indicated for an adult population (≥18 years).  Technology 
appraisals were excluded from the analysis for any of the following reasons:  i) they 
focused on a non-adult population; ii) they appraised non-pharmaceutical interventions; 
iii) marketing authorisation was withdrawn; or iv) the full report was not publicly 
available. 
 
6.2.2 Outcome variable 
To address the research question, CVZ decisions were analysed through considering 
HTA outcomes in three categories, where the new technology can be:   
• recommended for routine use 
• recommended for restricted use 
or 
• not recommended 
 
Table 6.1  Classification of CVZ coverage decisions  
Recommended Technology Restricted Technology Not Recommended 
Technology 
If technology placed in: 
  
Reimbursement lists 1A or 1B;  
or 
 
Expensive drug list;  
 
 
If technology placed in: 
 
 List 2 
 
or 
 
If patient co-payment is 
necessary to access medication 
If words ‘not recommended’ 
were indicated on the CVZ 
advice  
 
and 
 
Technology was not included 
on any reimbursement list 
 
For the CVZ, where the decision was to place the technology in the basic package 
(‘basis paket’), ie. Lists 1A or 1B, without any restriction or patient co-payment, or 
listed in the expensive drug list (Dure geneesmiddelen Beleidsregel) was considered to 
be recommended.  Where the decision was to place the technology in the basis paket, 
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but only for use in a sub-population or with a patient co-payment, this technology was 
considered as restricted.  And the technology was considered as not recommended when 
it was designated as ‘not recommended’ and was not included on any reimbursement 
list (Table 6.1).   
 
6.2.3 Explanatory variables 
In line with the hypothesised drivers of HTA decision-making highlighted in Chapter 3, 
the CVZ dataset includes 39 explanatory variables. The first set of variables was related 
to the technology itself – the nature of the clinical evidence available, disease 
characteristics, whether cost-effectiveness evidence was put forward, and if so, the 
characteristics of that evidence.  The second set of variables captured information 
relating to the process by which the recommendation was issued. Included in this 
second set were a few variables that were specifically collected for the CVZ, such as 
information on whether the technology is for use within an inpatient setting 
(intramurale middelen) or an outpatient setting (extramurale middelen).  The reasons 
for collecting this information is that the reimbursement regulations and payers vary 
according to the setting in which the technologies are used.  Another variable specific to 
the CVZ was related to whether or not the technology was included in the expensive 
drug list (Dure geneesmiddelen lijst).  Thus, information was extracted as to whether a 
request was made for those technologies placed on the expensive list,  and this enabled 
the collection of data on real-life use of the technology as a condition for 
reimbursement.  In this category-set, data also was extracted on whether a patient co-
payment was attached to a particular technology or not.  Finally, the third set of 
variables of the data extraction form captured information on the context in which the 
guidance was issued (healthcare system, economic and social context), and thus aimed 
to capture information on health policy and socio-economic characteristics of the 
Netherlands.   
 
6.2.4 Data extraction form 
Similar to the form utilised to extract data from NICE and SMC guidance (see Chapters 
4 and 5), this form contained the definitions and decision rules used when extracting the 
data from the assessment documents issued by CVZ, and other data sources. The data 
extraction form was organized into three segments, relating to the three components of 
analysis that are integral to this research.  The method for data extraction are described 
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in Chapter 3.    Table 6.2 provides the list of variables extracted to create the CVZ 
dataset, as well as the accompanying decision rules and definitions. 
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Table 6.2 CVZ dataset:  Included Variables, their Definition, Data Extraction Rule and Data Sources 
# Variable Descriptor Unit measure Definition Data Sources 
1 Number of RCTs considered 
in decision 
Count The number of distinct Randomised Controlled Trials (RCTs) that 
provide data related to the therapeutic indication under evaluation 
 
Excluded:  studies that are single arm, that have no randomization, or 
that are non-interventional.  
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
2 Size of population included 
in RCTs 
Numeric Mean number of patients per RCT.   CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
3 Length/extent of follow-up in 
RCT 
Numeric Mean number of weeks that data is collected on patients that entered 
the RCTs (see variable no. 1).  
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
4 Statistically Significant 
results 
Categorical 
(yes/no/inconsistent
) 
Presence of statistically significant superiority of technology vs. 
comparator for primary endpoint(s). 
 
If more than one RCT was considered, and the technology showed 
statistically significant superiority in one trial, but not in another, the 
results were considered to be ‘inconsistent’ and classified as such.  
RCTs designed as ‘non-inferiority’ studies were classified as not 
showing any statistically significant superiority (i.e. ‘no’).    
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
5 Relevance of RCT to payer 
decision 
Numeric Percentage of RCTs where active comparator was used.   CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
6 Number of observational 
studies considered in 
guidance 
Count Number of observational studies providing information to support 
study drug.   
 
Observational studies in this circumstance are defined as studies that 
are non interventional (i.e. do not explicitly request the patient to take 
particular medication or the physician to follow particular protocol).   
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
7 Priority disease area Categorical – 
yes/no 
This variable aims to capture the health policy context in which payer 
decision is made, by capturing whether the pharmaceutical in question 
is linked to a disease area that is prioritized by the ministry of health.   
Priority disease areas were identified by examining government 
plans/health documents that highlight national health care system 
Ministerie van Volksgezondheid, 
Welzijn en Sport  (2003, 2007) 
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# Variable Descriptor Unit measure Definition Data Sources 
focus. 
8 Orphan Status Categorical – 
yes/no 
This variable captured information on whether or not the technology 
was recognized by the European Medicines Agency (EMA) as an 
orphan designated medicine.   
European Medicines Agency (2010)  
9 Therapeutic Area Categorical – 13 
categories 
The British National Formulary (BNF) categories were used to classify 
each technology into the corresponding therapeutic area.   
British National Formulary (2010) 
10 Prevalence of disease/clinical 
condition 
Numeric Reported number of patients eligible for treatment, as per the Summary 
Product Characteristics and indication of the medication under 
evaluation is indicated.   
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
11 Availability of alternative 
therapies in current treatment 
setting. 
Categorical – 
yes/no  
An alternative was considered to be available if comparators were 
clearly defined in the review by the HTA agency.  An alternative was 
considered NOT to be available if it was stated as such in the appraisal, 
or if ‘best supportive care’ or ‘palliative care’ was specified as the 
comparator. 
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
12 Consideration of Cost Utility 
Analysis in guidance 
Categorical – CUA 
performed or no 
CUA 
Presence or absence of a cost-utility analysis.   Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
13 Incremental Cost-utility ratio 
of technology vs. comparator 
in base case 
Numeric ICER (Cost per QALY) reported in the report for base case as accepted 
by the CFH.  This is defined as the ICER that is related to the 
recommendation.  If more than one ICER is presented as the 
recommendation covers more than one population, than the ICER 
pertaining to the larger of the populations was reported.   
 
If technology is reported as dominant or dominated, record as such in 
data extraction sheet.   
Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
14 Multiple CUA/CEA models 
reported 
Categorical - 
Yes/No 
Whether more than one cost-utility or cost-effectiveness model was 
considered during the appraisal 
Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
 15   If yes – provide 
range 
If yes, report range of base case ICERs presented between the different 
models reported. The difference between the lowest and highest ICER 
will be calculated. 
Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
16 Uncertainty around the base 
case ICER reported in 
submission (probabilistic) 
Numeric  This should be reported as the percentage probability of acceptance at 
the threshold used by the agency.  For the CFH the probability of the 
medication being cost-effective was reported at a EUR €50,000 
threshold. 
Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
17 Uncertainty around base case Numeric This should be reported as the range of ICERs (min-max) resulting Farmaco-economisch rapport, 
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# Variable Descriptor Unit measure Definition Data Sources 
ICER reported in submission 
(univariate) 
from univariate sensitivity on the base case.     Vraagstelling doelmatigheidstoets 
18 Non-cost per QALY cost-
effectiveness analyses 
submitted 
Yes/No Indicates if non-cost per QALY economic analyses were submitted and 
reviewed.   
Farmaco-economisch rapport, 
Vraagstelling doelmatigheidstoets 
19 Anticipated budgetary 
impact of introduction of 
new technology in health 
care system 
Numeric Estimated annual budgetary impact of introducing new medication into 
the current treatment setting, if the pharmaceutical were to be 
introduced without any restriction.  Drug cost only (per year). 
 
Kostenprognose Rapport 
20 Prevalence of disease/clinical 
condition 
Numeric Reported number of patients eligible for treatment, as per the Summary 
Product Characteristics and indication of the medication under 
evaluation is indicated.   
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f; or  Kostenprognose Rapport, 
section 2.2 
21 Availability of alternative 
therapies in current treatment 
setting. 
Categorical – 
yes/no  
An alternative was considered to be available if comparators were 
clearly defined in the review by the HTA agency.  An alternative was 
considered NOT to be available if it was stated as such in the appraisal, 
or if ‘best supportive care’ or ‘palliative care’ was specified as the 
comparator. 
CFH-rapport , section 2a;  
Farmacotherapeutisch rapport, section 
3, 4a-f 
22 Inclusion of patient 
submission 
Categorical – 
yes/no 
A patient submission was considered to have been included as part of 
the appraisal process if a submission from a patient group was posted 
on the webpage pertaining to the guidance.  
CVZ (2010a) 
23 Number of decision makers 
accountable 
Numeric Captures the number of decision-makers accountable for guidance 
issued, as reported.   
CFH (2011)  
24 Cost-effectiveness evaluation 
component in process 
Categorical – 
yes/no 
Captures whether or not cost-effectiveness is a component of the 
decision-making process. If cost-effectiveness analysis is a formal part 
of the appraisal process, this variable was marked as ‘yes’.  
CFH (2006) 
25 Budget impact as a 
component of decision-
making process 
Categorical – 
yes/no 
Captures whether budget impact considerations are part of decision-
making process 
CFH (2006) 
26 Pricing known during 
appraisal process 
Categorical – 
yes/no 
Captures whether the price of the technology under appraisal was 
known during the assessment.     
CVZ (2010a) 
27 Number of technologies 
appraised simultaneously 
Count This variable captures the number of technologies appraised 
simultaneously in the appraisal.   
CFH-rapport , section 2a;  CFH (2006) 
28 Accountability of drug 
budget 
Categorical – 
yes/no 
The HTA agency was examined to assess whether or not the agency 
making the funding decisions is also accountable for the drug budget or 
Sorenson et al. (2008) 
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# Variable Descriptor Unit measure Definition Data Sources 
not.  
29 Independence of decision-
making agency 
Categorical – 
yes/no 
This pertains to whether the HTA body is independent of Ministry of 
Health or part of it. 
Sorenson et al. (2008)  
30 Date guidance was issued Numeric Year when coverage decision was issued Letter from the minister van 
Volksgezondheid, Welzijn en Sport 
31 Population size – Agency 
coverage 
Numeric Estimate of population size within remit of the agency performing the 
evaluation. 
Centraal Bureau voor de Statistiek 
(CBS)Statline  
32 GDP-healthcare expenditure Numeric (%) Percentage of GDP spent on healthcare, during year of decision from OECD Health Data 2009, OECD 
2010 
33 Healthcare expenditure on 
pharmaceuticals per patient 
per year 
Numeric (€) Healthcare budget spent on pharmaceuticals per patient per year, 
during the same year in which the appraisal was published.  
Centraal Bureau voor de Statistiek 
(CBS)Statline 
Genees- en hulpmiddelen Informatie 
Project (GIP), accessed February 2010 
34 Drug funding process within 
healthcare system – whether 
centralized or decentralized 
Categorical – 
centralized, 
decentralized 
States whether drug funding process within the healthcare system  is 
centralized at a national level or whether funding decisions are 
decentralized to the regional level 
Sorenson et al. (2008) 
35 Election year at time of 
decision 
Categorical – 
yes/no 
This variable captures whether the payer decision was made within an 
election year.  An election year was defined as a year in which either 
national government or regional elections took place.     
Todosijevic et al. (2010) 
36 Inpatient Use Categorical – yes/ 
no 
This variable was extracted for the CFH and provides information on 
whether or not the technology was specified for use within an inpatient 
setting or not.   
Letter from the minister van 
Volksgezondheid, Welzijn en Sport 
37 Post-approval Study request Categorical – yes/ 
no 
This variable was extracted for the CFH, and provides information on 
whether reimbursement was granted with the condition that real-life 
observational data on the technology would be provided within a 
specified time period.  
Letter from the minister van 
Volksgezondheid, Welzijn en Sport;  
38 Co-payment Categorical – yes/ 
no 
This variable was extracted for the CFH to identify those technologies 
where patients are requested to pay a percentage of the drug cost in 
order to access the technology.   
Medicijnkosten (2009) 
39 Expensive Drug Categorical – yes/ 
no 
Collected for the CFH.  A technology was considered to be an 
expensive drug if it was reported on the “Duuregeneesmiddel lijst” 
published by the CFH.   
BELEIDSREGEL CI-891 (2006), 
BELEIDSREGEL CI-891 (2008) 
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6.2.5 Statistics 
The methods for the descriptive statistics and multivariate analyses were described in 
Chapter 3.  Descriptive statistics were calculated for each extracted variable, stratified 
by outcome group (recommended, restricted or not recommended).  Following a 
descriptive analysis of the dataset, a multinomial logit regression was modelled.  The 
objective of this analysis was to obtain a parsimonious model that best reflected the 
main drivers of CVZ decision-making. 
 
6.3 Results 
6.3.1  Sample characteristics  
A total of 277 drug reviews issued between January 2004 and June 2009 were retrieved 
from the CVZ website.  Of these, 244 full submissions, representing 256 coverage 
decisions, were included for analysis. 33 drug reviews were excluded from the analysis 
for the following reasons:  i) full guidance was not available (n=13); or ii) they focused 
on a non-adult population (n=20).  In the CVZ sample, the variables with the highest 
proportion of incomplete entries were those related to the prevalence and budget impact 
estimate for the technology.  Approximately 100 of 256 coverage decisions did not 
report prevalence and budget impact estimates for the technology.   
 
The most common coverage decision by the CVZ was to recommend new technologies 
(51%), followed by restriction of funding (33%), while 16% of coverage decisions 
advocated not funding the technology (Table 6.3).   
 
Table 6.3 Outcome of CVZ Guidance issued between 2004-June 2009 
CVZ guidance  Number of coverage decisions Percentage 
Recommended 130 51% 
Restricted 86 33% 
Not recommended 40 16% 
Total 256 100% 
 
6.3.2 Descriptive statistics 
Clinical Evidence 
Descriptive statistics for the CVZ sample are summarized in Table 6.4.   On average 
CVZ took into consideration 3 RCTs in their review process, with an average sample 
size of 830 patients, and duration of 39 weeks. There appeared to be a statistically 
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significant difference between the outcome groups with regard to these clinical 
variables (p<0.05).      
 
Aside from the size and number and duration of RCTs, the results of the RCTs were 
also captured.  Of the non recommended technologies, 25% of them had demonstrated 
superiority in their primary endpoint, compared with 45% of recommended 
interventions and 35% of restricted interventions (p= 0.046). 
 
The comparator used within the clinical trial programme was assessed – in particular, 
the percentage of comparisons made to ‘active’ comparators as opposed to placebo was 
recorded.  The interventions recommended for use had a higher number of trials with 
active comparators (51%) than interventions that were restricted or not recommended 
(45%, 21% of RCTs with active comparators, respectively).  The differences observed 
between the groups were statistically significant. 
 
Consideration of non-randomised observational data was also recorded.   Overall, in the 
majority of technology reviews, observational data was not considered and there were 
no significant differences between outcome groups.   
 
Disease Characteristics 
The CVZ review process requires information on the number of patients eligible for 
treatment with the technology under review.  This ranged from 61,816 patients for 
recommended interventions to 41,087 and 268,145 patients in the restricted and not 
recommended interventions (p<0.05). The availability of alternative therapies was 
assessed to ascertain if it differed between recommended and restricted or not 
recommended interventions.  In the majority of technologies appraised, an alternative 
was available (in 79% of cases, all decisions considered).  There were minor differences 
between groups which were not statistically significant (p= 0.276). 
 
For each technology review, in order to assess whether the type of disease impacted on 
decision making, the disease was coded using BNF categories – 13 categories are used 
ranging from cardiovascular, central nervous system to infections, and skin diseases.  
Across all decisions – the majority of decisions were linked to technologies for 
malignant disease and immunosuppression, central nervous system, and muscoskeletal 
and joint diseases.  This differed, however, between the decision categories:  for 
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example, musculoskeletal and joint diseases appeared to be more likely to fall in the 
‘restricted’ category (16%) than in the recommended (6%) or not recommended groups 
(6%).  The most common disease category in the recommended group was therapies 
linked to malignant disease and immunosuppression (30% of recommendations made 
for this disease category).   However, it was also the most common disease area in the 
‘not recommended’ group.  The restricted group had a more even representation of 
several disease areas – malignant disease and immunosuppression (18%), muscoskeletal 
and joint diseases (16%), cardiovascular system (13%) and central nervous system 
(13%).   
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Table 6.4  CVZ Coverage Decisions:  Descriptive statistics for extracted variables, by coverage decision (recommended, restricted, not recommended)  
Variable Total (n=256) Recommended (n=130) Restricted (N=86) Not Recommended (n=40) 
 mean 95% Confidence interval mean 95% Confidence interval mean 95% Confidence 
interval 
mean 95% Confidence 
interval 
Number of RCTs 
considered in 
decision 
2.6 2.3 3.0 2.2 1.8 2.5 2.8 2.2 3.5 3.8 2.0 5.6 
Size of 
population 
included in RCTs 
830 494 1165 525 366 684 1364 447 2281 588 232 945 
Length/extent of 
follow-up in RCT 
(weeks) 
39 33 46 44 34 54 31 24 38 44 24 65 
Statistically 
Significant 
results -                   
yes 
39% 33% 45% 45% 37% 54% 35% 25% 45% 25% 11% 39% 
No 29% 23% 34% 20% 13% 27% 35% 25% 45% 45% 29% 61% 
inconsistent 17% 13% 22% 18% 11% 24% 17% 9% 26% 15% 3% 27% 
Use of Active 
Comparator in 
RCT 
44% 38% 51% 51% 42% 60% 45% 35% 55% 21% 8% 34% 
Number of 
observational 
studies 
considered in 
guidance 
0.6 0.4 0.7 0.6 0.3 0.8 0.6 0.2 0.9 0.5 0.1 0.8 
Consideration of 
Cost Utility 
Analysis in 
guidance 
11% 7% 15% 12% 7% 18% 7% 1% 12% 18% 5% 30% 
Incremental Cost-
effectiveness 
ratio of 
technology vs. 
€ 36,621 € 10,217 € 63,024 € 51,854 € 2,005 € 101,704 € 17,963 € 11,339 € 24,588 € 18,502 € 9,103 € 27,901 
  
 
183 
Variable Total (n=256) Recommended (n=130) Restricted (N=86) Not Recommended (n=40) 
 mean 95% Confidence interval mean 95% Confidence interval mean 95% Confidence 
interval 
mean 95% Confidence 
interval 
comparator in 
base case 
More than one 
CUA submitted 
1% 0% 2% 2% 0% 5% 0% 0% 0% 0% 0% 0% 
If More than one 
CUA submitted - 
low range 
€ 100,592 -€ 234,954 € 436,138 € 100,592 -€ 234,954 € 436,138 . . . . . . 
If More than one 
CUA submitted - 
high range 
€ 261,851 € 238,338 € 285,363 € 261,851 € 238,338 € 285,363 . . . . . . 
Uncertainty 
around the base 
case ICER 
reported in 
submission 
(probabilistic) 
66% 42% 90% 79% 43% 115% 52% -66% 170% 55% -168% 277% 
Uncertainty 
around base case 
ICER reported in 
submission 
(univariate)  Low 
€ 17,954 € 5,128 € 30,779 € 31,462 -€ 19,406 € 82,331 € 13,402 -€ 16,808 € 43,611 € 10,465 € 2,373 € 18,557 
Uncertainty 
around base case 
ICER reported in 
submission 
(univariate) High 
€ 109,737 -€ 7,514 € 226,987 € 192,709 -€ 106,725 € 492,142 € 48,132 -€ 43,192 € 139,455 € 43,739 -€ 539 € 88,017 
Prevalence of 
disease/clinical 
condition 
94,543 31,394 157,693 61,816 -     16,081 139,713 41,087 8,932 73,242 268,145 11,852 524,440 
Potential 
budgetary impact  
(million) 
€ 36.4 € 6.9 € 65.9 € 6.7 € 4.3 € 9.0 €66.0 -€ 17.6 €76.0 € 268,145 -€ 26.5 € 175 
Societal 1% 0% 1% 1% -1% 3% 0% 0% 0% 0% 0% 0% 
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Variable Total (n=256) Recommended (n=130) Restricted (N=86) Not Recommended (n=40) 
 mean 95% Confidence interval mean 95% Confidence interval mean 95% Confidence 
interval 
mean 95% Confidence 
interval 
Perspective 
adopted 
Availability of 
alternative 
therapies in 
current treatment 
setting. 
79% 74% 84% 76% 68% 83% 85% 77% 93% 78% 64% 91% 
Inclusion of 
patient 
submission 
4% 2% 6% 2% 0% 5% 2% -1% 6% 13% 2% 23% 
Number of 
Decision Makers 
Accountable 
20 20 20 20 20 20 20 20 20 20 20 20 
Cost-
effectiveness 
evaluation 
component in 
process 
67% 61% 73% 65% 57% 74% 64% 54% 74% 78% 64% 91% 
Budget impact as 
a component of 
decision-making 
process 
 
 
 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Price of 
technology  
known during 
appraisal 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Number of 
technologys 
appraised in same 
appraisal 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
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Variable Total (n=256) Recommended (n=130) Restricted (N=86) Not Recommended (n=40) 
 mean 95% Confidence interval mean 95% Confidence interval mean 95% Confidence 
interval 
mean 95% Confidence 
interval 
Accountability of 
drug budget 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Date guidance 
was issued 
2006 2006 2006 2006 2006 2006 2006 2006 2006 2007 2006 2007 
Population size – 
Agency coverage 
(millions) 
16.30 16.30 16.40 16.30 16.30 16.40 16.30 16.30 16.30 16.40 16.30 16.40 
GDP-healthcare 
expenditure 
10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 
Healthcare 
expenditure on 
pharmaceuticals 
€ 294 € 291 € 296 € 293 € 289 € 296 € 292 € 287 € 296 € 302 € 296 € 309 
Election year at 
time of decision 
20% 15% 24% 23% 16% 30% 20% 11% 28% 8% -1% 16% 
Priority disease 
area 
55% 49% 61% 61% 52% 69% 43% 32% 54% 60% 44% 76% 
Orphan 
Designated 
 
 
9% 5% 12% 11% 5% 16% 9% 3% 16% 0% 0% 0% 
Technology has 
EU Marketing 
Authorisation 
92% 88% 95% 92% 88% 97% 94% 89% 99% 85% 73% 97% 
Future Cost-
Effectiveness 
Analyses 
requested 
9% 5% 13% 16% 10% 23% 1% -1% 3% 3% -3% 8% 
Expensive Drug 12% 8% 16% 23% 16% 30% 0% 0% 0% 0% 0% 0% 
Patient 
Copayment 
4% 2% 7% 2% -1% 4% 9% 3% 16% 3% -3% 8% 
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Variable Total (n=256) Recommended (n=130) Restricted (N=86) Not Recommended (n=40) 
 mean 95% Confidence interval mean 95% Confidence interval mean 95% Confidence 
interval 
mean 95% Confidence 
interval 
needed 
BNF1 
cardiovascular 
system 
9% 5% 12% 4% 0% 7% 15% 7% 23% 10% 0% 20% 
BNF2 central 
nervous system 
16% 12% 21% 15% 9% 22% 15% 7% 23% 23% 9% 36% 
BNF3 ear, nose 
and oropharynx 
1% 0% 2% 2% 0% 5% 0% 0% 0% 0% 0% 0% 
BNF4 endocrine 
system 
6% 3% 9% 5% 1% 8% 8% 2% 14% 5% -2% 12% 
BNF5 eye 2% 0% 3% 3% 0% 6% 0% 0% 0% 0% 0% 0% 
BNF6 gastro-
intestinal system 
5% 2% 7% 5% 1% 9% 5% 0% 9% 3% -3% 8% 
BNF7 infections 9% 5% 12% 6% 2% 10% 12% 5% 19% 10% 0% 20% 
BNF9 
musculoskeletal 
and joint diseases 
10% 6% 14% 7% 3% 11% 19% 10% 27% 3% -3% 8% 
BNF10 nutrition 
and blood 
 
 
7% 4% 10% 8% 3% 12% 8% 2% 14% 3% -3% 8% 
BNF11 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
3% 1% 5% 1% -1% 2% 7% 1% 12% 3% -3% 8% 
BNF12 
respiratory 
system 
4% 1% 6% 2% -1% 4% 0% 0% 0% 18% 5% 30% 
BNF13 skin 5% 2% 7% 5% 1% 9% 2% -1% 6% 8% -1% 16% 
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Orphan designation is granted by the EMA to technologies that fulfil specific criteria, 
namely related to the prevalence of the disease, the clinical profile of the disease and the 
level of unmet need. Across 2004-2009, 9% of technologies reviewed by the CVZ had 
an orphan designation.  A higher proportion of orphan designated therapies were in the 
recommended and restricted groups (11% and 9% respectively), compared to the not 
recommended interventions (0%) (p = 0.10). 
 
Economic Evidence 
A range of economic related variables were included for analysis.  Only 11% of CVZ 
decisions were backed by the use of a CUA.  There was no statistically significant 
difference between recommended (12%), restricted (7%) or not recommended 
interventions (18%).  Only 1% of reviews considered more than one CUA – in almost 
all cases a single CUA was reviewed.   For the interventions supported by a CUA, the 
average incremental cost-effectiveness ratio (ICER) across all groups was €36,620.  The 
mean ICER differed between the interventions, but not in the anticipated direction.  The 
mean ICER for the recommended interventions was €51,854, compared to the restricted 
interventions (mean ICER of €37,481), and the interventions not recommended for use 
(mean ICER of €18,501).  However, these differences were not statistically significant. 
 
For those interventions that reported an ICER, information on the uncertainty around 
base-case ICER estimates was collected.  This was done by recording results of 
probabilistic sensitivity analyses (the probability of ICER remaining below a set 
threshold), and by recording univariate sensitivity analyses (lowest ICER, highest 
ICER).    The probability of the ICER remaining below €20,000 was 79% for 
recommended interventions, 52% for restricted interventions and 55% for interventions 
not recommended for use.  However, these differences were not statistically significant 
across any of the tests performed, and the sample size was very small (n=14).  With 
regard to univariate sensitivity analyses, the statistical tests performed do not suggest a 
statistically significant difference between the decision groups.  Aside from examining 
the results of CUA considered by the CVZ review committee, information was also 
captured on whether alternative cost-effectiveness models (non-CUA) were considered 
in the decision-making process; 15% of interventions were supported by non-CUA 
models.   The use of non-CUA analyses occurred in 15% of recommended 
interventions, 9% of restricted interventions and 28% of interventions not recommended 
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for use. The differences observed between decision outcome groups were statistically 
significant (p=0.016). 
 
The potential budget impact of a positive recommendation also was analysed - the mean 
estimated maximum yearly budget impact across all decisions was in the order of € 36 
million.  This ranged from €7 million for the recommended interventions to €66 and 
€75 million for the restricted and not recommended interventions, respectively 
(p=0.0001).   
 
CVZ process characteristics 
A series of variables related to the decision-making process were recorded.  Less than 
1% of decisions formally considered a societal perspective in the review process.  In 
very few decisions (4%), patient-group submissions were formally considered in the 
appraisal.  The CVZ committee operates on a pre-defined number of 20 committee 
members who can serve on the committee for eight years.  It was not clear from the 
information provided on the webpage, how the committee processed the technology 
reviews (i.e. if there were lead reviewers etc).  In all of the decisions there was a budget 
impact component.  The cost-effectiveness component was added as part of the review 
process in 2006, and is applicable in those instances where the manufacturer requests 
reimbursement for a compound in the 1B reimbursement list, or listing on the expensive 
drug list.    The CVZ review process considers only one compound at a time (one 
exception noted in one appraisal on a group of anti-allergen therapies). None of the 
above variables differed significantly between outcome groups.   
 
Aside from reviewing therapies that have received marketing authorisation, the CVZ 
also has the role of reviewing technologies that do not have marketing authorisation, but 
that could be of value as ‘last resort’ treatment options for patients with very severe 
illnesses resistant to standard therapy.  This is the case in 8% of CVZ decisions 
reviewed in this research project.  This percentage was constant across the three groups. 
 
In the Netherlands, patients can be asked to provide a co-payment for their prescription.  
This is determined by whether or not a certain technology falls within a ‘basis pakket’ 
of insurance or not.  For the purposes of this research, it was considered that, for those 
technologies where a patient co-payment is necessary, these would fall under the 
‘restricted’ category.  The rationale for this coding is that although the medication is 
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recommended for use by the Ministry of Health, it is not reimbursed 100% and 
therefore there is a restriction on its access, which is in fact the co-payment.  Of the 256 
decisions made, only 4% of these are associated with a patient co-payment.  These were 
all placed within the ‘restricted’ decision category.    
 
Socio-economic context of CVZ decision-making 
A series of variables were recorded to capture the socio-economic context in which 
CVZ decisions were made.  In particular, information was recorded on the year of the 
appraisal (mean 2006), size of population under the CVZ’s remit (approximately 16.3 
million), % of GDP spent on healthcare (10% on average across groups), whether 
appraisal coincided with an election year and whether the technology under appraisal 
was linked to a disease considered to be a ‘priority’ by the Ministry of Health (55% of 
technologies appraised were directly linked to a priority disease area).  There was strong 
correlation between the year of appraisal and the other socio-economic factors.  The 
year of appraisal, population size and healthcare expenditure on pharmaceuticals, 
appeared to vary significantly between outcome groups (p=0.05).  The rest of the 
variables did not differ significantly between outcome groups.   
 
Summary of descriptive statistics 
In total, within the CVZ sample, of the 40 explanatory variables that were explored, 
descriptive analysis suggests that 16 factors may play an important contributing factor 
in determining SMC decision-making (Table 6.5).  For these variables, statistically 
significant differences were observed between interventions that were recommended, 
restricted and not recommended (p ≤ 0.05).   Highly statistically significant differences 
(p ≤ 0.01) were observed for variables highlighted in bold in the Table 6.5.     
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Table 6.5  CVZ Descriptive statistics: statistically significant variables (p≤ 0.05) 
Evidence factors Variables 
Clinical Package Number of RCT 
Size of RCT 
RCT duration 
Superiority demonstrated 
Use of active comparator 
Economic Package Non-CUA analyses submitted 
Budget Impact
Disease characteristics Prevalence of disease 
Disease categories (BNF): musculoskeletal and joint diseases; 
obstetrics, gynaecology and urinary-tract disorders; respiratory 
system; cancer; cardiovascular system 
Process factors Presence of patient submission 
Priority disease 
Request for future CEA 
Patient co-payment 
Socio-economic context factors Date of Review 
Pharmaceutical expenditure per patient 
Size of the national population 
Note:  variables in bold text were statistically significant at the p ≤ 0.01 level 
 
6.3.3 Multivariate analysis 
Following the model specification process described in Chapter 3 which included the 
development of a preliminary model (Appendix C), the CVZ base case model was 
developed which contains nine variables, including a mixture of clinical, economic and 
process variables (Table 6.6).  The model resulted in a pseudo R-squared of 0.17, 
suggesting that the model explains approximately 17% of the variability in CVZ 
coverage decisions. Clinical variables that had a significant impact on the CVZ model 
include the presence of an active comparator, which decreased the log odds of a 
restriction or non-recommendation relative to recommendation, although this effect was 
only statistically significant for the latter (p=0.239and p<0.001 respectively).    
Demonstration of superiority in the clinical trial also decreased the odds of a restriction 
or non-recommendation relative to recommendation (p=0.022, p<0.001 respectively).  
The lack of information on the duration of the RCT increased the odds of a non-
recommendation (p=0.001) and restriction (not statistically significant) relative to 
recommendation.  The budget impact of the technology appeared to impact significantly 
on CVZ decision-making:  a unit increase in the budget impact increased the probability 
of a restriction (p=0.051) relative to recommendation, but was not statistically 
significant on the log odds of a non recommendation relative to recommendation. 
Technologies indicated for the treatment of cancer decreased the log odds of a 
restriction or non recommendation relative to recommendation, and this impact was 
statistically significant on the log odds of a restriction (p<0.001) and borderline 
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significant on the log odds of a non recommendation relative to recommendation 
(p=0.177).   Technologies indicated for the treatment of cardiovascular disease, and 
obstetrics/gynaecology/ urinary-tract disorders increased the probability of a restriction 
relative to recommendation, and this was statistically significant.   
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Table 6.6  Multivariate analysis of CVZ coverage decisions 2004-2009:  base case model results   
Restricted Log Odds P value 95% Confidence Interval 
Use of active comparator in RCT -0.49 0.239 -1.31 0.33 
Demonstrated clinical superiority in RCT -0.82 0.022 -1.53 -0.12 
Budgetary Impact 0.0069 0.051 -0.000031 0.014 
Cancer therapy -1.59 <0.001 -2.47 -0.72 
Therapies for cardiovascular diseases 1.40 0.017 0.25 2.55 
Therapies for obstetrics, gynaecology, and 
urinary-tract disorders 2.40 0.032 0.20 4.59 
Prevalence of target population -0.0000014 0.091 -0.0000029 0.0000002 
Patient Submission -0.15 0.879 -2.08 1.78 
Lack of data on duration of RCT 0.24 0.560 -0.58 1.06 
Constant 0.28 0.459 -0.46 1.03 
Not Recommended Log Odds P value 95% Confidence Interval  
Use of active comparator in RCT -2.54 <0.001 -3.84 -1.24 
Demonstrated clinical superiority in RCT -1.85 <0.001 -2.82 -0.89 
Budgetary Impact 0.0047 0.217 -0.0028 0.012 
Cancer therapy -0.70 0.177 -1.71 0.31 
Therapies for cardiovascular diseases 0.82 0.338 -0.86 2.51 
Therapies for obstetrics, gynaecology, and 
urinary-tract disorders 2.20 0.141 -0.73 5.12 
Prevalence of target population -0.000000016 0.982 -0.0000014 0.0000014 
Patient Submission 1.79 0.032 0.16 3.41 
Lack of data on duration of RCT 1.78 0.001 0.74 2.81 
Constant 0.066 0.878 -0.78 0.91 
Note:  Recommended technologies are the reference case. Multinomial logistic regression, pseudo R-
squared: 0.17.   
 
Impact of alternative model specifications – sensitivity analyses 
Sensitivity analyses were conducted on the base-case model of CVZ coverage decisions.  
This included i) examining the impact of a binary rather than three-category outcome 
variable; ii) restricting the base case analysis to complete observations, thus excluding 
observations with imputed values, and (iii) examining the impact of assuming the 
coverage decisions are ordinal.     
 
In the first sensitivity analysis, the model was run using a binary outcome variable.  
This was done by considering a ‘covered’ and ‘not covered’ approach:  the 
recommended and restricted categories were grouped together, and the not 
recommended category was kept as in the base case analysis.  A logistic regression was 
performed examining the log likelihood and the odds of coverage versus no coverage by 
the healthcare system (Table 6.7).   
 
In this binary model, the use of an active comparator in the clinical trial and the 
demonstration of superiority remained significant variables,   as did whether a patient 
submission was completed.  The budget impact, duration of the RCT and whether the 
technology was indicated for cancer, cardiovascular disease or obstetrics/gynaecology 
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diseases were no longer significant variables.  The pseudo R-squared was 0.21; 
suggesting that the model can explain approximately 21% of the variability in CVZ 
coverage decisions, higher than the pseudo R-squared observed in the base-case model 
(0.17).  New variables not present in the base case model that showed significance in 
this sensitivity analyses were:  date of appraisal, and therapies for infectious diseases.   
The use of an active comparator in the clinical trials and the demonstration of 
superiority in the primary endpoint increased the probability of listing vs. non-listing 
(p=0.003 and p=0.058 respectively).  The effect of these explanatory variables observed 
in this sensitivity analysis was similar to that observed in the base-case analysis. The 
date of appraisal, the inclusion of a patient submission and if the technology was 
indicated for the treatment of infectious diseases decreased the probability of coverage 
(p=0.081, p=0.017, p=0.002 respectively).     In the base-case model, the impact of 
patient submissions differed on the log odds of restriction or non recommendation.  The 
presence of patient submissions increased the log odds of a recommendation relative to 
a restriction (although this was not statistically significant), while the presence of 
submissions increased the log odds of non-recommendation (p=0.032).  Using a binary 
outcome category removes the ability to explore the impact of the same factor on the 
odds of different types of coverage decisions.   
 
Table 6.7  Sensitivity Analysis 1. Multivariate analysis of CVZ coverage decisions 2004-2009:  sensivitiy 
analysis using binary outcome variable 
  Odds of Listing P value 95% Confidence Interval  
Use of active comparator in RCT 1.70 0.003 0.58 2.82 
Demonstrated clinical superiority in RCT 0.80 0.058 -0.027 1.63 
Therapy for Infectious diseases -2.84 0.002 -4.60 -1.07 
Prevalence of target population -0.00000077 0.11 -0.0000017 0.00000018 
Patient Submission -1.74 0.017 -3.16 -0.31 
Date of Appraisal -0.24 0.081 -0.50 0.03 
Constant 477.57 0.081 -58.42 1013.56 
 
In the second sensitivity analysis, the observations with missing entries were removed 
from the sample. This reduced the sample of observations for analysis to 98 appraisals 
(vs. 256 in the base case sample) (Table 6.9).   The results suggest that, firstly, the 
majority of observations within the CVZ have unavailable data for at least one of the 
explanatory variables.  In addition, the results suggest that the model’s ability to explain 
the variability in CVZ decision-making is reduced, as the pseudo R-squared is 0.12, 
lower than the base case (0.17).  A unit increase in the budget impact has a border-line 
statistically significant effect on the log odds of a restriction and non-recommendation.  
This echoes the results of the base-case model, although the statistical significance of 
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the budget impact estimate is weaker in this sensitivity analysis.  The demonstration of 
superiority or the duration of the RCT maintains a similar direction of effect and 
statistical significance as observed in the base-case model.  The use of an active 
comparator continues to be important in increasing the log odds of a recommendation 
vis a vis a restriction or non recommendation, although not statistically significant on 
the log odds of restriction.  Similarly to the base case, when the technology is indicated 
for cardiovascular diseases it increases the log odds of a restriction (p=0.03).   
 
Table 6.8  Sensitivity Analysis 2. Multivariate analysis of CVZ coverage decisions 2004-2009:  sensivitiy 
analysis excluding incomplete observations from sample of analysis (n=98) 
Restricted Log Odds P value 95% Confidence Interval  
Use of active comparator in RCT -0.68 0.292 -1.96 0.59 
Demonstrated clinical superiority in RCT -0.39 0.480 -1.45 0.68 
Budgetary Impact 0.03 0.136 -0.0086 0.063 
Therapies for cardiovascular diseases 1.57 0.030 0.15 3.00 
Constant 382.89 0.273 -302.11 1067.89 
Not Recommended Log Odds P value 95% Confidence Interval  
Use of active comparator in RCT -1.68 0.044 -3.31 -0.04 
Demonstrated clinical superiority in RCT -1.34 0.027 -2.54 -0.15 
Budgetary Impact 0.03 0.139 -0.0088 0.063 
Therapies for cardiovascular diseases 1.11 0.208 -0.62 2.83 
Constant -252.23 0.528 -1035.63 531.18 
Note:  Recommended technologies are the reference case 
 
In the third sensitivity analysis, ordinality of the outcome variable was assumed.  This is 
in contrast with the base case analysis, where ordinality was not assumed and 
multinomial logistic regression was used.  In this sensitivity analysis ordinal logistic 
regression was used.  The detailed results of this analysis are provided in Appendix G, 
and show that while they yielded a slightly higher pseudo R-squared than in the base 
case model (0.19 vs. 0.17), the explanatory variables remained significant as observed 
in the base case model of CVZ decision-making. 
 
6.4 Discussion 
The overall objective of this chapter was to examine the factors that influence decisions 
made by CVZ to recommend, restrict or not recommend new technologies for use in the 
Dutch healthcare system.  In line with the hypothesised drivers of HTA decision-
making highlighted in Chapter 3, and in light of evidence review presented in Chapter 
2,  a wide range of explanatory variables were included in the analysis, reflecting the 
clinical and economic characteristics of the technology under appraisal, the appraisal 
process itself and the socio-economic context in which the CVZ operates. In addition to 
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the general aims of the research, specific hypotheses relevant for CVZ decision-making 
were explored and are discussed below. 
 
The analysis of CVZ included 256 pharmaceutical technology appraisals.  The internal 
validity of the results obtained in this analysis was examined in two ways - firstly, by 
comparing the results with published analyses of CVZ decision-making, and secondly 
by sharing the base-case model results for review with members of the CVZ (Dr. 
Graaff, M; Dr. Goettsch, W, Dr. S. Kleijnen,)1.   The aim of this interaction was to 
ascertain if the CVZ characteristics were accurately captured in the sample used for the 
analysis, if the approach to the analysis was clear and in particular, to gauge the reaction 
to the model results and potential for suggestions or additional analyses.   
 
6.4.1 Pattern of CVZ coverage decisions 
The most common coverage decision by the CVZ was to recommend new technologies 
(51%), followed by restriction of funding (33%), while 16% of coverage decisions 
advocated for not funding the technology.   No published information on CVZ decision-
making was identified to allow for a comparison of the pattern of coverage decision 
observed in this analysis.   
 
 
6.4.2 Role of clinical evidence and disease characteristics on CVZ decision-making 
The use of an active comparator and demonstration of clinical superiority were 
important factors that significantly impacted on CVZ decision-making.  The majority 
(51%) of recommended technologies were supported by RCTs with active comparator 
arms, as opposed to 45% of restricted technologies and 21% of technologies not 
recommended for funding.  Not only were recommended technologies more likely to be 
compared to active treatments, but the RCTs also demonstrate clinical superiority of the 
technology 45% of appraisals, compared with 35% and 25% for restricted and not 
recommended technologies.  Other RCT characteristics (size, duration) appeared to be 
less important in CVZ decision-making. Of interest in the multivariate analysis is the 
effect of lack of evidence of trial duration which statistically significantly increases the 
log odds of non-recommendation relative to recommendation.   This represents 37 
                                                 
1 Dr. Martin van der Graaff, Secretary medicines evaluation committee (CVZ); Dr. Wim Goettsch; 
Sarah Kleijnen (M.Sc. ) Project coordinator EUnetHTA WP5.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on January 6th 2011.  Meeting minutes are provided in Appendix E.    
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appraisals in which information on duration of RCT was lacking. Amongst this subset 
of appraisals, 56% (21 of 37) appraisals supported largely by non-interventional non-
randomised clinical evidence, and 46% of appraisals were focused on technologies for 
which there were no alternative treatments available.   
 
Interestingly, in this model, the impact of the therapy area for which the technology was 
indicated played an important role in coverage decisions.  It was hypothesised that 
differences would be observed in the outcome variable according to the therapeutic area 
which was targeted by the appraised technologies.  In a discrete choice experiment 
amongst Dutch healthcare professionals, the analysis of choices made suggested that 
severity of disease was one of the most significant criteria driving coverage decisions 
(Koopmanschap et al. 2010).  In the CVZ multivariate analysis presented in this 
chapter, cancer therapies, which could be approximated to represent severe disease, 
significantly decreased the log odds of restriction relative to recommendation.  In 
contrast, technologies for the treatment of cardiovascular disease, and 
obstetrics/gynaecology/urinary-tract disorders increased the probability of a restriction.   
 
6.4.3 Role of Economic evidence in CVZ decision-making 
It was hypothesised that the introduction of cost-effectiveness analysis criteria in CVZ 
decision-making in 2006 would play a role in its decision-making.  However, unlike 
NICE and SMC models, the role of the ICER is not observed in this analysis.  Only 
11% of CVZ appraisals reported an ICER, and amongst those technologies for which 
ICERs were reported there was no statistically significant difference between outcome 
variables in the ICERs.    However, in Koopmanschap et al. (2010), results of the 
discrete choice experiment suggest that CUA is an important criterion for Dutch 
healthcare decision-makers.  Plausible explanations for this difference could be due to 
variation between hypothetical reimbursement decisions versus real-life decision-
making, and the fact that CUA was first introduced in the CVZ process in 2005, and is 
only utilised as a criterion for inclusion of technologies on List 1B.  It has been 
highlighted that the role of CUA within the CVZ appraisal process may increase in the 
future (Dr. Graaff, M; Dr. Goettsch, W, Dr. S. Kleijnen)2.  
 
                                                 
2 Dr. Martin van der Graaff, Secretary medicines evaluation committee (CVZ); Dr. Wim Goettsch; 
Sarah Kleijnen (M.Sc. ) Project coordinator EUnetHTA WP5.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on January 6th 2011.  Meeting minutes are provided in Appendix E.    
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An additional hypothesis was made about the role of budgetary impact evidence in CVZ 
decision-making.  Specifically, increasing budgetary impact was hypothesised to 
increase the log-odds of non-recommendation or restriction relative to recommendation.  
The analysis showed that the size of the estimated budget impact associated with the 
introduction of the technology had a significant effect on CVZ decisions:  a unit 
increase in the budget impact increased the log odds of a restriction relative to 
recommendation.  The mean estimated budget impact for technologies recommended by 
the CVZ was €6.7 million compared with €66.0 million for restricted technologies and 
€76 million for not recommended technologies.  However, the effect of budgetary 
impact considerations was not statistically significant on the odds of a non-
recommendation relative to recommendation, suggesting there are other factors that 
better explain non-recommendations than budgetary impact considerations.   For 
example, the size of the eligible patient population for restricted technologies is lower 
(mean eligible population is 41,087 patients) compared to non-recommended 
technologies (268,145).  In addition, the clinical evidence for restricted technologies is 
supported by a higher mean number of trials (2.8 vs. 3.8 trials), with larger mean sample 
size (1363 vs. 588 patients) and more frequently use active comparators than non-
recommended technologies (45% vs. 21%).    
 
6.4.4 Role of process and socio-economic context variables in CVZ decision-making 
It is of interest to note that, with the exception of the patient submissions and the 
introduction of the ICER discussed above, none of the other appraisal process 
characteristics or socio-economic factors appeared to have significant effects on 
coverage decisions.  This suggests the general stability of the appraisal process and 
socio-economic context of decision-making, and therefore the lack of significant 
variation within the period for which coverage decisions were extracted.  In addition, it 
should be noted that socio-economic factors varied at the agency level, rather than at the 
decision-level:  thus, the degree of variability was substantially reduced to annual 
changes in socio-economic factors.  The relative importance of socio-economic and 
process factors will be examined further in the pooled analysis of coverage decisions 
from all four HTA bodies, presented in Chapter 8.   
 
6.4.5 Limitations 
When examining the results of the multivariate analyses, there are several limitations 
that need to be taken into account.  An important limitation is related to the ability to 
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access information that is publicly available, as the CVZ presents in the public domain 
the information that corresponds to the final recommendation.  For instance, a 
technology that is recommended for GVS List 1A, meaning that it is clustered with 
therapies already available within the Dutch healthcare system, will have the 
report/information used to support this coverage decision are made publicly available.  
However, it is possible that a manufacturer may have submitted a request for the drug to 
be included in GVS List 1B i.e. where the technology is found to have therapeutic 
benefit to the degree that it is not clustered with existing therapies.  This type of 
submission would have required the technology to demonstrate its cost-effectiveness 
and thus the manufacturer may have submitted cost-effectiveness analyses. However, if 
the decision by the CVZ/CVZ was that there was no added therapeutic benefit to justify 
inclusion in the 1B list, then the cost-effectiveness criteria would not have been applied, 
and therefore the information about the cost-effectiveness analyses that were performed 
would not be disclosed in the public domain.  From one perspective, the lack of access 
to cost-effectiveness data that was not actually taken into account in the coverage 
decision does not have significant implications for the analysis, given that the aim is to 
identify those factors that impact on decisions.  However, this perspective assumes that 
the availability of cost-effectiveness data has no impact on the decision to cluster or not 
cluster the technology.  To some degree the implications of incomplete observations 
was addressed through imputation techniques, coupled with the use of dummy variables 
to identify the impact of incomplete data on coverage decisions, and  an additional 
sensitivity analysis in which the model was restricted to those technologies with 
complete observations.  This sensitivity analysis highlighted that the majority of 
observations from the CVZ were incomplete (98 of 256 were included in the analysis).  
This suggests that, on the one hand, the variables chosen for extraction, while standard 
across the various HTA bodies, may not have been appropriate for the CVZ given their 
reporting and decision-structure.  It also suggests that there may be substantial 
additional considerations and data provided to the CVZ that are not disclosed (e.g. 
patient submissions, physician organisation interaction, cost-effectiveness analyses etc).  
Therefore, greater transparency in the evidence received or submitted may help to 
further increase the understanding of CVZ decision-making.   
 
As with the SMC appraisal process, the CVZ also relies on manufacturer submissions in 
formulating its advice.  There is no third party or significant additional new analysis 
performed on the evidence submitted by the manufacturer.  Given the lack of 
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accessibility to manufacturer submissions in the public domain, it was not possible to 
take into account in the analyses to what degree the CVZ  recommendation was driven 
by the manufacturer submission strategy relative to CVZ decision-making criteria.  For 
example, for a technology which was accepted in the GVS 1A list (clustered 
technologies), it was not possible to ascertain if the inclusion in this list was proposed 
by the CVZ, or whether the inclusion on GVS 1A list was proposed by the manufacturer 
in their submission.  Despite the lack of access to such information, it does not detract 
from the possibility of being able to assess the degree to which key characteristics and 
factors vary according to the coverage decision made.   
 
While the base-case model was based on a three-category outcome variable, a 
sensitivity analysis was conducted to assess the effect of using a binary outcome 
category as has been done in published literature (Devlin and Parkin 2004; Clement et 
al. 2009).  The results of this sensitivity analysis suggests that several of the explanatory 
variables which were important in the base-case model continued to be significant in 
this binary model.  For example, the use of an active comparator and the demonstration 
of clinical superiority maintained their effect and significance, suggesting that the role 
of these variables in explaining CVZ coverage decision-making is robust to changes in 
model-specification.  Other variables, including the budget impact, were no longer 
found to have a significant effect in this sensitivity analysis, suggesting that the use of 
binary outcome category does not allow for a more detailed exploration of the impact of 
the budget impact on different coverage decisions, and thus when examined in this 
sensitivity analysis its overall impact was not significant.  Moreover, variables that were 
not included in the base-case model were found to have a significant role in this 
sensitivity analysis – this included the year of appraisal and technologies indicated for 
the treatment of infectious diseases.  This suggests that the use of binary outcome 
categories can yield an alternative perspective on CVZ decision-making, at the expense 
of reducing visibility on the impact of explanatory variables on specific types of 
coverage decisions.  
 
In summary, the overall objective of this chapter was to examine the factors that 
influence decisions made by CVZ to recommend, restrict or not recommend 
pharmaceutical technologies for use in the Dutch healthcare systems, with a focus on 
research hypotheses specific to CVZ decision-making. The results suggest that the 
variability in coverage decisions observed can be explained by a combination of 
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clinical, disease and economic factors.   The analysis confirmed the hypothesis that 
pharmaceutical budget impact estimates impact significantly on CVZ outcomes – 
increasing budgetary impact increases the odds of restriction relative to 
recommendation.  The differential impact of the therapeutic area for which the 
technology is indicated was also observed – cancer therapies decreased the log odds of 
restriction and non-recommendation relative to recommendation, while therapies for 
cardiovascular disease, for example, increased the log odds off restriction and non-
recommendation relative to recommendation.  The analyses did not support the 
hypothesis that the introduction of cost-effectiveness component in the CVZ process has 
impacted on its decision-making.   
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7 Empirical analysis of HAS coverage decisions 
 
 
Adalimumab is indicated for the treatment of ankylosing spondylitis22, and was reviewed by 
NICE, SMC, CVZ and HAS to assess whether it should be funded by the healthcare system.  
HAS provided the following guidance: 
 
The Transparency Committee considers that HUMIRA provides the 
same improvement in actual benefit (ASMR II) as the other TNF 
antagonists (etanercept and infliximab) in the treatment of severe, 
active ankylosing spondylitis in adults responding inadequately to 
conventional treatment.  (HAS 2006 section 4.2) 
 
In contrast to NICE, SMC and the CVZ, HAS did not apply an explicit restriction to the use 
of adalimumab, nor a formal stopping rule, and in addition, awarded the compound with an 
ASMR of ‘II’.  The ASMR – Amelioriation du Service Medicale Rendu– reflects the 
incremental medical improvement the compound brings versus currently available therapies 
in France.  Compounds are given a score between I and V; I being a compound that brings 
exceptional medical value, and V a compound that is judged to bring no incremental medical 
value.  An ASMR of II reflected the HAS Committee’s view that adalimumab has the 
potential to provide high medical value to patients with ankylosing spondylitis.    Given the 
HAS coverage decision for adalimumab, what is the impact of evidence, process and context 
factors on HAS decisions?  Is the difference in recommendation observed in this single case 
study a signal that the factors driving decision-making within the HAS appraisal process are 
different to those driving NICE, SMC or CVZ decisions?  Or is this particular case study 
simply an outlier?   
 
This chapter provides empirical analyses of coverage decisions made by HAS during the 
period 2004-2009.  First, an overview of HAS, its objectives and appraisal process is 
provided.  The methods for the analysis are then outlined, building upon the methods 
discussed in Chapter 3.  Following this, the results of these multivariate analyses on HAS 
                                                 
22 Adalimumab (Humira) is an anti-inflammatory medicine and is indicated, among other diseases, for the 
treatment of  adults with severe active ankylosing spondylitis (a disease causing inflammation and pain in the 
joints of the spine) who have not responded adequately to other treatments (European Medicines Agency 2009 
EPAR Adalimumab) 
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coverage decisions are reported and explored, and limitations considered.  The chapter 
concludes with a brief discussion about the empirical analyses performed for HAS. 
 
7.1 HAS Appraisal Process 
The Haute Autorité de Sante (HAS) in France was founded in 200423  as an independent 
scientific body, with the over-arching aim to support solidarity in the healthcare system and 
to reinforce the quality of treatment for the benefit of patients (HAS 2004).  Among its many 
activities, HAS gives its advice on the therapeutic value of technologies reimbursed by the 
healthcare system.  This advice is generated by a specific committee known as the 
Transparency Commission (Commission de la Transparence) whose main objective is to 
evaluate the therapeutic benefit of technologies newly licensed by a regulatory agency and 
for which there is a formal request for reimbursement that is submitted by the manufacturer 
to HAS.   The Commission can appraise technologies for several purposes: i) to advise on 
whether to include the technology in the reimbursement list; ii) to give a new assessment due 
to a modification in the license of the technology (e.g. new indication); or iii) due to a 
renewal of reimbursement.  In addition, upon request by the Minister of Health the 
Commission can evaluate whether or not a technology should be maintained on the 
reimbursement list.  In order for a technology to be reimbursed, it must be included in the 
positive list known as the Liste de Specialites Pharmaceutiques Remboursables aux Assures 
Sociaux (Bellanger et al., 2005).   
 
The Transparency Commission includes 31 members (Zentner et al. 2005) and is composed 
of physicians, pharmacists and specialists in epidemiology and research methods, who may 
serve on the Commission for a period of three years (HAS 2011). The appraisal also includes 
support from another group within HAS known as the Direction de l’Evaluation Medicale, 
Economique et de Sante Publicque (DEMESP). In addition, if needed, external experts may 
also be called to support the evaluation process.  However, HAS does not operate a third 
party appraisal process like NICE and its MTA procedure.   
 
There are several criteria upon which the appraisal is based (Secretariat General de la 
Commission de la Transparence 2005).  Firstly, the evaluation is performed for each 
indication separately.  For instance, even if a technology is indicated for two cancer types, the 
                                                 
23 Decret n°2004-1398 du 23 décembre 2004. 
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appraisal process will treat each separately.  The recommendation of the Commission is 
based on an assessment of the medical service rendered by the technology (‘Service Medical 
Rendu’- SMR), by taking into consideration various factors including the severity of the 
disease, the efficacy and safety profile demonstrated, and the importance of the management 
of this disease from a public health standpoint.  In addition, the Commission makes a 
recommendation on the incremental medical service rendered (l’Amelioriation du Service 
Medical Rendu, -ASMR) defined by examining the efficacy and safety profile of the 
technology relative to a specified comparator.  There are five levels of ASMR as defined in 
the Commission’s regulations, ranging from ASMR I which represents technologies that 
bring highly significant incremental medical value, and ASMR V which represents 
technologies that show no incremental medical value.  The Commission also considers the 
target population for the technology and, for example, the nature of the technology in terms 
of its duration of treatment and dosing.  It is important to note that the cost of the technology 
is not considered during the appraisal process and the price is not known during the appraisal 
by the Transparency Commission.   
 
Once an appraisal is completed, the Commission’s conclusion is transmitted to three parties:  
the Ministry of Health, the manufacturer and the Comite Economique des Produits de Sante 
(CEPS).  This last committee is responsible for setting the price of medicines through 
negotiation with the manufacturers.  These negotiations are based on several components, 
although they are primarily driven by the ASMR rating which represents the incremental 
benefit of the technology compared to the standard of care. Additional factors taken into 
consideration in price negotiations include the size of the target population, the 
manufacturer’s research expenditure and advertising costs (Sorenson et al. 2008; Bellanger et 
al. 2005; Sandier et al. 2004). An ASMR of I-III allows the technology to obtain a premium 
price versus the comparator defined in the appraisal.   An ASMR of IV defines a situation in 
which price parity price in relation to the comparator is implemented.  An ASMR of V means 
that, per legislation, the technology cannot be included on the reimbursement list as it does 
not show any incremental benefit versus the comparators.  The only condition upon which it 
could be included is if it provides cost-savings to the healthcare system. The National Union 
of Health Insurance Funds (Union Nationale des Caisse d’Assurance Maladie – UNCAM) has 
the authority to formally place a technology on a positive list, although the Ministry of Health 
and Social Security has the final say (Bellanger et al. 2005, Sorenson et al. 2008).  Inclusion 
on the positive list is for a 5 year period after which there is a re-evaluation.     
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The clinical criteria considered by the Transparency Commission in its appraisal include 
information on the characteristics of the technology, particularly the indication and 
composition, information on the marketing authorisation granted in terms of dose, and contra-
indications both within the EU and for marketing authorisations granted outside of the EU. 
To establish the therapeutic profile of the technology, an analysis of the clinical efficacy data 
is performed, vis á vis the formally identified comparator.  Safety data are also reviewed and 
compared with the comparator.  Priority is given to data emerging from randomised control 
trials, although the appraisal process also includes consideration of non-randomised 
observational data.  In order to establish the medical service rendered by the technology, 
review of the seriousness of the disease is performed, and note is taken of the availability of 
alternatives and the need for treatment from a public health standpoint.  The target population 
is established by considering the prevalence of the disease or condition in the French 
population and also includes, where appropriate, the estimation of the target population that 
would most particularly benefit from the treatment.    
 
7.2 Methods 
The overall objective was to examine 
the factors that influence decisions 
made by HAS to recommend, restrict 
or not recommend new technologies 
for use in the healthcare system.  In 
addition to the general aims described 
in Chapter 1, the particular 
hypotheses relevant for the analysis of 
coverage decisions by HAS are 
highlighted in Box 7.1.  Building on 
from the methods described in 
Chapter 3, this section describes the 
methods used to select the sample for 
analysis, the outcome variable and 
explanatory variables considered, and 
the statistical techniques adopted.    
 
Box. 7.1 In light of the discussions outlined in Chapter 
2, HAS-specific research objectives were to test 
whether: 
• Clinical evidence variables (and hence 
‘proof’ of degree of medical service 
rendered) impact on ASMR ratings – such 
that technologies achieving ASMR ratings I-
II are accompanied by higher quality of 
evidence than those technologies achieving 
ASMRs of III or below.   
• The political context, assessed by examining 
whether an election took place in the year of 
appraisal, impacts significantly on HAS 
decision-making by favouring higher ASMR 
ratings (I-II vs. III-IV or V) 
• The pattern of coverage decision-making by 
HAS is changing over time– it is 
hypothesised that the proportion of ASMR V 
ratings is increasing over time relative to 
ASMR I-II ratings. 
• The ASMR ratings reflected the nature of the 
disease for which the technology is indicated 
– therapeutic areas where unmet medical 
needs can be hypothesised to be high (e.g. 
rare diseases and/or cancer) positively on the 
odds of ASMRI-II versus ASMR III-IV or 
versus ASMR V.
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7.2.1 Sample  
The drug technology appraisals performed by HAS formed the basis for the sample 
included in this analysis.  The sample included all drug technology appraisals (as 
opposed to medical devices or other interventions) made during 2004-2009 indicated for 
an adult population (≥18 years).  Technology appraisals were excluded from the 
analysis for any of the following reasons: i) they focused on a non-adult population; ii) 
they appraised non-drug interventions; iii) marketing authorisation was withdrawn; iv) 
the ASMR was not reported (HAS only); or v) the full guidance was not available. 
 
Additional inclusion criteria were employed for this analysis of HAS which has 
numerous responsibilities, one of which is the provision of advice on new technologies 
available for patients.  In total, the Transparency Commission issued more than 2000 
recommendations in 2004-2009.  Given the resource constraints available, it was not 
possible to review all 2000 recommendations to identify those of relevance for this 
research (i.e. not all recommendations provide ASMR, some recommendations are 
related to new mode of administration, new safety information or a re-review of 
technologies licensed prior to 2004 etc).  In order to extract a relevant sample for this 
research, a list of technologies included in the SMC and NICE appraisals was created, 
and all the HAS recommendations linked to these technologies were extracted for 
review.  The benefit of this approach was that it increased the opportunity for 
comparability across agencies by collecting information on a common list of 
compounds, and secondly it facilitated the streamlining of data extraction to those 
appraisals relevant for the research question.   
 
7.2.2 Outcome variable 
To address the research question, HAS  decisions were analysed through considering 
HAS outcomes in three categories, where the new technology can be classified as 
bringing of:   
• Significant incremental medical benefit (ASMR I-II) 
• Modest incremental medical benefit (ASMR III-IV) 
or 
• No incremental medical benefit (ASMR V) 
 
  
 
207
The Transparency Commission’s main role is to ascertain the incremental medical 
improvement that the technology brings versus currently available therapies in France 
through the ASMR.  The level of funding, specifically its price and volume, is 
dependent upon the ASMR rating.  For the purposes of this analysis, the five ASMR 
categories were ‘collapsed’ into three categories.  Those decisions with an ASMR of I 
or II were combined in one category (equivalent to ‘recommend’ in the analyses of 
other HTA bodies), those with an ASMR III or IV were combined to create a second 
category (equivalent to ‘recommend with restrictions’), and those decisions concluding 
with an ASMR of V were considered as the third category (equivalent to ‘not 
recommended’).  An alternative categorisation of the outcome variable was tested in a 
sensitivity analysis.   
 
7.2.3 Explanatory variables 
In line with the hypothesised drivers of HTA decision-making highlighted in Chapter 3, 
the HAS dataset includes 31 explanatory variables of interest.  The first set of variables 
was related to the technology itself – the nature of the clinical evidence available, 
disease characteristics, whether cost-effectiveness evidence was put forward, and if so, 
the characteristics of that evidence.  The second set of variables captured information 
relating to the process by which the recommendation was issued.  Finally, the third set 
of variables in the data extraction form captured information on the context in which the 
guidance was issued (healthcare system, economic and social context), and thus aimed 
to capture information on variables linked to French health policy, and socio-economic 
status.   
 
HAS differed from the three other HTA bodies in that no economic criteria were used 
by the Transparency Commission in its assessment of the technology.  Therefore, no 
economic related variables were extracted for HAS.  However, the clinical variables and 
variables related to the process and context of decision-making were extracted in a 
similar fashion to those extracted for NICE, SMC, and CVZ. In addition, for HAS, a set 
of specific variables were collected to reflect the specificities of the appraisal process.  
The first is related to the request for appraisal – that is, information was collected on the 
rationale for the request for review made by the manufacturer, including whether it was 
a request to review a new technology, or a new indication of an existing technology, or 
because it was a class review, or a re-review etc.  This is a specific aspect of the HAS 
reimbursement review system for which relevant information was collected.  In 
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addition, information was extracted about whether the technology was intended for 
inpatient or outpatient use, similar to what was collected for the CVZ.  The rate of 
reimbursement was collected, which is determined by specific legislation and is driven 
primarily by the chronic nature and severity of the disease and on the profile of the 
technology, but not by the ASMR.  With regard to post-reimbursement commitments, 
data was extracted on whether a request was made for an observational study to be 
conducted, featuring the newly reimbursed technology.   
 
7.2.4 Data extraction form 
The data set was created by extracting data from appraisal reports/documents made 
available on the HAS website .  The process of data extraction followed the protocol set 
out in Chapter 3.   Table 7.1 provides the list of variables extracted to create the HAS 
dataset, as well as the accompanying decision rules and definitions. 
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Table 7.1 HAS dataset:  Included Variables, their Definition, Data Extraction Rule and Data Sources 
# Variable Descriptor Unit measure Definition Data Sources 
1 Number of RCTs 
considered in decision 
Count The number of distinct Randomised Controlled Trials (RCTs) that provide 
data related to the therapeutic indication under evaluation.   
Excluded:  studies that are single arm, that have no randomisation, or that 
are non-interventional.  
Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
 
2 Size of population included 
in RCTs 
Numeric Mean number of patients per RCT.   Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
3 Length/extent of follow-up 
in RCT 
Numeric Mean number of weeks that data is collected on patients that entered the 
RCTs (see variable no. 1).  
 
 
Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
 
4 Statistically Significant 
results 
Categorical 
(yes/no/inconsistent
) 
Presence of statistically significant superiority of technology versus the 
comparator for primary endpoint(s). 
 
If more than one RCT was considered, and the technology showed 
statistically significant superiority in one trial, but not in another, the 
results were considered to be ‘inconsistent’ and classified as such.  RCTs 
designed as ‘non-inferiority’ studies were classified as not showing any 
statistically significant superiority (i.e. ‘no’).    
Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
 
5 Relevance of RCT to payer 
decision 
Numeric Percentage of RCTs where active comparator was used.   Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
6 Number of observational 
studies considered in 
guidance 
Count Number of observational studies providing information to support study 
drug.  Observational studies in this circumstance are defined as studies 
that are non interventional (i.e. do not explicitly request the patient to take 
particular medication or the physician to follow particular protocol).   
Advice from the Commission de la 
Transparence, section 3 (3.1 – 3.3) 
 
7 Priority disease area Categorical – 
yes/no 
This variable aims to capture the health policy context in which the payer 
decision is made, by capturing whether the pharmaceutical in question is 
linked to a disease area that is prioritized by the ministry of health.   
Priority disease areas were identified by examining government 
plans/health documents that highlight national health care system focus. 
CNRS (2004) 
8 Orphan Status Categorical – 
yes/no 
This variable captured information on whether or not the technology was 
recognized by the European Medicines Agency (EMA) as an orphan 
designated medicine.   
European Medicines Agency (accessed 
2010-2011); Cover Page of Avis from the 
Commission de la Transparence 
9 Therapeutic Area Categorical – 13 The British National Formulary (BNF) categories were used to classify British National Formulary (2010) 
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# Variable Descriptor Unit measure Definition Data Sources 
categories each technology into the corresponding therapeutic area.   
10 Prevalence of 
disease/clinical condition 
Numeric Reported number of patients eligible for treatment, as per the Summary 
Product Characteristics and indication of the medication under evaluation.  
Advice from the Commission de la 
Transparence, section 4.4 
11 Availability of alternative 
therapies in current 
treatment setting. 
Categorical – 
yes/no  
An alternative was considered to be available if comparators were clearly 
defined in the review by the HTA agency.  An alternative was considered 
NOT to be available if it was stated as such in the appraisal, or if ‘best 
supportive care’ or ‘palliative care’ was specified as the comparator. 
Advice from the Commission de la 
Transparence, sections 2.2 and 2.3, and 
4.3 
12 Consideration of Cost 
Utility Analysis in 
guidance 
Categorical – CUA 
performed or no 
CUA 
Presence or absence of a cost-utility analysis.   Secretariat General de la Commission de 
la Transparence (2005) 
13 Inclusion of patient 
submission 
Categorical – 
yes/no 
A patient submission was considered to have been included as part of the 
appraisal process if a submission from a patient group was acknowledged 
within the appraisal document (e.g. SMC, CVZ) or  posted on the 
webpage pertaining to the guidance (NICE).  
Secretariat General de la Commission de 
la Transparence (2005) 
14 Number of Decision 
Makers Accountable 
Numeric Captures the number of decision-makers accountable for guidance issued, 
as reported.  For NICE, this information was extracted from Appendix B 
of each guidance, for the SMC, from the minutes of the meeting.  For the 
CVZ and HAS, directly from the description of the committee webpages.   
Zentner et al., 2005; Secretariat General 
de la Commission de la Transparence 
(2005)  
 15 Cost-effectiveness 
evaluation component in 
process 
Categorical – 
yes/no 
Captures whether cost-effectiveness is a component of the decision-
making process or not. If cost-effectiveness analysis is a formal part of the 
appraisal process, this variable was marked as ‘yes’.  
Secretariat General de la Commission de 
la Transparence (2005) ; Sorenson et al. 
(2008) 
16 Budget impact as a 
component of decision-
making process 
Categorical – 
yes/no 
Captures whether budget impact considerations are part of decision-
making process 
Secretariat General de la Commission de 
la Transparence (2005) ; Sorenson et al. 
(2008) 
17 Pricing known during 
appraisal process 
Categorical – 
yes/no 
Captures whether the price of the technology under appraisal was known 
during the assessment.     
Secretariat General de la Commission de 
la Transparence (2005) 
18 Number of technologies 
appraised simultaneously 
Count This variable captures the number of technologies appraised 
simultaneously in the appraisal.   
Secretariat General de la Commission de 
la Transparence (2005) 
19 Different process for 
medications destined for 
hospital or retail use 
Categorical – 
yes/no 
Records whether funding decisions for medications follow different 
processes depending on whether they are destined for hospital or retail 
prescription.  
Secretariat General de la Commission de 
la Transparence (2005) 
20 Accountability of drug 
budget 
Categorical – 
yes/no 
The HTA agency was examined to assess whether or not the agency 
making the funding decisions is also accountable for the drug budget.  
Sorenson et al. (2008) 
21 Independence of decision-
making agency 
Categorical – 
yes/no 
This pertains to whether the HTA body is independent of Ministry of 
Health or part of it. 
Sorenson et al. (2008) 
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# Variable Descriptor Unit measure Definition Data Sources 
22 Date guidance was issued Numeric Year when coverage decision was issued Cover Page of Avis from the Commission 
de la Transparence 
23 Population size – Agency 
coverage 
Numeric Estimate of population size within remit of the agency performing the 
evaluation. 
Eurostat (2010) 
 
24 GDP-healthcare 
expenditure 
Numeric (%) Percentage of GDP spent on healthcare, during year of decision OECD (2009) 
25 Healthcare expenditure on 
pharmaceuticals 
Numeric (%) Percentage of healthcare budget spent on pharmaceuticals per patient per 
year, during the same year in which the appraisal was published.  
Econ-Sante` France (2010) ;  IRDES 
(2009) 
26 Drug funding process 
within healthcare system – 
whether centralized or 
decentralized 
Categorical – 
centralized, 
decentralized 
States whether drug funding process within the healthcare system  is 
centralized at a national level or whether funding decisions are 
decentralized to the regional level 
Sorenson et al. (2008) 
27 Election year at time of 
decision 
Categorical – 
yes/no 
This variable captures whether payor decision was made within an 
election year.  An election year was defined as a year in which either 
national government or regional elections took place.     
Le ministre de l'intérieur, de l'outre-mer, 
des collectivités territoriales et de 
l'immigration (2004) and (2007)   
28 Inpatient Use Categorical – yes/ 
no 
This variable provides information on whether or not the technology was 
specified for use within an inpatient setting.   
Cover Page of Avis from the Commission 
de la Transparence and section 4.5 
29 Post-approval Study 
request 
Categorical – yes/ 
no 
This variable provides information on whether reimbursement was granted 
with the condition that real-life observational data on the technology 
would be provided within a specified time period.  
Advice from the Commission de la 
Transparence, section 4.4 
30 Reason for Reimbursement 
request 
Categorical – 5 
categories 
Collected for HAS only – captures the rationale for the reimbursement 
request – including whether the review was for a new technology, a 
technology with an indication extension, a class review, a modification of 
mode of administration/dosage.  Extracted directly from first page of 
appraisal report.    
Cover Page of Avis from the Commission 
de la Transparence 
31 Reimbursement Level Numeric (%) For HAS only. This captures information on the level of reimbursement 
granted for the technology as per national legislation which attributes 
levels of reimbursement based on characteristics of the compound.  This 
information was extracted from the last section of the HAS appraisal 
report.  
Advice from the Commission de la 
Transparence, section 4.5 
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7.2.5 Statistics 
The methods for the descriptive statistics and multivariate analyses were described in 
Chapter 3.  Descriptive statistics were calculated for each extracted variable, stratified 
by outcome group (recommended, restricted or not recommended).  Following a 
descriptive analysis of the dataset, a multinomial logit regression was modelled.  In the 
multivariate analysis, the base outcome utilised was the ‘AMSR I-II’ outcome.  The 
objective of this analysis was to obtain a parsimonious model that best reflected the 
main drivers of HAS decision-making. 
 
7.3 Results 
7.3.1 Sample characteristics  
A total of 351 technology appraisals performed between January 2004 and June 2009 
were retrieved from the HAS website.  Of these, 315 full submissions were included for 
analysis. 36 drug reviews were excluded from the analysis for the following reasons:  
either the ASMR was not reported (n=20) or the review focused on a non-adult 
population (n=16). 
 
Table 7.2a shows the HAS guidance issued between 2004- June 2009, and the 
distribution of drugs by ASMR rating.  Within this five-year period, of the 315 HAS 
decisions analysed, 3% of decisions awarded an ASMR of 1, meaning that the 
technology was considered to bring highly significant medical benefit, and 15% of 
decisions awarded an ASMR of II, in instances where the committee considered that the 
technology would bring significant medical improvement.  The majority of decisions 
(44%) concluded that there was no medical improvement associated with the 
technology (ASMR V).    Table 7.2b shows the proportion of technologies in ASMR I-
II, ASMR III-IV and ASMR V categories.   
 
Table 7.2a Outcome of HAS guidance issued between 2004-June 2009 – HAS decisions stratified by ASMR 
HAS guidance 
ASMR 
Number of coverage 
decisions 
Percentage 
I 11 3% 
II 45 15% 
III 60 19% 
IV 60 19% 
V 139 44% 
Total 315 100% 
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Table 7.2b Outcome of HAS Guidance issued between 2004-June 2009 – HAS decisions stratified by ASMR 
category 
HAS guidance  Number of coverage 
decisions 
Percentage 
ASMR I-II 56 18% 
ASMR III-IV  120 38% 
ASMR V 139 44% 
Total 315 100% 
 
7.3.2 Descriptive statistics 
Clinical Evidence 
Descriptive statistics for HAS are summarized in Table 7.3.  On average HAS took into 
consideration 2 RCTs per appraisal in its review process, with an average sample size of 
1154 patients, and duration of 49 weeks.  Decision outcomes differed in terms of the 
number of RCTs considered by the committee, as well as the duration.  Perhaps 
unexpectedly, ASMRI-II interventions had a lower number of RCTs considered by the 
HTA committee (1.8 trials), compared to interventions that had an ASMR III-IV or 
ASMR V (2.4 and 2.5 respectively), and this difference between outcome categories 
was statistically significant (p=0.013).  In addition, differences between outcome 
categories were observed in the duration of clinical trials considered:  this ranged from 
63 to 51 to 43 weeks for the ASMRI-II, ASMRIII-IV and ASMR V groups respectively 
(p=0.0013).  While differences in the number and duration of clinical trials was 
observed, differences in the size of the clinical trials considered in the Transparency 
Commission’s reviews was not statistically significant between outcome groups 
(ranging from 917 – 1199 patients).   
 
Aside from the size and number and duration of RCTs, the results of the RCTs were 
also captured.  The majority (73%) of technologies rated ASMRI-II for reimbursement 
by HAS were supported by RCTs demonstrating superiority of the technology with 
regard to the primary endpoint(s).  This is in contrast to the ASMRIII-IV and ASMR V 
technologies, where the proportion of RCTs demonstrating superiority was lower (56% 
and 31% respectively).  This difference between groups in terms of demonstration of 
superiority was statistically significant (p<0.001).    The comparator used within the 
clinical trial programme was assessed – in particular, the percentage of comparisons 
made to ‘active’ comparators as opposed to placebo was recorded.  Unexpectedly, 
interventions rated ASMRI-II had a lower number of comparisons to active agents 
(25%) than interventions that were ASMRIII-IV or ASMR V (40% and 50% of RCTs 
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with active comparators, respectively).  The differences observed between the groups 
were statistically significant (p=0.0137).   
 
Consideration of non-randomised observational data was also recorded.   Overall, in the 
majority of drug reviews, observational data was not considered and there were no 
significant differences between outcome groups.   
 
Economic Evidence 
None of the HAS reviews included the evaluation of the economic characteristics of the 
technology.  This is entirely driven by the HAS review process which does not 
incorporate such information in its reimbursement recommendation.  Therefore, no 
economic variables are described. 
 
Disease characteristics 
The HAS review process requires information on the number of patients eligible for 
treatment with the drug under review.  This ranged from 61,776 patients for ASMR I-II 
interventions to 246,940 and 907,741 patients in the ASMRIII-IV and ASMRV 
interventions.  All statistical tests performed suggested that these differences were 
highly statistically significant.  
 
The availability of alternative therapies was assessed to ascertain if it differed between 
ASMR I-II and ASMRIII-IV or ASMR V interventions.  In the majority of technologies 
appraised, an alternative was available (in 89% of cases, all decisions considered).  
There were differences across the outcome groups which were statistically significant 
(p= 0.014). 
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Table 7.3 HAS Coverage Decisions:  Descriptive statistics for extracted variables, by coverage decision (ASMR I-II, ASMR III-IV, ASMR V)   
Variable Total (n=315)   ASMR 1 + 2 (n=56)   ASMR 3 + 4 (n=120)   ASMR V (n=139)   
  mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI   
Number of RCTs 
considered in 
decision 
2.3 2.1 2.6 1.8 1.4 2.2 2.4 2.0 2.8 2.5 2.1 3.0 
Size of population 
included in RCTs 
1154 824 1484 917 293 1541 1194 632 1756 1199 690 1708 
Length/extent of 
follow-up in RCT 
(weeks) 
49 41 57 63 47 78 51 38 65 43 30 55 
Statistically 
Significant results -   
                        yes 
(1) 
47% 33% 43% 73% 38% 65% 56% 37% 55% 31% 19% 33% 
no (0) 20% 21% 31% 10% 4% 21% 12% 19% 35% 30% 24% 39% 
inconsistent (2) 33% 12% 20% 18% 0% 14% 32% 5% 15% 38% 18% 32% 
Relevance of RCT 
to payer decision 
42% 37% 48% 25% 13% 38% 40% 31% 49% 50% 42% 59% 
Number of 
observational 
studies considered 
in guidance 
0.3 0.2 0.4 0.5 0.0 1.0 0.3 0.1 0.6 0.2 0.1 0.3 
Consideration of 
Cost Utility 
Analysis in 
guidance 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Prevalence of 
disease/clinical 
condition 
         
511,047  
               
314,122  
      
707,972  
                
61,776  
-      
31,135  
    
154,687  
                    
246,940  
       
118,391  
     
 375,489  
                  
907,741  
       
489,394  
   
1,326,088  
Social Perspective 
adopted 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Availability of 
alternative 
therapies in current 
89% 85% 92% 81% 70% 92% 86% 80% 92% 94% 90% 98% 
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Variable Total (n=315)   ASMR 1 + 2 (n=56)   ASMR 3 + 4 (n=120)   ASMR V (n=139)   
  mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI   
treatment setting. 
Inclusion of patient 
submission 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Cost-effectiveness 
evaluation 
component in 
process 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Budget impact as a 
component of 
decision-making 
process 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Pricing and 
Reimbursement 
decided jointly 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Accountability of 
drug budget 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Date guidance was 
issued 
2007 2006 2007 2006 2006 2006 2006 2006 2007 2007 2007 2007 
Population size – 
Agency coverage 
(thousands) 
       
63,400  
                 
63,300  
       
63,500  
                
63,200  
       
64,400  
       
63,000  
                    
63,300  
       
63,200  
        
63,500  
                  
63,500  
        
63,400  
      
  63,600  
GDP-healthcare 
expenditure 
11% 11% 11% 11% 11% 11% 11% 11% 11% 11% 11% 11% 
Healthcare 
expenditure on 
pharmaceuticals 
519 € 517 € 522 € 512 € 506 € 518 € 517 € 512€ 521 € 524 € 520 € 527 € 
Election year at 
time of decision 
30% 25% 36% 30% 18% 43% 38% 30% 47% 24% 17% 31% 
Priority disease 
area 
70% 64% 75% 71% 59% 84% 73% 64% 81% 66% 58% 74% 
Orphan Designated 9% 6% 12% 23% 12% 35% 12% 6% 17% 1% -1% 3% 
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Variable Total (n=315)   ASMR 1 + 2 (n=56)   ASMR 3 + 4 (n=120)   ASMR V (n=139)   
  mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI   
Reimbursement 
Level 
70% 68% 73% 73% 68% 79% 74% 70% 77% 67% 64% 70% 
Hospital use only 51% 46% 57% 74% 61% 86% 56% 46% 65% 39% 31% 48% 
Request for post-
marketing study 
24% 19% 28% 33% 20% 47% 30% 21% 38% 15% 9% 21% 
Reason for HAS 
review 
                        
Inscription on 
social 
security/reimburse
ment list 
44% 38% 49% 36% 23% 49% 48% 38% 57% 44% 36% 52% 
Re-evaluation of 
previous appraisal 
8% 10% 23% 7% 0% 28% 8% 5% 25% 9% 9% 29% 
Extension of 
indication 
34% 86% 118% 36% 68% 146% 28% 60% 110% 38% 90% 139% 
Renewal of 
inscription on 
social security 
13% 37% 67% 21% 41% 130% 14% 31% 82% 9% 16% 53% 
New 
reimbursement 
criteria 
1% -1% 10% 0% 0% 0% 3% -2% 27% 0% 0% 0% 
BNF Category                         
cardiovascular 
system 14% 10% 18% 18% 8% 28% 13% 7% 20% 13% 7% 19% 
central nervous 
system 18% 14% 23% 2% -2% 5% 20% 13% 27% 24% 17% 31% 
ear, nose and 
oropharynx 0% 0% 1% 0% 0% 0% 0% 0% 0% 1% -1% 2% 
endocrine system 6% 4% 9% 4% -1% 9% 7% 2% 11% 7% 3% 12% 
eye 2% 0% 3% 2% -2% 5% 2% -1% 4% 2% 0% 5% 
gastro-intestinal 
system 3% 1% 6% 2% -2% 5% 2% -1% 4% 6% 2% 10% 
infections 12% 8% 15% 2% -2% 5% 13% 7% 20% 14% 8% 20% 
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Variable Total (n=315)   ASMR 1 + 2 (n=56)   ASMR 3 + 4 (n=120)   ASMR V (n=139)   
  mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI   
malignant disease 
and 
immunosuppression 24% 19% 29% 39% 26% 52% 26% 18% 34% 17% 10% 23% 
musculoskeletal 
and joint diseases 9% 6% 12% 25% 13% 37% 8% 3% 12% 4% 1% 8% 
nutrition and blood 3% 1% 6% 7% 0% 14% 3% 0% 5% 3% 0% 6% 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 0% 0% 1% 0% 0% 0% 0% 0% 0% 1% -1% 2% 
respiratory system 2% 1% 4% 0% 0% 0% 2% -1% 4% 4% 0% 7% 
skin 4% 2% 7% 0% 0% 0% 6% 2% 10% 5% 1% 9% 
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For each drug review, in order to assess whether the type of disease impacted on 
decision making, the disease was coded using BNF categories – 13 categories are used 
ranging from cardiovascular and central nervous system to infections, and skin diseases.  
Across all decisions, the majority of decisions were linked to medications for malignant 
disease and immunosuppression, central nervous system, and cardiovascular disease and 
infections.  This differed, however, between the decision categories:  for example, 
technologies for the treatment of malignant disease and immunosuppression appeared to 
be more likely to fall in the ASMR I-II category (39%) than in the ASMR III-IV (26%) 
or ASMR V groups (17%).  The most common disease category in the ASMR I-II 
group was therapies linked to malignant disease and immunosuppression (39% of 
recommendations made for this disease category).   It was also the most common 
disease area in the ASMR III-IV group.  In the ASMR V group, technologies were most 
frequently linked to the management of diseases related to the central nervous system 
(24%).  The differences observed between outcomes groups in terms of the distribution 
of decisions by BNF categories were statistically significant (p≤ 0.001). 
 
Orphan designation is given to specific therapies by the EMA if they fulfil specific 
criteria, namely related to the prevalence of the disease, the clinical profile of the 
disease and level of unmet need. During 2004-2009, 9% of reviewed drugs had an 
orphan designation.  A higher proportion of orphan medicines were in the ASMR I-II 
group (23%) compared to the ‘ASMR III-IV’ (12%) and ‘ASMRV’ interventions (1%).  
These differences between outcome groups were statistically significant (p ≤ 0.001). 
 
HAS assessment process characteristics 
A series of variables related to the decision-making process were recorded.  Firstly, the 
HAS review process does not foresee input from patient groups.  Secondly, with regard 
to economic considerations, the HAS review process does not incorporate economic 
considerations in its decision making – therefore, it was not possible to include neither 
cost-effectiveness/cost-utility analyses, nor budget impact estimates in this analysis.     
Finally, it is not part of the HAS appraisal process to decide on funding and pricing 
decisions jointly – indeed, once the Transparency Commission has given its decision, 
this information is provided to the Economic Committee (Comittee Economique) which 
negotiates the price and volume with the respective manufacturer.   In general, the HAS 
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reviews single technologies, although there are a few cases where class reviews are 
performed, in which case several technologies may be reviewed simultaneously.    
 
The HAS not only reviews new technologies for reimbursement purposes, but also 
reviews decisions either after a specific time period, or if there is a new indication, or a 
class review.  Therefore, there are a number of rationales for HAS to conduct a review.  
The most frequent reason, occurring in 44% of cases, is the so called ‘Inscription 
Securite Sociale et Collectivites’, related to the registration of the technology on the 
reimbursed list, or positive list.  The second most common reason (34%) is related to a 
review due to an expansion of the indication/use of the technology.  The reasons for 
HAS appraisal were not statistically significantly different between the ASMR groups.   
 
Related to the HAS review process is whether the technology is considered to be 
available for use exclusively in a hospital setting or outpatient setting.  Of the reviewed 
technologies, approximately 52% of ASMRIII-IV were for hospital use only.  This 
differed between the outcome groups – more of the ASMRI-II interventions were for 
hospital use only (76%) compared to the restricted – ASMR III-IV - (56%) or not 
reimbursed – ASMR V-  interventions (39%).  These differences are statistically 
significant (p=0.0001).  
 
As part of its process the HAS also specifies the level of reimbursement for the 
technology – this is governed by Ministry of Health criteria based on the disease area, 
whether the disease is chronic, if it is predominantly a paediatric condition or a 
condition prevalent in the elderly etc.  Based on this algorithm, the technology is 
associated with a reimbursement level.  Such information was collected as part of this 
research.  The average reimbursement rate is 70%, across the 315 appraisals; ranging 
from approximately 73% in the ASMRI-II and ASMRIII-IV groups to 66% in the 
ASMR V group1.  The difference observed in the mean level of reimbursement between 
the ASMRIII-IV and ASMR V interventions is statistically significant (p=0.0082) 
 
One of the characteristics of the HAS process is the possibility for the Transparency 
Commission to request an observational study to ascertain the effectiveness/use/safety 
of the technology once used within the French healthcare system.  Of the HAS reviews 
                                                 
1 It should be noted that ASMR V medications cannot be inserted in the reimbursement list unless they 
are associated with lower treatment costs than standard care.  
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considered, in 24% of cases HAS requested these post-launch observational studies.  
There were more requests made for such research for ASMRI-II and ASMRIII-IV 
interventions than for interventions considered to have no incremental medical benefit 
(ASMR V).  These differences were statistically significantly different (p=0.004).   
 
Finally, as part of the HAS appraisal process, the Commission can indicate whether the 
reimbursement should be granted for the indicated population, a subset of the 
population or for none of the population.  The last scenario is very rare (1% of reviewed 
decisions).  The most common is that the HAS recommends use for the entirety of the 
indicated population (71%) of cases.  However, this varies between the outcome groups.  
Those interventions that have an ASMR I-II, the use of the technology for the entirety 
of the population is granted in 91% of cases, as opposed to 66% and 69% of cases for 
interventions that are rated ASMRIII-IV or ASMR V, respectively.  The differences 
observed were statistically significant (p= 0.009). 
 
Socio-economic context of HAS decision-making 
A series of variables were recorded to capture the socio-economic context in which 
HAS decisions were made.  In particular, information was recorded on the year of the 
appraisal (mean 2007), size of population under HAS remit (approx. 63.4 million), 
percentage of GDP spent on healthcare (11%), and whether appraisal coincided with an 
election year (30% of cases).  There was strong correlation between the year of 
appraisal and the other socio-economic factors.  The year of appraisal, population size, 
healthcare expenditure on pharmaceuticals and percentage of decisions made within an 
election year, appeared to vary significantly between outcome groups.  For example, 
during the election year, there were more recommendations (30%) and restrictions 
(38%) made than there were ‘non recommendations’ (24%).  These differences were 
statistically significant (p=0.039).       
 
Summary of descriptive analysis 
In order to assess the factors that impact on funding decisions in France, 315 decisions 
made by the HAS in the period 2004-2009(June) were reviewed.  These 315 appraisals 
correspond to the compounds that had been included in SMC and NICE reviews in the 
same period. The HAS recommendations were analysed according to the ASMR that 
was attributed to the technology for the specific patient population under review.  The 
ASMR levels were grouped into three categories – ASMR I-II, ASMR III-IV, and 
  
 
222
ASMR V.   To identify those factors that can explain HAS decision-making patterns, 
information on 31 explanatory variables was collected for decisions made by HAS in 
2004-2009. 
 
Of these variables, descriptive analysis suggests that approximately half of the tested 
variables appear to be a contributing factor in determining HAS decision-making (Table 
7.4).  For these variables, statistically significant differences were observed between 
interventions that had an ASMR I-II, III-IV and V (p≤0.05).   Highly statistically 
significant differences (p≤0.01) were observed for variables highlighted in bold.   
 
Table 7.4  HAS descriptive statistics: statistically significant variables (p ≤ 0.05) 
Component 1 Variables 
Clinical Package No of RCTs 
RCT demonstrates superiority 
Duration of RCT 
Active comparator used 
Economic Package -- 
Disease characteristics Prevalence of disease 
Availability of alternatives 
Orphan status 
Therapeutic area:  cancer therapies, musculoskeletal/joint 
diseases, cardiovascular disease, central nervous system 
diseases, infectious diseases 
 
Component 2 – Process 
Characteristics 
Level of reimbursement 
Hospital use only 
Request for post-launch study 
Reason for request 
 
Socio-economic Context  
Date of Review 
Pharmaceutical Exp per patient 
National Population size 
Election year 
Note:  variables in bold text were statistically significant at the  p ≤ 0.01 level 
 
7.3.3 Multivariate analysis 
Following the model specification process described in Chapter 3 which included the 
development of a preliminary model (Appendix D), the base case model of HAS 
decision-making was developed which contains eight variables impacting significantly 
on HAS decisions, including clinical, disease and process related variables.  The model 
yielded a pseudo R-squared value of 0.19, suggesting that it appears to explain 
approximately 19% of the variability observed in coverage decisions made by the HAS 
(Table 7.5).  There were variables which had a statistically significant impact on both 
coverage options (ASMR I-II vs. ASMR III-IV or ASMR V):  prevalence of disease; 
orphan designation; indicated for treatment of central nervous system (CNS) disorders, 
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infectious disease or musculoskeletal and joint diseases;  and the absence of data on 
prevalence all impacted significantly on HAS coverage decision-making.  Specifically, 
a unit increase in the prevalence of the target population, or an indication for the 
treatment of CNS disorders or infectious diseases increased the probability of an ASMR 
III-IV or ASMR V, while orphan designation, license for the treatment of 
musculoskeletal and joint diseases, and absence of information on the prevalence of the 
target population increased the log odds of an ASMR I-II.  If the technology was 
indicated for the treatment of musculoskeletal and joint diseases, this decreased the log 
odds of an AMSR I-II.  Oddly, the absence of prevalence data increased the odds of an 
ASMR I-II.   
 
Table 7.5  Multivariate analysis of HAS coverage decisions 2004-2009:  base case model results  (n=315) 
ASMR III-IV Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -0.42 0.277 -1.179 0.338 
Disease prevalence 0.00000049 0.113 -0.00000012 0.0000011 
Orphan designation status -1.27 0.010 -2.24 -0.30 
Central nervous system 2.87 0.007 0.79 4.95 
Infections 2.31 0.036 0.15 4.47 
Musculoskeletal and joint diseases -1.58 0.002 -2.61 -0.56 
Healthcare expenditure on pharmaceuticals 0.0091 0.273 -0.0072 0.025 
Missing data on prevalence of disease -2.15 0.001 -3.38 -0.91 
Constant -3.45 0.419 -11.81 4.91 
ASMR V Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.35 0.001 -2.17 -0.53 
Disease prevalence 0.00000088 0.005 0.00000027 0.0000015 
Orphan designation status -3.52 <0.001 -5.18 -1.86 
Central nervous system 3.17 0.003 1.07 5.27 
Infections 2.21 0.046 0.04 4.38 
Musculoskeletal and joint diseases -2.58 <0.001 -3.87 -1.28 
Healthcare expenditure on pharmaceuticals 0.024 0.008 0.0063 0.042 
Missing data on prevalence of disease -2.75 <0.001 -3.98 -1.51 
Constant -10.67 0.021 -19.73 -1.62 
Note:  Technologies with ASMR I-II are the reference case. Multinomial logistic regression, pseudo R-
squared: 0.19.   
 
There were other variables in the HAS model whose impact was observed in one of the 
two coverage alternatives.  In comparison to an ASMR I-II, the demonstration of 
clinically significant superiority decreased the log odds of an ASMR V, but did not 
impact statistically significantly on the log odds of an ASMR III-IV.  The 
demonstration of clinical superiority of the technology in a clinical trial statistically 
significantly decreased the log odds of an ASMR V relative to an ASMR I-II (p=0.001).  
A unit increase in pharmaceutical expenditure increased the odds of an ASMR V 
relative to an ASMR I-II (p=0.012), but did not demonstrate a statistically significant 
effect on the odds of ASMR III-IV.    
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Impact of alternative model specifications- sensitivity analyses 
Sensitivity analysis was conducted on the HAS regression model.  This included: i) 
examining the impact of a binary rather than three-category outcome variable; ii) 
restricting the base case analysis to observations without missing entries, thus excluding 
observations with imputed values; iii) an alternative categorization of the ASMR is 
used, and (iv) examining the impact of assuming ordinality of the coverage decision.   
 
In the first sensitivity analysis the ASMR ratings were collapsed into two categories:  
those technologies showing at least some incremental therapeutic benefit (ASMR I-IV) 
and those showing no incremental therapeutic benefit (ASMR V).  This binary outcome 
variable was regressed with each explanatory variable individually to ascertain whether 
those variables that impacted statistically significantly in the base case analyses were 
still significantly impacting on the binary coverage decision.  This sensitivity analysis 
using a binary outcome variable  includes seven variables, and obtains a R-squared of 
0.18, suggesting that it can explain approximately18% of variation in HAS decision-
making, similar to the base case model with a pseudo R-squared of 0.19.   A set of 
variables remained common in both models:  demonstration of superiority, the 
prevalence of the condition and lack of prevalence data, orphan designation, treatment 
for central nervous system diseases and musculoskeletal/joint diseases.  In this 
sensitivity analysis, technologies indicated for infectious diseases were no longer 
significant predictors of HAS decision-making.   
 
In this sensitivity analysis, three variables increased the odds of an ASMR V, namely 
the prevalence of the disease, the nature of the disease, and pharmaceutical expenditure.  
A unit increase in the prevalence of the licensed indication increased the odds of an 
ASMR V (p=0.006), as did a license for the treatment of central nervous system 
conditions (p=0.058).  A unit increase in the mean national drug expenditure per patient 
also increased the odds of an ASMR V (p=0.003).    
 
Conversely, a combination of clinical and disease variables increased the odds of an 
ASMR I – IV.  Demonstration of superiority in efficacy within the RCT, increased the 
odds of an ASMR ≥ IV (p=0.019).  Technologies licensed for the treatment of 
musculoskeletal/joint conditions increased the odds of an ASMR ≥ IV, and orphan 
designation also significantly increased the odds of an ASMR ≥ IV.  This was consistent 
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with the effect also observed in the base case analysis.  Oddly, and consistently with 
what was observed in the base case analysis, the lack of prevalence data increased the 
odds of an ASMR ≥ IV.    
 
Table 7.6 Multivariate analysis of HAS coverage decisions 2004-2009:  sensivitiy analysis using binary outcome 
variable (ASMR ≥ IV vs. ASMR V) (n=315) 
Odds of ASMR ≥ IV Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT 1.03 <0.001 0.48 1.57 
Disease prevalence -0.00000046 0.006 -0.00000078 -0.00000013 
Orphan designation status 2.63 0.001 1.13 4.12 
Central nervous system -0.62 0.058 -1.27 0.022 
Musculoskeletal and joint diseases 1.51 0.006 0.42 2.59 
Healthcare expenditure on pharmaceuticals -0.017 0.003 -0.029 -0.0058 
Missing data on prevalence of disease 1.08 0.007 0.30 1.86 
Constant 8.79 0.004 2.78 14.80 
 
Table 7.7  Multivariate analysis of HAS coverage decisions 2004-2009:  sensivitiy analysis excluding 
incomplete observations from the sample (n=235) 
ASMR III/IV Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.07 0.049 -2.13 -0.0069 
RCT duration of follow-up -0.0051 0.123 -0.012 0.0014 
Disease prevalence 0.000010 0.093 -0.000002 0.000023 
Orphan designation status -1.65 0.009 -2.89 -0.42 
Musculoskeletal and joint diseases -2.30 0.001 -3.63 -0.97 
Healthcare expenditure on pharmaceuticals 0.014 0.199 -0.0074 0.035 
Constant -4.95 0.375 -15.88 5.99 
ASMR V Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -2.17 <0.001 -3.29 -1.04 
RCT duration of follow-up -0.011 0.012 -0.02 -0.0023 
Disease prevalence 0.000011 0.078 -0.0000012 0.000023 
Orphan designation status -3.44 <0.001 -5.29 -1.59 
Musculoskeletal and joint diseases -2.73 0.001 -4.38 -1.08 
Healthcare expenditure on pharmaceuticals 0.035 0.003 0.012 0.058 
Constant -15.20 0.012 -27.05 -3.36 
Note:  Technologies with ASMR I or II are the reference case. Multinomial logistic regression, pseudo R-
squared: 0.23.  
 
The second sensitivity analysis restricted the analysis to the sample of observations 
without missing entries.  Thus, imputation was not used in this analysis, and the total 
sample covered 235 observations (n=315 in base case analysis).  The regression model 
on the subset of complete observations results in a pseudo R-squared of 0.23, suggesting 
it can explain approximately 23% of variability in HAS decision making.   This figure is 
higher than observed in the base-case model, where the pseudo R-squared was 0.19.  
The sensitivity analysis regression model confirmed the important impact of several 
variables including:  the demonstration of superiority in the clinical trial which 
increased the probability of an ASMR I-II, the prevalence of the target population, 
orphan designation, and treatment of musculoskeletal/joint diseases.  The impact of 
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infectious disease or CNS disorder indications was no longer observed in this sensitivity 
analysis.  A new variable, RCT duration, whose effect was not observed in the base case 
model, was found to have a significant effect in this sensitivity analysis.  The mean 
duration of RCTs included in the appraisal significantly impacted on HAS decision-
making:  a unit increase in trial duration decreased the odds of an ASMR V (p=0.009), 
and also decreased the odds of an ASMR III-IV, but this was borderline statistically 
significant (p=0.123).  National mean drug expenditure per patient was also found to 
significantly impact on HAS decision-making:  an increase in drug expenditure was 
associated with an increase in the odds of an ASMR III-IV or V, although it was only 
significant in the latter case (p=0.003).    
 
The third sensitivity analysis examined the impact of a different use of ASMR ratings 
within the regression analysis.  In the base case analysis, the ASMR ratings are grouped 
as follows:  ASMR I-II, ASMR III-IV and ASMR V.  An alternative grouping is 
proposed in which ASMR I-III are grouped together, followed by ASMR IV and V 
assessed separately.  This is related to the fact that the pricing legislation in France 
(Social Security Code, article L. 162-16-4) specifies that the price of a technology is 
determined primarily by the ASMR granted to the technology, as well as price of 
comparator technologies,  and expected volume of patients indicated for the technology.  
It is also specified that only those technologies that bring incremental medical value (i.e. 
ASMR I-IV) or a reduction in the cost of treatment can be added to the reimbursement 
list (Article R.163-5 du code de la sécurité sociale).   Therefore, legislation specifies 
that those medications with an ASMR of V cannot be inserted in the reimbursement list 
unless they are associated with lower treatment costs.  Finally, the price of medications 
considered to be innovative (ASMR I-III) are ‘fixed’ through a reference pricing 
mechanism, such that the price of technologies with an ASMR I-III in France cannot be 
lower than the price in the reference European countries.   It is due to these 
particularities that it was considered relevant to run a sensitivity analysis in which 
technologies with ASMR I-III were grouped together.   
 
The resulting model included seven variables with an accompanying pseudo R-squared 
value of 0.20, similar to that obtained in the base case model (0.19).  With the exception 
of the impact of technologies for infectious diseases, all other variables, found to be 
significant in the base-case analyses maintained their significant impact on HAS 
coverage decisions even when the ASMR categorization was altered.  This included the 
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demonstration of superiority in the clinical trial, the prevalence of the target population 
(and lack of such information), orphan designation, treatment for CNS disorders and 
musculoskeletal/joint diseases, and pharmaceutical expenditure.  In the majority of 
variables the size and direction of the impact on the outcome variable was similar 
between the two types of categorization.  Two exceptions are noted for two variables 
that were no longer statistically significant in the ASMR IV arm of the model.  A unit 
increase in the prevalence of the target population increased the odds of an ASMR IV 
but was no longer statistically significant (p=0.478).  Similarly, orphan drug designation 
no longer had a statistically significant impact on the odds of an ASMR IV (p=0.174).     
 
Table 7.8  Multivariate analysis of HAS coverage decisions 2004-2009:  sensivitiy analysis using an alternative 
categorisation of the outcome variable (ASMR I-III, vs. ASMR IV or ASMR V) (n=315) 
ASMR IV Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -0.54 0.139 -1.26 0.18 
Disease prevalence 0.00000019 0.478 -0.00000034 0.00000073 
Orphan designation status -0.73 0.174 -1.78 0.32 
Central nervous system 2.67 <0.001 1.51 3.84 
Musculoskeletal and joint diseases -1.74 0.030 -3.31 -0.16 
Healthcare expenditure on pharmaceuticals 0.025 0.002 0.009 0.041 
Missing data on prevalence of disease -1.36 0.025 -2.54 -0.17 
Constant -13.35 0.002 -21.67 -5.03 
ASMR V Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.26 <0.001 -1.89 -0.62 
Disease prevalence 0.00000055 0.010 0.00000014 0.00000097 
Orphan designation status -2.94 <0.001 -4.51 -1.37 
Central nervous system 2.27 <0.001 1.13 3.41 
Musculoskeletal and joint diseases -2.01 0.001 -3.19 -0.83 
Healthcare expenditure on pharmaceuticals 0.028 <0.001 0.014 0.042 
Missing data on prevalence of disease -1.66 0.001 -2.60 -0.72 
Constant -13.61 <0.001 -20.72 -6.50 
Note:  Technologies with ASMR I - III are the reference case. Multinomial logistic regression, pseudo R-
squared: 0.20.  
 
In the fourth sensitivity analysis, ordinality of the outcome variable was assumed.  This 
is in contrast with the base case analysis, where ordinality was not assumed and 
multinomial logistic regression was used.  In this sensitivity analysis ordinal logistic 
regression was used.  The detailed results of this analysis are provided in Appendix G, 
and show that assuming the ordinality assumption and modelling using a five-category 
outcome variable does not increase the ability for the model to explain a larger 
percentage of HAS decision-making, suggesting that a multinomial approach using a 3-
category variable may be appropriate.  The results however, of this sensitivity analysis, 
reveal more detail in how the factors behave within the different levels of ASMR.   
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7.4 Discussion    
The overall objective of this chapter was to examine the factors that influence decisions 
made by the HAS to define the incremental medical value for technologies through the 
ASMR rating system which ranks technologies with either an ASMR I, representing the 
highest medical value, or ASMR V, representing no incremental medical value.  In line 
with the hypothesised drivers of HTA decision-making highlighted in Chapter 3, and in 
light of evidence review presented in Chapter 2,  a wide range of explanatory variables 
were included in the analysis, reflecting the clinical and disease characteristics of the 
technology under appraisal, the appraisal process itself and the socio-economic context 
in which the HAS operates. In addition to the general aims of the research, specific 
hypotheses relevant for HAS decision-making were explored and are discussed below.  
Unfortunately, it was not possible to incorporate insights from HAS representatives in 
appraising the results of this research.  
 
7.4.1 Pattern of HAS decision-making 
In exploring the factors driving coverage decisions made by the HAS, 315 technology 
appraisals were reviewed.  A primary result is that 3% of decisions were awarded an 
ASMR I, meaning that the technology was considered to bring highly significant 
incremental medical benefit and 15% of decisions were awarded an ASMR II, in 
instances where the commission considered that the technology would bring significant 
medical improvement.  The majority of decisions (44%) concluded that there was no 
medical improvement associated with the technology (ASMR V).  When HAS coverage 
decision were modelled, nine clinical, disease and socio-economic variables appeared to 
have a statistically significant impact on the odds of ASMR III-IV or ASMR V relative 
to ASMR I-II.  No economic variables were included as HAS does not include 
economic criteria in its appraisal process.   
 
7.4.2 The impact of clinical evidence and disease characteristics on HAS decision-
making 
Given that the HAS process focuses primarily on the demonstration of incremental 
medical value, it was hypothesised that variables which captured the quality of the 
clinical evidence provided would significantly impact on HAS decision-making.  
Clinical and disease characteristic variables played an important role in HAS decision-
making in this model.  The results support the hypothesis that technologies achieving 
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ASMR ratings I-II are accompanied by higher quality of evidence than those 
technologies achieving ASMRs of III or below.  Technologies that demonstrated 
clinical superiority increased the log odds of an ASMR I-II.  Within the HAS model, as 
in the previous models, it was observed that the same factor could impact differently on 
the odds of a restriction or on the odds of a non-recommendation relative to a 
recommendation.  For instance, while a unit increase in pharmaceutical expenditure per 
patient per annum decreased the log odds of an ASMR V, its effect on the odds of an 
ASMR III-IV was the opposite,  although not statistically significant.  Demonstration of 
clinical superiority decreased the odds of both ASMR III-IV and ASMR V.  This could 
be seen to reflect the focus of the HAS appraisal process on the incremental benefit 
associated with the technology, and demonstration of clinical superiority being a key 
piece of evidence to substantiate the presence of incremental medical benefit.   
 
Counter-intuitive to the hypothesis presented, the results suggest that in HAS decision-
making the demonstration of superiority outranks the nature of that superiority (whether 
demonstrated versus placebo or an active treatment).  Specifically, examination of the 
dataset showed that for those technologies which demonstrated clinical superiority, this 
superiority was demonstrated only 25% of the time versus an active comparator.   For 
those technologies that did not demonstrate clinical superiority, 68% were compared to 
active comparators.  It would appear that the criteria prioritized by HAS in its 
assessment of medical value matches closely with that used by regulatory agencies 
which also accept, and indeed in several circumstances recommend, comparison to 
placebo as an appropriate means of demonstrating clinical benefit.   
 
When examining disease characteristics and their impact on HAS decision-making, an 
unexpected result was observed related to the impact of the prevalence of disease on 
ASMR ratings.  When information on the size of the target population was lacking, this 
increased the odds of an ASMR I-II.  This result was unexpected in that it had been 
hypothesized that lack of evidence should, in principle, reduce the odds of a high 
ASMR rating.  However, upon further examination of the sample of technologies 
concerned (n=39), it was observed that amongst these technologies, 62% were being 
evaluated to renew their previously obtained reimbursement status.  These technologies, 
by default, were therefore technologies which were already reimbursed five years 
previously, and which needed to renew their reimbursement status.  It was likely 
therefore, that in these particular submissions, reference was made to previous target 
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population estimates, without reporting new figures.  This could therefore explain the 
impact of non-reporting of epidemiology information within the HAS multivariate 
model.       
 
It was hypothesised that ASMR ratings reflected the nature of the disease for which the 
technology was indicated.  The analysis of HAS decision-making found that 
technologies that had an orphan designation decreased the log odds of an ASMR III-IV 
or V relative to an ASMR I-II.  This could be explained by the fact that orphan 
designated technologies tend to be rare and indicated for diseases with no therapeutic 
alternatives.  When the features of orphan technologies were further examined, they 
were found to be characterised by small patient populations (mean estimated target 
population for orphan technologies was 1,356 patients vs. 570,408 patients for non-
orphan technologies).  In addition, orphan technologies were indicated for diseases with 
low availability of alternative therapy (38% of cases alternative technologies were 
available) and therefore correspondingly higher level of clinical need for treatment.  For 
non-orphan technologies, in 80% of cases alternative therapies were available within the 
French healthcare system.  Orphan designation increased the odds of high ASMR 
ratings despite the fact that, compared to non-orphan technologies, orphan technologies 
on average were supported by fewer RCTs (1.5 vs. 2.8), had mean shorter trial duration 
(29 weeks vs. 53 weeks), were supported by smaller trials with, on average, fewer 
patients (255 patients vs. 1,228 patients), and had a higher proportion of instances in 
which an active comparator within the clinical trial was not available (34% vs. 16%).  
This evidence would support the hypothesis that therapeutic areas where unmet medical 
needs are high impact significantly on HAS decision-making.  In addition, the evidence 
generated in this analysis suggest that the HAS may be willing to place more emphasis 
on the potential for the technology to fill a specific clinical need, at the expense of the 
quality of clinical evidence.    
 
In addition to the effect of orphan designation on HAS decision-making, the impact of 
specific disease areas on coverage decisions was also examined and found to be 
important within HAS decision-making – providing additional evidence to support the 
hypothesis that ASMR ratings reflect the nature of the disease for which the technology 
is indicated.  Technologies that had a license for the treatment of musculoskeletal and 
joint diseases decreased the log odds of an ASMR III-IV or V relative to ASMR I-II.  In 
contrast, indications for the treatment of CNS disorders and infectious diseases 
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increased the probability of an ASMR III-IV and ASMR V relative to ASMR I-II.  This 
could be explained by the fact that a higher proportion of technologies indicated for the 
treatment of musculoskeletal and joint diseases were supported by clinical trials with 
active comparator arms (55%).  Use of active comparators in clinical trials confers more 
useful evidence to ascertain the incremental clinical benefit of a technology to standard 
of care.  Placebo controlled trials are less useful in that they provide evidence of 
incremental benefit of a technology relative to a comparator which does not exist in 
clinical practice (i.e. placebo is not used to treat patients).  In contrast, technologies for 
infectious disease or CNS disorders had a lower proportion of studies with active 
comparators (36% and 22%, respectively). Overall, the multivariate model emphasized 
the role of key clinical and disease criteria on ASMR ratings from HAS.  
  
7.4.3 The impact of socio-economic context on HAS decision-making 
It was hypothesised that the political context in particular would impact significantly on 
HAS decision-making, and that this could be measured by capturing information on 
whether the HAS decision took place during a government election.  In descriptive 
analyses of HAS decision-making, it was noted that there was a higher proportion of 
ASMR I-IV ratings than ASMR V ratings made during an election year, which was 
statistically significant.  However, in the multivariate analysis the effect of election on 
HAS decision-making was no longer significant.   Additional variables capturing 
information about the socio-economic context within which the HAS operates were also 
analysed.  In the multivariate analysis, pharmaceutical expenditure was found to have a 
statistically significant impact on the log odds of both ASMR III-IV and V relative to 
ASMR I-II.  Specifically, a unit increase in pharmaceutical expenditure, in this case 
national average per patient expenditure per year, appeared to increase the odds of an 
ASMR III-IV or ASMR V, albeit statistically significant only in the latter.  This would 
seem counter-intuitive in that the increase in pharmaceutical spending would generally 
suggest an increase in the available budget for reimbursed technologies.  However, a 
possible explanation is perhaps that an observed increase in pharmaceutical expenditure 
may have triggered more stringent assessment of incremental medical value.  This is 
conjecture that cannot be further examined with this dataset, and highlights that caution 
is needed in the interpretation of the role of socio-economic factors such as national 
pharmaceutical expenditure as there are numerous unmeasured factors that could be 
associated with this particular variable (e.g. overall trends in GDP, change in treatment 
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algorithms, healthcare system approach, physician and patient behaviour, industrial 
policy, and increases in marketing authorisations for pharmaceuticals).   
 
It was hypothesised that the pattern of HAS decision-making has changed over time.  
The descriptive analyses supported the view that outcome groups varied significantly in 
the mean year of appraisal.  Figure 7.1 below describes the pattern of HAS decision-
making over time suggesting a decrease over time in the proportion of technologies 
awarded an ASMR I-II and an increase in technologies receiving an ASMR V.    The 
effect of time was however not found to have a strong effect in the multivariate analyses 
when taking other explanatory variables into account.   
 
Figure 7.1 Pattern of HAS coverage decisions 2004-2009 
 
7.4.4 Limitations 
When examining the results of the multivariate analyses, there are several limitations 
that need to be taken into account.  An important limitation of this analysis is that it was 
not possible to schedule an interview with a representative of the HAS to discuss the 
internal validity of the model results.  An additional limitation of this analysis  is that 
HAS, compared with other agencies like NICE, provides relatively limited information 
in the public domain on the evidence reviewed and considered in its decision-making 
process.  In general, HAS reports made publicly available provide concise summaries of 
key issues in a summarised format that do not document details on the various clinical 
considerations or disease characteristics which were considered.  The lack of detail in 
reporting did lead to instances of non-reporting of information of interest for this 
research.  The lack of data linked to this reporting style was managed by using 
imputation techniques in the multivariate analysis.  The implications of using such 
  
 
233
techniques, versus restricting the analysis to complete observations were assessed in a 
sub-analysis in which the multivariate analysis was conducted on the sample of 
coverage decisions for which the data was complete.    The results of these sensitivity 
analysis showed that limiting the analysis to complete observations, may lead to bias in 
the coverage decisions included in the analysis.  Despite this potential for bias, the 
sensitivity analysis regression model confirmed the important impact of several 
variables including:  the demonstration of superiority in the clinical trial which 
increased the probability of an ASMR I-II, the prevalence of the target population, 
orphan designation, and treatment of musculoskeletal/joint diseases.  The impact of 
infectious disease or CNS disorder indications was no longer observed in this sensitivity 
analysis.     
 
Another important factor to take into account when examining HAS coverage decisions 
is that the sample of appraisals included in the analysis was in fact a subset of the total 
pool of appraisals conducted by HAS.  This sub-sample of technologies used for 
analyses corresponded to those technologies that had been appraised by NICE and the 
SMC in 2004-2009.  All the HAS recommendations linked to these technologies were 
extracted for review.   The rationale for this approach was due to the fact that HAS has 
numerous responsibilities, one of which is the provision of advice on new technologies 
available for patients.  In total, the Transparency Commission issued more than 2600 
recommendations related to medications in 2004-2009 (HAS 2009).  Given the resource 
constraints available, it was not possible to review all 2600 recommendations to identify 
those of relevance for this research (i.e. not all recommendations provide ASMR, some 
recommendations are related to new mode of administration, new safety information or 
a re-review of technologies licensed prior to 2004).  The benefit of this approach was 
that it increased the opportunity for comparability across agencies by collecting 
information on a common list of compounds, and secondly it facilitated the streamlining 
of data extraction to those appraisals relevant for the research question.   
 
A further limitation associated with the HAS analyses lies in the fact that it opens a 
window into the understanding of the factors driving HAS assessment of the degree to 
which technologies bring incremental medical benefit to the French population.  It does 
not however, provide information on the degree to which the French healthcare system 
is willing to pay for such incremental benefit.  This is directly linked to the role of HAS 
which is focused on evaluating the medical benefit of the technology.  The output of 
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this assessment is then used by a separate organisation (CEPS) to negotiate a final price 
for the technology in question.  Thus, understanding of the HAS decision-making may 
not provide a full perspective on coverage decisions within France and how public 
funding is allocated to pharmaceuticals.  On the other hand, it is recognised within 
French legislation that the degree of medical benefit (as defined by the ASMR) directly 
impacts on price.  Technologies with no incremental benefit are not included on the 
reimbursement list unless they are discounted to the available treatments already 
reimbursed by the system.  Technologies with an ASMR IV can obtain, at a maximum, 
a parity price to the already reimbursed comparator.  It is only technologies with a 
ASMR I-III rating that can aspire to potential premium prices.  The pricing negotiations 
and discounted prices are not available in the public domain, thus preventing the 
inclusion of an economic component in the HAS analyses. Thus, while the multivariate 
analyses of HAS decisions presented here cannot directly examine the economic value 
that the French system attaches to particular degrees of medical benefit, it does provide 
an indirect view, by examining the factors that drive HAS allocation of ASMR ratings 
to the technologies it assesses.    
 
In summary, the overall objective of this chapter was to examine the factors that 
influence coverage decisions made by HAS during the period 2004-2009 with a focus 
on research hypotheses specific to HAS decision-making. The results suggest that the 
variability in coverage decisions observed can be explained by a combination of 
clinical, disease, and socio-economic criteria.  Strong evidence was provided to support 
the hypothesis that technologies supported by high quality evidence to support the 
incremental medical value of the technology have a decreased log odds of obtaining 
ASMR III or less, relative to ASMR I-II.  Evidence was also shown which supported 
the hypothesis that ASMR ratings reflect the nature of the disease for which the 
technology is indicated – technologies indicated within therapeutic areas characterised 
by high levels of unmet need (e.g. rare disease and/or cancer) had decreased log odds of 
obtaining ASMR III or less, relative to ASMR I-II.  The socio-economic context within 
which the HAS operates was also shown to play a role.  Pharmaceutical expenditure 
was shown to have a significant effect HAS decision-making in the multivariate 
analysis, although this was not in the direction anticipated - increasing pharmaceutical 
expenditure appeared to increase the odds of an ASMR III-IV or ASMR V relative to an 
ASMR I-II. Descriptive analyses suggested that HAS decision-making has changed 
over time, and that it may be influenced by the presence of governmental elections.  
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Neither time nor the presence of an election were shown to impact significantly in 
multivariate analyses of HAS decision-making.   
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8 Empirical analysis of a pooled dataset of NICE, SMC, CVZ and 
HAS coverage decisions 
 
 
Having examined the role of clinical, economic and socio-economic factors within 
individual HTA bodies, this chapter examines how the same factors behave within a 
pooled sample of technologies appraised by different HTA bodies.  This pooled analysis 
is entered into cautiously, with the realisation that comparative analyses of HTA 
coverage decisions must face significant challenges; however, it was felt appropriate to 
pursue such an analysis while recognising and addressing to some extent the identified 
challenges.   
 
This chapter provides an empirical analysis of the pooled dataset.  Firstly, the methods 
for the pooled analysis are summarised, including an overview of the sample used, as 
well as the descriptive and multivariate methods adopted.  Descriptive statistics are 
calculated for the pooled sample and the results discussed.  Subsequently, multivariate 
analyses are performed, accompanied by a series of sensitivity analyses. The results of 
these analyses are reported and explored, and limitations considered when formulating 
concluding remarks about the empirical analyses performed here. 
 
8.1 Methods  
The objective of this analysis is 
examine the impact of a range of 
evidence, process and socio-
economic explanatory variables 
on coverage decisions made in 
that could help explain coverage 
decision-making across HTA 
bodies.  An important objective of 
the pooled analysis was to 
describe the characteristics of the pooled data set and identify differences between HTA 
bodies the evidence considered, the process through which HTA bodies appraised and 
the socio-economic context in which the appraisals took place.  In addition, the 
particular hypotheses relevant for the pooled analyses are highlighted in Box 8.1.      
Box. 8.1 In light of the discussions outlined in Chapter 
2, specific pooled analysis research objectives were to 
test whether: 
 
• An “HTA body effect” is observed on the odds 
of recommendation, restriction or non-
recommendation while adjusting for a range of 
confounding factors.   
• Among those HTA bodies that consider the 
ICER, the effect of the ICER is similar to that 
observed in the individual HTA analyses 
• Process and socio-economic context variables 
play an important role in explaining coverage 
decision-making within a pooled sample of 
analysis 
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Building on from the methods described in Chapter 3, this section describes the 
methods used to select the sample for analysis, the outcome variable and explanatory 
variables considered, and the statistical techniques adopted.    
 
8.1.1 Sample  
Guidance issued by NICE, SMC, CVZ and HAS in 2004-2009 was combined to create 
the sample for this analysis.  The sample for each individual HTA body was described 
in Chapters 4-7.  The merging of the data from the individual HTA bodies was 
facilitated by the fact that a similar data extraction approach was utilised and a similar 
set of variables extracted across the agencies.  Figure 8.1 outlines the procedure 
followed to arrive at the pooled sample. In order to allow for effective pooling of the 
data, a standardised approach to defining the outcome variable was needed. This is 
described further below.  
 
Figure 8.1  Flowchart of Pooled Sample including technology appraisals performed by NICE, SMC, CVZ and 
HAS during 2004-2009 
 
 
8.1.2  Variables 
Outcome Variable 
In order to be able to facilitate the analysis of the factors driving decision-making across 
HTA bodies, it was necessary to standardise the way the outcome variable was defined.  
Each agency has its own method for defining and thinking about coverage decisions.  
However, there are similarities in the types of coverage decisions made, which have 
been capitalised on to arrive at a series of ‘rules’ on how to define and classify coverage 
NICE 2004-2009
•99 TAs 
•34 TAs excluded
•65 TAs included
SMC 2004-2009
•531 drug reviews
•243 excluded
• 288 included
CVZ 2004-2009
•277 reports
•33 excluded
•244 included
HAS 2004-2009
•351 appraisals
•36 excluded
•315 included
European Multi-HTA sample
977 technology appraisals performed in 
2004-2009
118 
technology/indication 
combinations
288 
technology/indication 
combinations
256 
technology/indication 
combinations
315
technology/indication 
combinations
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decisions by NICE, SMC, CVZ and HAS to allow for comparison and pooling (Table 
8.1).    
  
The analysis is based on using a three category outcome variable where the new 
technology can be:   
• recommended for routine use 
• recommended for restricted use 
or 
• not recommended 
 
HAS represents a specific challenge, in that the ASMR rating reflects the incremental 
value associated with a technology and impacts on the willingness of the healthcare 
system to approve increased funding for technologies that achieve high levels of ASMR 
(I or II) or restrict funding for those technologies with a low ASMR (V).  The ASMR 
does not represent the final funding decision; rather, a separate committee, the CEPS, 
has this responsibility as it is the entity responsible for finalising the price and volume 
agreements for technologies (See Chapter 7).  While recognising that the ASMR 
represents a different form of reimbursement decision than the coverage decisions made 
by SMC, NICE and CVZ, to allow for pooling a classification of ASMR ratings was 
adopted (described in Table 8.1).  This was felt to be appropriate given that the price of 
the technology, and hence the funding of the technology, is primarily driven by the 
ASMR rating. An alternative classification was  tested in a sensitivity analysis of HAS 
decision-making (Chapter 7) and found similar results to the base case analysis.   
 
Recommended technologies were defined as those technologies where full coverage 
was granted for the totality of the licensed population.  For NICE guidance, where a 
recommendation was made for a technology to be used in a population identical to its 
licensed indication, it was considered ‘recommended’ (See also Chapter 4).  For the 
CVZ, where the decision was to place the technology in the ‘basis paket’ (List 1A or 
1B), or listed in the expensive drug list (Duregeneesmiddelen Beleidsregel) without any 
restriction or patient co-payment, the technology was considered to be recommended 
(See also Chapter 6).  In France, the ASMR was used to classify outcomes.  
Recommended technologies in this analysis were considered to be those with an ASMR 
I- II, representing technologies with important incremental medical value relative to 
standard of care (See also Chapter 7).     
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Table 8.1  Classification of coverage decisions into a 3-category outcome variable:  definitions per HTA body 
HTA 
body 
Recommended Restricted Not Recommended 
NICE Full coverage was granted for 
the totality of the licensed 
population  
A sub-population of the 
licensed indication and/or 
with restrictions in terms of 
acquisition cost or utilization 
(e.g. monitoring or specialist 
use required) 
“Not recommended” stated in 
section 1 of guidance 
SMC If word “recommended” used 
in summary statement 
If word “restricted” was used 
in summary statement 
If words “not recommended” 
were used in summary 
statement 
CVZ If technology was placed in 
reimbursement lists 1A or 
1B, or the expensive drug list 
If technology placed in List 
2, or if patient co-payment is 
necessary to access 
medication 
If the technology was not 
included in any 
reimbursement list 
HAS ASMR I-II ASMR III-IV ASMR V 
 
Restricted technologies were defined as those technologies where coverage was granted 
for a sub-population of the licensed indication and/or with restrictions in terms of 
acquisition cost or utilization (e.g. monitoring or specialist use required) (Raftery 2006).  
For NICE and the SMC, a coverage decision was considered to be a restriction if it was 
recommended for use in a sub-population of its licensed indication; in a second line or 
higher line of therapy; required monitoring, lowest acquisition cost or prescription by a 
specialist. For the CVZ, where the decision was to place the technology in the ‘basis 
paket’, but only for use in a sub-population or with a patient co-payment, this 
technology was considered as restricted.  With regard to HAS, technologies with ASMR 
III-IV representing modest or minor medical value are associated with lower price 
levels (and hence funding) than technologies with ASMR I-II.  These were considered 
to be restricted technologies.  
 
Not recommended technologies were those for which no coverage was granted.  A 
medication was considered to be not recommended for use by NICE or SMC guidance 
if the words “not recommended” were stated in the guidance/report.   Within CVZ 
decisions, the technology was considered to be not recommended when it was stated to 
be not recommended in the CVZ ‘advies’ statement and was not included in any 
reimbursement list.  With regard to HAS, technologies with an ASMR V offer no 
incremental benefit versus the comparators, and as per legislation cannot be included on 
the reimbursement list.  An ASMR V was therefore considered to be ‘not 
recommended’.   It should be noted however, that for HAS, technologies with an ASMR 
V can obtain reimbursement from the healthcare system, but only if associated with 
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cost-savings.  This is different from the CVZ where technologies not recommended for 
funding are excluded from the reimbursement list.  Other research conducted on the 
ASMR has made a similar assumption whereby technologies with ASMR V were 
considered to represent non-recommendation (Kanavos et al. 2010).  While for the 
purposes of this analysis it was felt appropriate to consider ASMR V as a non-
recommendation, it is important to bear in mind that the implications of an ASMR V 
may not be the same as the implications of non recommendation from the SMC or 
NICE, for example.   
 
Explanatory Variables  
The variables included in this cross HTA body comparative analysis are consistent with 
the variables considered in the single HTA body analyses presented in previous chapters 
(4-7).  The selection of variables is directly linked to the analytical framework and the 
variables included ranged from clinical trial and disease characteristics to economic 
cost-utility model information and from appraisal process characteristics to the socio-
economic context in which the appraisal was performed. Across the four HTA bodies, 
in addition to a core set of variables, a series of variables were collected specifically for 
each HTA body to reflect the nature of the appraisal process as accurately as possible in 
the individual analyses (e.g. use of MTA vs. STA by NICE or information on the reason 
for the appraisal request within the HAS ).  However, these variables were not included 
as explanatory variables in the pooled sample to allow for a more homogeneous 
platform upon which to compare HTA bodies using a quantitative approach.  The 
impact of these variables was assessed in Chapters 4-7 where individual HTA 
multivariate analyses were run.   
 
In addition to the core set of variables, a new variable was introduced specifically for 
this pooled analysis which aimed to capture the role of the HTA body itself on the 
impact of coverage decisions.  The aim was to establish the effect of the HTA body on 
the odds of restriction or non-recommendation, while holding other factors constant.  
The statistical methods adopted in the multivariate analysis are described further below.   
 
8.2 Statistical Analyses 
The methods for the descriptive statistics and multivariate analyses were described in 
Chapter 3.  Descriptive statistics were calculated for the pooled sample of NICE, SMC, 
CVZ and HAS.  Following a descriptive analysis of the dataset, a multinomial logit 
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regression was modelled, according to the model specification process described in 
Chapter 3.  The objective of this analysis was to obtain a parsimonious model that best 
reflected the main drivers of decision-making.  
 
Among the challenges identified for performing a pooled analysis across HTA bodies 
(Chapter 3, section 3.1.5, Chapter 8, Section 8.1-8.2),  a key challenge encountered was 
the fact that variation was observed between HTA bodies in the factors relevant to their 
decision-making process.  The most obvious difference is linked to the HAS:  the 
variables related to the economic characteristics of the technology under appraisal are 
not available, as economic considerations are not a formal criteria in the HAS appraisal 
process.  To address this challenge, two options were examined in multivariate 
analyses: 1) to include all four HTA bodies in the pooled analysis accompanied by fixed 
effects, but to exclude variables that are not common across the four (in particular 
ICER-related variables); 2) exclude HTA bodies that do not consider the cost-
effectiveness of technologies to avoid imputation of information that was not formally 
considered (Table 8.2).   
 
An additional key challenge is the fact that there is heterogeneity between the four HTA 
bodies in the criteria used to select technologies for appraisal.  While the selection of 
technologies for appraisal by NICE are related to consultation with the Department of 
Health, the SMC, HAS and CVZ operate on a system where all new technologies and 
new indications are appraised systematically.  NICE, HAS and CVZ re-review a sub-set 
of the technologies after a specified time period, but this is not the case for SMC.  This 
leads to a situation where the role of a specific factor and the pattern of coverage 
decisions observed may be confounded by the method and timing with which 
technologies are selected for appraisal.  In the base case analysis, heterogeneity between 
HTA bodies in the technologies appraised is adjusted for by including BNF disease 
categories in the model.   This was thought to be a valid approach for two reasons.  
Firstly, it was not possible to adjust for the technology itself, as there were not enough 
observations for each of the 348 technologies appraised to implement such a strategy.  
Secondly, it was assumed that differences in technologies appraised between HTA 
bodies would, in many cases, correspond with differences between HTA bodies in the 
disease areas appraised.  It was therefore felt that by including disease category 
descriptors (namely BNF categories) in the model would increase the homogeneity of 
the sample for analysis.  In addition, to examine this issue further, a sub-set of 
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technologies which were appraised by all four HTA bodies was used as the basis for a 
sensitivity analysis.  Similarly, a sensitivity analysis was also performed restricting the 
analysis to technologies indicated for the treatment of cancer diseases (Table 8.2).   The 
analysis was performed using the STATA data analysis software (Intercooled (IC) Stata 
version 10.1). 
 
 Table 8.2  Multivariate analyses performed on pooled data set – base case and alternative specifications 
 
 Key attributes 
of analysis  
Rationale Analysis 
characteristics 
Results 
shown  
B
as
e 
C
as
e1
 
Analysis 
without 
economic 
variables 
To assess whether HTA bodies differ 
amongst themselves in terms of the 
coverage decisions they make, while 
adjusting for a range of confounders 
N=977 
 
Included HTA bodies: 
NICE, SMC, CVZ, 
HAS 
Excluded variables: 
ICER (uncertainty 
estimates), budget 
impact assessment 
Includes fixed effect 
for HTA body 
Ch. 8, 
8.3.3, 
Table 
8.3  
B
as
e 
C
as
e 
2 
Analysis with 
economic 
variables 
excluding 
HAS 
Explore the degree of impact of a range of 
evidence, process and socio-economic 
factors on coverage decisions.   
Excluding HAS allows for economic 
variables to be explored without imputing 
economic values for HAS appraisals 
N=662 
 
Included HTA bodies: 
NICE, SMC, CVZ 
Economic Variables 
included 
In 
appendix 
H, Table 
8.5 
B
as
e 
C
as
e 
3 
Analysis of 
NICE&SMC 
only 
Explore the degree of impact of a range of 
evidence, process and socio-economic 
factors on coverage decisions.  
NICE & SMC frequently use cost-utility 
evidence as part of appraisal (unlike HAS 
and CVZ (less than 11% of decisions report 
ICER in latter) 
N=406 
 
Included HTA bodies: 
NICE, SMC 
Economic Variables 
included 
 
Ch. 8, 
8.3.3, 
Table 
8.4 
A
lte
rn
at
iv
e 
sp
ec
ifi
ca
tio
ns
 
Analysis 
utilising binary 
outcome 
variable 
To examine the effect of alternative 
methods for categorising coverage 
decisions on model outcome 
Run on base case 1 
N=977 
Binary outcome 
category used (covered 
vs. not covered) 
 
Ch. 8, 
8.3.3, 
Table 
8.5 
Analysis 
including 
cancer 
therapies only 
To standardise the baseline sample used in 
the multivariate analysis 
Used base case 1 
N= 247 
Ch. 8, 
8.3.3, 
Table 
8.6 
Analysis 
including 
common set of 
technologies 
only 
To standardise the baseline sample used in 
the multivariate analysis 
Run on base case 1 
N=192 
 
Ch. 8, 
8.3.3, 
Table 
8.7 
Analysis with 
economic 
variables 
including HAS 
To keep all four HTA bodies in the pooled 
analysis and to consider in the analysis the 
factors shown to have impact on individual 
HTA body analyses 
Imputation used to generate values for 
economic indicators in HAS dataset with 
accompanying interaction term  
N=977 
All HTA bodies 
included 
Economic variables 
included 
 
In 
appendix 
H, Table 
8.4 
  
 
244
 
8.3 Results 
8.3.1 Sample characteristics 
Outcome Variable 
In total, 977 HTA decisions were reviewed and analysed, including 118 NICE 
decisions, 288 SMC decisions, 256 CVZ decisions and 315 HAS decisions made during 
2004-2009.   Within the pooled data set, 27% of decisions recommended funding of the 
technology, 39% restricted funding and 35%  did not recommend funding the 
technology.The most common decision by NICE was to restrict funding (58%), whereas 
for the CVZ the most common decision was to recommend (51%).  For both the SMC 
and HAS, the most common decision was to not recommend (46% and 44%).  For 
NICE and CVZ, the least common coverage decision was to not recommend (14% and 
16% respectively) while for SMC and HAS the least common decision was to 
recommend (19% and 18% respectively).  It is noteworthy that the outlier in terms of 
recommendations, without any restrictions, was the CVZ, with 51% of its decisions to 
recommend funding for treatment.  This compares to 27% for NICE, 19% for SMC and 
18% for HAS (Figure 8.2).   
 
Figure 8.2 Coverage decisions by NICE, SMC, CVZ and HAS between 2004-2009 Total sample (n=977) 
 
The trends in coverage decisions over time (January 2004- June 2009) for each HTA 
body are presented in Figure 8.3.  These data suggest that within HAS and NICE there 
has been a decrease in the proportion of recommendations made over time and a 
corresponding increase in the proportion of non-recommendations.  The CVZ and SMC 
on the other hand, appear to maintain relatively stable rates of recommendations, 
restrictions and non-recommendations over time.    
27%
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  Figure 8.3  NICE, SMC, CVZ and HAS coverage decisions between 2004-2009 (June), by year (n=977) 
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Coverage decisions across HTA bodies were also described for two sub-samples, both 
of which were designed to increase the homogeneity of the technologies appraised.  The 
first sample represented the set of coverage decisions linked to a common basket of 
technologies appraised across all four HTA bodies (Figure 8.4).  In this particular sub-
sample, the pattern of coverage decisions observed in NICE, SMC and HAS datasets 
was similar to that observed in the total sample, while for the HAS, a lower proportion 
of technologies were not recommended (20% versus 44% in the total HAS sample). In 
the second  sub-sample of appraisals that examined cancer therapies (n=247), the 
pattern of coverage decisions by HTA agencies was different in that recommendations 
appeared to be more common than when examining the pattern of coverage decisions 
across the total sample, with the exception of the SMC (Figure 8.5).  The SMC was the 
only agency in which a small decrease in recommendations was observed when the 
analysis was restricted to cancer therapies alone (from 19% to 15%), and in general the 
coverage pattern for the SMC did not appear to alter when considering the total SMC 
pool and the cancer technology subset.  Unlike the SMC, NICE recommendations 
increased from 27% to 36%; CVZ recommendations from 51% to 76% and HAS 
recommendations from 18% to 29%.  While this trend needs to be examined more 
carefully with appropriate statistical methods, it does suggest that comparison of 
coverage decisions across HTA bodies needs to take into account the characteristics of 
the technologies included in the sample.  Careful interpretation of multivariate analyses, 
and sensitivity analyses to test base case model specifications is needed, when 
attempting to compare HTA decision outcomes and factors driving those decisions. 
 
Figure 8.4 Technologies common to all HTA bodies- coverage decisions by NICE, SMC, CVZ and HAS 
between 2004-2009 (n=192) 
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Figure 8.5 Cancer therapies - coverage decisions by NICE, SMC, CVZ and HAS between 2004-2009 (n=247) 
 
 
8.3.2 Descriptive statistics 
Descriptive statistics were calculated for the total sample as well as for each decision 
outcome.  These are summarized in Appendix H Tables 1 – 5.  Results for each category 
of explanatory variable are provided below.    
 
Clinical Evidence 
The clinical characteristics of the technologies appraised were statistically significantly 
different across the coverage decision types (Appendix H Table 1) as well as across the 
four HTA bodies in terms of the number of RCTs considered, their size, statistical 
significance of RCT results, follow-up and comparator used within the trials (all 
variables statistically significant at p≤0.01) (Appendix H Table 2).  The greatest 
difference was observed between NICE and the remaining three HTA bodies.  The 
mean number of RCTs considered in SMC, CVZ and HAS decision making was 2-3 
studies (compared with 7 studies for NICE), and the duration of follow-up that they 
considered in the appraisal ranged from 39-49 weeks compared to 76 weeks for NICE.    
The RCT mean sample size ranged from 830 in appraisals by the CVZ to 1249 by 
NICE, and differences were statistically significant.  On average 42% - 52% of RCTs 
included active comparators (as opposed to placebo comparators), and differences 
between the HTA bodies were demonstrated to be statistically significant.  When 
examining the nature of the clinical evidence across recommended, restricted and not 
recommended technologies, the latter tended to be supported by a fewer number of trials 
of shorter duration and size than recommended and restricted technologies.   
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Descriptive analysis of the clinical package included in the appraisal process was also 
conducted for each decision outcome.   Within the sub-set of recommended, restricted 
and not recommended technologies, the pattern observed was similar to that noted in the 
total sample (Appendix H Tables 3-5).  That is, technologies appraised by NICE tended 
to be supported by a higher number of trials of longer duration and larger sample size 
than technologies reviewed by the other three HTA bodies.   The majority of 
technologies restricted by NICE did not demonstrate superiority in efficacy.  In contrast, 
approximately half of SMC and HAS restricted technologies had demonstrated 
statistically significant superiority.  However, in 40%-53% of cases superiority was 
demonstrated versus placebo rather than an active comparator.  Amongst the appraisals 
by NICE, HAS and CVZ that resulted in non-recommendation, approximately 65% of 
the technologies did not demonstrate statistically significant superiority in their RCTs.  
SMC was a clear outlier in this regard, where 58% of technologies that were not 
recommended did demonstrate statistically significant superiority (p<0.01).  Within the 
non-recommended technologies, the proportion with active comparators as opposed to 
placebo comparators differed between HTA bodies ranging from 21% in CVZ 
appraisals to 50% in HAS appraisals (p<0.05).     
    
The technologies appraised also differed, across coverage type and HTA body, in terms 
of the diseases for which they were indicated.  Across all HTA bodies, the majority of 
appraisals were conducted for technologies where alternative therapies were already 
available in the healthcare system (p<0.01).  Within the recommended technologies, 
approximately 90% of recommendations by the SMC and NICE were for technologies 
where alternatives were available, while for the HAS and CVZ alternatives were 
available in approximately 70% of cases (p<0.05).   A similar pattern was observed 
within the restricted and not-recommended technologies.   
 
Orphan designated medicines made up approximately 10% of CVZ, SMC and HAS 
technologies appraised, while NICE considered very few orphan medicines (3 of 118 
technologies) (p<0.05).  Within the sample of recommended technologies, the 
proportion of recommendations for orphan medicines differed considerably between 
HTA bodies (p<0.01):  24% of HAS recommendations were orphan medicines, in 
contrast to 6% of SMC and 5% of CVZ recommendations.  Among the sub-set of 
technologies that were not recommended for funding, very few were orphan medicines 
  
 
249
within the HAS (1%), NICE (0%) and CVZ (0%) samples.  In contrast, in SMC 
appraisals, 18% of non-recommended technologies were orphan medicines.   
 
The proportion of technologies indicated for the treatment of musculoskeletal diseases, 
obstetrics and endocrine system disorders differed significantly between HTA bodies.    
Within the recommended technologies, a higher proportion of SMC technologies were 
indicated for infectious diseases than compared with other HTA bodies, while none of 
the recommended SMC technologies were indicated for musculoskeletal and joint 
diseases.  Within the sub-set of restricted technologies, there was variation in the 
proportion of restricted technologies indicated for malignancies and musculoskeletal 
diseases across HTA bodies (p<0.01), as well as in the proportion of technologies 
indicated for obstetrics and gynaecology disorders.    These differences across HTA 
bodies were also observed in the sub-set of technologies that were not recommended for 
public funding.   
 
In terms of population treated, the prevalence of the diseases considered in the 
appraisals were for NICE 2.4 million patients, SMC 0.11 million patients, CVZ 0.94 
million patients, and HAS 0.51 million patients.  Amongst the recommended 
technologies, the prevalence of the diseases linked to recommended technologies were 
for NICE 0.4 million patients, SMC 0.04 million patients, CVZ 0.061 million patients 
and HAS 0.139 million patients.  The prevalence of the diseases considered in the 
appraisals that resulted in restricted funding were for NICE 3.2 million patients, SMC 
0.07 million patients, CVZ 0.04 million patients, and HAS 0.24 million patients 
(p<0.01).  Within the subset of technologies not recommended for funding, the 
prevalence of the diseases considered in the appraisals were 2.3 million patients for 
NICE, 0.004 million patients for the SMC, 0.27 million patients for the CVZ, and HAS 
0.91 million patients.   
 
Economic Evidence 
HAS does not formally consider economic criteria in its appraisal process, therefore no 
results for the HAS are presented in this section.  The three remaining HTA bodies 
differed markedly in the percentage of appraisals that considered cost-utility evidence 
and this difference was statistically significant (p<0.01).  Of the three HTA bodies, 
NICE most frequently considered cost-utility evidence, as opposed to the CVZ which 
rarely considered it.  This pattern was observed within the total pooled sample, as well 
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as in the subset of recommended, restricted and not-recommended technologies.  In the 
total sample, cost-utility evidence was considered in the majority of appraisals by NICE 
(95%), followed by the SMC (74%).  Within the subset of recommended technologies, 
100% of technologies recommended by NICE were supported by CUA, compared with 
67% for the SMC, and 12% for the CVZ.  Among those technologies that were not 
recommended for public funding, the following proportion of technologies were 
supported by cost-utility analyses:  88% of NICE appraised technologies, followed by 
the SMC (75%) and the CVZ (18%).  Amongst technologies appraised by the CVZ, 
only a small proportion of technologies (<18%) included cost-utility analysis, despite 
the inclusions of cost-effectiveness criteria in its formal appraisal process in 2006.   
 
Not only was NICE the most likely to review cost-utility evidence in its appraisals, it 
was also most likely to review several cost-utility models – 63% of its appraisals 
contained reference to more than one cost-utility model.  This was not the case in either 
the SMC or CVZ appraisals, and this difference was statistically significant (p<0.01).  
The use of multiple cost-effectiveness models by NICE captured in the total sample was 
observed consistently across recommended, restricted and not recommended technology 
subsets.      
 
Among the reported cost-utility results, the average cost-utility ratio across the three 
decision outcomes was statistically significantly different (p<0.05).  When comparing 
the mean cost per QALY across HTA bodies the following ICERs were observed:  
£31,266 cost per QALY for NICE and £34,055 cost per QALY for the SMC.  For the 
few appraisals that contained cost-utility analyses in CVZ appraisals, the average ICER 
was £30,977 per QALY.   The SMC most frequently considered non-cost utility 
analyses – 30% of its appraisals considered such economic data, compared to NICE 
(23%) and CVZ (15%).   
 
In terms of budget impact, the average budget impact estimated for the appraised 
technology was £701 million for NICE, compared with the £1.192 million for the SMC 
and £31 million for CVZ.  In terms of budget impact for recommended technologies, 
the average budget impact estimated for the appraised technology was lower in the 
recommended group that in the total sample:  £36 million for NICE, £1.9 million for the 
SMC and £5.8 million for CVZ.  For the restricted technologies, the average budget 
impact estimated for the appraised technology was £829 million for NICE, compared 
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with the £1.3 million for the SMC and £66.8 million for CVZ (p<0.01).  Mean budget 
impact estimates within the non-recommended subset of technologies were considerably 
higher than in restricted or recommended technologies, with the exception of the SMC:  
the average budget impact estimated for the appraised technology was £1632 million for 
NICE, compared with the £0.9 million for the SMC and £63 million for CVZ (p<0.01).   
 
Appraisal process 
Patient group submissions were commonly included as part of the evidence appraised 
by NICE – in 87% of appraisals compared to 42% compared to the SMC.  None of the 
HAS submissions included evidence from patient group submissions as this is not a 
formal component of the appraised evidence, and the CVZ very rarely reported the 
inclusion of  patient group submissions (4% of appraisals).  These differences in use of 
evidence from patient group submissions was statistically significant (p<0.0001).  A 
similar pattern was observed within the recommended sample of technologies:  in 91% 
of NICE appraisals compared to 27% SMC appraisals and 2% of CVZ appraisals.  In 
comparison with the recommended technologies, the proportion of restricted 
technologies supported by patient submissions was similar for NICE (84% vs. 91%), 
but twice as high for the SMC (45% of restricted technologies supported by patient 
submissions vs. 27% for recommended technologies), and 2% of CVZ appraisals.   The 
pattern observed within the recommended technologies was similar to that observed 
within the not recommended technologies:  94% of NICE appraisals compared to 44% 
of SMC appraisals and 13% of CVZ appraisals (p>0.01).   
 
Information on the number of decision-makers involved in the appraisal process was 
available for all four HTA bodies.  For the CVZ and HAS, a fixed number of members 
are involved in each appraisal (n=20 and n=31 respectively), while for NICE and SMC 
this appeared to vary: on average 30 members in NICE appraisal committees and 25 in 
SMC committees.  The differences observed in the size of the appraisal committees 
were shown to be statistically significant (p<0.01) and were consistently observed 
across decision outcomes.   
 
The cost-effectiveness component was a formal part of the appraisal process for both 
NICE and the SMC, and became part of the formal process by the CVZ from 2006 
onwards.  Thus, for the CVZ approximately 67% of appraisals were conducted after 
2006 when the cost-effectiveness component became part of the process. As seen above 
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however, this did not mean that all appraisals post-2006 included cost-effectiveness 
evidence.    In terms of budget impact, NICE, SMC and CVZ included a budget impact 
component in their decision-making.  The HAS did not have economic components 
within its appraisal process. The differences between HTA bodies in the use of the cost-
utility component, as well as the budget impact components, in the appraisal process 
were statistically significant (p<0.01).   
 
Of the four HTA bodies, NICE is the only HTA body that can appraise technologies 
individually or collectively.  This led to a statistically significant difference in the 
average number of technologies appraised across the HTA bodies.  For recommended 
technologies, the average number of technologies appraised by NICE was 2 compared 
with 1 technology for the remaining HTA bodies (p<0.01).    Within the restricted 
sample, the mean number of technologies appraised by NICE was 3.4, and within the 
not recommended group the mean number of technologies appraised by NICE was 2.  
 
Socio-economic context factors 
Information on a selection of socio-economic factors was collected, including 
population size, healthcare expenditure, whether there was an election year and what the 
priority disease areas were for the healthcare systems in which the HTA bodies were 
operating.  The population to which the HTA systems made their recommendations 
ranged from 5 million in Scotland to 63 million in France (p<0.01).  Healthcare 
expenditure, as measured by percentage of gross domestic product (GDP) ranged from 
an average of 8% in England and Wales and Scotland to 11% in France (p<0.01).  In 
terms of average expenditure on pharmaceuticals, this ranged from £175 per patient in 
England and Wales to £439 per person in France, and was statistically significantly 
different (p<0.01).  Interestingly, the proportion of decisions made within an election 
year varied between HTA body (p<0.01):  7% of decisions by NICE were made during 
a governmental election year, as opposed to 40% by the SMC. In the Netherlands, 20% 
of CVZ decisions were made in an election year and in France, 30% of HAS decisions 
were made in an election year.   Relatively similar proportions of appraisals were 
conducted for technologies related to the treatment of priority diseases.   
 
A descriptive analysis of the socio-economic context was also conducted for each 
decision outcome – although in general, as the socio-economic factors were external to 
decision-making, while variation in these factors was observed between HTA bodies, 
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there was no additional variation observed between decision outcomes across HTA 
bodies.    A larger proportion of recommendations by the CVZ, SMC and HAS were 
made in an election year, compared with NICE:  6% of recommendations by NICE were 
made during a governmental election year, as opposed to 48% by the SMC, 23% by the 
CVZ and 31% by the HAS (p<0.01). For NICE, the proportion of decisions made within 
an election year remained the same across coverage categories (6%-7%).  For HAS 
there were fewer non-recommendations made in an election year (25% vs. 31% 
recommendations and 37% restrictions).   Similar to HAS, the CVZ saw a lower 
proportion of non-recommendations (8%) made in an election year than 
recommendations (23%) and restrictions (20%).   
 
Summary of descriptive statistics 
Within the pooled sample of NICE, SMC, CVZ and HAS coverage decisions, of the 
explanatory variables examined, descriptive analyses suggest that the following factors 
may play an important role in determining coverage decision-making.  For these 
variables (Table 8.3), statistically significant differences were observed between 
interventions that were recommended, restricted and not recommended (p ≤ 0.05).     
 
Table 8.3  Pooled HTA sample:   statistically significant variables (p≤ 0.05)   
Component 1 – Evidence 
characteristics 
Variables 
Clinical Package Number of RCTs reviewed 
Superiority in primary endpoint 
RCT duration of follow-up 
Use of observational studies 
Economic Package Use of Multiple CE models 
ICER 
Probabilistic sensitivity analysis 
Univariate uncertainty estimates 
Disease characteristics Prevalence 
Disease indications 
Therapies indicated for: infectious diseases, central nervous 
system, ear/nose, eye, malignant diseases, musculoskeletal/joint 
conditions, obstetrics, respiratory diseases 
Component 2 – Process 
characteristics  
Inclusion of patient submission/evidence 
Number of decision-makers 
CE included in process 
Budget Impact Assessment included in process 
Number of technologies appraised 
HTA body 
Component 3 – Socio-economic 
characteristics 
Year of appraisal 
National Population 
GDP health expenditure 
Pharmaceutical expenditure per patient per year 
 
  
 
254
8.3.3 Multivariate analysis 
Following the model specification process described in Chapter 3, three base case 
analyses were conducted, in accordance with Table 8.2.  Base case model 1 included all 
four HTA bodies, but excluded economic variables as explanatory variables in the 
model.  The model included 20 variables yielding a pseudo R-squared of 0.13, 
suggesting that the model explains approximately 13% of the variability in coverage 
decisions across the pooled sample (Table 8.4).  Base case model 2 included NICE, 
SMC and CVZ and included economic variables in the analysis.  The HAS was 
excluded from the analysis as it does not formally incorporate cost-effectiveness 
considerations in its appraisal process.  In this analysis, the ICER was found not to have 
a statistically significant impact on the log odds of restriction versus recommendation or 
non-recommendation versus recommendation.  When the rationale for this result was 
explored, attention was drawn to the low reporting of ICERs within the CVZ appraisals 
(11% of appraisals reported ICERs see Chapter 6, Table 6.4).  This is in part driven by 
the fact that cost-effectiveness considerations were formally introduced in the CVZ 
process in 2006 and cost-effectiveness results are only reported for those technologies 
that are associated with incremental therapeutic benefit to patients.  The results of base 
case 2 model are displayed in Appendix H, Table 8.5.   In light of the results observed 
in base case model 2, a third base case analysis was conducted which included both 
NICE and the SMC, incorporating the ICER as an explanatory variable.  The model 
included 19 variables yielding a pseudo R-squared of 0.16, suggesting that the model 
explains approximately 16% of the variability in coverage decisions across the pooled 
sample (Table 8.5).    
 
With regards to the effect of clinical variables within these base case analyses, the 
number of RCTs, as well as their duration, choice of comparator and design, impacted 
significantly on the log-odds of restriction or non-recommendation versus 
recommendation.  Specifically, if the technology demonstrated clinical superiority, the 
log-odds for restriction relative to recommendation decreased (p=0.023), as did the log-
odds of non recommendation relative to recommendation (p=0.001), while holding all 
other variables constant.  A unit increase in the number of RCTs, and a unit increase in 
their duration increased the log-odds of a non-recommendation, and had the same effect 
on the odds of a restriction, although this was not statistically significant.  The use of an 
active comparator as opposed to a placebo comparator within the clinical trial was a 
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significant explanatory influence on both the log-odds of restriction and non 
recommendation.   
 
With regard to economic variables, these were examined in base case model 3, 
combining appraisals by NICE and SMC in a pooled analysis (Table 8.5).  A unit 
increase in the ICER was shown to increase the odds of restriction relative to 
recommendation (p=0.011) and the log odds of non-recommendation, relative to 
recommendation (p=0.001).  These results confirmed the important role of the ICER in 
NICE and SMC decision-making, while adjusting for a range of confounders.   
 
Process factors also had significant impact on coverage decisions in this pooled 
analysis.  In base case model 1, an increase in the number of technologies appraised 
simultaneously exerted a increased impact on the log-odds of a restriction (p=0.002), 
and the log-odds of a non-recommendation (NS).  In the model examining NICE and 
SMC (base case 3), an increase in the number of technologies significantly increased the 
odds of both restriction and non-recommendation relative to recommendation (p=0.001 
and p=0.074, respectively).  The inclusion of patient submissions and patient evidence 
as part of the process was linked with an increase in the log-odds of a restriction and 
non-recommendation, although this was statistically significant in the latter case only 
(p=0.008) in the base case model 1.   
 
Of interest is the role of the HTA bodies themselves in explaining variation in coverage 
decisions.  In base case model 1, which incorporated all four HTA bodies, when the 
impact of NICE, SMC and HAS on coverage decisions was examined relative to the 
CVZ, the results suggest that NICE and HAS assessment bodies are strongly associated 
with a decreased odds of a restriction or non recommendation.  This can be contrasted 
with the effect of the SMC, which was found to statistically significantly increase the 
log-odds of both restriction and non-recommendation in all base case models.  The 
impact of the HTA body was highly statistically significant across all assessments.    
 
Socio-economic factors also contribute to explaining the variability in coverage 
decisions across the HTA bodies.  With regard to the size of the population within the 
HTA body remit, a unit increase in the population size increased the odds of both 
restriction and non-recommendation, and both effects were statistically significant in 
both base case models 1 and 3.    
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Table 8.4  Base case 1:  BASE CASE 1 with all four HTA bodies (but no ICER, and including fixed effects for each HTA body) (n=977) 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.018 0.402 -0.061 0.025 -0.060 0.058 -0.122 0.002 
RCT duration of follow-up -0.001 0.453 -0.0044 0.00198 -0.003 0.112 -0.007 0.001 
Use of active comparator in RCT -0.535 0.011 -0.949 -0.121 -0.932 <0.001 -1.383 -0.481 
Clinical superiority demonstrated in 
RCT -0.433 0.023 -0.807 -0.059 -0.762 <0.001 -1.176 -0.349 
Size of eligible patient population 5.00E-07 0.093 -0.00000134 0.00000010 0.000 0.633 0.000 0.000 
Orphan designation status -0.311 0.294 -0.891 0.269 -0.749 0.023 -1.397 -0.101 
Patient submission included 0.391 0.203 -0.211 0.993 0.833 0.008 0.215 1.452 
Number of technologies appraised 
simultaneously 0.523 0.002 0.197 0.849 0.146 0.546 -0.328 0.620 
National population size 0.0000005 0.024 0.00000007 0.0000009 0.000 <0.001 <0.001 <0.0001 
Central nervous system 0.213 0.464 -0.357 0.784 0.381 0.209 -0.213 0.976 
eye -1.443 0.047 -2.866 -0.021 -1.314 0.075 -2.761 0.134 
Malignancy/immunosuppresion 
therapy -0.532 0.031 -1.016 -0.048 -0.457 0.087 -0.981 0.067 
musculoskeletal and joint diseases -0.200 0.536 -0.833 0.433 -0.958 0.017 -1.747 -0.169 
obstetrics, gynaecology, and urinary-
tract disorders 2.292 0.034 0.171 4.413 1.700 0.148 -0.603 4.003 
Respiratory system 0.492 0.511 -0.974 1.958 1.747 0.012 0.378 3.116 
Cardiovascular disease 0.067 0.828 -0.540 0.675 -0.290 0.39 -0.952 0.372 
Skin -0.011 0.980 -0.856 0.834 -0.302 0.529 -1.242 0.639 
NICE -18.526 0.027 -34.957 -2.096 -37.714 <0.001 -55.265 -20.163 
SMC 6.666 0.0080 1.761 11.571 13.270 <0.001 8.034 18.506 
HAS -22.156 0.033 -42.550 -1.762 -44.951 <0.001 -66.727 -23.175 
Constant -8.412 0.022 -15.589 -1.235 -16.638 <0.001 -24.299 -8.977 
Note:  Recommended technologies are the reference case. Multinomial logistic regression, pseudo R-squared: 0.26.   
  
 
257 
Table 8.5 Base-case 3:  Multivariate analysis of pooled sample of NICE and SMC coverage decisions 2004-2009 (n=406) 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.035 0.198 -0.089 0.018 -0.103 0.052 -0.206 0.001 
RCT duration of follow-up -0.004 0.196 -0.009 0.002 -0.009 0.011 -0.015 -0.002 
Use of active comparator in RCT -0.708 0.050 -1.415 -0.001 -0.897 0.022 -1.662 -0.131 
Clinical superiority demonstrated in RCT -0.523 0.111 -1.166 0.120 -0.352 0.323 -1.050 0.346 
ICER 0.000025 0.011 0.0000057 0.0000448 0.000033 0.001 0.000013 0.000053 
Size of eligible patient population -0.00000036 0.405 -0.0000012 0.0000005 -0.00000079 0.332 -0.0000024 0.0000008 
Number of technologies appraised simultaneously 0.648 0.001 0.277 1.018 0.466 0.074 -0.044 0.977 
National population size 0.00000094 0.087 -0.00000014 0.0000020 0.00000174 0.029 0.00000018 0.0000033 
Central nervous system 0.882 0.319 -0.852 2.616 1.356 0.151 -0.493 3.205 
Malignancy/immunosuppression therapy 0.906 0.295 -0.788 2.600 1.282 0.171 -0.553 3.117 
Respiratory system 1.415 0.302 -1.271 4.102 2.172 0.118 -0.554 4.899 
Cardiovascular disease 0.355 0.685 -1.359 2.070 0.453 0.638 -1.431 2.336 
Endocrine system 0.443 0.647 -1.453 2.339 0.263 0.802 -1.790 2.316 
Gastro-intestinal disorders 0.240 0.869 -2.615 3.095 2.001 0.141 -0.661 4.664 
Infections 0.363 0.678 -1.348 2.074 -0.063 0.949 -1.976 1.851 
musculoskeletal and joint diseases 0.348 0.721 -1.561 2.256 0.290 0.786 -1.806 2.386 
Nutrition and blood 0.224 0.835 -1.879 2.327 1.033 0.351 -1.137 3.204 
Skin 0.566 0.564 -1.358 2.490 -0.249 0.828 -2.498 1.999 
SMC 46.499 0.083 -6.060 99.059 86.641 0.027 10.061 163.222 
Constant -51.408 0.083 -109.603 6.786 -95.335 0.027 -180.057 -10.613 
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Impact of alternative model specifications:  sensitivity analyses 
Sensitivity analyses were conducted on the multivariate analysis of the pooled sample.   
This included: i) examining the impact of a binary rather than three-category outcome 
variable, ii) restricting the base-case analysis to observations related to cancer therapies, 
and iii) restricting the base-case analysis to observations related to technologies 
common across the four HTA bodies included in the analysis.   
 
A sensitivity analysis was conducted using a binary outcome variable.  The model using 
a binary outcome category provided similar results to the base-case pooled analysis 
(Table 8.6).  The R-squared was 0.14, suggesting that this model specification could 
explain 14% of variability in a pooled sample of coverage decisions, similar to the 
pseudo R-squared obtained in the base-case model (0.13).  The impact of the factors 
observed in the base-case model was reflected in this binary model to a large extent, 
although there were some variables for which the impact on coverage decisions was no 
longer statistically significant (e.g. disease areas including technologies for eye-related 
disorders, or cancer).   
 
Clinical trial results and the disease area continued to play a role in this sensitivity 
analysis as they did in the base-case analysis.  As observed in the base-case analysis, 
demonstration of superiority in the clinical trials increased the odds of a coverage 
relative to non-coverage (p=0.004).  The disease area in which the technology was 
indicated did not play as clear a role in this sensitivity analysis as in the base case 
model.  Of the five disease areas that were found to have a significant effect on the 
base-case analysis, two remained significant – technologies for respiratory diseases and 
for musculoskeletal/joint diseases.  The former decreased the odds of coverage, while 
the latter increased the odds of coverage.    The impact of cancer therapies on the odds 
of coverage was no longer observed in this binary analysis.  The economic variables 
were not found to have a significant effect in this binary analysis.   
 
Process and socio-economic characteristics remained important in this binary analysis 
as in the base-case analysis.  The inclusion of patient group submissions continued to be 
an important factor, decreasing the odds of coverage (p=0.014).  A unit increase in the 
number of technologies appraised simultaneously appeared to increase the odds of 
coverage relative to no coverage, but was not statistically significant (p=0.247).   The 
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population size served by the HTA body continued to impact significantly in this 
sensitivity analysis:  a unit increase in the population size decreased the odds of 
coverage (p<0.0001).  Finally, the effect of the HTA body, all other factors held 
constant, was also observed in this binary outcome model.  NICE and HAS were 
associated with increased odds of coverage (p<0.001), while the SMC was linked to 
significantly decreasing the odds of coverage (p<0.001).   
 
In general, the binary model confirmed the results of the base-case 1 analysis in that the 
majority of factors found to impact on coverage decisions in the base-case analysis also 
had an impact in this model using binary outcome categories.  However, use of binary 
outcome reduced access to information about whether factors behave differently when 
coverage is complete or restricted.   
 
Table 8.6  Sensitivity Analysis 1: Multivariate analysis of pooled sample of coverage decisions of NICE, SMC, 
CVZ, HAS 2004-2009 (base case 1):  using binary outcome variable 
  Listed vs. Not Listed 
Variables Log Odds P value 95%  Conf. Interval 
Number of Trials 0.045 0.107 -0.010 0.100 
RCT duration of follow-up 0.00226 0.176 -0.00102 0.00553 
Use of active comparator in RCT 0.58 0.001 0.23 0.94 
Clinical superiority demonstrated in 
RCT 0.48 0.004 0.15 0.82 
Size of eligible patient population -0.00000025 0.218 -0.00000065 0.00000015 
Orphan designation status 0.565 0.038 0.031 1.098 
Patient submission included -0.59 0.014 -1.06 -0.12 
Number of technologies appraised 
simultaneously 0.232 0.247 -0.161 0.624 
National population size -0.0000007 0.000 -0.0000010 -0.0000003 
Central nervous system -0.22 0.323 -0.66 0.22 
Eye 0.63 0.357 -0.71 1.97 
Malignancy/immunosuppresion 
therapy 0.15 0.494 -0.28 0.58 
musculoskeletal and joint diseases 0.826 0.015 0.159 1.493 
obstetrics, gynaecology, and urinary-
tract disorders 0.07 0.916 -1.21 1.35 
Respiratory system -1.45 0.002 -2.36 -0.54 
Cardiovascular disease 0.30 0.261 -0.22 0.83 
Skin 0.29 0.451 -0.46 1.04 
NICE 24.73 <0.0001 11.85 37.60 
SMC -8.75 <0.0001 -12.59 -4.91 
HAS 29.36 <0.0001 13.36 45.37 
Constant 11.49 <0.0001 5.87 17.11 
 
In a second sensitivity analysis, a pooled analysis was also conducted on the sample of 
technologies indicated for cancer treatment.  As highlighted in the descriptive analyses, 
HTA bodies varied in the nature of the diseases for which their respective technologies 
were indicated.  It was hypothesised that this underlying variation in the disease areas 
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appraised could act as an important confounder in the analyses and lead to variation in 
the HTA coverage decisions.  To address this concern, in the base-case analysis specific 
variables reflecting BNF disease categories were used to control for such variation.  In 
this sensitivity analysis, an alternative method was applied that restricted the analysis of 
coverage decisions to a specific disease area.  Cancer therapy was selected as a pertinent 
disease area to focus on, and technologies with BNF 8 category were considered as a 
proxy.  Of the 977 appraisals, 247 included cancer therapies. The coverage decisions 
made for cancer therapies were modelled using a multinomial logit regression, where 
coverage decisions were regressed against the same set of explanatory variables as was 
used in the base-case analysis.  The aim of this analysis was to understand whether 
those factors driving decision-making across the four HTA bodies vary by disease area, 
and also to increase consistency of the sample upon which the analysis was made by 
focusing on a specific therapy area.    
 
The resulting multinomial logit model of coverage decisions for cancer therapies across 
four HTA bodies is shown in Table 8.7.  The pseudo R-squared was 0.24, suggesting 
that this model specification could explain approximately 24% of variability in a pooled 
sample of coverage decisions, almost double the pseudo R-squared obtained in the base-
case model (0.13).  The clinical factors of relevance in the base-case model continued to 
be of importance in this model restricted to cancer therapies.  An increase in the number 
and duration of RCTs, the use of an active comparator and the demonstration of 
superior efficacy were all found to increase the odds of recommendation relative to non-
recommendation, the majority of which were statistically significant.  In terms of 
disease characteristics, orphan designation increased the odds of a recommendation 
relative to non-recommendation, and those effects were statistically significant 
(p=0.014).  Increasing the size of the eligible patient population increased the odds of a 
restriction and non-recommendation, the latter effect was statistically significant 
(p=0.001).    
 
Process and socio-economic factors identified in the base-case model remained 
significant in this sensitivity analysis.  Process factors present in the base-case model, 
namely the use of patient submissions and number of technologies appraised, had a 
similar impact in this model.  The presence of patient submissions increased the odds of 
restriction and non-recommendation (statistically significant in the latter with p=0.014). 
As more technologies were appraised simultaneously this increased the odds of a 
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restriction and non-recommendation, although this effect was not statistically 
significant.  Finally, as a reflection of socio-economic factors, a unit increase in the size 
of the population covered by the HTA body increased the odds of a restriction 
(p=0.255) and non-recommendation (p=0.066).  The effect of the HTA body observed 
in this sensitivity analysis was consistent with that observed in the base case 1 model.   
 
Thus, the results of the pooled sensitivity analyses focusing on coverage decisions for 
cancer therapies by the four HTA bodies suggests that the factors driving these 
decisions are similar to those factors explaining variation in coverage decisions  in the 
total pooled sample.  In addition, the factors within this sensitivity analysis were able to 
explain 24% of variability in coverage decisions compared with 13% in the base case 
model.    
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Table 8.7  Sensitivity Analysis 2: Multivariate analysis of pooled sample of coverage decisions of NICE, SMC, CVZ, HAS 2004-2009:  sensivitiy analysis using sub-sample of cancer therapies 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.155 0.217 -0.402 0.0914 -0.308 0.043 -0.605 -0.0102 
RCT duration of follow-up -0.002 0.462 -0.0071 0.00321 -0.009 0.019 -0.0157 -0.00139 
Use of active comparator in 
RCT -0.491 0.234 -1.298 0.316 -0.717 0.110 -1.597 0.162 
Clinical superiority 
demonstrated in RCT 0.556 0.187 -0.269 1.381 -0.641 0.160 -1.534 0.252 
Size of eligible patient 
population 0.00000444 0.589 -0.000011700 0.00002050 0.00002290 0.001 0.000008900 0.00003680 
Orphan designation status -0.714 0.142 -1.668 0.240 -1.406 0.014 -2.532 -0.280 
Patient submission included -0.026 0.969 -1.338 1.287 1.686 0.014 0.343 3.030 
Number of technologies 
appraised simultaneously 0.431 0.200 -0.228 1.090 -0.100 0.840 -1.070 0.870 
National population size 0.0000005 0.255 -0.0000003 0.0000013 0.0000008 0.066 -0.0000001 0.0000017 
NICE -15.524 0.321 -46.178 15.130 -29.899 0.081 -63.486 3.688 
SMC 8.172 0.080 -0.980 17.323 12.657 0.014 2.574 22.739 
HAS -19.698 0.309 -57.663 18.268 -36.070 0.090 -77.746 5.606 
Constant -9.687 0.158 -23.127 3.752 -14.584 0.054 -29.439 0.272 
Note:  Recommended technologies are the reference case.  Multinomial logistic regression, pseudo R-squared: 0.25. 
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In the third sensitivity-analysis, a sub-set of the pooled sample was utilised which 
included those technologies that had been appraised by all four HTA bodies at least 
once.  This sub-sample included a total of 192 appraisals of 26 technologies from 2004-
2009.  The rationale for this sub-analysis was to create a more homogeneous platform 
for comparison across HTA bodies, by selecting those technologies in common among 
them.  The hypothesis was that some of the variation in coverage observed between 
HTA bodies could be due to differences in the technologies appraised.  By focusing the 
analysis on those technologies reviewed across all four HTA bodies, the nature of the 
factors driving decisions within this sample could be assessed and compared with the 
base-case analysis.   
 
The regression model of the sub-sample of technologies appraised by all four HTA 
states was associated with a pseudo R-squared which was more than double that of the 
base-case analysis (0.27 in this sub-analysis and 0.13 in the base-case pooled analysis) 
(Table 8.8).  As in the base-case pooled analysis, the demonstration of superiority in the 
clinical trial primary endpoint in this sub-sample statistically significantly decreased the 
log-odds of a restriction and non-recommendation relative to a recommendation. A unit 
increase in the number of RCTs and duration of the RCT appraised decreased the log 
odds of a non-recommendation, and this was statistically significant (p=0.002, 
p=0.012).  The effect of the number of RCTs and duration of the RCT on the odds of a 
restriction was not statistically significant.  The use of an active comparator within the 
clinical trial(s) decreased the odds of a restriction (p=0.103) and for non-
recommendation (p=0.161).   
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Table 8.8   Sensivity Analysis 3:  Multivariate analysis of pooled sample of coverage decisions of NICE, SMC, CVZ, HAS 2004-2009:  sensivitiy analysis using sub-sample of common 
technologies 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.200 0.131 -0.460 0.060 -0.612 0.002 -1.009 -0.216 
RCT duration of follow-up -0.002 0.772 -0.012 0.0088 -0.020 0.012 -0.035 -0.0044 
Use of active comparator in RCT -0.802 0.103 -1.764 0.161 -0.814 0.161 -1.951 0.323 
Clinical superiority demonstrated in RCT -1.005 0.054 -2.025 0.016 -1.383 0.032 -2.645 -0.122 
Size of eligible patient population 0.0000043 0.273 -0.0000034 0.000012 0.000012 0.019 0.0000019 0.000021 
Orphan designation status 0.484 0.544 -1.078 2.047 -0.410 0.683 -2.377 1.557 
Patient submission included 0.448 0.584 -1.156 2.052 1.698 0.055 -0.038 3.435 
Number of technologies appraised 
simultaneously 0.858 0.098 -0.159 1.875 1.153 0.054 -0.019 2.325 
National population size 0.000 0.006 0.000 0.000 0.000 0.002 0.000 0.000 
Central nervous system 0.433 0.685 -1.662 2.528 -2.044 0.081 -4.340 0.253 
Malignancy/immunosuppresion therapy 0.624 0.395 -0.815 2.064 -0.868 0.261 -2.382 0.646 
musculoskeletal and joint diseases 0.481 0.550 -1.098 2.060 -2.821 0.007 -4.864 -0.778 
Cardiovascular disease 0.495 0.576 -1.240 2.230 -4.067 0.007 -7.006 -1.129 
Skin 1.531 0.161 -0.609 3.672 -1.424 0.291 -4.069 1.222 
NICE -56.052 0.007 -96.555 -15.549 -86.996 0.003 -143.759 -30.233 
SMC 18.646 0.002 6.563 30.728 30.322 0.000 13.314 47.331 
HAS -70.036 0.006 -120.233 -19.839 -108.219 0.003 -178.755 -37.683 
Constant -25.532 0.005 -43.260 -7.804 -38.376 0.002 -63.052 -13.700 
Note:  Recommended technologies are the reference case.  Multinomial logistic regression, pseudo R-squared: 0.30.
  
 
265
 
Aside from clinical and economic factors, two process factors, namely the use of patient 
submissions and the number of technologies appraised were also significant in 
explaining variation in coverage decisions in this sub-sample.  The inclusion of patient 
group submissions within the appraisal process increased the log-odds of a non 
recommendation versus a recommendation (p=0.055).   The number of technologies 
appraised statistically significantly increased the log-odds of restriction or non-
recommendation(p=0.098, p=0.054, respectively). 
 
In terms of socio-economic factors, the national population which falls within the 
HTA’s remit appeared to impact on coverage decisions:  a unit increase in the 
population size increased the odds of a restriction (p=0.006) and non-recommendation 
(p=0.002).  Finally, when examining the role of the HTA body, all other factors held 
constant, NICE and HAS increased the log-odds of recommendation, while the SMC 
increased the odds of restriction and non-recommendation.  These observations were 
statistically significant and consistent with the effects observed in base case model 1. 
 
Overall, the results of this third sensitivity analysis suggest that compared to the base 
case model 1, the explanatory power of the combination of clinical,  process and socio-
economic factors is higher in the sensitivity analysis including only those technologies 
that all four HTA bodies hold in common (as implied by the higher pseudo R-squared).   
 
8.4 Discussion 
The aim of this chapter was to model the factors driving coverage decisions observed 
within the pooled data set of appraisals performed by four European HTA agencies:  
NICE, SMC, CVZ and CVZ.  Analysis of pooled coverage decisions across HTA 
bodies is characterised by significant challenges.  However, there were two advantages 
to running a pooled analysis.  The first benefit is the maximisation of sample size to 
examine the role of factors in decision-making.  The combined data set consisted of 977 
appraisals, representing currently the largest dataset of HTA appraisals in Europe, 
compared with analyses available in the published literature.  Secondly, the data set was 
created by extracting information on the selection of explanatory variables from each 
appraisal and each HTA body by the same researcher.  This, coupled with the use of a 
formal extraction protocol described in Chapter 3, increased consistency in how the data 
were extracted.   
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8.4.1 Pattern of coverage decisions in pooled analysis 
The evolution in coverage decisions by NICE, SMC, CVZ and HAS was examined 
through descriptive analyses which mapped the yearly patterns of coverage decisions 
during the period 2004-2009.  This showed firstly that the pattern of coverage decision-
making evolved over time, generally moving towards increasing levels of restriction 
and non-recommendation primarily within the NICE and HAS samples.  In addition, the 
descriptive analyses highlighted similarities and differences between HTA bodies in the 
characteristics of the recommended, restricted and non recommended technologies.   
 
8.4.2 The impact of clinical variables and disease characteristics on decision-making 
within a pooled HTA analysis 
In general, clinical and disease explanatory variables, reflecting higher quality clinical 
evidence and specific disease characteristics, tended to increase the log-odds of a 
recommendation versus a restriction or non recommendation. Orphan designation 
statistically significantly increased the log odds of recommendation relative to non-
recommendation,  and technologies indicated for cancer or eye disorders were 
associated with statistically significantly increased log-odds of recommendation relative 
to a restriction and non-recommendation in base case 1 model.  No statistically 
significant effect of orphan designation was noted in base case model 3 which assessed 
pooled decisions from NICE and SMC. The results of the pooled analysis were 
consistent with the observed effects of clinical and disease characteristics within the 
individual HTA analyses.   
 
8.4.3 The impact of economic evidence on decision-making within a pooled HTA 
analysis 
A specific base case analysis was presented to evaluate the role of economic variables, 
in particular the ICER, amongst the HTA bodies that routinely consider this information 
in their appraisal process.  The pooled analysis of NICE and SMC appraisals confirmed 
the hypothesis that the effect of the ICER is similar to that observed in the individual 
HTA analysis.  That is, an increasing ICER increases the log odds of restriction and 
non-recommendation relative to recommendation, and this effect is highly statistically 
significant.  This analysis represents one of the largest analyses of the effect of cost-
effectiveness on HTA decision-making with a sample of over 400 appraisals.   
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8.4.4 The impact of the appraisal process on decision-making within a pooled HTA 
analysis 
Evidence of the impact of patient group submissions on coverage decision-making 
within this pooled analysis supports the hypothesis of the increasing role of process 
factors in explaining decision-making within a pooled analysis.  HTA bodies varied in 
the use of evidence provided from patient group submissions.  While patient group 
submissions were commonly included as part of the evidence appraised by NICE (in 
87% of appraisals) but less so by the other HTA bodies (42% in SMC decision-making, 
0% HAS submissions and 4% within CVZ appraisals).  These differences in use of 
evidence from patient group submissions was statistically significant (p<0.0001).   
Within the multivariate analysis, the availability of patient submissions increased the 
odds of restriction relative to recommendation in the base case (1) analysis.  Appraisals 
supported by evidence from patient submissions tended to be for technologies indicated 
for cancer treatment (32% of appraisals vs. 23% for appraisals not supported by cancer 
therapies), and representing on average a smaller target patient population (78,858 
patients vs. 106,289 patients, on average).  Whether supported or not supported by 
patient evidence, the characteristics of the RCTs, the year of appraisal and the 
proportion of orphan designations, and the availability of alternative therapies were 
similar.   
 
An additional process aspect relates to the number of technologies that can be appraised.  
NICE regularly allows the appraisal of multiple technologies simultaneously, while for 
other HTA bodies this is rare (CVZ, HAS) or not part of the process (SMC).  The 
multivariate analyses confirmed that an increase in the number of technologies 
appraised simultaneously statistically significantly increased the odds of restriction 
relative to recommendation in both base case models and a statistically significant effect 
on the odds of non-recommendation relative to recommendation in the base case model 
3 which includes NICE and SMC appraisals.   Descriptive analysis of the distribution of 
coverage decisions according to the number of technologies appraised simultaneously 
illustrates the trend towards increasing restriction as the number of technologies 
appraised increases (Figure 8.6, note small sample sizes in certain categories) Barbieri 
et al. (2009), in their comparison of NICE and SMC coverage decisions, attempted to 
explain differences in coverage decisions through the fact that NICE uses third party 
assessment, while SMC does not.  However, the lack of an adequate sample size 
impeded the authors from firstly demonstrating the presence of statistically significant 
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differences in coverage decisions between the two bodies, and secondly, from 
demonstrating if these differences were driven by third party technology assessment 
processes, rather than other factors (e.g. use of clinical/economic evidence, the agency’s 
mission, other process elements such as inclusion of patient groups etc).   
 
Figure 8.6  NICE, SMC, CVZ and HAS coverage decisions stratified by number of technologies appraised 
simultaneously (n=977) 
 
8.4.5 The impact of socio-economic context on decision-making within a pooled HTA 
analysis 
National population size was shown to impact significantly on HTA decision-making in 
this pooled analysis, an effect which was not previously observed in the individual 
analysis and which supports the hypothesis of the increasing role of socio-economic 
factors in explaining decision-making within a pooled analysis.  An increasing 
population size increased the odds of both restriction and non-recommendation relative 
to recommendation, and the effects were statistically significant in both base case 
models.  It is not clear to what extent this result reflects the effect of the absolute size of 
the patient population eligible for treatment – this variable also increases the odds of 
restriction and non-recommendation but its effect is only statistically significant in base 
case model 1 (on odds of restriction relative to recommendation).       
 
8.4.6 The “HTA body effect”  
The results of the base case 1 analyses provided evidence that confirm the hypothesis of 
a strong “HTA body effect” impacting on decision-outcomes, even when adjusting for a 
range of confounding factors.  The impact of the HTA body was highly statistically 
significant across all assessments.  Relative to the CVZ, the results suggest that NICE 
and HAS assessment bodies are associated with a decreased odds of a restriction or non 
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recommendation relative to recommendation, while the SMC is associated with an 
increased log odds of both restriction and non-recommendation relative to 
recommendation.   
 
While not examining across multiple European HTA agencies, Clement et al. (2009) 
produced a thorough descriptive analysis comparing NICE with Australian and 
Canadian HTA agencies, obtaining results that are relevant to this research.  The results 
of Clement et al. (2009) suggest that there are statistically significant differences in the 
nature of the coverage decisions made by NICE, PBAC and CDR.  Statistically 
significant differences in the nature of coverage decisions were also observed between 
the four HTA agencies considered in this thesis. Additionally, the results show that 
there are differences in the characteristics of the technologies appraised by the agencies, 
and the evidence that supports them (Clement et al. 2009).  This was also a finding in 
the pooled descriptive analyses of this research.    However, the study by Clement et al. 
(2009) was not able to clarify the relative importance of each of the examined factors, as 
a regression model was not attempted to allow for adjustment of the effect of individual 
factors on one another.  Nor was the study able to provide direct evidence of the impact 
of variation in a specific variable leading to variation in coverage decisions.   The 
multivariate analysis conducted in this thesis therefore provides additional evidence that 
examines the role of individual factors on coverage decisions made across HTA bodies, 
while adjusting for the presence of other characteristics/factors known to impact on 
decision-making. 
 
8.4.7 Limitations 
Significant limitations must be taken into account when interpreting the results of this 
pooled analysis.  A significant challenge in conducting pooled analyses of coverage 
decisions is that across the four HTA bodies analysed, coverage decision are not 
communicated in the same way.  For instance HAS uses ASMR ratings to define 
incremental therapeutic value, CVZ attributes technologies to different reimbursement 
lists, SMC uses a three-category coverage system and NICE a binary category system.  
Aside from differences in the communication of coverage decisions, the concept of a 
‘restricted’ category is heterogeneous both within and across HTA bodies and thus 
suggests that there may be a limitation in using a three category outcome variable that 
uses ‘restricted’ technologies as one such category.  To attempt to address this 
limitation, a sensitivity analysis was implemented using a binary outcome variable that 
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combined recommended and restricted categories into a single ‘covered’ category, and 
not recommended decisions as ‘not covered’.  The aim of this sensitivity analysis was to 
evaluate to what degree changes in the classification of the outcome variable altered the 
role of factors from the base-case model.  The model using a binary outcome category 
provided very similar results to the base-case pooled analysis.  In addition, the 
sensitivity analysis suggested that use of a binary outcome variable reduced access to 
useful information about how the role of factors may change between different 
‘degrees’ of coverage: i.e. between recommended and restricted technologies.  Thus, 
based on the available analyses conducted, it would seem that although there is 
heterogeneity between HTA bodies in how coverage decisions are communicated and 
what they consist of (e.g. restricted decisions), the use of a three-category outcome 
variable provides a greater level of insight into the ‘behaviour’ of factors between 
different types of coverage decisions, compared to use of a binary outcome variable.     
 
When combining coverage decisions across HTA agencies, it is challenging to create as 
homogenous a platform as possible upon which to model.  A key limitation identified in 
this research is that HTA bodies utilise different criteria to define the sample of 
technologies they appraise.  The SMC, HAS and CVZ review all new technologies and 
new indications of existing technologies.  CVZ also reviews existing technologies for 
non-licensed indications.  NICE technologies included for appraisal are the result of a 
complex selection process involving the Department of Health and other stakeholders, 
and is not driven solely by the availability of a new technology or a new indication.  In 
addition, NICE, HAS and CVZ re-review a sub-set of the technologies after a specified 
time period, which is not done by the SMC.  This resulted in a situation in which, in the 
pooled sample, less than 10% of 348 technologies were reviewed by all four HTA 
bodies.  To overcome the potential limitations associated with this, two approaches 
were tested.  In the base case model, the heterogeneity of the samples across HTA 
bodies was adjusted for by including in the model variables that captured the nature of 
the disease corresponding to the technologies appraised.  In addition, two sensitivity 
analyses were conducted that restricted the sample upon which the multivariate analyses 
were performed.  A specific analysis was conducted on the sub-population of 
technologies reviewed by all four agencies, representing a total of 192 appraisals.  The 
aim of this sub-analysis was to create a more homogenous platform to better estimate 
the impact of the selected variables on the likelihood of a recommendation versus a 
restriction or non recommendation.   Overall, the results of this sub-analysis show that 
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the explanatory power of the combination of clinical, economic, process and socio-
economic factors is higher in the sub-analysis including only those technologies 
appraised by all four HTA bodies.  This may suggest that increasing the homogeneity of 
the sample facilitates a more robust analysis of the role of explanatory variables on 
coverage decisions.  On the other hand, homogeneity is obtained at the expense of 
significantly restricting the sample of analysis to less than 20% of the total available 
sample, increasing the odds of bias in the sample.  
 
Another means of creating a more homogeneous platform for comparison was tested by 
limiting the analysis to appraisals performed within a specific disease area:  in this case, 
cancer.  This analysis was performed as an alternative means of addressing the 
limitation that variability in the technologies appraised due to differing selection process 
between HTA states could reduce the usefulness and generalisability of the results.  To 
achieve this aim, 247 appraisals were identified that appraised technologies for the 
treatment of cancer.  The results of this analysis suggest that the factors driving these 
decisions may be different from those that have been found to be of significance in the 
total pooled sample.  In particular, in the cancer therapy sub-population, there appears to 
be a greater impact of process-related characteristics, rather than clinical characteristics.  
Thus, it may be appropriate to consider that HTA bodies may not utilise the same 
criteria in their decision-making across all disease areas.   
 
Overall, the results of the quantitative analysis of pooled coverage decisions made by 
NICE, SMC, CVZ and HAS was useful to demonstrate that a combination of evidence, 
process and socio-economic context factors help explain variability in coverage 
decisions made across these four HTA bodies.  The analyses also represent the first 
model of coverage decisions across four European HTA bodies based on 30+ 
explanatory variables extracted directly from their appraisals.  This analysis suggests 
that those factors of importance in explaining variation in coverage decisions across 
HTA bodies may not be the same as those factors explaining variation in coverage 
decisions within each HTA body – namely, process and socio-economic context factors 
play a more evident role in this analysis than in the single HTA analyses.  At the same 
time, the impact of the clinical and disease factors observed in the single analysis 
remains very significant in the pooled analysis.  Across all HTA bodies, recommended 
technologies tended to have higher quality clinical data (higher number of clinical trials 
of larger size and longer duration, with use of an active comparator).  The descriptive 
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analyses suggested that there was most variation between HTA bodies in the restricted 
technologies, and least variation between HTA bodies in the technologies that were not 
recommended.   
 
The pooled analyses provide new evidence that differences exist between HTA bodies 
in the nature of technologies appraised and the clinical evidence considered, the process 
through which HTA bodies appraised the technologies and the socio-economic context 
in which the appraisals took place.  Importantly, the evidence also shows that the HTA 
body effect is present which contributes significantly to decision-making, even when 
adjusting for a range of confounding variables.  The analyses also emphasise that, 
amongst those HTA bodies that consider cost-effectiveness analyses, the ICER has a 
significant effect on the coverage decision.  The pooled analysis has also provided an 
opportunity to examine the role of process and socio-economic factors on decision-
making.  Having examined the factors driving coverage decisions both at individual 
HTA body level and across agencies, Chapter 9 concludes by reflecting on the results 
presented and their policy implications.   
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9 Conclusion 
 
“Each [EU Member State] has developed its own approach to 
maintaining a regulatory equilibrium between public health, 
healthcare and industrial policy interests, reflecting particular 
national circumstances and requirements.”  
(Permanand 2006 p. 5) 
 
“…patients across Europe do not have equitable access to new 
innovative cancer drugs.” (Wilking and Jonsson 2005 p. 91) 
 
 
 
9.1 Thesis Overview 
Within European healthcare systems, coverage decisions represent a key decision point 
within the complex process that governs funding and access for pharmaceuticals.  The 
interest in analysing coverage decisions made by European HTA bodies is related to the 
realisation that, ultimately, such decisions not only impact on the technology’s price and 
volume, but also impact on patient access to treatment.  As demand for healthcare 
increases while governments and healthcare providers struggle to manage healthcare 
expenditure, the need for difficult decision-making with regard to healthcare spending 
and allocation of resources is amplified, and tensions arise between HTA agencies, 
patients, providers, healthcare policy makers and manufacturers as coverage decisions 
are made.  In this context of difficult decision-making, there is a recognized need for a 
greater understanding of the processes and criteria adopted by HTA bodies in making 
decisions about the public funding of pharmaceutical technologies.   
 
HTA decision-making poses an interesting paradox.  On the one hand, it is characterised 
by the desire to rely on rigorous scientific criteria to justify its coverage decision (e.g. 
NICE 2008); on the other hand, it is characterised by the need to serve the healthcare 
system in which it operates, governed by public health, health policy and industrial 
policy concerns relative to the national context (Permanand 2006).  Hand-in-hand with 
this apparent paradox, existing theoretical models propose alternative perspectives on 
the drivers of HTA coverage decisions (Weiss 1979):  namely the ‘problem-solving 
model’ and the ‘interactive model’.  The ‘problem-solving model’ represents a world in 
which decision-making is driven by bespoke evidence resulting from aligned interaction 
between decision-maker and researcher.  The latter model, the ‘interactive model’, 
proposes that decision-making is driven by interactions between different stakeholders 
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and factors within the decision-making process, of which evidence is only one 
component.  The question that follows from this is: where do European HTA bodies sit 
within these theoretical models of decision-making?  Are they primarily driven by 
evidence, process or context, or influenced by a combination of factors?   
 
This thesis  has aimed to analyse the factors that drive HTA coverage decisions on 
pharmaceuticals in a selection of EU Member States, focusing specifically on NICE and 
SMC in the United Kingdom, alongside the CVZ in the Netherlands and HAS in 
France.  The thesis has aimed to address this research question by developing an 
appropriate evidence base and a corresponding set of methods that created a robust 
platform for analysing the extent to which evidence, process and context factors 
influence coverage decisions.  An important stepping stone in identifying the focus and 
methods for this research was the analysis of the literature to gain an awareness of the 
current knowledge and understanding of factors driving coverage decisions by HTA 
bodies in Europe.   
 
Following an introductory chapter, Chapter 2 identified the gaps in the literature that 
this thesis sought to address, and provided the analytical framework for the research.  
The chapter on methods (Chapter 3) described the process through which a bespoke 
dataset was created, and the statistical methods adopted to analyse the factors that had 
been identified as potential determinants of coverage decisions.  Chapters 4 to 7 
provided analyses of coverage decisions for each individual HTA body, while Chapter 8 
set out an analysis of pooled coverage decisions from all four HTA bodies. This chapter 
discusses the overall results in more detail and outlines some policy implications and 
areas that would warrant further research. 
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Table 9.1  Summary of statistically significant explanatory variables in descriptive analyses (p≤ 0.05) and multivariate analyses (p≤ 0.10) in NICE, SMC, CVZ and HAS coverage decisions 
made between 2004-2009 
Note:  Variables highlighted in bold text had a statistically significant impact on coverage decisions in the multivariate analyses. 
Explanatory 
Variables 
NICE SMC CVZ HAS 
Component 1 - 
Evidence 
Clinical Package 
No. of RCTs 
Size of RCT population 
Duration of RCT 
Statististical Significance 
Superiority demonstrated in RCT 
Active comparator used 
Consideration of observational data 
Size of RCT population 
Duration of RCT 
Active comparator used 
Superiority not demonstrated 
Number of RCT 
Size of RCT 
RCT duration (lack of data) 
Superiority demonstrated 
Use of active comparator 
No of RCTs 
RCT demonstrates superiority 
Duration of RCT 
Active comparator used 
Economic 
Package 
ICER 
Range of ICERs 
Uncertainty around ICER: 
probabilistic, univariate 
Use of non-CUA economic  models 
Maximum budget impact 
ICER 
Uncertainty around ICER: 
probabilistic, univariate 
 
Non-CUA analyses submitted 
Budget Impact 
-- 
 
Disease 
characteristics 
Prevalence of disease 
Technologies for treatment of CNS 
disorders 
Prevalence of disease 
Alternative 
Orphan designated status 
BNF categories (infectious diseases, 
skin diseases) 
Prevalence of disease 
BNF categories (therapies for 
malignancies, cardiovascular 
diseases, obstetrics/gynaecology) 
Prevalence of disease 
Availability of alternatives 
Orphan status 
BNF category 
Component 2 - 
Process 
Use of STA vs. MTA process 
No. of technologies reviewed 
simultaneously 
-  Presence of patient submission 
Priority disease 
Request for future CEA 
Patient co-payment 
 
Level of reimbursement 
Hospital use only 
Request for post-launch study 
Reason for request 
Component 3 - 
Context 
Date of appraisal 
National population size 
Percentage GDP spent on healthcare 
Pharmaceutical expenditure per patient 
per year 
 
Date of Review Date of Review 
Pharmaceutical expenditure per 
patient per year 
National population size 
 
Date of Review 
Pharmaceutical Expenditure per 
patient  per year 
National population size Election 
year 
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9.2 Discussion of Results  
9.2.1  NICE 
“Our job is to make sure taxpayers’ money is only spent on 
healthcare that works and is good value” (NICE statement in 
BBC Breakfast News, 13 May 2008)  
 
“It's a system of blocking. They're [NICE] not looking at patients 
and saying "how can we fund it?", they are saying, "how can we 
not fund it?"…[Cancer] medicines are licensed and working yet 
we in Britain aren't allowed to access them. While we wait for 
Nice to decide, patients are dying.”  (Kate Spall1 on BBC 
Breakfast News 13th May 2008) 
 
 
The above excerpts provide two contrasting perspectives on the role of NICE and its 
impact on funding of technologies within the NHS in England and Wales.  The 
assessment of NICE’s decision-making in 2004-2009 presented here, and performed 
through descriptive and multivariate analyses, provides useful glimpses into the factors 
driving its decision-making.  The analysis of NICE coverage decisions involved the 
review of appraisals of 118 technologies performed in 2004-2009.  The majority of 
NICE coverage decisions involved restricting funding2 to the appraised technology 
(58% of technologies were restricted), while the least common coverage decision was 
non-recommendation (14% of technologies were not recommended by NICE for NHS 
funding).  Therefore, the pattern of coverage decisions issued by NICE, in which either 
full or restricted coverage is advocated more than 80% of the time,  does not 
substantiate the claim made in the second quote cited above, that NICE is refusing 
patients access to new technologies in a generalised way.   However, it should be noted 
that, when the pattern of NICE coverage decisions is examined across time, there has 
been a trend towards an increasing proportion of restrictions and non-recommendations 
relative to recommendations (see Chapters 4 and 8).   
 
This pattern is not dissimilar to that reported in Kanavos et al. (2010) which examined 
NICE coverage decisions in 2007-2009:  that analysis revealed that of the technologies 
appraised, 19% were recommended, 63% were restricted and 18% were not 
recommended.  Clement et al. (2009) examined NICE coverage decisions between 
                                                 
1 Kate Spall is a member of the public who has been involved in helping more than 50 patients across 
England and Wales to receive funding from local Primary Care Trusts ( PCTs) for new cancer drugs that 
had not yet been reviewed by NICE.   
2 Technologies that were restricted by NICE ranged from major restrictions where the use of the 
technology was limited within a sub-set of the licensed population, to minor restrictions such as the need 
to monitor the use of the technology. 
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2001- 2008 and reported 87% of technologies as listed (recommended or restricted), 
leaving 13% of technologies as not recommended.  In the analysis of NICE decision-
making during 2000-2003 produced by Dakin et al. (2006) it was reported that 21% of 
technologies were recommended for routine use, 66% for restricted use and 13% were 
not recommended.   Devlin and Parkin (2004) reported NICE outcomes using a binary 
outcome variable, and during the period 2000-2002 reported that 71% of appraisals 
recommended use of the technology and 29% of appraisals did not recommend use of 
the technology. Therefore, the coverage pattern observed within the data set used in this 
thesis seems similar to that observed in other reports, suggesting that the method of 
classification and data extraction used was robust.   
 
As highlighted by the results presented in Chapter 4, the characteristics of 
recommended, restricted and non-recommended technologies were compared 
descriptively, and they were found to differ significantly in terms of clinical and 
economic characteristics, as well as in relation to the process and context in which the 
decisions were made.  Guided by the results of the descriptive analyses, multivariate 
analyses were performed to examine the relative role of various explanatory variables in 
explaining NICE decision-making.  When NICE coverage decisions were analysed 
through multivariate analyses, the results suggested that variation in NICE coverage 
decisions could be explained by four variables:  whether statistical superiority of the 
primary endpoint in the RCT was demonstrated, the incremental cost-effectiveness 
ratio, the number of technologies considered within the appraisal, and the year of 
appraisal (Table 9.1).   
 
In the analysis of NICE decision-making presented here, demonstration by the 
technology under appraisal of statistically significant superiority in its primary endpoint 
increased the odds of recommendation.  This result can be seen to reflect the role of 
evidence-based medicine in coverage decisions and the fact that NICE defines the value 
of the compound in terms of the ability of the technology to demonstrate, with greater 
certainty, its incremental clinical value through superiority designed trials that provide 
stronger data to support a funding decision than technologies not able to provide 
evidence of superior efficacy.  Contrasting this result with those previously published in 
the literature (Dakin et al. 2006; Devlin and Parkin 2004), it is noteworthy that Devlin 
and Parkin (2004) did not consider the demonstration of clinical superiority as a 
variable in their analysis while in Dakin et al. (2006), this variable was measured but 
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was not found to have a statistically significant impact, although the sample size was 
smaller than that used within the analyses presented here, and pertaining to NICE 
appraisals made in 2000-2003.   
 
Other clinical variables which were tested included information on the characteristics of 
RCTs used in the appraisal (number, size, duration).  Within descriptive analyses, these 
variables were found to differ between coverage decisions, at statistically significant 
levels.  However, they were not key drivers within the multivariate analyses.  This is not 
to say that the characteristics of RCTs are not important or not considered within the 
NICE appraisal process, but that within the multivariate analysis the demonstration of 
superiority and the contribution of other factors, such as the ICER, had a more 
significant impact.  This result is not dissimilar to that observed in the analysis of NICE 
decisions by Dakin et al. (2006), in which RCT size was not found to have statistically 
significant effects on the odds of a restriction or non recommendation relative to a 
recommendation within their multivariate analysis.  The number of RCTs, however, did 
have a statistically significant impact in the Dakin et al. (2006) model, which was not 
observed in the analyses presented here.  This could be due to differences in the samples 
analysed:  Dakin’s analysis was smaller (n=60 vs. n=118 in this analysis) and the 
analysis included NICE appraisals published in a different time period (2000-2003).  
The analyses by Dakin et al. (2006) also show that the use of systematic literature 
reviews within the NICE appraisal process appear to decrease the odds of non 
recommendation and restriction relative to a recommendation at statistically significant 
levels.  This variable was not examined in this analysis because it was noted in a review 
of appraisals that the majority of appraisals post 2004 included systematic reviews of 
the clinical and economic literature as part of the process.   
 
Looking at the other major variables impacting on NICE’s decision-making, the 
importance of the incremental cost-effectiveness ratio in this analysis highlights NICE’s 
focus on identifying “healthcare that works and is good value”.   An increase in the 
ICER decreased the odds of a recommendation, and this was highly statistically 
significant.  This would suggest that, in addition to the strength of the clinical data, the 
incremental costs and benefits associated with the technology, and the resulting ICER, 
play a significant role in coverage decisions by NICE, and represent the agency’s focus 
on maximising the efficiency of public healthcare spending on technologies.   The 
impact of the ICER observed in this analysis of NICE coverage decisions appears to 
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confirm the findings in the literature which have also previously found the ICER to be a 
key driver of NICE decision-making.  Devlin and Parkin (2004) concluded from their 
analyses that the ICER has a significant impact on NICE decision-making.  However, 
their use of a binary outcome variable precluded an assessment of whether the role of 
the ICER was important across coverage decisions.  Dakin et al. (2006) used a three-
category outcome variable and showed that the ICER had a significant effect on the 
odds of both a restriction relative to recommendation and non-recommendation relative 
to recommendation – which was also observed in the analyses presented here, 
confirming that the ICER is a highly important factor that drives NICE decision-
making.   
 
But the model developed here also suggests that there are process and context factors, 
beyond evidence considerations which explain NICE coverage decisions. When 
considering appraisal process-related factors, the results of the model suggest that an 
increase in the number of technologies reviewed simultaneously within the same 
appraisal increased the odds of a restriction relative to a recommendation.  It was 
hypothesised that this may reflect the fact that NICE assessment processes differ 
according to the number of technologies under appraisal.   Single technologies are 
evaluated using the STA process (in use since 2006) while multiple technologies are 
evaluated using the MTA process.  The latter involves the use of third-party 
assessments to provide bespoke research to support NICE assessment, while the STA 
process relies on manufacturer submissions similar to the process undertaken by the 
SMC in Scotland.   However, when the model specification was altered to include a 
variable capturing the use of MTA or STA processes, the effect was not statistically 
significant.  Thus, the effect on coverage decisions arising from the appraisal of 
multiple technologies simultaneously could not be explained by the use of MTA or STA 
alone.  It was suggested by Professor P. Littlejohns3, that the increased odds of 
restriction associated with higher number of technologies appraised simultaneously may 
reflect an approach in which a ‘winner’ is picked among the technologies, with the 
remainder recommended for restricted use or non-recommendation.   None of the 
published multivariate analyses of NICE decision-making examined the role of process 
factors, and thus a comparison with previous analyses is not possible.   
                                                 
3 Littlejohns, Peter. Professor, Clinical and Public Health Director National Institute for Health and 
Clinical Excellence.  Interviewee: Karin Cerri.  Interviewed by telephone, on February 2nd 2011.  Meeting 
minutes are provided in Appendix E.    
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In terms of the socio-economic context of NICE decision-making, the results of the 
model show that the year of appraisal impacted significantly on the coverage decision – 
moving from 2004 to 2009 increased the odds of a restriction or non-recommendation.  
The year of appraisal may reflect multiple socio-economic factors, including the 
political climate, a change in key staff of the HTA body, a change in societal 
preferences or the overall economic context.  By way of comparison, Dakin et al. (2006) 
included this variable in their analyses, and also found a statistically significant effect of 
the time of appraisal on outcome.  In particular, more recent appraisals had higher odds 
of non recommendation.  However, Dakin et al. (2006) did not observe the effect of 
appraisal date on the odds of a restriction relative to a recommendation. 
 
Having presented the results of the model it should be borne in mind that the analysis of 
NICE decision-making has been limited by several factors including:  i) dependence on 
publicly available information for the creation of the dataset; ii) heterogeneity in the 
definition of ‘restricted’ technologies; and iii) challenges with data extraction.    
 
The database constructed for these analyses of NICE decision-making was dependent 
on publicly available information.  Thus, it is possible that considerations or rationales 
discussed by the appraisal committee in oral format were not captured in the 
documentation of the appraisal.  In addition, the dependence on public information 
meant that in situations where the information was incomplete, it was not possible to 
ascertain if this was because the information was never considered in the appraisal or if 
it was considered but not recorded in the documentation.  The presence of non-reporting 
reflects a lack of transparency associated with the documentation of the appraisal 
process. This was noted particularly with regard to the non-reporting of uncertainty 
information around the cost-utility/effectiveness results, both in terms of probabilistic 
sensitivity analyses as well as univariate sensitivity analyses.  Both forms of sensitivity 
analysis are an integral part of NICE methods, requested as part of its reference case, 
and the value of parameter and decision-uncertainty information is very high (Claxton et 
al. 2005).   Incomplete observations were imputed in the multivariate analyses and 
dummy variables were created that captured the instances in which a particular variable 
was incomplete, so as to be able to examine whether the presence or absence of 
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information on that variable had any explanatory value.  It should be noted that none of 
these dummy variables had a statistically significant effect in the base case model.   
 
There was also heterogeneity in the means through which technologies were restricted 
within NICE coverage decisions.  The notion of restriction within NICE coverage 
decisions ranged from major restrictions, including restriction for use within a sub-set of 
the licensed indication, to minor restrictions such as the need to monitor the use of the 
technology.  The notion of major and minor restrictions was suggested in research by 
Raftery (2006) on NICE guidance in which various sub-types of restrictions were 
presented.  It is a limitation for this analysis to have such heterogeneity in the degree of 
restriction and hence of access to pharmaceuticals within a single category.  However, 
the use of a third coverage category (ie. restriction) within the analysis was felt to better 
reflect the real-life decision-making in which there are multiple options available to 
HTA bodies, rather than the binary alternatives of simply listing (recommendation) or 
not listing (not recommending).   
 
Challenges were also faced with regard to the creation of the dataset of NICE decision-
making due to the dispersal of information between various documents, and potential 
for inconsistency between NICE guidance drafts, manufacturer reports and Assessment 
Group reports, leading to a reduction in the transparency of the information that was 
considered by NICE.  This challenge was managed by creating a specific data extraction 
protocol with specific rules on the nature of the data that should be extracted and how to 
select the data of most relevance.  For example, it was not uncommon for multiple 
models to be submitted and considered.  In these instances, the model that provided the 
ICER which drove the decision-making was selected and included in the dataset.   
 
9.2.2  SMC 
“The purpose of the Scottish Medicines Consortium (SMC) is to 
accept for use those newly licensed drugs that clearly represent 
good value for money to NHS Scotland.” (SMC 2011 p1) 
 
SMC decision-making was analysed to understand the factors used to identify 
technologies that demonstrate “good value for money to NHS Scotland” relative to 
those technologies not able to demonstrate this value.  The analysis of SMC decisions 
involved the review of 288 technology appraisals during 2005-2009.  The most common 
coverage decision by the SMC was to not recommend the new technology for use (46% 
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of appraisals), followed by accept for restricted use (35% of appraisals), and accept for 
use (19% of appraisals).  It would seem, therefore, that the SMC identified in 
approximately half its appraisals technologies that represented value for money. Other 
analyses of coverage decisions made by the SMC provide different proportions of 
coverage types, although this appears to be due to differences in time horizon.  For 
example, the SMC Annual Report (SMC 2008) summarises coverage decisions for 
2008:  31% accepted for use, 36% of technologies accepted for restricted use, and 33% 
technologies not recommended for use.  In a similar exercise but looking at decisions in 
the period 2007-2009, Kanavos et al. (2010) find that the SMC recommended 28% of 
technologies, restricted 40% of them and did not recommend 32% of technologies.  
Thus, the period used within the analyses produced in this thesis, spanning 2005-2009, 
has a higher proportion of non-recommendations in its sample than observed in other 
publications reporting SMC decision-making.  Dr. A. Walker4, suggested that such 
differences can be attributed to the use of different time horizons (2005-2009 vs. 2007-
2009 or single years) and also to the fact that publications report SMC coverage 
decisions across all types of submissions, whether full submissions, resubmissions, 
abbreviated submissions or IRPs.  Within the SMC sample used for this thesis, only full 
or re-submissions were included.    
 
Multivariate analysis of SMC decision-making suggest that seven variables appear to 
have a significant effect on coverage decisions:  the sample size and duration of the 
RCT(s), the ICER, if the technology was indicated for use in infections or skin diseases, 
the prevalence of the disease in question, as well as whether there was an alternative 
therapy available within NHS Scotland (Table 9.1).  An increase in the ICER had a 
significant positive effect on the odds of a restriction and non-recommendation relative 
to a recommendation.  This result is in line with the stated objective of the SMC which 
is to recommend for use those technologies representing value for money for NHS 
Scotland.  The fact that budget impact of new technologies was not found to impact on 
the outcomes within the models described here reinforce the fact that the SMC is 
focused on promoting ‘efficiency’ of funding rather than a concern for affordability.  
The ICER and disease prevalence were the only variables that had significantly 
                                                 
4 Walker, Andrew. Senior Lecturer in Health Economics, University of Glasgow and member of the New 
Drugs Committee at the Scottish Medicines Consortium.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on December 20th 2010.  Meeting minutes are provided in Appendix E.    
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increased the odds of both a restriction and non-recommendation, relative to a 
recommendation.    
 
Clinical evidence and disease characteristics were found to be key drivers of SMC 
decision-making. The odds of non-recommendation decreased with increasing RCT size 
and duration, reflecting the impact of the clinical evidence base on SMC decision-
making.  When comparing restricted versus recommended technologies, an increase in 
the sample size of the RCT appeared to have an effect in the opposite direction:  it 
appeared to increase the log odds of a restriction, and decrease the log odds of a non 
recommendation.  However, only the latter effect was statistically significant.  This 
suggests that use of a multinomial outcome variable facilitates the ability to identify 
potential differences in impact that would not have been possible with a binary outcome 
category.  In addition to clinical variables, disease characteristics were found to increase 
the odds of recommendation.  Moreover, technologies indicated for the management of 
infectious diseases or skin diseases also increased the odds of a recommendation.   
 
The presence of an alternative therapy indicated in the same population to the 
technology under evaluation appears to impact significantly on SMC coverage 
decisions, although perhaps not in the direction that could have been hypothesised based 
on the literature.  The analysis suggests that the availability of an alternative therapy 
increases the odds of a recommendation.  In other words, those technologies where no 
alternative was present had increased odds of non-recommendation, relative to those 
technologies where an alternative was already available in NHS Scotland, all other 
things being equal.  It is noteworthy that about 40% of those technologies with no 
alternatives were orphan-designated technologies.  In addition, those technologies 
where no alternative was available had higher mean ICERs compared to those 
technologies where alternatives were available – almost three times as high (£62,021 vs. 
£20,679 respectively).  The fact that technologies for which alternatives were not 
readily available within the Scottish NHS were more likely to not be recommended 
suggests that while clinical characteristics and need are recognised criteria within SMC 
decision-making, the ICER would appear to have a greater impact on coverage 
decisions.  This observation is supported by research of SMC coverage decisions for 
orphan-designated pharmaceuticals in which the 49% of technologies that were not 
recommended had higher ICERs than those recommended or restricted (Vegter et al. 
2010).  While the authors did not adjust for other confounding factors in the analysis, 
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their descriptive analysis confirms that focus of the SMC on “value for money”.  In 
addition, these results raise questions about the extent to which the SMC encourages 
innovation in the pharmaceutical industry.  As highlighted by the two quotes at the 
beginning of this chapter, there is a balance that needs to be struck between encouraging 
‘value for money’ and patient access to innovative care.  These particular results would 
suggest that the SMC, while fulfilling its objective of recommending the use of 
technologies that demonstrate value for money, may be achieving this objective at the 
expense of access to innovative care.    
 
When examining the results of the SMC multivariate analyses, there are several 
limitations that need to be taken into account.  The first is that the SMC, compared with 
other agencies like NICE, provides relatively limited information in the public domain 
on the evidence reviewed and considered in its decision-making process.  In general, the 
publicly available SMC Advice reports provide a concise review of key issues in a 
summarised format that do not document details on the various clinical considerations 
or economic arguments to which they were exposed or considered, but primarily those 
considerations which were found to be drivers of their decision.  On the one hand, this 
helps the data extraction process by providing the key data that was felt, by the agency, 
to drive its decision-making.  On the other hand, the aim of this thesis and analysis was 
to collect as much objective evidence as possible on factors driving decision-making.  
The lack of detail in reporting led to higher rates of non-reporting of variables of 
interest for this research, particularly with regard to information on the uncertainty 
around incremental cost-effectiveness ratios, compared to agencies like NICE where a 
larger quantity of information is publicly available, including manufacturer submissions 
(depending on the appraisal process used).  The lack of data linked to this reporting 
style was managed by using imputation techniques in the multivariate analysis.  The 
implications of using such techniques, versus restricting the analysis to complete 
observations, were assessed in a sensitivity analysis in which the multivariate analysis 
was conducted on the sample of coverage decisions for which the data was complete 
(130 of 288 appraisals).    It is recognised that excluding incomplete observations may 
lead to bias in the coverage decisions included in the analysis due to the fact that 
incomplete observations may be systematically different from complete observations.  
Despite this potential for selection bias, four of the seven variables that were significant 
in the base-case analysis remain significant in this sensitivity analysis, confirming their 
important role in SMC coverage decisions.   
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An important factor to take into account when examining SMC coverage decisions is 
the agency’s reliance on manufacturer submissions in formulating advice.  There is no 
third party or significant additional new analysis performed on the evidence submitted 
by the manufacturer. The focus of the SMC is to critically review the submitted 
evidence in order to ascertain the degree of certainty around the effects and value for 
money of the technology under appraisal.  Given the lack of accessibility to 
manufacturer submissions in the public domain, it was not possible to take into account 
in the analyses to what degree the SMC advice was driven by the manufacturer 
submission strategy relative to SMC decision-making criteria.  For example, for a 
technology which was accepted for restricted use, it was not possible to ascertain if this 
restriction was proposed and implemented by the SMC, or whether the restriction was 
proposed by the manufacturer in their submission.  While there was a lack of complete 
information on the evidence and manufacturer strategy used within SMC assessments, 
the analysis presented in Chapter 5 was able to give insights into the effect and 
significance of clinical, economic and disease characteristics of the technologies 
assessed by the SMC on its coverage decisions.   
 
9.2.3 CVZ 
“The [Dutch] government policy aimed at reducing drug 
expenditure appears to bear fruit. Total drug expenditure 
increased this year by 2.6 percent to 5.2 million [euros] per year.  
In 2007 the increase was three times as high.”  (NOS 2008 p1) 
 
The analysis of the Dutch HTA agency (CVZ) looked at 256 technology appraisals.  
The most common coverage decision by the CVZ was to recommend new technologies 
(51%), followed by restriction of funding (33%), while 16% of coverage decisions did 
not recommend funding the technology.  The model of coverage decisions by the CVZ 
included nine variables, representing a mixture of clinical, economic and process 
variables (Table 9.1).  Unlike the NICE and SMC models, the ICER did not have an 
impact in the CVZ model.  However, budget impact associated with the introduction of 
the technology had a significant effect:  a unit increase in the budget impact increased 
the log odds of a restriction.  This may reflect the fact that the Dutch Reimbursement 
system aims to reduce the growth in out-patient drug expenditure while maintaining 
high quality healthcare and patient outcomes (Pronk and Bonsel 2004).  The impact of 
budgetary impact considerations on the odds of a non-recommendation was not 
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statistically significant, suggesting there are other factors that better explain non-
recommendations.  Interestingly, in this model, the impact of the therapy area for which 
the technology was indicated played an important role in coverage decisions.  
Technologies for cancer were associated with an increased probability of 
recommendation, while technologies for the treatment of cardiovascular disease, and 
obstetrics/gynecology/urinary-tract disorders increased the probability of a restriction.  
These results obtained within the CVZ sample suggest that coverage decision-making is 
a complex decision process involving numerous clinical, disease and affordability 
considerations.  This fits well with the argument presented by Stolk and Poley (2005) 
that an understanding of CVZ coverage decisions requires a holistic and comprehensive 
assessment of multiple factors.   
 
While the base-case model was based on a three-category outcome variable, a 
sensitivity analysis was conducted to assess the effect of using an alternative 
classification of the outcome variable, in this case a binary outcome category.  The 
results of this sensitivity analysis suggest that several of the explanatory variables which 
were important in the CVZ base-case model continued to be significant in this binary 
model.  For example, the use of an active comparator and the demonstration of clinical 
superiority maintained their effect and significance, suggesting that the role of these 
variables in explaining CVZ coverage decision-making is robust to changes in model-
specification.  Other variables, including the budget impact, were no longer found to 
have a significant effect in this sensitivity analysis, suggesting that the use of binary 
outcome category does not allow for a more detailed exploration of the impact of the 
budget impact on different coverage decisions, and thus when examined in this 
sensitivity analysis its overall impact was not significant.  Variables that were not 
included in the base-case model were found to have a significant role in this sensitivity 
analysis - the year of appraisal and technologies indicated for the treatment of infectious 
diseases.  This suggests that the use of binary outcome categories can yield an 
alternative perspective on CVZ decision-making, at the expense of reducing visibility 
on the impact of explanatory variables on specific types of coverage decisions.  It also 
shows that the majority of factors during CVZ decisions retain their effect on the 
outcome variable despite the use of a binary outcome variable.   
 
The results obtained within the CVZ multivariate model can also be compared with the 
results of a discrete choice experiment performed amongst Dutch healthcare 
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professionals who were asked to select, among 27 choice sets, the technology they 
would chose to reimburse (Koopmanschap et al. 2010).  The choices made were 
analysed using multinomial logistic regression and suggested that severity of disease, 
cost-utility analysis, patient outcomes and budget impact were the most significant 
criteria driving coverage decisions (Koopmanschap et al. 2010).  These results have 
strong similarities with the results of the CVZ multivariate analyses performed within 
this thesis.  Cancer therapies, which could be approximated to represent severe disease, 
significantly increased the odds of recommendation.  Budget impact was also found to 
play a significant role in CVZ decision-making.  An important difference between this 
analysis of CVZ decision-making and the analysis performed by Koopmanschap et al. 
(2010) is the effect of the CUA on coverage decisions which was noted in the latter 
study.  In Koopmanschap et al. (2010), results of the discrete choice experiment suggest 
that CUA is an important criterion for CVZ decision-making.  This was not found to be 
the case in the multivariate analyses performed within the context of this research.  
Plausible explanations for this difference could be due to variation between hypothetical 
reimbursement decisions versus real-life decision-making, and the fact that CUA was 
first introduced in the CVZ process in 2005, and is only utilised as a criterion for 
inclusion of technologies on List 1B.  It has been highlighted that the role of CUA 
within the CVZ appraisal process may increase in the future (Dr. Graaff, M; Dr. 
Goettsch, W, Dr. S. Kleijnen)5.  
 
Interpretation of CVZ multivariate results needs to take limitations into account.  An 
important limitation is related to the ability to access only information that is publicly 
available.  The CVZ only presents in the public domain the information corresponding 
to the final recommendation.  For instance, a technology that is recommended for GVS 
List 1A, meaning that it is clustered with therapies already available within the Dutch 
healthcare system, will have the report/information used to support this coverage 
decision are made publicly available.  However, it is possible that a manufacturer may 
have submitted a request for the drug to be included in GVS List 1B i.e. where the 
technology is found to have therapeutic benefit to the degree that it is not clustered with 
existing therapies.  This type of submission would have required the technology to 
demonstrate its cost-effectiveness and thus the manufacturer may have submitted cost-
                                                 
5 Dr. Martin van der Graaff, Secretary medicines evaluation committee (CVZ); Dr. Wim Goettsch; 
Sarah Kleijnen (M.Sc. ) Project coordinator EUnetHTA WP5.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on January 6th 2011.  Meeting minutes are provided in Appendix E.    
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effectiveness analyses. However, if the decision by the CVZ/CVZ was that there was no 
added therapeutic benefit to justify inclusion in the 1B list, then the cost-effectiveness 
criteria would not have been applied, and therefore the information about the cost-
effectiveness analyses that were performed would not be disclosed in the public domain  
(See Chapter 6). 
 
From one perspective, the lack of access to data that was not actually taken into account 
in the coverage decision does not have significant implications for the analysis, given 
that the aim is to identify those factors that impact on decisions.  However, this 
perspective assumes that the availability of data has no impact on the committee’s 
decision to cluster or not cluster the technology.  To some degree the implications of 
incomplete evidence was addressed through imputation techniques, coupled with the 
use of dummy variables to identify the impact of incomplete observations data on 
coverage decisions, and  an additional sensitivity analysis in which the model was 
restricted to those technologies with complete observations.  This sensitivity analysis 
highlighted that the majority of observations from the CVZ were incomplete (96 of 256 
were included in the analysis).  This suggests that there is considerable additional 
evidence and data provided to the CVZ that is not disclosed (e.g. patient submissions, 
physician organisation interaction, cost-effectiveness analyses etc).  Therefore, greater 
transparency in the evidence received or submitted may help further increase the 
understanding of CVZ decision-making.   
 
As with the SMC appraisal process, the CVZ also relies on manufacturer submissions in 
formulating its advice.  There is no third party or significant additional new analysis 
performed on the evidence submitted by the manufacturer.  Given the lack of 
accessibility to manufacturer submissions in the public domain, it was not possible to 
take into account in the analyses to what degree CVZ recommendations are driven by 
the manufacturer submission strategy relative to CVZ decision-making criteria.  For 
example, for a technology which was accepted in the GVS 1A list (clustered 
technologies), it was not possible to ascertain if the inclusion in this list was proposed 
by the CVZ, or by the manufacturer in their submission.  Despite the lack of access to 
such information, it does not detract from the possibility of being able to assess the 
degree to which key characteristics and factors vary according to the coverage decision 
made.   
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9.2.4 HAS 
“The ASMR obtained reflects the recognition of quantitative 
improvement (the efficacy of A is twice the efficacy of B), a 
qualitative improvement (A treats patients not responding to B), 
and/or a tolerability improvement, compliance improvement, or 
improvement in the therapeutic maintenance of effect over 
time...” (Bouvenot 2006 p. 11) 1 
 
The analysis of HAS decision-making focused on understanding the factors driving 
ASMR ratings.  These ratings reflect the perceived incremental medical value 
associated with the appraised technology relative to standard of care, and as highlighted 
by the quote above, the ASMR rating can reflect a variety of forms of therapeutic 
benefit.  In exploring the factors driving coverage decisions made by HAS, 315 
technology appraisals were reviewed: 3% of technologies were awarded an ASMR I, 
meaning that the technology was considered to bring highly significant incremental 
medical benefit and 15% of technologies were awarded an ASMR II, in instances where 
the committee considered that the technology would bring important incremental 
medical improvement.  The majority of decisions (44%) concluded that there was no 
medical improvement associated with the technology (ASMR V).  When HAS coverage 
decisions were modelled, nine clinical, disease and socio-economic variables appeared 
to have a statistically significant impact on the odds of ASMR III-IV or ASMR V 
relative to ASMR I-II.  No economic variables were included as the HAS does not 
include economic criteria in its appraisal process.   
 
Clinical and disease characteristic variables played an important role in HAS decision-
making in this model (Table 9.1).  Technologies that demonstrated clinical superiority 
increased the log odds of an ASMR I-II.  This could be seen to reflect the focus of the 
HAS appraisal process on the incremental medical benefit associated with the 
technology, demonstration of clinical superiority being a key piece of evidence to 
substantiate the presence of incremental medical benefit.  It is noteworthy, however, 
that for those technologies that demonstrated clinical superiority, this superiority was 
demonstrated only 25% of the time versus an active comparator.   For those 
technologies that did not demonstrate clinical superiority, 68% were compared to active 
                                                 
1Translated from the following original quotation: “L’obtention d’une ASMR peut traduire la 
reconnaissance soit d’un progrès quantitatif (A est deux fois plus efficace que B) soit d’un progrès 
qualitatif (A permet d’atteindre des patients non-répondeurs ou insuffisamment répondeurs à B) ou 
traduire une meilleure tolérance, une meilleure observance ou un meilleur taux de maintenance 
thérapeutique…”  
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comparators.  Therefore, these results would suggest that with regard to HAS decision-
making, the demonstration of superiority in itself outranks the nature of that superiority 
(whether demonstrated versus placebo or an active treatment).  This may also suggest 
that the criteria prioritized by HAS in its assessment of medical value matches closely 
with that used by regulatory agencies that also accept, and indeed in several 
circumstances recommend, comparison to placebo as an appropriate means of 
demonstrating clinical benefit.   
 
When examining disease characteristics and their impact on HAS decision-making, 
technologies that had an orphan designation increased the log odds of an ASMR I-II.  
This could be explained by the fact that orphan-designated technologies tend to be rare, 
indicated for diseases with no alternatives.  When the features of orphan technologies 
were further examined, they were found to be characterised by small patient populations 
(mean estimated target population for orphan technologies was 1,356 patients vs. 
570,408 patients for non-orphan technologies).  In addition, orphan technologies were 
indicated for diseases with low availability of alternative therapy (in 38% of cases 
alternative technologies were available) and therefore a correspondingly higher level of 
clinical need for treatment.  For non-orphan technologies, in 80% of cases alternative 
therapies were available within the French healthcare system.  Orphan designation 
increased the odds of high ASMR ratings despite the fact that, compared to non-orphan 
technologies, orphan technologies on average were supported by fewer RCTs (1.5 vs. 
2.8), had mean shorter trial duration (29 weeks vs. 53 weeks), were supported by 
smaller trials with, on average, fewer patients (255 patients vs. 1,228 patients); and had 
a higher proportion of instances in which an active comparator within the clinical trial 
was not available (34% vs. 16%).  This evidence would support the hypothesis that the 
HAS, in its assessment of orphan technologies, may be willing to place more emphasis 
on the potential for the technology to fill a specific clinical need, at the expense of the 
quality of clinical evidence.    
 
The impact of specific disease areas on coverage decisions was also examined and 
found to be important within HAS decision-making.  Technologies that had a license for 
the treatment of musculoskeletal and joint diseases increased the log odds of an ASMR 
I-II.  In contrast, indications for the treatment of CNS disorders and infectious diseases 
increased the probability of an ASMR III-IV and ASMR V.  This could be explained by 
the fact that a higher proportion of technologies indicated for the treatment of 
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musculoskeletal and joint diseases were supported by clinical trials with active 
comparator arms (55%).  Use of active comparators in clinical trials confers more useful 
evidence to ascertain the incremental clinical benefit of a technology to standard care.  
Placebo-controlled trials are less useful in that they provide evidence of incremental 
benefit of a technology relative to a comparator which does not exist in clinical practice 
(i.e. placebo is not used to treat patients).  In contrast, technologies for infectious 
disease or CNS disorders had a lower proportion of studies with active comparators 
(36% and 22%, respectively). Overall, the multivariate model emphasised the role of 
key clinical and disease criteria on ASMR ratings from the HAS.   
 
In terms of socio-economic factors, pharmaceutical expenditure was found to have a 
statistically significant impact on the log-odds of both ASMR III-IV and V.  A unit 
increase in pharmaceutical expenditure, in this case national average per patient 
expenditure per year, appeared to increase the odds of an ASMR III-IV or ASMR V, 
albeit statistically significant only in the latter.  This would seem counter-intuitive in 
that the increase in pharmaceutical spending would generally suggest an increase in the 
available budget for reimbursed technologies.  However, it could be that an observed 
increase in pharmaceutical expenditure may have triggered more stringent assessment of 
incremental medical value.  This is conjecture that cannot be further examined with this 
dataset, and highlights that caution is needed in the interpretation of the role of socio-
economic factors such as national pharmaceutical expenditure as there are numerous 
unmeasured factors that could be associated with this particular variable (e.g. overall 
trends in GDP, change in treatment algorithms, healthcare system approach, physician 
and patient behaviour, industrial policy, increases in marketing authorisations for 
pharmaceuticals etc).   
 
When examining the results of the HAS multivariate analyses, there are several 
limitations that need to be taken into account.  The first is that HAS, compared with 
NICE for example, provides relatively limited information in the public domain on the 
evidence reviewed and considered in its decision-making process.  In general, HAS 
reports made publicly available provide concise synopses of key issues in a summarised 
format that do not document details on the various clinical considerations or disease 
characteristics which were considered.  The lack of detail in reporting did lead to 
instances of non-reporting of variables of interest for this research.  The lack of data 
linked to this reporting style was managed by using imputation techniques in the 
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multivariate analysis.  The implications of using such techniques, versus restricting the 
analysis to complete observations were assessed in a sub-analysis in which the 
multivariate analysis was conducted on the sample of coverage decisions for which the 
dataset was complete.  The results of these sensitivity analyses confirmed the important 
impact of the majority of indentified variables in the base case analysis.   
 
Another important factor to take into account when examining HAS coverage decisions 
is that the sample of appraisals included in the analysis was, in fact, a subset of the total 
pool of appraisals conducted by the Agency.  This sub-sample included technologies 
that also had been appraised by NICE and the SMC in 2004-2009.  All the HAS 
recommendations linked to these technologies were extracted for review.   The rationale 
for this approach was the fact that HAS has numerous responsibilities, one of which is 
the provision of advice on new technologies available for patients, and in total, its 
Transparency Commission issued more than 2600 recommendations related to 
medications in 2004-2009 (HAS 2009).  Given the resource constraints available, it was 
not possible to review all 2600 recommendations to identify those of relevance for this 
research (i.e. not all recommendations provide ASMR, some recommendations are 
related to new mode of administration, new safety information or a re-review of 
technologies licensed prior to 2004).  The benefit of the approach employed here, i.e. in 
taking a sub-sample, was that it increased the opportunity for comparability across 
agencies by collecting information on a common list of technologies, and secondly it 
facilitated the streamlining of data extraction to those appraisals of relevance for the 
research question.   
 
A further limitation associated with the HAS analyses is that this HTA body focuses on 
determining an ASMR rating.  Therefore, HAS does not provide information on the 
degree to which the French healthcare system is willing to pay for incremental medical 
benefit (as defined by the ASMR rating).  This is directly linked to the role of the HAS 
which is focused on evaluating the medical benefit of the technology.  The output of 
this assessment is then used by a separate organisation (CEPS) to negotiate a final price.  
Thus, understanding HAS decision-making may not provide a full perspective on 
coverage decisions within France and how public funding is allocated to 
pharmaceuticals.  On the other hand, it is recognised within French legislation that the 
degree of medical benefit (as defined by the ASMR) directly impacts on the price of a 
technology.  Technologies with no incremental benefit are not included on the 
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reimbursement list unless they are discounted below the level of the other available 
treatments already reimbursed by the system.  Technologies with an ASMR IV can 
obtain, at a maximum, a price that is equal to the comparator that is already reimbursed 
while it is only those technologies with an ASMR I-III that can aspire to potential 
premium prices.  Since details of pricing negotiations and discounted prices are not in 
the public domain this prevented the inclusion of an economic component in the HAS 
analyses. Thus, while the multivariate analyses of HAS decisions presented here cannot 
directly examine the economic value that the French system attaches to particular 
degrees of medical benefit, it does provide an indirect view, by examining the factors 
that drive HAS allocation of ASMR ratings to the technologies it assesses.    
 
9.2.5 Pooled analysis 
In addition to modelling coverage decision-making for each agency separately, a pooled 
analysis of all coverage decisions across HTA bodies was conducted.  An important 
objective of the pooled analysis was to describe the characteristics of the pooled data set 
and identify differences between HTA bodies in the nature of technologies appraised 
and the clinical evidence considered, the process through which HAS appraised the 
technologies and the socio-economic context in which the appraisals took place.  In 
addition, an important objective was to test whether an “HTA body effect” on the odds 
of recommendation, restriction or non-recommendation while adjusting for a range of 
confounding factors.   Before embarking on a pooled analysis of coverage decisions 
across HTA bodies, the pros and cons of such an analysis were assessed.  Firstly, in 
favour of conducting a pooled analysis was that it could provide data to help explain 
variation in coverage decisions across HTA bodies, which is of direct relevance to the 
research question.  Secondly, the pooling together of appraisals from four HTA 
agencies could significantly increase the sample size to 977 appraisals, creating the 
largest single set of data in Europe on HTA coverage decisions and accompanying 
appraisal characteristics.  Pooling across HTA bodies was felt to be feasible due to the 
fact that the data set was created specifically for this research project, and all data were 
extracted by the same researcher with a specific data extraction protocol that increased 
consistency in how the data was extracted.     
 
Overall, the results of the quantitative analysis of pooled coverage decisions made by 
NICE, SMC, CVZ and HAS was useful to demonstrate that a combination of evidence, 
process and socio-economic context factors help explain variability in coverage 
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decisions made across these four HTA bodies.  The analyses also represent the first 
model of coverage decisions across four European HTA bodies based on 30+ 
explanatory variables extracted directly from their appraisals.  This analysis suggests 
that those factors of importance in explaining variation in coverage decisions across 
HTA bodies may not be the same as those factors explaining variation in coverage 
decisions within each HTA body – namely, process and socio-economic context factors 
play a more evident role in this analysis than in the single HTA analyses.  At the same 
time, the impact of the clinical and disease factors observed in the single analysis 
remains very significant in the pooled analysis.   
 
While the results of the pooled analysis were felt to be meaningful and helpful in 
increasing the understanding of drivers of coverage decisions, it is important to 
recognise the important limitations that must be taken into account when interpreting 
the results of this pooled analysis.  Firstly, a significant challenge in conducting pooled 
analyses of coverage decisions is that across the four HTA bodies analysed, coverage 
decision are not formulated in the same way, and that heterogeneity was observed 
within the ‘restricted’ category in how HTA bodies implemented restrictions of 
coverage.    To evaluate the robustness of the base case model, a sensitivity analysis was 
implemented using a binary outcome variable; this provided very similar results to the 
base-case pooled analysis.   
 
A second important challenge identified in implementing a pooled analysis of coverage 
decisions is to create as homogenous a platform as possible upon which to model.  To 
overcome the potential limitations associated with this, in the base case model, the 
heterogeneity of the samples across HTA bodies was adjusted for by including in the 
model variables that captured the nature of the disease corresponding to the 
technologies appraised.  In addition, two sensitivity analyses were conducted in a sub-
set of the total sample that was hypothesised to increase the homogeneity of the 
technologies assessed between HTA bodies. Overall, the results of these sensitivity 
analyses show that the explanatory power of the combination of clinical, economic, 
process and socio-economic factors is higher in the sub-analysis including only those 
technologies appraised by all four HTA bodies.  This may suggest that increasing the 
homogeneity of the sample facilitates a more robust analysis of the role of explanatory 
variables on coverage decisions.  On the other hand, homogeneity is obtained at the 
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expense of significantly restricting the sample of analysis to less than 20% of the total 
available sample, increasing the odds of selection bias in the sample.  
 
Overall, the pooled analyses provide new evidence that differences exist between HTA 
bodies in the nature of technologies appraised and the clinical evidence considered, the 
process through which HTA bodies appraised the technologies and the socio-economic 
context in which the appraisals took place.  Importantly, the evidence also shows that 
the HTA body effect is present which contributes significantly to decision-making, even 
when adjusting for a range of confounding variables.  The analyses also emphasise that, 
amongst those HTA bodies that consider cost-effectiveness analyses, the ICER has a 
significant effect on the coverage decision.  The pooled analysis has alos provided an 
opportunity to examine the role of process and socio-economic factors on decision-
making.   
 
9.3 General limitations  
In addition to specific limitations and challenges encountered in the individual and 
pooled HTA analyses, there are some overarching limitations that apply more generally.  
The selection of HTA agencies included in the analysis was in part limited by data 
availability.  In particular, only those HTA agencies that put their decision-making 
process and reports into the public domain were considered for analysis.  Thus, 
extrapolating to other HTA bodies not included in this research is not advisable without 
having a more concrete understanding of their decision-making processes.  In addition, 
the generalisation of results, even within the respective agencies, must be attempted 
cautiously.  HTA agencies are continuously evolving and factors that may have driven 
their decision-making during 2004-2009 may not be the same or remain constant over 
time.  For example, it was highlighted in an interview with CVZ representatives (Dr. 
Graaff, M; Dr. Goettsch, W, Dr. S. Kleijnen)2, that the role of cost-effectiveness 
evidence may become more prominent within CVZ decision-making in the future.  The 
Conservative-Liberal Democrat government elected in the UK in May 2010 has 
indicated that they will change NICE's role in England and Wales such that its 
reimbursement recommendations will only have advisory status.  While this change in 
NICE’s role may or may not impact on the factors driving its decision-making, these 
                                                 
2 Dr. Martin van der Graaff, Secretary medicines evaluation committee (CVZ); Dr. Wim Goettsch; 
Sarah Kleijnen (M.Sc. ) Project coordinator EUnetHTA WP5.  Interviewee: Karin Cerri.  Interviewed by 
telephone, on January 6th 2011.  Meeting minutes are provided in Appendix E.    
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changes would appear to impact most significantly on the implementation of NICE 
guidance by the health services (further discussed in section 9.5.2).   
 
While every effort was made to create a dataset and analysis that was comprehensive in 
its inclusion of explanatory variables, it was not feasible to capture all variables 
presumed to have a potential impact on coverage decisions.  Although the analysis 
captured information on the ICER and the uncertainty around it, these indicators do not 
provide information on the nature of the economic model, the design, comparators and 
subtleties of the analysis.  Moreover, the use of surrogate outcomes was not captured as 
a specific variable in the dataset:  there is growing interest in better understanding the 
use of surrogate endpoints in decision-making (Velasco Garrido et al. 2009). As the 
literature does suggest that most clinical trials utilise surrogate endpoints, it was 
considered impractical to include this as a variable due to potential lack of variability 
between technologies, and other variables linked to the clinical characteristics of the 
technology were prioritised instead (such as use of active comparator in trial and 
demonstration of superiority in clinical trial).   
 
The speed of the appraisal process was also not factored in the analysis.  The fact that 
the SMC takes 3 months and NICE takes 12 months to complete an appraisal could 
have an impact on the nature of the evidence considered and the impact of the process 
on outcomes.  The analysis is also limited in that it cannot systematically examine time-
to-coverage decisions as a specific outcome of analysis.  Finally, the data base excluded 
those appraisals for which no documentation was available.  This includes situations 
where manufacturers did not make a submission, and therefore no appraisal was 
conducted.  This could be considered as a bias in the sample in that it did not consider 
the characteristics of those technologies that were not appraised.  However, as 
information was not publicly available, such analyses could not be conducted.  In 
general, the proportion of such cases excluded due to non-submission was relatively low 
(e.g. four non-submissions in the NICE dataset in 2004-2009).  Within the SMC 
appraisal process, if non-submission takes place, the technology receives a ‘non 
recommendation’.  Thus, the exclusion of these non-submitted appraisals may lead to an 
under-estimate in the sample of the true proportion of non-recommendations.  However, 
the level of non-submission within the SMC was also low.   
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Socio-economic indicators, such as GDP, are known to be influenced by many different 
factors.  Indeed, such indicators act as a surrogate for many characteristics of the 
country it applies to.  In addition, such indicators that vary at the HTA body level, rather 
than the technology appraisal level, are unlikely to have a very strong effect, due to the 
limited number of HTA bodies in this analysis.  Therefore, the interpretation of the 
impact of such broad indicators, such as the percentage of GDP spent on healthcare, will 
need to take into consideration the risk that variations observed in such indicators across 
HTA bodies may be correlated with other factors.   
 
Finally, it is important to consider the research findings within the context of the 
respective origins and objectives of NICE, SMC, CVZ and HAS.  The evolution of the 
HTA bodies, their origins and their roles within pharmaceutical regulation and coverage 
decisions vary.  In particular, their roles within their respective healthcare systems are 
very much driven by the context and characteristics of the healthcare system, and each 
HTA agency has peculiarities in their roles linked directly to that system.  HTA bodies, 
both within and outside of Europe, vary in their objectives, and in the approach and 
methods used to implement HTA within their jurisdictions (Neumann et al. 2010).  The 
scope of this thesis was limited to national level HTA bodies.  In addition, the analysis 
of factors influencing coverage decisions were performed on decisions made within 
HTA processes.  However, within a healthcare system, where funding/reimbursement 
decisions are confirmed at a national level, regional and local payers may re-assess 
whether funding/reimbursement should be provided.   Due to time constraints, factors 
influencing regional/local funding/reimbursement decisions were not assessed. 
 
9.4 How this thesis contributes to the literature 
The literature has made important contributions to assessing the role of evidence, 
process and context factors on coverage decision making.   However, limitations were 
identified in the literature in terms of scope, analytical methodology and 
comprehensiveness that hampered the ability to robustly examine how HTA agencies 
address the paradox of coverage decision-making, and the balance between evidence, 
process and context factors that drive decision-making.  In relation to these gaps, this 
thesis provides new evidence that contributes in a number of ways: the inclusion and 
comparison of multiple European HTA bodies, a comprehensive analysis of multiple 
factors through the creation of a bespoke database, and the adoption of multivariate 
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analyses to identify those factors that drive coverage decisions within each HTA body 
and across HTA bodies.   
 
This research includes four different HTA agencies from different countries, thus 
broadening the scope of evidence available on factors driving European HTA coverage 
decisions.   Much of the currently available literature on European HTA bodies 
currently available focuses on NICE as an example of HTA in Europe, despite the fact 
that in recent years there has been a growth in the use of HTA across EU Member States 
(OECD, 2005).  In addition, where cross-agency analyses have been performed, these 
included Anglophone agencies, namely NICE and SMC, alongside CDR in Canada and 
PBAC in Australia.   Moreover, where multiple European HTA agencies have been 
compared and contrasted, this literature has examined the characteristics and differences 
in processes between HTA bodies, but without linking such differences in 
characteristics and processes to explain variation in coverage decisions (Sorenson et al. 
2008; Hutton et al. 2006; Kanavos et al. 2010).  In providing a fresh perspective on 
factors driving HTA decisions within four distinct HTA bodies, this thesis contributes to 
and augments the existing evidence base in this area of research.        
 
In addition to adopting a broader scope to provide new evidence on HTA decision-
making in Europe, this thesis was designed to contribute to the understanding of HTA 
coverage decisions in Europe by considering a broad range of evidence, process and 
context variables in understanding coverage decisions.    The current literature that 
examines factors driving decision-making has, to a large extent, focused on specific 
types of factors (e.g. economic factors or process factors).  Few have combined factors 
(e.g. Clement et al. 2009; Dakin et al. 2006; Devlin and Parkin 2004), and there are no 
studies which have aimed to compare HTA decision-making using a dataset that 
combines evidence, process, and socio-economic context variables extracted directly 
from HTA reports and related sources.  While process and context-related factors have 
been identified as potentially important influencers of coverage decisions, and 
differences in these factors between HTA bodies have been described, few authors have 
in fact made a link between differences in process and context factors within coverage 
decisions.  Thus, this thesis contributes to the literature by capturing within a single 
analysis a comprehensive range of evidence, process and context factors.   
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A key contribution of this thesis is the use of a bespoke dataset to capture information 
on a broad range of factors thought to impact on the decision process, and which has the 
ability to observe the interaction of these factors and their relative contribution to 
coverage decision-making relative to one another.  In the literature, an important gap 
was observed in terms of the analytical methods adopted to assess coverage decisions 
and relevant factors, and the ability to distinguish the role of one factor while adjusting 
for the presence of other important characteristics.  Important exceptions are the models 
of coverage decisions that have been developed for NICE (Dakin et al. 2006; Devlin 
and Parkin 2004).  With respect to other HTA bodies, neither single-agency analyses 
nor comparative analyses across several European HTA bodies have been conducted to 
robustly assess the relative contribution of a range of factors on coverage-decisions. 
Comparative analyses across HTA bodies were primarily qualitative or have adopted 
descriptive quantitative methodologies (Barbieri et al. 2009; Clement et al. 2009; 
Kanavos et al. 2010; Vegter et al. 2010).  Such descriptive analytical techniques make it 
difficult to interpret the relative contribution of each factor, given the absence of 
adjustment for other factors in the analysis.   In response, this research created a 
bespoke dataset of HTA coverage decisions from four HTA bodies over a five-year 
period and utilised statistical methods of analysis to assess the relative contribution of a 
comprehensive range of factors on coverage decisions both within and across HTA 
bodies.    
 
9.5 Implications of this research 
9.5.1 Heterogeneity between HTA bodies - implications for healthcare systems and 
patients 
The thesis has shown that British, Dutch and French HTA bodies differ in the pattern of 
coverage decisions, and each is governed by a specific mix of evidence, process and 
context factors that drive decision-making.  The factors that best explain the variation in 
coverage decisions for NICE are not the same as those that explain the variation in 
coverage decisions for SMC, CVZ or HAS.  This research confirms through 
quantitative analysis that there is a difference between HTA bodies in the pattern of 
coverage decision made, and key differences in the factors that drive decision-making.    
 
From one perspective, such differences in coverage patterns and the factors that drive 
those coverage decisions can be explained by the fact that each HTA body is designed 
to match as closely as possible the specific healthcare system it serves.  Therefore, 
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variation observed across HTA bodies could be considered to reflect the reality of the 
healthcare market in Europe;  that is, HTA bodies are actors within specific healthcare 
systems, operating within the context of regulatory systems that combine “... public 
health, healthcare and industrial policy interests, reflecting particular national 
circumstances and requirements” (Permanand 2006 p. 5).  Unlike other functions which 
have been centralised at the European Union level, such as regulatory processes and 
marketing authorisations, the subsidiarity principle allows for the independent 
development of  EU Member State healthcare systems to continue.  From this point of 
view, acceptance of autonomy and variation in healthcare systems in Europe should 
imply acceptance of variation in HTA coverage decisions and the factors driving such 
decisions.   
 
However, from another perspective, differences in the proportion of recommendations, 
restrictions and non-recommendations can be seen to be contrary to the principle of 
equitable access to treatment in Europe (Wilking and Jonsson 2005).   This is due to the 
fact that coverage decisions impact on the ability of patients to access pharmaceuticals, 
and that variation in coverage decisions are then linked to variation in patient access to 
pharmaceuticals.  Proponents of equitable access to pharmaceuticals have argued in the 
literature, the media and through patient and physician lobby groups, that variation in 
access to pharmaceuticals is unacceptable for patients:  
 “…differences in access to new innovative oncology drugs 
cannot persist: cancer patients in Europe will not accept that a 
standard of care available in one European country is not 
available in other countries” (Wilking and Jonsson 2005 p. 94) 
 
This quotation highlights the importance given to consistency of access to 
pharmaceuticals as a key concern for patients in Europe.  From this perspective, the 
notion of one HTA body recommending and another HTA body not recommending the 
same technology for use is incongruent with the belief that patients living with the same 
condition in different European Member States should have the possibility to access the 
same pharmaceuticals.   Research findings within this thesis confirm that HTA bodies 
diverge significantly in the coverage decisions made for the same set of technologies.  
Such differences between HTA bodies were observed while adjusting for a range of 
clinical, disease, economic, process and socio-economic factors within a sample of 
technologies that was common to all four bodies.  
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While the decisions of HTA bodies may impact differently, some more favourably than 
others, on the possibility of patients accessing pharmaceuticals, there is also evidence to 
suggest that HTA bodies are sensitive to the issue of patient access, perhaps contrary to 
some media reports.  Descriptive and multivariate analyses found that orphan 
technologies were more likely to be in the recommended group rather than the restricted 
or not recommended group by NICE, HAS and CVZ.  Treatment of severe diseases, in 
particular cancer, were found to be more likely to increase the probability of 
recommendation rather than non recommendation in NICE, CVZ and HAS decision-
making.  This increase in probability of recommendation was observed across the 
pooled sample of technologies and despite the fact that both orphan-designated 
technologies and cancer therapies tended to have a weaker evidence base and less 
certainty around the cost-effectiveness profile.  It is noteworthy, however, that the 
impact of orphan status or cancer therapy was not observed within the SMC sample.  In 
contrast to the other three HTA bodies, the odds of recommendation tended to decrease 
for technologies without any alternative available within NHS Scotland, of which 40% 
were orphan designated technologies.   
 
It is also important to recognise that HTA bodies are not the sole determinants of access 
to pharmaceuticals in Europe.  Affordability at the level of the provider is an important 
factor in determining patient access to pharmaceuticals.  The decentralisation of 
healthcare systems in many European countries has meant that affordability decisions 
are increasingly made at regional and local levels.  The process of decentralisation has 
taken on multiple forms across Europe from the devolution of decision-making powers 
to privatization, driven by healthcare systems’ specific needs and structures (Saltman et 
al. 2007).  Such variation in the definitions and concepts of decentralisation, and 
variation in implementation, impact on local decision-making, and lead to diversity in 
the funding and availability of technologies (Delamothe 2008).  A specific example 
related to the implementation of NICE schizophrenia guidance suggests that 
implementation is variable between Primary Health Trusts (PCTs) in England (Mears et 
al. 2008), which the authors attribute to differences in commitment and the leadership of 
executive staff within these Trusts.  McGuire and Litt (2003) highlight that in addition 
to the aggregate health-care budget available to the healthcare system, local incentives 
play an important part in the degree to which efficient allocation of health-care budget is 
achieved.  A review of expenditure on cancer treatment by cancer patients across PCTs 
shows large variation between regions (£17,028 in Nottingham City Primary Care Trust 
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to £5,182 in Oxfordshire PCT) (Gubb 2008).  Budget constraints at local level mean 
that trade-offs need to be made by local-decision bodies on which technologies to fund 
(Leatherman and Sutherland 2008).  A recent analysis of variation in access to 
healthcare in England highlights that there are multiple supply- and demand-side factors 
that can impact on the degree of variation in access to healthcare (Appleby et al. 2011).  
Variation in demand for healthcare is driven by variation in a number of factors 
including commissioning priorities, morbidity, patient choices, GP decisions (Appleby 
et al. 2011).   Variation in the supply of healthcare can also lead to variation in access to 
healthcare: such variation in supply can arise from government policy, availability of 
resources, service configuration, and clinical decisions (Appleby et al. 2011).   
 
Thus, while there may be national HTA guidance on the use of a technology, the same 
technology may not be incorporated into all formularies across the country.  This 
highlights the usefulness of distinguishing between access as the availability of a 
specific treatment versus defining access as actual equality in utilisation.  Certainly, 
HTA decisions that do not recommend a technology for public funding will limit the 
availability of that technology, which is perhaps why negative recommendations receive 
significant attention.  However, it is important to note that positive HTA 
recommendations may not necessarily translate into patient access.  While a positive 
recommendation makes a particular technology formally available to the healthcare 
system, the autonomy of member state healthcare systems, decentralisation, local 
affordability, and professional support for guidance play an important role in 
determining patient access.  Figure 9.1 outlines the various forces that influence patient 
access to pharmaceuticals (Eichler et al. 2010).   Therefore, the findings of this research, 
and the role of HTA within the wider debate on patient access to pharmaceuticals, need 
to be considered in the light of the broader healthcare systems and the public funding 
processes.     
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Figure 9.1  Decision makers on the road to market access 
 Source: Eichler et al. 2010 p.278  
 
9.5.2 Implications for the pharmaceutical sector: reward for innovation?  
“Pharmaceutical innovation requires novelty of effectiveness.  
Pharmaceutical innovations create value to society by making it 
possible to generate improvements in patient health (net of 
treatment risks) that were previously unattainable” (Morgan et al. 
2008 p.4) 
 
In the literature on innovation in pharmaceutical care, and as highlighted in the quote 
above, innovation is linked to the fulfilment of an unmet medical need.  The degree of 
innovation can be defined according to the degree to which it improves health outcomes 
or meets significant unmet clinical needs (Morgan et al. 2008; Sermet 2007; 
Achilladelis and Antonakis 2001; De Cock 2010).  The larger the medical need that is 
fulfilled, the larger the innovation (Morgan et al. 2008).  Innovation is recognised as a 
cyclical process, through which future innovations are dependent on current innovations 
gaining access to healthcare systems, and ultimately to patients, thus providing 
pharmaceutical companies with revenue to invest in future innovations (Attridge 2006).  
Innovation can be seen to benefit not only the pharmaceutical industry, but ultimately 
also patients, healthcare systems, and generics manufacturers (Teece 1987, in Attridge 
2006).   
 
The degree to which the HTA bodies examined in this thesis reward innovation can be 
observed by considering the coverage decisions made for orphan-designated 
technologies and/or technologies for diseases for which there is no alternative therapy.  
Based on the definitions of innovation presented above, such technologies would 
represent significant innovation either by providing treatment for conditions that were 
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previously not treated, or for providing treatments that impact on health outcomes for 
patients with severe and rare diseases.  In this regard, the first finding of this research is 
that orphan designation and technologies for which there is no alternative tend to 
increase the likelihood of coverage by NICE, CVZ and HAS.  Technologies with a lack 
of alternative or orphan designation were more frequently found in the recommended or 
restricted groups.  However, this was not observed within the SMC sample.  The results 
of the analyses performed on SMC coverage decisions suggest that for technologies 
developed for disease areas which are rare and/or for which no specific treatment is 
available in the healthcare system prior to the technology under assessment, a higher 
proportion are not recommended for use in the Scottish NHS.  When the incremental 
cost-effectiveness ratio was examined for these particular technologies, it was clear that 
the mean ICER for those technologies without alternatives available in the NHS was 
almost three times higher than the ICERs for technologies with alternatives.  Similar 
results were observed in an analysis of SMC coverage of orphan-designated 
technologies (Vegter et al. 2010).  The analyses conducted in this thesis would suggest 
that introducing a newly licensed technology in an indication for which other 
technologies already exist would have a higher chance of recommendation than a new 
technology for which no alternatives exist.  Such technologies are generally referred to 
as ‘me-too’ technologies, and represent new technologies that belong to a class of 
technologies already available to the healthcare system for the same patient population.  
In the NICE, CVZ and HAS samples of coverage decisions, this trend was not observed.   
 
The changes currently proposed by the UK coalition government for NICE are in line 
with strengthening a signal to the pharmaceutical industry that innovative medicines 
will be rewarded.  It has set out plans to implement a Value-Based Pricing (VBP) 
system that will replace the current pricing and reimbursement system.  The VBP 
system aims to “…improve NHS patients’ access to effective and innovative drugs by 
ensuring they are available at a price that reflects the value they bring” (DH 2010 p. 6). 
This change is set to occur in 2014, and until then, technologies will be appraised via 
the current mechanisms.  The DH is currently reviewing the output of the consultation 
process which has recently closed, and therefore all available details of this new system 
are liable to change.   
 
Under the VBP system as currently outlined in the DH (2010) consultation document, 
the level of value of medicines will be defined through a variety of criteria.  Criteria that 
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will play a role in determining the value of a technology will include not only health-
related benefits but also societal benefits, and the degree to which the technology targets 
areas of significant unmet medical need. In addition, the new system aims to incentivize 
innovation within the pharmaceutical industry (DH 2010).   
 
The VBP system, as currently described, will impact directly on NICE.  Firstly, under 
this new system, the implementation of NICE guidance will no longer be enforced by 
law.  Affordability will be determined at the local level rather than by NICE at the 
national level.  Secondly, given the broader scope through which value will be assessed 
may lead to changes in the range of factors considered by NICE in its technology 
appraisals so as to “reflect all the components that contribute to a treatment’s full impact 
on health and quality of life” (DH 2010 p.10).  Thirdly, a key aspect driving current 
NICE decision-making - cost-effectiveness - is likely to evolve as a concept used within 
NICE decision-making and NHS pricing.  As currently set out in the consultation 
document, it is proposed that multiple cost-effectiveness thresholds would be made 
available within the VBP system to reflect the incremental value of the technology in 
terms of its innovation, its ability to address a high unmet need, and its ability to 
generate benefits to the wider society (DH 2010).  A base-case cost-effectiveness 
threshold would be defined, representing the maximum value that the NHS would pay 
for technologies that are associated with no incremental value.  The cost-effectiveness 
threshold would then be adjusted according to the degree to which the technology could 
provide incremental value in the various domains.   To some degree it can be argued 
that NICE is already applying differential cost-effectiveness thresholds:  a descriptive 
analysis of NICE decision-making found that while the ICER was an important factor in 
decision-making, exceptions were observed where technologies with above-threshold 
ICERs were recommended or vice-versa (see Chapter 4).   In addition, in 2009 NICE 
included in its methodology guidelines specific advice to the appraisal committee when 
appraising so called ‘end-of-life’ technologies that may be life-extending (NICE 2009).  
Under the VBP system however, the presence and use of these proposed thresholds may 
become more explicit.  Whether considering the future implications of the public 
funding of pharmaceuticals in the UK, or other European Member States, from a 
pharmaceutical manufacturer perspective, the implications of the research in this thesis 
suggest that coverage decisions can provide signals to the pharmaceutical industry that 
either stimulate or dampen innovation.   
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9.5.3 Implications for harmonizing the evidence needs of regulatory and 
reimbursement agencies 
Across the HTA bodies examined within this thesis, a significant proportion of coverage 
decisions in 2004-2009 did not recommend the use of particular technologies within 
their healthcare systems.   Non recommendation was observed in 14% and 16% of 
NICE and CVZ coverage decisions, and 44% and 46% of HAS3 and SMC coverage 
decisions, respectively.  These technologies were not recommended for reimbursement 
despite obtaining a license for use within Europe from regulatory agencies, primarily 
the European Medicines Agency (EMA).  This would suggest the presence of 
significant inconsistency between regulatory agencies such as the EMA and HTA 
bodies in the definition of value and the criteria used to determine the value of 
technologies.  It is well known that regulatory bodies and payers are driven by different 
roles and objectives.  On the one hand, regulatory bodies aim to examine the benefit-
risk profile of a technology to ensure that the benefits outweigh safety risks (Eichler et 
al. 2010).  On the other hand, payers, broadly speaking, assess whether a new 
technology represents value-for-money by considering the degree to which the 
technology provides incremental benefits over an existing therapy.  While a placebo-
controlled study may be suitable and efficient trial design for regulatory purposes, it is 
less able to provide evidence to facilitate comparison of new technologies with existing 
treatment options (Haynes 1999).  It also does not generate relevant information for 
physicians given that the choice made in clinical practice does not usually use of using a 
placebo.  In addition, regulatory trial design often relies on surrogate endpoints rather 
than ‘hard’ outcomes to demonstrate efficacy – while efficient from a development cost 
perspective and to illustrate efficacy, surrogate endpoints do not provide evidence of the 
effectiveness of the technology to achieve incremental medical benefit when measured 
using a hard endpoint or outcome.   
 
When the clinical, economic and disease characteristics of the technologies appraised by 
NICE, SMC, CVZ and HAS were examined, the descriptive and multivariate analyses 
suggested that, compared to recommended or restricted technologies, non recommended 
technologies tended to have a weaker evidence base, higher ICERs, and specific disease 
characteristics compared with recommended or restricted technologies.  Non 
recommended technologies also tended to be indicated for populations with higher 
                                                 
3 It should be noted that within the HAS analysis, technologies with an ASMR V were considered as not 
recommended for the purposes of the pooled analyses.   
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target population size and, in relation to this, higher estimated drug budget impact.  In 
terms of disease characteristics, non recommended technologies tended to be for 
diseases where alternatives where available, with the exception of the SMC where the 
opposite was observed.  In general, non recommended technologies tended to have a 
smaller evidence base (fewer trials, shorter duration, smaller sample size), were less 
likely to have an active comparator within their clinical trial programme and were also 
less likely to demonstrate superiority of efficacy within their trial.  The limitations of 
RCTs are encapsulated in an example provided by Herland et al. (2005) who examined 
the proportion of patients in a GP and specialist practice that match the selection criteria 
in an asthma-related clinical trial.  Of the total pool of GP and specialist practice asthma 
patients, less than 4% met the RCT inclusion criteria.  Such obstacles have led 
researchers to conduct observational studies to supplement RCT analyses.  For example, 
Cazzola et al. (2010) identified the need to assess the effectiveness of an asthma therapy 
(omalizumab) in a real-life clinical practice setting due to the fact that the clinical trial 
data included patients that did not represent the majority of patients in their clinical 
practice, and secondly the trial data did not provide sufficient information to be able to 
identify those patients that would be most likely to benefit from the treatment.   In this 
thesis, as part of the analysis of evidence considered by HTA bodies in their appraisal 
process, information was gathered on the use of observational data, defined as non-
randomised non-interventional study designs.  Across the four HTA bodies, the use of 
such evidence was very rare (less than 5% of coverage decisions).  This may be 
primarily due to the fact that in most cases the technology is appraised upon entry to the 
healthcare system, and as such has not yet had sufficient time to collect real-life clinical 
data on its use and effectiveness.  These findings suggest that the evidence needed to 
obtain regulatory approval and the evidence needed to obtain HTA recommendation 
may not be fully aligned.   
 
9.5.4  Implications for a harmonised European HTA system 
The European Network for Health Technology Assessment (EUnetHTA) was created to 
increase European-wide co-operation between HTA agencies, with the objectives of 
increasing efficiency in the implementation of HTA (Kristensen et al. 2009).  One of the 
chosen means for supporting an increased efficiency in cooperation between HTA 
bodies has been through the development of tools to support health technology 
assessments in Europe (Kristensen et al. 2009).  The “Joint Action on HTA” programme 
launched in 2010 by the European Commission and implemented by EUnetHTA, aims 
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to focus, as a first step, on standardising the methodologies used by HTA agencies in 
Europe.   A pilot project examining harmonisation of HTA for orphan designated 
technologies is currently underway.  In addition, the European Parliament (2011) 
recently voted in favour of the EU Cross-border Healthcare Directive.  This Directive, 
once implemented, will provide a legal basis for an improved exchange of HTA-related 
information between member states.  This legal basis is encapsulated in Article 14 
which states that: 
“The Union shall support and facilitate cooperation and the 
exchange of scientific information among Member States within 
a voluntary network connecting national authorities or bodies 
responsible for health technology assessment designated by the 
Member States” (European Parliament 2011 p.47) 
  
Article 14 states that the cooperation aims to support EU countries with “objective, 
reliable, timely, transparent, comparable and transferable” evidence regarding both 
efficacy and potentially effective health technologies, and to improve efficiency of HTA 
by reducing duplication of efforts (European Parliament 2011 p. 47).   
 
Having examined four key HTA bodies within Europe, it is relevant to consider the 
implications of this research for the strengthening of a European HTA network.  An 
interesting finding is that the number of technologies appraised by all four HTA bodies 
for the same indication within the same year is limited to 7 out of 348 technologies, and 
26 out of 348 technologies when the time window is expanded to 5 years.  Thus, the 
actual proportion of technologies that are appraised by all four HTA bodies is limited.  
These results would suggest that, in addition to harmonising the assessment of specific 
aspects of the HTA process, there would be a need to harmonise the technologies 
selected.  Otherwise, the usefulness of adapting one appraisal from another would be 
severely limited by the difference in timing of availability of such appraisals, and the 
risk of information being out-dated across adaptations.   The analyses of HTA bodies 
conducted within this thesis imply that the nature of EU-wide HTA reports would need 
to be carefully considered and planned to contribute to national HTA initiatives, given 
differences in the timing and scoping considered as part of the assessment. 
 
9.6 Recommendations for future research 
This thesis has argued that within the four European HTA bodies examined, coverage 
decision-making is a complex process influenced by clinical and economic evidence, 
process factors and socio-economic context factors.   One important area for further 
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research would be to investigate, in more detail, a method for standardising coverage 
decisions made by HTA bodies in Europe, so as to further improve the platform for 
evaluation of such decisions across European HTA bodies.  O’Neill and Devlin (2010) 
proposed a methodology to standardise coverage decisions by calculating ‘M’ – the 
proportion of patients covered by public funding relative to the total eligible population.  
One of the key limitations recognised by O’Neill and Devlin (2010) is access to the data 
needed to calculate ‘M’.  Data collection relevant to ‘M’ and the application of ‘M’ to 
additional HTA bodies in Europe may represent a fruitful avenue for further research.   
 
Furthermore, exploring to what degree, and through what mechanisms, coverage 
decisions by one HTA body can impact on another such body represents another 
potentially fruitful area for further research.  Such research could be of particular 
relevance to improve the understanding of the factors that can help explain coverage 
decision-making across HTA bodies. By exploring the degree and mechanisms (whether 
formal or informal) through which HTA bodies influence one another other, it would be 
possible to provide an additional perspective on how European HTA bodies interact and 
the factors driving their decisions.   
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A. Chapter 4 Appendices 
NICE coverage decisions 2004-2009: List of Technology Appraisals included for 
analysis 
Technology Appraised Ref Year Guidance was issued 
Pegylated interferon (in ribavirin combination 
therapy) or as monotherapy 
TA75 2004 
gabapentin TA76 2004 
zaleplon TA77 2004 
clopidogrel TA80 2004 
pimecrolimus TA82 2004 
Drotrecogin alfa  TA84 2004 
Basiliximab TA85 2004 
imatinib TA86 2004 
clopidogrel TA90 2005 
paclitaxel TA91 2005 
irinotecan TA93 2005 
atorvastatin TA94 2006 
adefovir dipivoxil TA96 2006 
capecitabine TA100 2006 
docetaxel TA101 2006 
efalizumab TA103 2006 
etanercept TA104 2006 
peginterferon alfa-2a TA106 2006 
trastuzumab TA107 2006 
paclitaxel TA108 2006 
docetaxel TA109 2006 
rituximab TA110 2006 
donepezil TA111 2007 
anastrozole TA112 2006 
buprenorphine TA114 2007 
naltrexone TA115 2007 
gemcitabine TA116 2007 
cinacalcet TA117 2007 
bevacizumab TA118 2007 
fludarabine TA119 2007 
alteplase TA122 2007 
varenicline TA123 2007 
pemetrexed TA124 2007 
adalimumab TA125 2007 
rituximab TA126 2007 
natalizumab TA127 2007 
bortezomib TA129 2007 
adalimumab TA130 2007 
ezetimibe TA132 2007 
omalizumab TA133 2007 
infliximab TA134 2008 
pemetrexed TA135 2008 
rituximab TA137 2008 
infliximab TA140 2008 
abatacept TA141 2008 
Darbepoetin alfa TA142 2008 
adalimumab TA143 2008 
cetuximab TA145 2008 
adalimumab TA146 2008 
entecavir TA153 2008 
telbivudine TA154 2008 
pegaptanib TA155 2008 
dabigatran TA157 2008 
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amantandine TA158 2008 
alendronate TA160 2008 
alendronate TA161 2008 
erlotinib TA162 2008 
infliximab TA163 2008 
febuxostat TA164 2008 
amantandine TA168 2009 
sunitinib TA169 2009 
rivaroxaban TA170 2009 
lenalidomide TA171 2009 
cetuximab TA172 2009 
 
   
 319
 
NICE Data-set: Missing Data 
 
Between January 2004-June 2009, the National Institute for Health and Clinical 
Excellence (NICE) made 118 funding decisions – either recommending, restricting or 
not recommending use of NHS resources to fund new health technologies (in this 
research analysis, the health technologies are restricted to pharmaceutical products).  
 
A data set of information pertaining to NICE appraisals was created collecting 
information on variables relating to (i) the clinical and economic characteristics of the 
technology under appraisal, as well as information on (ii) the process used to come to a 
decision, and (iii) the socio-economic context in which these decisions were made. 
 
In order to prepare the data set for analysis, understanding the data set is important.  
Here, the aim is to characterise the presence of missing data across variables and 
decisions to inform the need for imputing missing data.   
 
Distribution of Missing Data within NICE data set 
In the total NICE sample, there is about 8% of entries were incomplete.  The 
distribution of missing data across each variable was examined.   The total number of 
observations per variable is 118.  The variables with the highest number of ‘not 
reported’ information are those related to the economic characteristics of the 
technology.  11 variables have no missing data.   The extent of missing data was also 
examined across appraisals.  These appraisals span almost 5 years of decision making.  
The range of variables where information was missing ranged from 0-9.  The mean 
number of variables where information was missing was 3. 
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Figure A.1 NICE Distribution of missing data by variable (n=118) 
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NICE Dataset – Testing of Normality Assumption 
 
Method 
To determine the relevant statistical tests to use in assessing the significance of 
differences observed between means, it was necessary to assess whether the normality 
assumption was valid for the variables under consideration.  This would then determine 
the use of parametric or non-parametric tests.  For all variables, the sample is >30.  It 
has been suggested    that when analysing sample sizes of >30, even when the normality 
assumption is violated, parametric tests may still be performed (Pallant 2007, SPSS 
Survival Manual, 3rd edn, Maidenhead, OUP/McGraw-Hill).  Prior to making a decision 
on which variables to apply parametric or non-parametric tests, the distribution for each 
variable will be further examined.   
 
To test the normality assumption the following was performed for each non-categorical 
variable: 
• Skeweness was calculated 
• Kurtosis was calculated 
• The standardized normal probability plot (P-P plot) was graphed 
The graph and calculations are presented for each non-categorical variable and an 
assessment is made of whether the normality assumption is met or not.  A variable will 
be considered to meet the normal distribution assumption if  
• skewness is within the range ±1 
• Kurtosis value is within range ±3 
• P-P plot shows distribution of dataset is approximately linear 
 
In those circumstances where there is inconsistency between the three tests, if 2 of the 
tests suggest normal distribution, then it will be considered as such (but then tested 
using both parametric and non-parametric tests in sensitivity analyses).  
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Number of RCTs considered in appraisal (No_RCT) 
 
• Skewness 4.402407 
• Kurtosis     30.86422 
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This variable is not normally distributed.  
Mean sample size of RCTs considered in appraisal (RCTsize) 
• Skewness       4.995812 
• Kurtosis       33.70005 
 
This variable is not normally distributed.  
Superiority demonstrated 
Normality test not performed as this is a categorical variable.  
Duration of RCT (RCTfwup) 
• Skewness       1.151972 
• Kurtosis       3.870274 
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This variable is not normally distributed. 
 Active-Comp 
• Skewness       .1479741 
• Kurtosis       1.216005 
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This variable is normally distributed.  
Observational Studies 
• Skewness  8.428139 
• Kurtosis       80.60793 
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This variable is not normally distributed.  
 
CUA performed 
Normality test not performed as this is a categorical variable.  
ICER 
• Skewness       6.973113 
• Kurtosis       59.67012 
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This variable is not normally distributed.  
ICER SA – Probabilistic 
• Skewness       .3108645 
• Kurtosis        1.50603 
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This variable is normally distributed.  
ICER SA – Univariate Low 
• Skewness       6.018749 
• Kurtosis       41.22995 
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This variable is not normally distributed.  
 
ICER SA – Univariate high 
• Skewness       4.760234 
• Kurtosis        28.4462 
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Multiple Models submitted 
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Normality test not performed as this is a categorical variable.  
Multiple Models: Range of ICERs - LOW 
• Skewness       1.325258 
• Kurtosis       4.990431 
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This variable could be considered to approximate to a normal distribution. 
 
Multiple Models: Range of ICERs – HIGH 
• Skewness       4.245608 
• Kurtosis       24.62567 
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This variable is not normally distributed.  
Non_CUA submitted 
Normality test not performed as this is a categorical variable.  
BIM 
• Skewness   3.788561 
• Kurtosis       15.36788 
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This variable is not normally distributed.  
Prevalence 
• Skewness       2.785481 
• Kurtosis       9.566752 
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This variable is not normally distributed.  
 
Societal 
Normality test not performed as this is a categorical variable.  
Alternative Available 
Normality test not performed as this is a categorical variable.  
Group_Size 
• Skewness       1.122694 
• Kurtosis       3.750685 
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This variable could be considered to approximate to a normal distribution. 
Ethics 
Normality test not performed as this is a categorical variable.  
Cost-Effectiveness part of Process 
Normality test not performed as this is a categorical variable.  
BIM part of Process 
Normality test not performed as this is a categorical variable.  
Joint reimbursement & pricing decision 
Normality test not performed as this is a categorical variable.  
MTA vs STA 
Normality test not performed as this is a categorical variable.  
No of Drugs appraised 
• Skewness       .7873726 
• Kurtosis       2.516377 
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Perhaps this is actually a categorical variable? 
Accountability for drug budget 
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Normality test not performed as this is a categorical variable.  
Independence of HTA agency from MoH 
Normality test not performed as this is a categorical variable.  
Year of appraisal 
Skewness -.3891203 
Kurtosis       1.978506 
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Perhaps this is actually a categorical variable? 
Population under HTA remit 
Skewness       -.327666 
Kurtosis       1.985149 
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Perhaps this is actually a categorical variable? 
 
% of GDP expenditure on health 
• Skewness      -1.063346 
• Kurtosis        2.47445 
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Perhaps this is actually a categorical variable? 
Drug expenditure per person 
Skewness      -.8687147 
Kurtosis       2.346379 
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Funding mechanism – centralised or decentralised 
Normality test not performed as this is a categorical variable.  
Election year 
Normality test not performed as this is a categorical variable.  
Priority Disease Area 
Normality test not performed as this is a categorical variable.  
BNF Category 
Normality test not performed as this is a categorical variable. 
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NICE dataset: descriptive statistics 
  Chi2 ANOVA T-Test (Rec vs 
Res) 
T-Test (Res vs 
NR) 
Kruskal-Wallis 
Number of RCTs 
considered in decision 
  0.2152 0.7448 0.0002 0.021 
Size of population 
included in RCTs 
  0.0221 0.2017 0.8035 0.0504 
Statistically Significant 
results -                           
yes 
0.013         
no 0.143         
inconsistent 0.207         
Length/extent of follow-
up in RCT 
  0.3069 0.0411 0.3734 0.2129 
Relevance of RCT to 
payor decision 
  0.7077 0.015 0.7454 0.0544 
Number of 
observational studies 
considered in guidance 
  0.2569 0.2247 0.0032 0.1361 
Consideration of Cost 
Utility Analysis in 
guidance 
0.187         
Incremental Cost-
effectiveness ratio of 
technology vs. 
comparator in base case 
  - 0.054 0.1158 0.0001 
More than one CUA 
submitted 
0.716         
If More than one CUA 
submitted - low range 
  0.0024 0.0448 0.1697 0.0229 
If More than one CUA 
submitted - high range 
  - 0.3745 0.1332 0.0002 
Uncertainty around base 
case ICER reported in 
submission (univariate)  
Low 
  0.033 0.044 0.000 0.001 
Uncertainty around base 
case ICER reported in 
submission (univariate) 
High 
  - 0.1271 0.2866 0.0496 
Uncertainty around the 
base case ICER reported 
in submission 
(probabilistic) 
  - 0.3215 0.0893 0.0002 
Non-CUA analyses 
submitted 
0.056         
Anticipated budgetary 
impact of introduction 
of new technology in 
health care system 
  0.0772 0.046 0.4718 0.4057 
Prevalence of 
disease/clinical 
condition 
  0.0027 0.0026 0.4413 0.183 
Societal Perspective 
adopted 
0.77         
Availability of 
alternative therapies in 
current treatment 
setting. 
0.935         
Inclusion of patient 
submission 
0.431         
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Number of Decision 
Makers Accountable 
  0.5187 0.1522 0.2735 0.4027 
Cost-effectiveness 
evaluation component in 
process 
 -  -  -  -  - 
Budget impact as a 
component of decision-
making process 
 -  -  -  -  - 
Price of technology 
known during appraisal 
 -  -  -  -  - 
Use of STA process 0.031         
Number of drugs 
appraised in same 
appraisal 
  0.7214 0.0001 0.0015 0.0006 
Accountability of drug 
budget 
 -  -  -  -  - 
Independence of 
decision-making agency 
 -  -  -  -  - 
Date guidance was 
issued 
  0.0166 0.4447 0.0714 0.0501 
Population size – 
Agency coverage 
  0.0166 0.4191 0.0714 0.0501 
GDP-healthcare 
expenditure 
  0.0166 0.2573 0.1702 0.2022 
Healthcare expenditure 
on pharmaceuticals 
  0.0166 0.4573 0.0605 0.0247 
Election year at time of 
decision 
0.971         
Priority disease area 0.702         
Orphan Designated 0.77         
cardiovascular system 0.322         
central nervous system 0.067         
ear, nose and 
oropharynx 
n/a         
endocrine system 0.699         
eye 0.185         
gastro-intestinal system 0.306         
infections 0.183         
malignant disease and 
immunosuppression 
0.122         
musculoskeletal and 
joint diseases 
0.754         
nutrition and blood 0.335         
obstetrics, gynaecology, 
and urinary-tract 
disorders 
n/a         
respiratory system 0.699         
skin 0.84         
 
 
 
NICE dataset:  preliminary multivariate model  
The pseudo R-squared for this model was 0.5528, which suggests that it explains 55% 
of the variability observed in NICE coverage decisions.     
 
Multivariate analysis of NICE coverage decisions 2004-2009:  preliminary model (n=118) 
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Restricted Log Odds P value 95%  Conf. Interval 
Clinical superiority 
demonstrated in RCT 3.059583 0.207 -1.694669 7.813835 
Lack of clinical superiority in 
RCT 4.830348 0.065 -0.3064264 9.967122 
No clinical superiority 
demonstrated in RCT 4.781009 0.044 1.29E-01 9.432898 
Number of RCTs -0.0642417 0.183 -0.1587155 0.030232 
RCT duration of follow-up -0.0002126 0.976 -0.0140222 0.013597 
Use of active comparator in 
RCT -0.9846096 0.270 -2.732692 0.7634723 
ICER 0.0000335 0.246 -0.0000231 0.0000901 
Uncertainty range around the 
ICER -0.00000423 0.083 -9.02E-06 0.000000555 
Probability of ICER < 30,000£  -1.630215 0.328 -4.897945 1.637514 
Use of non cost-utility analysis 0.9884623 0.350 -1.083165 3.06009 
Budget impact of new 
technology -0.0000693 0.902 -0.0011751 0.0010365 
Disease prevalence 0.000000153 0.386 -0.000000193 0.000000498 
Use of MTA process vs. STA 
process -0.4195647 0.689 -2.47E+00 1.633965 
Number of technologies 
appraised simultaneously 0.25413 0.355 -0.2848913 0.7931513 
Year of Appraisal 0.8785522 0.033 0.0703909 1.686714 
Technology indicated for cancer 
treatment -0.491717 0.644 -2.578527 1.595093 
No information on ICER 23.35165 0.000 17.92525 28.77805 
No information on uncertainty 
around ICER -0.1537224 0.852 -1.76E+00 1.456904 
No information on probabilistic 
sensitivity analysis around ICER 1.639982 0.049 0.0040381 3.275925 
Constant -1766.018 0.033 -3386.276 -145.7601 
Not Recommended Log Odds P value 95%  Conf. Interval 
Clinical superiority 
demonstrated in RCT -6.392912 0.153 -15.15638 2.37056 
Lack of clinical superiority in 
RCT -3.462322 0.459 -12.61755 5.692911 
No clinical superiority 
demonstrated in RCT 0.4864004 0.859 -4.89E+00 5.866077 
Number of RCTs -0.156669 0.460 -0.5726012 0.2592633 
RCT duration of follow-up 0.0456999 0.082 -0.0058245 0.0972242 
Use of active comparator in 
RCT -0.883584 0.643 -4.618792 2.851624 
ICER 0.0002064 0.044 0.00000565 0.0004072 
Uncertainty range around the 
ICER 0.00000244 0.268 -1.88E-06 0.00000677 
Probability of ICER < 30,000£ -1.847847 0.555 -7.990323 4.29463 
Use of non cost-utility analysis -56.91792 . . . 
Budget impact of new 
technology 0.0000328 0.962 -0.0013099 0.0013755 
Disease prevalence 0.00000032 0.362 -0.000000368 0.00000101 
Use of MTA process versus 
STA process 0.4392 0.833 -3.64E+00 4.521612 
Number of technologies 
appraised simultaneously -1.471622 0.096 -3.203731 0.2604862 
Year of Appraisal 0.9634825 0.174 -0.4260984 2.353063 
Technology indicated for cancer 
treatment -3.519016 0.165 -8.489831 1.451799 
No information on ICER 28.69518 . . . 
No information on uncertainty 
around ICER 1.780973 0.511 -3.532484 7.094431 
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No information on probabilistic 
sensitivity analysis around ICER 2.496638 0.173 -1.09E+00 6.083571 
Constant -1939.318 0.173 -4728.422 849.7874 
Note:  Recommended technologies are the reference case 
Sensitivity Analysis 
In a third sensitivity analysis, a categorical ICER variable was used as opposed to a 
continuous ICER variable used in the base case analysis.   This binary variable was 
created by distinguishing between those ICERs above £30,000 and those technologies 
with ICERs below or equal to £30,000. This model yielded a similar pseudo R-squared 
to the base case model (0.2867 for the sensitivity analysis model and 0.2642 for the base 
case) (Table 4.8).  In this analysis, being cost-effective (i.e. with ICER of less than 
£30,000), statistically significantly decreased the log odds of a restriction or a non 
recommendation.  When technologies were associated with ICERs that were above 
£30,000, this decreased the odds of a recommendation relative to a restriction (p=0.002) 
and relative to a non-recommendation (p<0.0001).   The direction of the effect and 
statistical significance of the remaining three variables was similar between this 
sensitivity analysis and the base case analysis.  This suggests that inclusion of the 
dominant/dominated technologies is important for fully capturing the impact of cost-
effectiveness on NICE decision-making.     
 
Table 4.1  Sensitivity Analysis 3.  Multivariate analysis of NICE coverage decisions 2004-2009:  alternative 
model using a categorical ICER variable (n=118) 
Restricted Log Odds P value 95%  Confindence Interval 
Clinical superiority demonstrated in RCT -1.611471 0.006 -2.766507 -0.4564342 
ICER below 30,000  -2.064262 0.002 -3.39123 -0.7372939 
Number of technologies appraised 
simultaneously 0.6299023 0.001 2.62E-01 0.9977285 
Year of Appraisal 0.5572081 0.010 0.1339199 0.9804963 
Constant -1116.647 0.010 -1965.812 -267.482 
Not Recommended Log Odds P value 95%  Confidence Interval 
Clinical superiority demonstrated in RCT -2.285657 0.009 -3.993731 -0.577583 
ICER below 30,000  -4.440024 0.000 -6.392607 -2.487441 
Number of technologies appraised 
simultaneously 0.3353649 0.231 -2.13E-01 0.8836412 
Year of Appraisal 1.026511 0.001 0.4016877 1.651335 
Constant -2058.042 0.001 -3311.775 -804.3086 
  Note:  Recommended technologies are the reference case 
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B. Chapter 5 Appendices 
 
SMC coverage decisions 2004-2009: List of Technology Appraisals included for 
analysis 
Technology Appraised SMC ID Year of 
appraisal 
adalimumab 218/05 2005 
anagrelide 163/05 2005 
Candesartan cilexetil 161/05 2005 
capecitabine 193/05 2005 
Carmustine 215/05 2005 
docetaxel 201/05 2005 
Eplerenone 136/04 2005 
Fosamprenavir 188/05 2005 
Mycophenolate 144/04 2005 
Oxaliplatin 211/05 2005 
Palonosetron 208/05 2005 
Pegylated interferon alfa 2a 186/05 2005 
TachoSil 168/05 2005 
adefovir 54/03 2005 
anastrozole 198/05 2005 
atomoxetine 153/05 2005 
bivalirudin 156/05 2005 
calcipotriol 09/02 2005 
caspofungin 147/04 2005 
Ciclesonide 184/05 2005 
duloxetine 195/05 2005 
Eflornithine 159/05 2005 
Etanercept 212/05 2005 
Exemestane 210/05 2005 
Iloprost 219/05 2005 
imiquimod 167/05 2005 
infliximab 101/04 2005 
letrozole 152/05 2005 
Montelukast 185/05 2005 
Oxybutynin 190/05 2005 
Oxycodone 197/05 2005 
pemetrexed 192/05 2005 
pioglitazone 115/04 2005 
pregabalin 145/04 2005 
Strontium 178/05 2005 
Valsartan 162/05 2005 
Vinorelbine 179/05 2005 
Voriconazole 194/05 2005 
Zonisamide 216/05 2005 
anagrelide 163/05 2005 
bemiparin 204/05 2005 
bemiparin 205/05 2005 
bemiparin 206/05 2005 
bemiparin 203/05 2005 
cetuximab 155/05 2005 
Cilostazol 86/04 2005 
Cinacalcet 169/05 2005 
diclofenac 199/05 2005 
docetaxel 209/05 2005 
Eflornithine 159/05 2005 
Erlotinib 220/05 2005 
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Gemcitabine/paclitaxel 154/05 2005 
glyceryl trinitrate 200/05 2005 
Ibritumomab 171/05 2005 
liposomal cytarabine 164/05 2005 
Metformin 148/04 2005 
Modafinil 183/05 2005 
Modafinil 63/03 2005 
Nicotonic acid 93/04 2005 
Pegvisomant 158/05 2005 
pregabalin 157/05 2005 
pregabalin 157/05 2005 
Solifenacin 129/04 2005 
Emtricitabine 105/04 2006 
entecavir 320/06 2006 
escitalopram 253/06 2006 
gemcitabine 154/05 2006 
Ibandronic acid 228/05 2006 
Olopatadine 59/03 2006 
posaconazole 256/06 2006 
pramipexole 247/06 2006 
zoledronic acid 317/06 2006 
adalimumab 300/06 2006 
anastrozole 322/06 2006 
carglumic 299/06 2006 
cetuximab 279/06 2006 
daptomycin 248/06 2006 
duloxetine 285/06 2006 
Erlotinib 220/05 2006 
fludarabine 176/05 2006 
Ibandronic acid 301/06 2006 
insulin glulisine 298/06 2006 
letrozole 251/06 2006 
Pegaptanib 290/06 2006 
rituximab 323/06 2006 
rituximab 330/06 2006 
ropinirole 165/05 2006 
Sildenafil 235/06 2006 
temozolomide 244/06 2006 
tigecycline 276/06 2006 
tigecycline 277/06 2006 
tipranavir 226/06 2006 
topiramate 297/06 2006 
Trastuzumab 278/06 2006 
aprepitant 242/06 2006 
bevacizumab 221/05 2006 
bevacizumab 221/05 2006 
bortezomib 302/06 2006 
buprenorphine 234/06 2006 
Cinacalcet 169/05 2006 
co-careldopa 316/06 2006 
esomeprazole 257/06 2006 
esomeprazole 274/06 2006 
Estradiol 230/05 2006 
estradiol/drospiren 227/05 2006 
fondaparinux 287/06 2006 
glyceryl trinitrate 200/05 2006 
Metformin 148/04 2006 
mitotane 328/06 2006 
Modafinil 63/03 2006 
natalizumab 329/06 2006 
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nebivolol 214/05 2006 
Nicotonic acid 93/04 2006 
omalizumab 259/06 2006 
paricalcitol 288/06 2006 
Pegvisomant 158/05 2006 
rasagiline 255/06 2006 
rasagiline 255/06 2006 
rasagiline 243/06 2006 
rasagiline 243/06 2006 
rotigotine 289/06 2006 
sodium oxybate 246/06 2006 
sorafenib 321/06 2006 
sunitinib 275/06 2006 
temozolomide 244/06 2006 
tipranavir 226/05 2006 
Tramadol 236/06 2006 
azelaic acid 359/07 2007 
budesonide/formoterol 362/07 2007 
busulfan 337/06 2007 
capecitabine 401/07 2007 
darunavir 378/07 2007 
esomeprazole 422/07 2007 
fondaparinux 420/07 2007 
nebivolol 214/05 2007 
pioglitazone 399/07 2007 
ranibizumab 381/07 2007 
rotigotine 289/06 2007 
TachoSil 344/07 2007 
varenicline 336/06 2007 
buprenorphine/naloxone 355/07 2007 
clopidogrel 390/07 2007 
darifenacin 377/07 2007 
dasatinib 370/07 2007 
deferasirox 347/07 2007 
dibotermin alfa 365/07 2007 
docetaxel 369/07 2007 
ertapenem 404/07 2007 
ertapenem 335/06 2007 
exenatide 376/07 2007 
infliximab 318/06 2007 
ivabradine 319/06 2007 
lanthanum 286/06 2007 
natalizumab 329/06 2007 
omalizumab 259/06 2007 
parathyroid 356/07 2007 
pioglitazone 354/07 2007 
posaconazole 379/07 2007 
rotigotine 392/07 2007 
sitagliptin 408/07 2007 
sitaxentan sodium 360/07 2007 
tacrolimus 346/07 2007 
topotecan 421/07 2007 
abatacept 400/07 2007 
adalimumab 417/07 2007 
alglucosidase alfa 352/07 2007 
beclometasone 166/05 2007 
betaine anhydrous 407/07 2007 
bortezomib 302/06 2007 
buprenorphine 234/06 2007 
clostridium botulinum 353/07 2007 
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dasatinib 371/07 2007 
dexrazoxane 361/07 2007 
erdosteine 415/07 2007 
escitalopram 406/07 2007 
glyceryl trinitrate 200/05 2007 
Ibritumomab 171/05 2007 
idursulfase 391/07 2007 
imiquimod 385/07 2007 
infliximab 363/07 2007 
infliximab 364/07 2007 
Interferon beta-1b 345/07 2007 
levetiracetam 395/07 2007 
levetiracetam 396/07 2007 
levetiracetam 397/07 2007 
lidocaine 334/06 2007 
liposomal cytarabine 164/05 2007 
omalizumab 259/06 2007 
pemetrexed 342/07 2007 
pregabalin 389/07 2007 
rufinamide 416/07 2007 
sevelamer 423/07 2007 
sodium oxybate 246/06 2007 
standardised allergen extract of grass pollen 367/07 2007 
sunitinib 343/07 2007 
sunitinib 384/07 2007 
testosterone 398/07 2007 
topotecan 366/07 2007 
ziconotide 405/07 2007 
atazanavir 520/08 2008 
botulinum 464/08 2008 
capecitabine 507/08 2008 
clobetasol 434/07 2008 
dabigatran 466/08 2008 
epoetin zeta 467/08 2008 
fondaparinux 439/08 2008 
levetiracetam 396/07 2008 
levetiracetam 395/07 2008 
Methoxy polyethylene glycol-epoetin beta 455/08 2008 
pegylated interferon alfa 2b plus ribavirin 488/08 2008 
rivaroxaban 519/08 2008 
sitagliptin 505/08 2008 
telbivudine 438/08 2008 
tenofovir 479/08 2008 
adalimumab 468/08 2008 
alemtuzumab 494/08 2008 
ambrisentan 511/08 2008 
anidulafungin 465/08 2008 
bivalirudin 516/08 2008 
daptomycin 449/08 2008 
diclofenac 446/08 2008 
docetaxel 481/08 2008 
fesoterodine 480/08 2008 
fosaprepitant 506/08 2008 
imiquimod 385/07 2008 
levetiracetam 397/07 2008 
lidocaine 334/06 2008 
methylnaltrexone bromide 518/08 2008 
micafungin 497/08 2008 
nelarabine 454/08 2008 
nilotinib 440/08 2008 
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pemetrexed 342/07 2008 
raltegravir 461/08 2008 
rituximab 493/08 2008 
rufinamide 416/07 2008 
vildagliptin 435/07 2008 
zoledronic acid 447/08 2008 
anidulafungin 465/08 2008 
aripiprazole 498/08 2008 
bevacizumab 469/08 2008 
buprenorphine 234/06 2008 
dexrazoxane 361/07 2008 
ferric carboxymaltose 463/08 2008 
glucosamine 471/08 2008 
glyceryl trinitrate 200/05 2008 
icatibant 476/08 2008 
lenalidomide 441/08 2008 
maraviroc 458/08 2008 
maraviroc 458/08 2008 
miconazole 517/08 2008 
paliperidone 453/08 2008 
paricalcitol 288/06 2008 
paricalcitol 478/08 2008 
pegylated liposomal doxorubicin 503/08 2008 
pemetrexed 342/07 2008 
Rabbit anti-human thymocyte immunoglobulin 489/08 2008 
salmeterol 450/08 2008 
sorafenib 482/08 2008 
standardised allergen extract of grass pollen 367/07 2008 
teriparatide 490/08 2008 
trabectedin 452/08 2008 
alitretinion 538/09 2009 
fluticasone furoate 544/09 2009 
testosterone undecanoate 308/06 2009 
thalidomide 525/08 2009 
doripenem 529/09 2009 
doripenem 539/09 2009 
fentanyl 510/08 2009 
lacosamide 532/09 2009 
pregabalin 157/05 2009 
rituximab 540/09 2009 
sugammadex 527/09 2009 
topotecan 545/09 2009 
aliskiren 462/08 2009 
aripiprazole 498/09 2009 
betaine anhydrous 407/07 2009 
buprenorphine transdermal patch 234/06 2009 
cetuximab 543/09 2009 
etonogestrel/ethinyl 502/08 2009 
etravirine 530/09 2009 
extended-release epidural morphine sulfate 528/09 2009 
lapatinib 526/09 2009 
micronised progesterone 542/09 2009 
oxycodone/naloxone 541/09 2009 
pemetrexed 531/09 2009 
pemetrexed 531/09 2009 
salmeterol 450/08 2009 
stiripentol 524/08 2009 
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SMC Dataset: Missing Data 
 
Between January 2004-June 2009, the Scottish Medicines Consortium (SMC) reviewed 346 
full submissions/resubmissions and made 346 funding decisions – either recommending, 
restricting or not recommending use of NHS resources to fund new health technologies (in 
this research analysis, the health technologies are restricted to pharmaceutical products).  
 
A data set of information pertaining to SMC appraisals was created collecting information on 
variables relating to (i) the clinical and economic characteristics of the technology under 
appraisal, as well as information on (ii) the process used to come to a decision, and (iii) the 
socio-economic context in which these decisions were made. 
 
In order to prepare the data set for analysis, understanding the data set is important.  Here, the 
aim is to characterise the presence of missing data across variables and decisions to inform 
the need for imputing missing data.   
 
Distribution of Missing Data within SMC data set 
In the total SMC sample, there are 10% of incomplete entries.  The rate of missing entries 
appears similar between groups. The distribution of missing data across each variable was 
also examined.   The total number of observations per variable is 288.     The variables with 
the highest number of ‘not reported’ information are those related to the economic 
characteristics of the technology.  17 variables have no missing data.  The extent of missing 
data was also examined across appraisals.  The average number of ‘not reported’ entries per 
appraisal was 3 (range 0-10).   
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Figure B.1. SMC Distribution of missing data by variable (n=288) 
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SMC Dataset – Testing of Normality Assumption 
 
Method 
To determine the relevant statistical tests to use in assessing the significance of 
differences observed between means, it was necessary to assess whether the normality 
assumption was valid for the variables under consideration.  This would then determine 
the use of parametric or non-parametric tests.  For all variables, the sample is >30.  It 
has been suggested    that when analysing sample sizes of >30, even when the normality 
assumption is violated, parametric tests may still be performed (Pallant 2007, SPSS 
Survival Manual, 3rd edn, Maidenhead, OUP/McGraw-Hill).  Prior to making a decision 
on which variables to apply parametric or non-parametric tests, the distribution for each 
variable will be further examined.   
 
To test the normality assumption the following was performed for each non-categorical 
variable: 
• Skeweness was calculated 
• Kurtosis was calculated 
• The standardized normal probability plot (P-P plot) was graphed 
The graph and calculations are presented for each non-categorical variable and an 
assessment is made of whether the normality assumption is met or not.  A variable will 
be considered to meet the normal distribution assumption if  
• skewness is within the range ±1 
• Kurtosis value is within range ±3 
• P-P plot shows distribution of dataset is approximately linear 
 
In those circumstances where there is inconsistency between the three tests, if 2 of the 
tests suggest normal distribution, then it will be considered as such (but then tested 
using both parametric and non-parametric tests in sensitivity analyses).  
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Number of RCTs considered in appraisal (No_RCT) 
Skewness       4.288793 
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This variable is not normally distributed.  
 
Mean sample size of RCTs considered in appraisal (RCTsize) 
Skewness       6.446803 
Kurtosis       51.49548 
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This variable is not normally distributed.  
Superiority demonstrated 
Normality test not performed as this is a categorical variable.  
 
Duration of RCT (RCTfwup) 
Skewness       2.127236 
Kurtosis       7.575711 
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This variable is not normally distributed. 
 
 Active-Comp 
Skewness      -.0439793 
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This variable could be considered to approximate to a normal distribution. 
 
Observational Studies 
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This variable is not normally distributed.  
 
CUA performed 
Normality test not performed as this is a categorical variable.  
ICER 
Skewness       7.445825 
Kurtosis       64.31506 
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This variable is not normally distributed.  
 
ICER SA – Probabilistic 
Skewness      -1.123912 
Kurtosis       2.282117 
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This variable is normally distributed.  
ICER SA – Univariate Low 
Skewness       5.214576 
Kurtosis       31.50543 
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This variable is not normally distributed.  
 
ICER SA – Univariate high 
Skewness       4.881428 
Kurtosis       26.57847 
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This variable is not normally distributed.  
Multiple Models submitted 
Normality test not performed as this is a categorical variable.  
 
Multiple Models: Range of ICERs - LOW 
Skewness       .3476502 
Kurtosis            1.5 
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This variable is normally distributed.  
 
Multiple Models: Range of ICERs – HIGH 
Skewness       .3954293 
Kurtosis            1.5 
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This variable is normally distributed.  
 
Non_CUA submitted 
Normality test not performed as this is a categorical variable.  
 
BIM 
Skewness       4.359358 
Kurtosis       27.93584 
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This variable is not normally distributed.  
 
Prevalence 
Skewness       13.63806 
Kurtosis       198.9334 
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This variable is not normally distributed.  
 
 
Societal 
Normality test not performed as this is a categorical variable.  
Alternative Available 
Normality test not performed as this is a categorical variable.  
Group_Size 
Skewness      -.4932935 
Kurtosis       3.410994 
This variable could be considered to approximate to a normal distribution. 
 
Cost-Effectiveness part of Process 
Normality test not performed as this is a categorical variable.  
BIM part of Process 
 349
Normality test not performed as this is a categorical variable.  
No of Drugs appraised 
Normality test not performed as all SMC reviews consider one drug at a time  - hence 
no variation present.  
Accountability for drug budget 
Normality test not performed as this is a categorical variable.  
Independence of HTA agency from MoH 
Normality test not performed as this is a categorical variable.  
 
Year of appraisal 
Skewness       .0317761 
Kurtosis        1.92267 
0.
00
0.
25
0.
50
0.
75
1.
00
N
or
m
al
 F
[(n
o_
R
C
T-
m
)/s
]
0.00 0.25 0.50 0.75 1.00
Empirical P[i] = i/(N+1)
 
 
Population under HTA remit 
Skewness       .1465455 
Kurtosis       1.770313 
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% of GDP expenditure on health 
Skewness      -.6356308 
Kurtosis       1.785118 
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Drug expenditure per person 
Skewness       .0882442 
Kurtosis       1.967974 
 
Funding mechanism – centralised or decentralised 
Normality test not performed as this is a categorical variable.  
Election year 
Normality test not performed as this is a categorical variable.  
Priority Disease Area 
Normality test not performed as this is a categorical variable.  
BNF Category 
Normality test not performed as this is a categorical variable. 
 
SMC dataset: descriptive statistics 
 
Variable Chi2 ANOVA T-Test 
(Rec vs 
Res) 
T-Test 
(Res vs 
NR) 
Kruskal-
Wallis 
Number of RCTs considered in decision   0.5898 0.8501 0.6054 0.3269 
Size of population included in RCTs   0.5156 0.7663 0.0048 0.0016 
Statistically Significant results -                 
yes  
0.452         
no 0.851         
inconsistent 0.068         
Length/extent of follow-up in RCT 
(weeks) 
  0.4304 0.4082 0.026 0.023 
Use of Active Comparator in RCT   0.0032 0.0788 0.0887 0.0153 
Number of observational studies 
considered in guidance 
  0.0962 0.3534 0.2185 0.5781 
Consideration of Cost Utility Analysis in 
guidance 
0.345         
Incremental Cost-effectiveness ratio of 
technology vs. comparator in base case 
  0.1312 0.1419 0.1755 0.0001 
More than one CUA submitted 0.652         
If More than one CUA submitted - low   -  -  - 0.2207 
 351
range 
If More than one CUA submitted - high 
range 
  -  -  - 0.2207 
Uncertainty around the base case ICER 
reported in submission (probabilistic) 
  0.6072 0.9909 0.0176 0.0713 
Uncertainty around base case ICER 
reported in submission (univariate)  Low 
  - 0.4548 0.0509 0.0015 
Uncertainty around base case ICER 
reported in submission (univariate) High 
  0.1901 0.4605 0.0365 0.0001 
Non-CUA analyses submitted 0.183       
Potential budgetary impact  (million)   0.8767 0.1941 0.1695 0.6868 
Prevalence of disease/clinical condition   0.0152 0.1114 0.3111 0.017 
Societal Perspective adopted 0.401         
Availability of alternative therapies in 
current treatment setting. 
0.031         
Inclusion of patient submission 0.105         
Number of Decision Makers 
Accountable 
  0.5704 0.8325 0.6133 0.8973 
Cost-effectiveness evaluation component 
in process 
-         
Budget impact as a component of 
decision-making process 
-         
Price of technology  known during 
appraisal 
-         
Number of drugs appraised in same 
appraisal 
  - - - 1 
Accountability of drug budget -         
Independence of decision-making 
agency 
-         
Date guidance was issued   0.2778 0.5807 0.4118 0.7234 
Population size – Agency coverage 
(millions) 
  0.2778 0.5605 0.4363 0.4254 
GDP-healthcare expenditure   0.2778 0.9852 0.1894 0.7234 
Healthcare expenditure on 
pharmaceuticals 
  0.2778 0.6243 0.3177 0.4254 
Election year at time of decision 0.906         
Priority disease area 0.792         
Orphan Designated 0.023         
Proportion of Advice following Full 
submission 
0.492         
BNF1 cardiovascular system 0.201         
BNF2 central nervous system 0.186         
BNF3 ear, nose and oropharynx 0.114         
BNF4 endocrine system 0.689         
BNF5 eye 0.078         
BNF6 gastro-intestinal system 0.028         
BNF7 infections 0.007         
BNF8 malignant disease and 
immunosuppression 
0.679         
BNF9 musculoskeletal and joint diseases 0.272         
BNF10 nutrition and blood 0.152         
BNF11 obstetrics, gynaecology, and 
urinary-tract disorders 
0.395         
BNF12 respiratory system 0.455         
BNF13 skin 0.127         
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SMC dataset: preliminary multivariate model 
The pseudo R-squared for this model was 0.1446, which suggests that it explains 15% 
of the variability observed in SMC coverage decisions.    
Multivariate analysis of SMC coverage decisions 2004-2009:  preliminary model  
 Coefficient P  value  95%  CI 
Restricted Technologies   
RCT size 0.1762491 0.152 -0.06505 0.4175436 
RCT duration of follow-up -0.0049669 0.14 -0.01156 0.0016277 
Use of active comparator in RCT -0.216627 0.661 -1.18434 0.7510889 
Lack of clinical superiority in RCT -3.39E-01 0.506 -1.34E+00 0.6598822 
ICER 9.88E-06 0.257 -7.22E-06 2.70E-05 
Probability of ICER below £30,000 threshold 0.0001091 0.195 -5.6E-05 0.0002739 
Disease prevalence -0.0000364 0.023 -6.8E-05 -4.96E-06 
Presence of alternative therapy -0.4746392 0.479 -1.78932 0.8400456 
Orphan designation status 0.0679678 0.935 -1.55539 1.691327 
Infectious Diseases 0.1210854 0.827 -0.96544 1.207608 
Musculoskeletal and joint diseases 21.42581 0.000 20.01821 22.83341 
Obstetrics/gynaecology& urinary-tract disorders 21.90404 0.000 19.93859 23.8695 
Skin diseases -0.4743365 0.523 -1.92943 0.9807586 
RCT size not available 0.9686335 0.297 -0.85345 2.790714 
RCT follow-up not available -0.1260203 0.884 -1.825 1.572959 
Use of active comparator not available -2.151319 0.164 -5.17925 0.8766147 
ICER not available 0.2078835 0.630 -0.63691 1.05268 
Prevalence not available 0.4113592 0.404 -0.5548 1.37752 
Constant 1.195231 0.099 -0.22414 2.614598 
Not Recommended Technologies 
RCT size -0.4019133 0.055 -0.8122 0.0083758 
RCT duration of follow-up -0.0100672 0.014 -0.01807 -0.0020671 
Use of active comparator in RCT -0.5402572 0.275 -1.51E+00 0.4306352 
Lack of clinical superiority in RCT -5.41E-01 0.295 -1.55506 4.72E-01 
ICER 8.49E-06 0.342 -9.01E-06 0.000026 
Probability of ICER below 30,000 threshold -0.0003433 0.054 -0.00069 6.26E-06 
Disease prevalence -1.46E-06 0.852 -1.68E-05 0.0000139 
Presence of alternative therapy -0.6815033 0.307 -1.98947 6.26E-01 
Orphan designation status 0.1081514 0.892 -1.45287 1.669176 
Infectious Diseases -1.890128 0.006 -3.23292 -0.5473376 
Musculoskeletal and joint diseases 20.37818 . . . 
Obstetrics/gynaecology& urinary-tract disorders 20.6625 . . . 
Skin diseases -2.123698 0.022 -3.94227 -0.3051237 
RCT size not available 1.142295 0.256 -0.82799 3.112579 
RCT follow-up not available 0.7903202 0.327 -0.78854 2.369185 
Use of active comparator not available -2.762684 0.062 -5.66286 0.1374896 
ICER not available 0.2390104 0.58 -0.60651 1.084535 
Prevalence not available -0.0428182 0.932 -1.01994 0.9343067 
Constant 2.92186 0.000 1.470452 4.373268 
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Note:  Recommended technologies are the reference case 
Sensitivity analyses 
The use of a categorical rather than continuous ICER variable was tested.  This was 
done to be able to include in the analysis dominated technologies which were excluded 
from the base-case analysis as they were challenging to quantify on a continuous scale.  
The categorical ICER variable was created by generating a binary variable which 
recorded whether the ICER was above or below £30,000.  This ICER threshold value 
was selected on the assumption that it represents the value upon which a technology is 
deemed to be cost-effective versus the comparator by the SMC.  To test how the new 
ICER variable impacted on the regression output, the continuous ICER variable in the 
above regression model was replaced with the binary ICER variable.  The results are 
shown in Table 5.7.  When compared to the base case regression output, the results of 
this sensitivity analysis suggest the model using a categorical ICER variable rather than 
a continuous ICER variable yields similar results.   The pseudo R-squared is similar 
(0.1239 vs. 0.1103 in the base case), and the categorical ICER variable maintains the 
statistically significant effect on the log odds of a restriction and non-recommendation 
relative to a recommendation.   
 Sensitivity Analysis 1. Multivariate analysis of SMC coverage decisions 2004-2009:  sensivitiy analysis using 
categorical ICER variable 
  Log Odds P value 95%  Conf. Interval 
Restricted Technologies  
RCT size 1.34E-05 0.841 -0.00012 0.000144 
RCT duration of follow-up -0.00301 0.315 -0.00889 0.002864 
ICER -1.36422 0.092 -2.95262 0.224181 
Infectious Diseases -0.58987 0.259 -1.61407 0.434338 
Skin Diseases -0.74685 0.324 -2.2303 0.736596 
Disease prevalence -1.6E-05 0.097 -3.4E-05 2.84E-06 
Presence of alternative therapy -0.84396 0.225 -2.20669 0.518771 
Constant 2.9919 0.003 0.984899 4.998901 
Not recommended technologies 
RCT size -0.00033 0.073 -0.0007 3.09E-05 
RCT duration of follow-up -0.00882 0.022 -0.01638 -0.00126 
ICER -2.35043 0.003 -3.91486 -0.786 
Infectious Diseases -2.16812 0.001 -3.49508 -0.84116 
Skin Diseases -1.85797 0.045 -3.67625 -0.03968 
Disease prevalence -2E-05 0.045 -3.9E-05 -4.78E-07 
Presence of alternative therapy -1.45758 0.039 -2.83982 -0.07534 
Constant 5.109186 0 3.089329 7.129043 
 
Note:  Recommended technologies are the reference case 
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C. Chapter 6 Appendices 
 
CFH coverage decisions 2004-2009: List of Technology Appraisals included for 
analysis 
Technology Appraised Date guidance was issued 
abacavir/lamivudine 2005 
abatacept 2007 
adalimumab 2005 
adalimumab 2006 
adalimumab 2007 
adalimumab 2007 
adalimumab 2008 
adalimumab 2008 
adalimumab 2008 
adapaleen 2005 
agalsidase alfa 2007 
agalsidase beta 2007 
alemtuzumab 2006 
alemtuzumab 2008 
alendroninezuur/colecalciferol 2005 
alfa1-proteinaseremmer 2007 
aliskiren 2007 
allergenen 2008 
allergenen 2008 
allergenen 2008 
allergenen 2008 
allergenen 2008 
ambrisentan 2008 
anagrelide 2005 
anakinra 2006 
anakinra 2006 
anidulafungine 2008 
aprepitant 2004 
aripiprazol 2004 
atazanavir 2004 
betaïneanhydraat 2007 
bevacizumab 2005 
bevacizumab 2007 
bevacizumab 2007 
bevacizumab 2008 
bortezomib 2005 
bortezomib 2007 
bortezomib 2008 
bosentan 2007 
buprenorfine 2007 
buprenorfine/naloxon 2009 
bupropion 2007 
carglumaatzuur 2006 
caspofungine 2008 
celecoxib 2004 
cetuximab 2007 
cetuximab 2007 
ciclesonide 2005 
cinacalcet 2005 
ciprofloxacine 2005 
clopidogrel 2004 
clopidogrel 2004 
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clopidogrel 2007 
clopidogrel 2009 
colesevelam 2007 
colistine 2005 
cytarabine 2007 
dabigatran 2008 
darbepoëtine 2006 
darbepoëtine-alfa 2007 
darifenacine 2005 
darunavir 2007 
dasatinib 2007 
deferasirox 2006 
dorzolamide 2006 
dorzolamide/timolol 2006 
drotrecogin-alfa 2006 
duloxetine 2004 
duloxetine 2005 
eculizumab 2008 
efalizumab 2005 
emtricitabine 2004 
entecavir 2006 
epinastine 2004 
eplerenon 2004 
epoëtine 2006 
erytromycine-zinkcomplex 2005 
escitalopram 2004 
escitalopram 2004 
escitalopram 2004 
estradiol/drospirenon 2004 
etanercept 2004 
etanercept 2004 
etanercept 2008 
etanercept 2008 
etanercept 2008 
ethinylestradiol 2004 
etravirine 2008 
everolimus 2004 
exenatide 2007 
fentanyl oromucosaal 2006 
fesoterodine 2008 
fluticasonfuroaat 2008 
fosamprenavir 2004 
fulvestrant 2004 
fumaarzuuresters 2004 
fumaarzuuresters 2004 
fumaarzuuresters 2004 
galsulfase 2007 
gamma hydroxyboterzuur 2006 
gepegyleerd liposomaal doxorubicine 2005 
gepegyleerd liposomaal doxorubicine 2005 
gepegyleerd liposomaal doxorubicine 2005 
gliclazide 2005 
humaan papillomavirusvaccin 2007 
humaan papillomavirusvaccin 2009 
ibandroninezuur 2004 
ibandroninezuur 2005 
ibandroninezuur i.v. 2006 
ibandroninezuur i.v. 2006 
ibandroninezuur i.v. 2006 
ibritumomab 2006 
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ijzerdextraan 2004 
iloprost 2008 
imiquimod 2005 
infliximab 2005 
infliximab 2005 
infliximab 2006 
infliximab 2006 
infliximab 2006 
infliximab 2007 
infliximab 2007 
insuline detemir 2004 
insuline glulisine 2005 
irinotecan 2005 
isosorbidedinitraat 2007 
ivabradine 2006 
ivabradine 2007 
lacosamide 2009 
lanthaancarbonaat 2006 
lapatinib 2009 
lenalidomide 2007 
levetiracetam 2005 
levetiracetam 2008 
levodopa/carbidopa 2005 
levodopa/carbidopa/entacapone 2004 
lidocaïnepleister 2008 
lomustine 2006 
lumiracoxib 2007 
macrogol/elektrolyten 2007 
maraviroc 2007 
melatonine 2004 
melatonine 2005 
melatonine 2008 
melatonine 2008 
memantine 2004 
memantine 2007 
menopauzegonadotrofine 2004 
methoxypolyethyleenglycolepoëtine beta 2007 
methylaminolevulinaat 2008 
methylaminolevulinaat 2008 
methylaminolevulinaat 2008 
methylnaltrexon 2008 
mexiletine 2006 
miconazol 2009 
miglustat 2009 
mitotane 2006 
mycofenolaatmofetil 2006 
mycofenolaatmofetil 2006 
mycofenolaatmofetil 2007 
mycofenolaatmofetil 2008 
mycofenolzuur 2004 
myrtol 2005 
natalizumab 2006 
nepafenac 2008 
nicotinezuur 2004 
nilotinib 2008 
ofloxacine 2006 
omega-3-vetzuren 2004 
orlistat 2004 
oseltamivir 2005 
oxybutynine 2005 
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palifermin 2006 
paliperidon 2007 
panitumumab 2008 
parathyroïd hormoon 2006 
paricalcitol 2008 
pegaptanib 2006 
peginterferon-alfa 2 2008 
pemetrexed 2005 
pemetrexed 2005 
pimecrolimus 2004 
pimecrolimus 2004 
pioglitazon 2007 
posaconazol 2006 
posaconazol 2007 
pregabaline 2004 
pregabaline 2004 
quetiapine 2008 
quetiapine 2008 
raltegravir 2008 
ranibizumab 2007 
rasagiline 2006 
rimonabant 2007 
rituximab 2006 
rituximab 2006 
rituximab 2006 
rivaroxaban 2009 
rivaroxaban 2009 
rivastigmine 2006 
rosiglitazon 2007 
rosiglitazon/metformine 2004 
rotigotine 2006 
rotigotine 2007 
sapropterin 2009 
sertindol 2006 
sildenafil 2006 
sitagliptine 2007 
sitagliptine 2008 
sitaxentan 2007 
solifenacine 2004 
sorafenib 2006 
sorafenib 2008 
sorafenib 2009 
strontiumranelaat 2005 
sunitinib 2006 
sunitinib 2006 
sunitinib 2007 
tacrolimus 2006 
telbivudine 2007 
temoporfine 2008 
temoporfine 2008 
temsirolimus 2008 
teriparatide 2004 
testosteron 2007 
testosteron gel 2004 
testosteronpleister 2008 
tetrabenazine 2007 
tetrabenazine 2009 
thalidomide 2007 
thalidomide 2007 
thalidomide 2007 
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timolol/brimonidine 2006 
tipranavir 2006 
tolcapon 2005 
tolcapon 2006 
topotecan 2008 
trabectedin 2008 
trastuzumab 2005 
treprostinil 2006 
tretinoïne 2005 
urofollitropine 2007 
urofollitropine 2007 
varenicline 2008 
vildagliptine 2008 
vinorelbine 2005 
vinorelbine 2005 
voriconazol 2008 
xycodon 2007 
zileuton 2008 
zinc acetate 2005 
zoledroninezuur 2004 
zoledroninezuur 2004 
zoledroninezuur 2005 
zoledroninezuur 2008 
zonisamide 2007 
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CFH Dataset: Missing Data 
 
Between January 2004-June 2009, the Commissie Farmaceutische Hulp (CFH) 
reviewed 256 submissions and made specific funding decisions – either recommending, 
restricting or not recommending use of Dutch health care resources to fund new health 
technologies (in this research analysis, the health technologies are restricted to 
pharmaceutical products).  
 
A data set of information pertaining to CFH appraisals was created collecting 
information on variables relating to (i) the clinical and economic characteristics of the 
technology under appraisal, as well as information on (ii) the process used to come to a 
decision, and (iii) the socio-economic context in which these decisions were made. 
In order to prepare the data set for analysis, understanding the data set is important.  
Here, the aim is to characterise the presence of missing data across variables and 
decisions to inform the need for imputing missing data.   
 
Distribution of Missing Data within CFH data set 
 In the total CFH sample, there are 9% of incomplete entries.  The rate of missing 
entries is similar across decision outcomes. The distribution of missing data across each 
variable was examined.   The total number of observations per variable is 256.  The 
variables with the highest number missing information are those related to the 
prevalence and budget impact of the technology, as well as the incremental cost-
effectiveness ratio and related variables.  This is linked partially to the fact that until 
2006, cost-effectiveness models were not a formal component of the CFH review 
process.  More than half of all variables (n=26) have no missing data.   
 
The extent of missing data was also examined across appraisals.  The level of missing 
variables per appraisal ranged from 0 – 8, mean number of missing entries per appraisal 
was 3.   
 
 
 
 
 
 
 360
Figure C.1. CVZ Distribution of missing data by variable (n=256) 
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CFH Dataset – Testing of Normality Assumption 
Method 
To determine the relevant statistical tests to use in assessing the significance of 
differences observed between means, it was necessary to assess whether the normality 
assumption was valid for the variables under consideration.  This would then determine 
the use of parametric or non-parametric tests.  For all variables, the sample is >30.  It 
has been suggested    that when analysing sample sizes of >30, even when the normality 
assumption is violated, parametric tests may still be performed (Pallant 2007, SPSS 
Survival Manual, 3rd edn, Maidenhead, OUP/McGraw-Hill).  Prior to making a decision 
on which variables to apply parametric or non-parametric tests, the distribution for each 
variable will be further examined.   
 
To test the normality assumption the following was performed for each non-categorical 
variable: 
• Skeweness was calculated 
• Kurtosis was calculated 
• The standardized normal probability plot (P-P plot) was graphed 
The graph and calculations are presented for each non-categorical variable and an 
assessment is made of whether the normality assumption is met or not.  A variable will 
be considered to meet the normal distribution assumption if  
• skewness is within the range ±1 
• Kurtosis value is within range ±3 
• P-P plot shows distribution of dataset is approximately linear 
 
In those circumstances where there is inconsistency between the three tests, if 2 of the 
tests suggest normal distribution, then it will be considered as such (but then tested 
using both parametric and non-parametric tests in sensitivity analyses).  
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Number of RCTs considered in appraisal (No_RCT) 
Skewness       5.058098 
Kurtosis       42.76271 
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This variable is not normally distributed.  
Mean sample size of RCTs considered in appraisal (RCTsize) 
Skewness        7.285689 
Kurtosis       60.86852 
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This variable is not normally distributed.  
Superiority demonstrated 
Normality test not performed as this is a categorical variable.  
Duration of RCT (RCTfwup) 
Skewness       2.550881 
Kurtosis       12.20497 
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This variable is normally distributed. 
 Active-Comp 
Categorical variable.   
Observational Studies 
Skewness       4.508569 
Kurtosis       29.06404 
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This variable is not normally distributed.  
 
CUA performed 
Normality test not performed as this is a categorical variable.  
ICER 
Skewness       3.950522 
Kurtosis       18.84594 
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This variable is not normally distributed.  
ICER SA – Probabilistic 
Skewness      -1.123912 
Kurtosis       2.282117 
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This variable is normally distributed.  
ICER SA – Univariate Low 
Skewness       5.214576 
Kurtosis       31.50543 
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This variable is not normally distributed.  
 
ICER SA – Univariate high 
Skewness       4.881428 
Kurtosis       26.57847 
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This variable is not normally distributed.  
Multiple Models submitted 
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Normality test not performed as this is a categorical variable.  
Multiple Models: Range of ICERs – LOW / HIGH 
Normality test not performed as there are only 2 observations for this particular 
variable.  
Non_CUA submitted 
Normality test not performed as this is a categorical variable.  
BIM 
Skewness       6.388764 
Kurtosis       44.28053 
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This variable is not normally distributed.  
Prevalence 
Skewness       7.605384 
Kurtosis        64.17695 
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This variable is not normally distributed.  
 
Alternative Available 
Normality test not performed as this is a categorical variable.  
Cost-Effectiveness part of Process 
Normality test not performed as this is a categorical variable.  
BIM part of Process 
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Normality test not performed as this is a categorical variable.  
Joint reimbursement & pricing decision 
Normality test not performed as this is a categorical variable.  
Accountability for drug budget 
Normality test not performed as this is a categorical variable.  
Independence of HTA agency from MoH 
Normality test not performed as this is a categorical variable.  
Year of appraisal 
Skewness       -.0679571 
Kurtosis        1.887242 
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Perhaps this is actually a categorical variable? 
Population under HTA remit 
Skewness       .3594944 
Kurtosis        2.930518 
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Perhaps this is actually a categorical variable? 
% of GDP expenditure on health 
Skewness       .1992813  
Kurtosis  2.01775 
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Drug expenditure per person 
Skewness        2.01775 
Kurtosis       1.457256 
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Funding mechanism – centralised or decentralised 
Normality test not performed as this is a categorical variable.  
Election year 
Normality test not performed as this is a categorical variable.  
Priority Disease Area 
Normality test not performed as this is a categorical variable.  
BNF Category 
Normality test not performed as this is a categorical variable. 
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CFH dataset: descriptive statistics 
 Chi2 ANOVA T-Test (Rec vs 
Res) 
T-Test (Res vs 
NR) 
Kruskal-Wallis 
Number of RCTs 
considered in decision 
  0.039 0.0595 0.1987 0.0912 
Size of population 
included in RCTs 
  0.1027 0.0357 0.2878 0.3042 
Statistically Significant 
results -                           
yes  
0.046         
no 0.003         
inconsistent 0.922         
Length/extent of follow-
up in RCT (weeks) 
  0.2398 0.0467 0.1109 0.2563 
Use of Active 
Comparator in RCT 
  0.0836 0.3306 0.0043 0.0081 
Number of observational 
studies considered in 
guidance 
  0.8655 0.9032 0.7112 0.7948 
Consideration of Cost 
Utility Analysis in 
guidance 
0.196         
Incremental Cost-
effectiveness ratio of 
technology vs. 
comparator in base case 
  0.5432 0.4799 0.9323 0.5335 
More than one CUA 
submitted 
0.23         
If More than one CUA 
submitted - low range 
  - - -   
If More than one CUA 
submitted - high range 
  - - -   
Uncertainty around the 
base case ICER reported 
in submission 
(probabilistic) 
  0.5774 0.4387 0.9362   
Uncertainty around base 
case ICER reported in 
submission (univariate)  
Low 
  0.5228 0.4939 0.6339 0.5538 
Uncertainty around base 
case ICER reported in 
submission (univariate) 
High 
  0.5344 0.4772 0.883 0.5538 
Prevalence of 
disease/clinical 
condition 
  0.0193 0.7033 0.0302 0.0027 
Potential budgetary 
impact  (million) 
  0.3603 0.0493 0.9044 0.0224 
Societal Perspective 
adopted 
0.623         
Availability of 
alternative therapies in 
current treatment setting. 
0.276         
Inclusion of patient 
submission 
0.009         
Number of Decision 
Makers Accountable 
  - - - 1 
Cost-effectiveness 
evaluation component in 
process 
0.287         
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Budget impact as a 
component of decision-
making process 
- - - -   
Price of technology  
known during appraisal 
-         
Number of drugs 
appraised in same 
appraisal 
  - - - 1 
Accountability of drug 
budget 
- - - -   
Independence of 
decision-making agency 
- - - -   
Date guidance was 
issued 
  0.1349 0.6864 0.0158 0.0333 
Population size – 
Agency coverage 
(millions) 
  0.1349 0.5654 0.0222 0.0333 
GDP-healthcare 
expenditure 
  0.1634 0.4856 0.3973 0.3365 
Healthcare expenditure 
on pharmaceuticals 
  0.1349 0.8511 0.0099 0.0333 
Election year at time of 
decision 
0.094         
Priority disease area 0.028         
Orphan Designated 0.1         
Technology has EU 
Marketing Authorisation 
0.207         
Future Cost-
Effectiveness Analyses 
requested 
0.0001         
Expensive Drug 0.0001         
Patient Copayment 
needed 
0.019         
BNF1 cardiovascular 
system 
0.014         
BNF2 central nervous 
system 
0.526         
BNF3 ear, nose and 
oropharynx 
0.23         
BNF4 endocrine system 0.541         
BNF5 eye 0.14         
BNF6 gastro-intestinal 
system 
0.752         
BNF7 infections 0.351         
BNF9 musculoskeletal 
and joint diseases 
0.005         
BNF10 nutrition and 
blood 
0.471         
BNF11 obstetrics, 
gynaecology, and 
urinary-tract disorders 
0.036        
BNF12 respiratory 
system 
0.0001         
BNF13 skin 0.382         
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CFH preliminary multivariate model 
The result of the multinomial regression yield a pseudo R-squared of 0.2276, suggesting 
that the model explains 23% of the variability in CFH coverage decisions.   
 
Multivariate analysis of CFH coverage decisions 2004-2009: preliminary model 
Restricted Log Odds P value 95% Confidence Interval 
Number of RCTs 0.0021636 0.975 -0.1338959 0.138223 
RCT duration of follow-up -0.0041777 0.435 -0.0146733 0.006318 
Use of active comparator in RCT -0.5027428 0.282 -1.419362 0.4138761 
Demonstrated clinical superiority in 
RCT -0.1743879 0.739 -1.199567 0.8507908 
Inconsistently demonstrated superiority 
in RCT 0.641352 0.212 -0.3665792 1.649283 
Budgetary Impact 0.0063992 0.243 -0.0043358 0.0171342 
Patient Submission 0.0931105 0.929 -1.961057 2.147278 
Cancer therapy -0.8279568 0.180 -2.039338 0.3834244 
Therapies for cardiovascular diseases 1.36122 0.036 0.0917759 2.630663 
Therapies for musculoskeletal and joint 
diseases 0.9945765 0.150 -0.3605296 2.349683 
Therapies for 
obstetrics/gynaecology/urinary-tract 
disorders 
2.24357 0.053 -0.0255119 4.512652 
Therapies for respiratory system -33.71069 1.000 -4.99E+07 4.99E+07 
National Population -6.96E-06 0.453 -0.0000251 0.0000112 
Pharmaceutical Expenditure per patient 
per year 0.0181555 0.495 -0.0339831 0.0702941 
Priority Disease area -0.4878657 0.316 -1.442324 0.4665928 
Election 0.0913282 0.833 -0.7568523 0.9395087 
Lack of data on duration of RCT 0.7001897 0.406 -0.9507739 2.351153 
Lack of data on use of active 
comparator -0.7064949 0.448 -2.532211 1.119221 
Lack of data on budgetary impact 0.2760691 0.480 -0.4906909 1.042829 
Constant 108.0983 0.453 -174.4742 390.6708 
Not Recommended Log Odds P value 95% Confidence Interval 
Number of RCTs -0.0529028 0.514 -0.2117183 0.1059126 
RCT duration of follow-up 0.0011882 0.856 -0.0116559 0.0140324 
Use of active comparator in RCT -2.111281 0.004 -3.546022 -0.6765408 
Demonstrated clinical superiority in 
RCT -0.5771367 0.434 -2.02204 0.8677663 
Inconsistently demonstrated superiority 
in RCT 0.924818 0.198 -0.4825063 2.332142 
Budgetary Impact 0.00698 0.206 -0.0038408 0.0178008 
Patient Submission 1.812627 0.049 0.0092095 3.616045 
Cancer therapy -1.062929 0.146 -2.49712 0.3712627 
Therapies for cardiovascular diseases 1.271848 0.141 -0.4202808 2.963977 
Therapies for musculoskeletal and joint 
diseases -1.540254 0.216 -3.981781 0.9012729 
Therapies for obstetrics, gynaecology, 
and urinary-tract disorders 2.334487 0.137 -0.7455755 5.41455 
Therapies for respiratory system 2.088872 0.122 -0.5611742 4.738918 
National Population -5.46E-06 0.620 -0.0000271 0.0000161 
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Pharmaceutical Expenditure per patient 
per year 0.0257991 0.428 -0.0379471 0.0895454 
Priority Disease area 0.3928719 0.539 -0.8610197 1.646763 
Election -0.5338336 0.468 -1.976561 0.9088942 
Lack of data on duration of RCT 2.065647 0.045 0.0442537 4.087041 
Lack of data on use of active 
comparator -1.050057 0.377 -3.379514 1.2794 
Lack of data on budgetary impact 0.0992704 0.852 -0.9404436 1.138984 
Constant 80.53906 0.638 -254.852 415.9302 
 
Note:  Recommended technologies are the reference case 
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D. Chapter 7 Appendices 
 
HAS coverage decisions 2004-2009: List of Technology Appraisals included for 
analysis 
 
Drug Name Ref HAS Date guidance was issued 
adalimumab 31648 2004 
adalimumab 31580 2004 
anastrozole 31571 2004 
Aprepitant 31576 2004 
aripiprazole 31711 2004 
atazanavir 31704 2004 
atorvastatin 31682 2004 
bortezomib 31654 2004 
Budesonide/eformoterol 31498 2004 
busulfan 31489 2004 
Calcipotriol and betamethasone 31508 2004 
docetaxel 31612 2004 
emtricitabine 31564 2004 
escitalopram 31652 2004 
esomeprazole 31649 2004 
etanercept 31531 2004 
fludarabine 31547 2004 
fondaparinux 31572 2004 
fondaparinux 31572 2004 
fosamprenavir 31613 2004 
fulvestrant 31665 2004 
gemcitabine 31666 2004 
ibandronic acid 31573 2004 
ibritumomab tiuxetan 31604 2004 
Iloprost 31558 2004 
imatinib 31565 2004 
imatinib 31565 2004 
infliximab 31623 2004 
infliximab 31624 2004 
infliximab 31623 2004 
Laronidase 31523 2004 
liposomal cytarabine 31574 2004 
mitotane 31673 2004 
Mycophenolate sodium 31573 2004 
oseltamivir 31516 2004 
Pegvisomant 31497 2004 
Pioglitazone 31544 2004 
pramipexole 31588 2004 
Rabeprazole 31701 2004 
rivastigmine 31577 2004 
ropinirole  31712 2004 
Rosiglitazone  31546 2004 
salmeterol fluticasone 31496 2004 
TachoSil medicated sponge 31707 2004 
tenofovir 31793 2004 
teriparatide 31532 2004 
topiramate 31693 2004 
adalimumab 32293 2005 
alendronate 32236 2005 
Anagrelide 31926 2005 
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Aprepitant 32229 2005 
azelaic acid 31882 2005 
bevacizumab 31832 2005 
bivalirudin 31807 2005 
Candesartan cilexetil 322368 2005 
capecitabine 31794 2005 
cetuximab 31761 2005 
cinacalcet 32205 2005 
levodopa/carbidopa 32603 2005 
Darbepoetin alfa 31725 2005 
docetaxel 31922 2005 
efalizumab 31789 2005 
erdosteine 32038 2005 
esomeprazole 31840 2005 
etanercept 31779 2005 
fludarabine 32288 2005 
fondaparinux 32191 2005 
fondaparinux 32192 2005 
galantamine 31914 2005 
imiquimod 31795 2005 
imiquimod 31777 2005 
Insulin detemir 31784 2005 
insulin glulisine 31808 2005 
letrozole 32287 2005 
letrozole 31762 2005 
micronised progesterone 32411 2005 
Modafinil 31902 2005 
Montelukast 31920 2005 
mycophenolate mofetil 31834 2005 
Nicotinic acid 31820 2005 
Olopatadine 32392 2005 
oxaliplatin 32312 2005 
Oxycodone 32209 2005 
Oxycodone 32210 2005 
peginterferon alfa-2a 31910 2005 
pemetrexed 31778 2005 
pregabalin 31785 2005 
pregabalin 31785 2005 
rituximab 31899 2005 
rosuvastatin  31730 2005 
rosuvastatin  32279 2005 
sirolimus 31913 2005 
Strontium ranelate 31773 2005 
trastuzumab 32203 2005 
Vinorelbine 32384 2005 
Vinorelbine 32283 2005 
zoledronic acid 32221 2005 
Zonisamide 32329 2005 
adalimumab 2893 2006 
Aprepitant 3093 2006 
bortezomib 32576 2006 
capecitabine 32591 2006 
Carmustine implant 32363 2006 
cetuximab 3135 2006 
daptomycin 2927 2006 
deferasirox 3381 2006 
dibotermin alfa  2410 2006 
dipyridamole 32797 2006 
docetaxel 32531 2006 
erlotinib 2253 2006 
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exemestane 2878 2006 
exenatide 4012 2006 
frovatriptan 3460 2006 
ibandronic acid 3518 2006 
infliximab 32588 2006 
infliximab 32588 2006 
infliximab 32588 2006 
Interferon beta-1b 3083 2006 
Ivabradine 3467 2006 
lanthanum carbonate 2164 2006 
Losartan 32650 2006 
Metformin hydrochloride 32503 2006 
nebivolol 2925 2006 
nebivolol 2321 2006 
omalizumab 2170 2006 
paclitaxel 32529 2006 
parathyroid hormone 3683 2006 
pegaptanib 3148 2006 
pegaptanib 3148 2006 
peginterferon alfa-2a 32520 2006 
pemetrexed 31778 2006 
posaconazole 32611 2006 
pravastatin 32553 2006 
pravastatin 32554 2006 
pravastatin 32555 2006 
raloxifene 2594 2006 
rasagiline 32476 2006 
Risperidone 32570 2006 
rituximab 3446 2006 
rituximab 3723 2006 
rivastigmine 2879 2006 
Rosiglitazone  32598 2006 
sildenafil 2255 2006 
simvastatin 32466 2006 
simvastatin 32620 2006 
sodium oxybate 2782 2006 
Solifenacin 1884 2006 
sorafenib  2905 2006 
Strontium ranelate 3304 2006 
sunitinib 3144 2006 
sunitinib 3144 2006 
TachoSil medicated sponge 1043 2006 
temozolomide  32614 2006 
teriparatide 3303 2006 
testosterone undecanoate 3318 2006 
tiagabine 32501 2006 
tigecycline  3108 2006 
Tipranavir  2482 2006 
Topotecan 32608 2006 
trastuzumab 3054 2006 
Travoprost  3731 2006 
vigabatrin 2522 2006 
abatacept 5592 2007 
adalimumab 4863 2007 
adefovir dipivoxil 4155 2007 
alendronate 4223 2007 
betaine anhydrous 5071 2007 
bortezomib 4139 2007 
Budesonide/eformoterol 4315 2007 
Calcipotriol and betamethasone 4258 2007 
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clopidogrel 4159 2007 
levodopa/carbidopa 4717 2007 
darunavir 4442 2007 
dasatinib 4070 2007 
dexrazoxane 4069 2007 
docetaxel 4136 2007 
donepezil 3132 2007 
drotrecogin alfa  824 2007 
duloxetine 2319 2007 
esomeprazole 4795 2007 
esomeprazole 3729 2007 
fondaparinux 4111 2007 
fondaparinux 5091 2007 
gabapentin 3850 2007 
galantamine 3146 2007 
Glyceryl trinitrate 4195 2007 
idursulfase 4169 2007 
infliximab 4627 2007 
lamotrigine 4625 2007 
Latanoprost 2984 2007 
lenalidomide 4856 2007 
levetiracetam 3913 2007 
memantine 4352 2007 
methadone 5198 2007 
Methoxy polyethylene glycol-epoetin beta 5111 2007 
naltrexone 4027 2007 
natalizumab 3657 2007 
paliperidone 5168 2007 
Palonosetron 3936 2007 
posaconazole 4628 2007 
posaconazole 4628 2007 
pramipexole 3918 2007 
pregabalin 4024 2007 
risedronate 4544 2007 
sitaxentan  4468 2007 
sodium oxybate 4626 2007 
sunitinib 4512 2007 
telbivudine 4976 2007 
topiramate 4325 2007 
zoledronic acid 5982 2007 
zopiclone 4439 2007 
adalimumab 5381 2008 
alemtuzumab 5602 2008 
aliskiren 5216 2008 
ambrisentan 5603 2008 
anidulafungin 5880 2008 
anidulafungin 5315 2008 
aripiprazole 5027 2008 
atazanavir 5432 2008 
bevacizumab 5075 2008 
bevacizumab 5390 2008 
botulinum neurotoxin type A 5377 2008 
buprenorphine/naloxone 5344 2008 
capecitabine 5238 2008 
Cilostazol 5444 2008 
clobetasol propionate 5185 2008 
Clostridium botulinum type A neurotoxin 5377 2008 
docetaxel 5360 2008 
entecavir 3487 2008 
escitalopram 5257 2008 
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etanercept 5041 2008 
etanercept 5041 2008 
etanercept 5041 2008 
etanercept 5041 2008 
etanercept 5041 2008 
fluticasone furoate 5384 2008 
fondaparinux 5418 2008 
fondaparinux 5405 2008 
lapatinib 5358 2008 
lidocaine 5354 2008 
maraviroc 5283 2008 
mycophenolate mofetil 5616 2008 
nilotinib 5206 2008 
Olopatadine 5271 2008 
oseltamivir 5375 2008 
Oxycodone 5917 2008 
peginterferon alfa-2a 5224 2008 
peginterferon alfa-2b 4821 2008 
peginterferon alfa-2b 5292 2008 
rasagiline 5435 2008 
risedronate 5491 2008 
rituximab 5656 2008 
rotigotine 5382 2008 
sevelamer 5276 2008 
sevelamer 5305 2008 
sirolimus 3455 2008 
sitagliptin 4513 2008 
sorafenib 5225 2008 
tacrolimus 5329 2008 
tacrolimus 4886 2008 
tacrolimus 5237 2008 
teriparatide 5200 2008 
teriparatide 5572 2008 
trabectedin 5252 2008 
zanamivir 4715 2008 
ziconotide  5245 2008 
aliskiren 6371 2009 
alitretinion 6204 2009 
alteplase 6722 2009 
aripiprazole 5831 2009 
aripiprazole 6282 2009 
atazanavir 6283 2009 
bevacizumab 5479 2009 
bevacizumab 6250 2009 
bivalirudin 6275 2009 
bortezomib 6647 2009 
capecitabine 6576 2009 
Cinacalcet 6202 2009 
dabigatran 5528 2009 
darunavir 6571 2009 
darunavir 6572 2009 
darunavir 6833 2009 
doripenem  5849 2009 
esomeprazole 6152 2009 
etravirine (Intelence) 6000 2009 
ezetimibe 6429 2009 
ezetimibe 6429 2009 
ezetimibe 6429 2009 
febuxostat 6315 2009 
fentanyl 6829 2009 
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icatibant 5904 2009 
imiquimod 5614 2009 
lacosamide 6048 2009 
methylnaltrexone bromide 5881 2009 
micafungin 5880 2009 
Modafinil 2921 2009 
nebivolol 6325 2009 
nebivolol 6325 2009 
peginterferon alfa-2b 5474 2009 
pegylated liposomal doxorubicin 6273 2009 
pemetrexed 5800 2009 
rivaroxaban 6017 2009 
Rosiglitazone  3161 2009 
rosuvastatin  5927 2009 
rufinamide 6044 2009 
salmeterol fluticasone 5503 2009 
sugammadex  6014 2009 
Temoporfin 5910 2009 
tenofovir 6085 2009 
thalidomide 5573 2009 
Topotecan 5514 2009 
vildagliptin 5731 2009 
Vinorelbine 6288 2009 
Vinorelbine 6287 2009 
zoledronic acid 6147 2009 
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HAS Dataset: Missing Data 
 
Between January 2004-June 2009, the Comittee de Transparence part of the Haute 
Autorite de Sante (HAS) reviewed 315 submissions and made specific 
recommendations as to the incremental medical value of the new therapies under 
review.  
 
A data set of information pertaining to HAS appraisals was created collecting 
information on variables relating to (i) the clinical and economic characteristics of the 
technology under appraisal, as well as information on (ii) the process used to come to a 
decision, and (iii) the socio-economic context in which these decisions were made. 
In order to prepare the data set for analysis, understanding the data set is important.  
Here, the aim is to characterise the presence of missing data across variables and 
decisions to inform the need for imputing missing data.   
 
Distribution of Missing Data within HAS data set 
 The outcome considered is the ASMR rating given by the HAS committee, which 
ranges from 1 (high incremental beneft) to 5 (no incremental benefit).  In the total HAS 
sample, there are 5% of missing entries.   
 
The distribution of missing data across each variable was examined.   The total 
number of observations per variable is 315.  The variables with the highest number of 
missing information are those related to the percentage reimbursement (‘taux de 
remboursement)  and clinical package.  Note that the HAS does not include as part of 
the review process any cost components.     
 
The extent of missing data was also examined across appraisals.   The level of missing 
variables per appraisal ranged from 0 – 8.  The average number of ‘missing entries per 
appraisal was less than 1.   
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Figure D.1. HAS Distribution of missing data by variable (n=315) 
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HAS Dataset – Testing of Normality Assumption 
 
Method 
To determine the relevant statistical tests to use in assessing the significance of 
differences observed between means, it was necessary to assess whether the normality 
assumption was valid for the variables under consideration.  This would then determine 
the use of parametric or non-parametric tests.  For all variables, the sample is >30.  It 
has been suggested    that when analysing sample sizes of >30, even when the normality 
assumption is violated, parametric tests may still be performed (Pallant 2007, SPSS 
Survival Manual, 3rd edn, Maidenhead, OUP/McGraw-Hill).  Prior to making a decision 
on which variables to apply parametric or non-parametric tests, the distribution for each 
variable will be further examined.   
 
To test the normality assumption the following was performed for each non-categorical 
variable: 
• Skeweness was calculated 
• Kurtosis was calculated 
• The standardized normal probability plot (P-P plot) was graphed 
The graph and calculations are presented for each non-categorical variable and an 
assessment is made of whether the normality assumption is met or not.  A variable will 
be considered to meet the normal distribution assumption if  
• skewness is within the range ±1 
• Kurtosis value is within range ±3 
• P-P plot shows distribution of dataset is approximately linear 
 
In those circumstances where there is inconsistency between the three tests, if 2 of the 
tests suggest normal distribution, then it will be considered as such (but then tested 
using both parametric and non-parametric tests in sensitivity analyses).  
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Number of RCTs considered in appraisal (No_RCT) 
Skewness       2.583494 
Kurtosis       13.64883 
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This variable is not normally distributed.  
Mean sample size of RCTs considered in appraisal (RCTsize) 
Skewness       5.551863 
Kurtosis       39.18887 
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This variable is not normally distributed.  
Superiority demonstrated 
Normality test not performed as this is a categorical variable.  
Duration of RCT (RCTfwup) 
Skewness       3.850601 
Kurtosis       25.89232 
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This variable is not normally distributed. 
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 Active-Comp 
Categorical variable.   
Observational Studies 
Skewness       7.092638 
Kurtosis       60.95931 
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This variable is not normally distributed.  
 
Prevalence 
Skewness       5.9439 
Kurtosis        44.58945 
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This variable is not normally distributed.  
 
 
Alternative Available 
Normality test not performed as this is a categorical variable.  
Ethics 
Normality test not performed as this is a categorical variable.  
Cost-Effectiveness part of Process 
Normality test not performed as this is a categorical variable.  
BIM part of Process 
Normality test not performed as this is a categorical variable.  
Joint reimbursement & pricing decision 
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Normality test not performed as this is a categorical variable.  
Accountability for drug budget 
Normality test not performed as this is a categorical variable.  
Independence of HTA agency from MoH 
Normality test not performed as this is a categorical variable.  
Year of appraisal 
Skewness       .0097271 
Kurtosis        1.799967 
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Perhaps this is actually a categorical variable? 
Population under HTA remit 
Skewness       -.1608239 
Kurtosis        1.858135 
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Perhaps this is actually a categorical variable? 
% of GDP expenditure on health 
Same percentage GDP level between 2004-2009.  Therefore, no variation in the 
distribution across groups.  
Drug expenditure per person 
Skewness        -.257072 
Kurtosis       1.663579 
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Funding mechanism – centralised or decentralised 
Normality test not performed as this is a categorical variable.  
Election year 
Normality test not performed as this is a categorical variable.  
Priority Disease Area 
Normality test not performed as this is a categorical variable.  
BNF Category 
Normality test not performed as this is a categorical variable. 
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HAS dataset – descriptive statistics 
  Chi2 ANOVA T-Test (Rec 
vs Res) 
T-Test (Res 
vs NR) 
Kruskal-
Wallis 
Number of RCTs considered in 
decision 
  0.013 0.0415 0.5424 0.3375 
Size of population included in 
RCTs 
  0.8813 0.5764 0.9895 0.2038 
Statistically Significant results -         
yes (1) 
0.0001         
no (0)  -  -  -  -  - 
inconsistent (2)  -  -  -  -  - 
Length/extent of follow-up in RCT   0.1757 0.3324 0.3474 0.0013 
Relevance of RCT to payor 
decision 
  0.074 0.0716 0.1067 0.0137 
Number of observational studies 
considered in guidance 
  0.2197 0.487 0.2443 0.9466 
Consideration of CUA in guidance  -  -  -  -  - 
Prevalence of disease   0.0156 0.0213 0.0033 0.0001 
Availability of alternative therapies 
in current treatment setting. 
0.014         
Inclusion of patient submission  -  -  -  -  - 
Number of Decision Makers 
Accountable 
 -  -  -  -  - 
Ethical Considerations included as 
part of submission 
 -  -  -  -  - 
Cost-effectiveness evaluation 
component in process 
 -  -  -  -  - 
Budget impact as a component of 
decision-making process 
 -  -  -  -  - 
Pricing and Reimbursement 
decided jointly 
 -  -  -  -  - 
Accountability of drug budget  -  -  -  -  - 
Independence of decision-making   -  -  -  -  - 
Date guidance was issued   0.009 0.1108 0.0214 0.0017 
Population size – Agency coverage   0.009 0.1384 0.0185 0.0017 
GDP-healthcare expenditure   n/a n/a n/a n/a 
Healthcare expenditure on 
pharmaceuticals 
  0.0043 0.1865 0.0101 0.0019 
Drug funding process within 
healthcare system – whether 
centralized or decentralised 
 -  -  -  -  - 
Election year at time of decision 0.039         
Priority disease area           
Orphan Designated 0.0001         
Taux de remboursement   0.0646 0.9737 0.0082 0.0864 
HAS recommendation 0.009         
recommended  -  -  -  -  - 
restricted  -  -  -  -  - 
not recommended  -  -  -  -  - 
Hospital use only 0.0001         
Request for post-marketing study 0.004         
Reason for request 0.094         
Inscription Sécurité Sociale et 
Collectivités 
 -  -  -  -  - 
Réévaluation  -  -  -  -  - 
extension d'indication  -  -  -  -  - 
renouvellement d'inscription  -  -  -  -  - 
Redéfinition du périmètre des 
indications remboursables 
 -  -  -  -  - 
BNF Category 0.0001         
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HAS preliminary multivariate analysis model 
 
Table 7.1  Multivariate analysis of HAS coverage decisions 2004-2009:  preliminary model (n=315) 
ASMR III-IV Log Odds P value 95%  Conf. Interval 
Number of RCTs -0.2843941 0.044 -0.5611727 -0.00762 
Clinical superiority demonstrated in RCT -3.436836 0.146 -8.070138 1.196467 
Lack of clinical superiority in RCT -3.545748 0.146 -8.331433 1.239936 
Inconsistent demonstration of clinical 
superiority in RCT -2.217476 0.334 -6.718472 2.283521 
RCT duration of follow-up -0.0033383 0.308 -0.0097539 0.003077 
Use of active comparator in RCT 0.7665676 0.189 -0.3780955 1.911231 
Disease prevalence 5.22E-07 0.182 -2.45E-07 1.29E-06 
Presence of alternative therapy 0.6985936 0.04 0.0317558 1.365431 
Year guidance was issued 1.109892 0.136 -0.3503391 2.570123 
Orphan designation status -0.5771616 0.359 -1.809676 0.655353 
Malignant disease and 
immunosuppression -0.1716978 0.826 -1.700147 1.356752 
Central nervous system 4.623967 0.015 0.9009441 8.346989 
Infections 2.744761 0.039 0.1401706 5.349351 
Musculoskeletal and joint diseases -1.2293 0.064 -2.528295 0.069695 
Respiratory system 23.22601 0.000 21.32679 25.12522 
Skin 21.50354 0.000 20.19059 22.81649 
Hospital use only -0.2385087 0.745 -1.675585 1.198568 
Healthcare expenditure on 
pharmaceuticals -0.07369 0.172 -0.1793296 0.03195 
Reimbursement level obtained -0.2492197 0.917 -4.920654 4.422215 
Missing data on numbers of RCTs 
considered 20.86546 . . . 
Missing data on duration of RCTs -0.0353642 0.984 -3.551916 3.481188 
Missing data on active comparators used 
in RCT -4.462134 0.071 -9.303942 0.379675 
Missing data on prevalence of disease -2.325411 0.005 -3.964093 -0.68673 
Missing data on level of reimbursement -0.337959 0.463 -1.240771 0.564853 
Missing data on hospital use 0.1355593 0.903 -2.036081 2.3072 
Constant -2184.194 0.136 -5059.288 690.8998 
ASMR V Log Odds P value 95%  Conf. Interval 
Number of RCTs -0.3918877 0.007 -0.6766837 -0.10709 
Clinical superiority demonstrated in RCT 14.13418 0.992 -2883.015 2911.283 
Lack of clinical superiority in RCT 15.67453 0.992 -2881.435 2912.784 
Inconsistent demonstration of clinical 
superiority in RCT 16.1639 0.991 -2881.056 2913.383 
RCT duration of follow-up -0.0042145 0.229 -0.0110837 0.002655 
Use of active comparator in RCT 1.101055 0.074 -0.1066088 2.308718 
Disease prevalence 9.50E-07 0.017 1.70E-07 1.73E-06 
Presence of alternative therapy 0.5738384 0.353 -0.6380268 1.785704 
Year guidance was issued 0.6479199 0.388 -0.8234194 2.119259 
Orphan designation status -3.089502 0.001 -4.989264 -1.18974 
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Malignant disease and 
immunosuppression 0.2362465 0.785 -1.459433 1.931926 
Central nervous system 4.959432 0.01 1.207159 8.711704 
Infections 2.691694 0.045 0.0651163 5.318272 
Musculoskeletal and joint diseases -2.397214 0.003 -3.987509 -0.80692 
Respiratory system 23.52017 . . . 
Skin 21.35004 . . . 
Hospital use only -0.1694243 0.826 -1.679657 1.340808 
Healthcare expenditure on 
pharmaceuticals -0.0245484 0.654 -0.1317318 0.082635 
Reimbursement level obtained -2.667338 0.281 -7.517837 2.18316 
Missing data on numbers of RCTs 
considered 21.26527 0.000 18.82152 23.70903 
Missing data on duration of RCTs -0.9071335 0.686 -5.310142 3.495875 
Missing data on active comparators used 
in RCT 14.28305 0.992 -2883.184 2911.75 
Missing data on prevalence of disease -2.916096 0.001 -4.578727 -1.25346 
Missing data on level of reimbursement -0.1922116 0.711 -1.207439 0.823016 
Missing data on hospital use -0.5220553 0.693 -3.112505 2.068394 
Constant -1298.865 . . . 
 
Note:  Technologies with ASMR I or II are the reference case.  
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E. Summary of Interviews with representatives of NICE, SMC, and 
CFH 
HTA Body NICE 
Date 2nd of February 2011 
Attendees Professor Peter Littlejohns 
Clinical and Public Health Director 
National Institute for Health and Clinical Excellence 
MidCity Place | 71 High Holborn | London WC1V 6NA | United 
Kingdom 
Tel: 44 (0)20 7045 2091 fax: 44 (0)845 003 7784 
 
Objectives The aim of this interaction was to ascertain if the NICE 
characteristics were accurately captured in the sample used for 
analysis, if the approach to analysis was clear and in particular 
the reaction to the model results and potential for suggestions or 
additional analyses. 
Discussion 
Summary 
Sample Characteristics 
o Prof. Littlejohns confirmed that a three-category outcome 
variable is a valid option to capturing the decision-making 
options available to the NICE.   It was recognised that 
both three-category and binary outcome variables had also 
been used in published assessments of NICE decision-
making.  
o The reported proportion of recommendations, restrictions 
and non-recommendations observed within the sample of 
analysis was felt to differ from other publically available 
statistics on the same.   
o Professor Littlejohns provided information on the 
distribution of coverage decisions made by NICE in 2000-
2010 for all technology types (including medical devices) 
and patient populations (including paediatrics).   
o The proportions differed from those observed within the 
analysis.  It was discussed that the potential sources for 
these differences could be due to a different time horizon 
and technologies included.  This dataset incorporated 
decisions made between January 2004 and June 2009, and 
included pharmaceuticals indicated for adult populations.  
o It was felt to be a plausible explanation for the differences 
observed.  
o The explanatory variables extracted for analysis were felt 
to be appropriate and reflect various aspects of the NICE 
decision-making process.  
Model results 
• A unit increase in the ICER was found to increase the 
odds of restriction or non-recommendation and in the 
discussion this was seen as reflecting NICE decision-
making and coherent with previous published research 
• The importance of clinical criteria shown in the model 
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was also considered to be coherent with NICE’s decision-
making process 
• An increase in the number of technologies appraised 
within the same appraisal was found to increase the odds 
of restriction.  While this had  had not previously been 
studied in other published literature, Professor  Littlejohns 
offered the interpretation that it could be plausible to 
assume that the appraisal of multiple technologies 
simultaneously may lead to a situation in which a single 
technology is recommended, and the rest are restricted or 
not recommended. 
• Professor Littlejohns stressed the importance of 
ascertaining the distribution of NICE decisions across the 
three outcome categories to ensure the validity of the 
results, but overall was able to state that the explanatory 
variables identified as significant in the model could 
plausibly reflect NICE decision-making.    
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HTA Body SMC 
Date 20th December 2010 
Attendees Dr Andrew Walker,  
Member of the SMC NDC Senior Lecturer in Health Economics,  
University of Glasgow 
 
Objectives The aim of this interaction was to ascertain if the SMC 
characteristics were accurately captured in the sample used for 
analysis, if the approach to analysis was clear and in particular the 
reaction to the model results and potential for suggestions or 
additional analyses. 
Discussion 
Summary 
Role of SMC 
• Dr. Walker commented that SMC does not assess the 
notion of affordability, unlike NICE. 
• Highlighted that the SMC issues decisions that either 
accept or reject technologies for use, and this subtlety 
should be reflected in how SMC outcomes are described 
• Dr. Walker confirmed that a three-category outcome 
variable accurately reflected the decision-making options 
available to the SMC.  It was noted that the proportion of 
recommendation was perhaps lower than what would be 
anticipated, although it was suggested that this is likely 
explained by the time horizon used in the analysis (2004-
2009), and to the fact that the analysis was restricted to 
full submissions and resubmissions (i.e. excluded 
abbreviated submissions).  
• The explanatory variables extracted for analysis were felt 
to be appropriate and reflect various aspects of the SMC 
decision-making process.  
Model results 
• Draft multivariate analysis of SMC decision-making was 
shared to gather feedback on the internal validity of the 
model.   
• An increasing trial duration was found to decrease the log 
odds of a restriction and non-recommendation, and this 
effect was found to be plausible within the SMC decision-
making process which places significant emphasis on the 
clinical evidence and quality of that evidence 
• An increasing ICER decreased the odds of 
recommendation and this was felt to reflect the SMC’s 
objective of determining and accepting technologies that 
demonstrated value-for-money. 
• The role of the budgetary impact was discussed at length.  
The draft model suggested that increasing budgetary 
impact was associated with an increased odds of 
recommendation.  The first comment was that this 
confirmed the results of descriptive analysis, suggesting 
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that SMC is not driven by budgetary impact concerns.  
This would also reflect the notion that SMC does not 
concern itself with the notion of affordability in the same 
way that NICE would.  Dr. Walker suggested that the 
direction of the effect associated with budget impact in the 
model may actually be a surrogate or proxy for other 
variables.  For example, it was plausible that technologies 
with orphan designation or with no alternative therapies 
could be associated with higher budgetary impact, but 
were also technologies more likely to be supported by 
weaker clinical evidence (non-comparative or placebo 
controlled trials, small sample size, short duration).  It was 
also suggested that technologies with weaker value-for-
money profiles may argue for budgetary neutrality as an 
argument for recommendation, and that the model 
reflected this strategy.     It was recommended by Dr. 
Walker to further examine the role of the budget impact 
variable in the model and consider alternative variables to 
explain this effect.   
• The impact of an indication for the treatment of skin 
diseases was also discussed.  It was not clear why such 
technologies, which represent a small proportion of 
technologies appraised by the SMC, should increase the 
odds of recommendation.  It was suggested by Dr. Walker 
to further explore and confirm the effect of this variable in 
the model. 
• The impact of an indication for infectious diseases was 
also discussed, particularly the reason for its diverging 
effect:  an infectious diseases indication appeared to 
decrease the odds of a non-recommendation but increase 
the odds of a restriction.  It was proposed that a plausible 
reason for this could be due to the fact that antibiotics are 
included as part of the infectious diseases group, and that 
while these technologies may not always be supported by 
high quality evidence there is reluctance to not-
recommend antibiotics because of the problems 
encountered with the development of resistance to 
antibiotics in clinical practice.  
• The effect of patient submission in the model decreased 
the odds of recommendation.  Dr. Walker suggested that 
this may reflect the fact that patient submissions tend to be 
made for diseases for which there is concern that a non-
recommendation is plausible, or for rare and severe 
diseases.  It should not be interpreted as reflecting the fact 
that patient evidence is not considered or that it impacts 
negatively on the decision outcome, but rather that it is a 
proxy for the characteristics of the technology being 
appraised.  It was suggested that further exploration 
should be conducted to understand the characteristics of 
those technologies with and without patient submissions.   
• An overall comment made by Dr. Walker was the need to 
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comment on those variables that were not found to be 
significant, as this is potentially as important as those that 
were found to be significant in their effect on SMC 
decisions 
• Overall, Dr. Walker commented that the variables found 
to be significant in the model reflected SMC decision-
making, with the exception of technologies for skin 
diseases which needed further confirmation.  In addition, 
he stressed the need to re-examine in more depth the 
mechanisms through which the budget impact and patient 
submissions were operating in the model.   
 
 
393 
 
 
HTA Body CFH of CVZ 
Date 6th of January 2011 
Attendees Dr. Martin van der Graaff, Secretary medicines evaluation 
committee (CFH) Dr. Wim Goettsch 
Sarah Kleijnen (M. Sc. ) Project coordinator EUnetHTA WP5 
 
College voor Zorgverzekeringen (CVZ) 
Health Care Insurance Board 
Eekholt 4 1112 XH Diemen 
Postbus 320 1110 AH Diemen 
 
Objectives The aim of this interaction was to ascertain if the CFH 
characteristics were accurately captured in the sample used for 
analysis, if the approach to analysis was clear and in particular the 
reaction to the model results and potential for suggestions or 
additional analyses.   
Discussion 
Summary 
CVZ characteristics 
• The interpretation of the analysis should take into account 
the fact that CVZ appraisals are not made in a 'static' 
context - in other words, there are changers over time in 
the processes that guide the appraisals, and in the outlook 
of the agency overtime.   
• Should refer to the CVZ not the CFH  
• Orphan drug list does not exist per se:  orphan 
technologies are either included like other technologies in 
the GVS (usually Iist 1B) or on the expensive drug list.  
• Not all expensive drugs are on the expensive drug list.  
Model variables 
• the categorisation of CVZ coverage decisions into 
'recommended', 'restricted', 'not recommended' categories 
was found to make sense, although it was recognised that 
such categorisation to some degree over simplifies the 
reimbursement options in the Dutch system.   
• Expensive drugs are appraised indication by indication, 
and inclusion on the expensive drug list is specific to the 
appraised indication.  Could therefore consider inclusion 
on expensive drug list as a form of restriction  
• Would be useful to capture severity of disease as a factor, 
and also end of life technologies. Currently, only disease 
categories are captured 
• CVZ decision-making is driven by the strength and the 
robustness of the scientific evidence supporting the 
technology.   
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Cost effectiveness 
• The use of cost effectiveness in the appraisal process: 
o officially part of the process as of 2006, and was 
used experimentally  until 2007-08 when CE 
criteria became more strongly used in  decision-
making.  Note that if a technology brings no added 
value, then no Cost-Effectiveness analysis is 
referred to in the report, even though it may have 
been submitted by the manufacturer. 
• In the CVZ appraisal process, used of cost effectiveness 
results is very different from NICE/SMC; threshold is not 
utilised yet.  Currently, the robustness/quality of the 
analysis drives the decision. In the future also the outcome 
of a cost-effectiveness analysis in Euro/QALY may play a 
role in the decision. 
Model results 
o in general, model results appear to fit with expectations.  
For example:  the presence of an active comparator and 
the demonstration of  superiority in a clinical trial decrease 
the odds of a restriction/ non recommendation.  This was 
considered to make sense by the participants. 
o The fact that cancer therapies were associated with an 
increased  odds of a recommendation also made sense, as 
did the fact that  technologies for Cardio-vascular, 
musculoskeltal diseases decreased the  odds of 
recommendation. 
o Increase in budget impact increased the odds of a 
restriction or non-recommendation.   
o The impact of patient submission was discussed.  
Appraisals for the 1b or expensive drug list frequently 
include the request for feedback from patient groups - 
however, these are not often reported in the final CVZ 
reports.  This strongly suggests that the proportion of 
technologies with patient submissions identified in the 
publicly available data is under-represented.  
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F. Imputation techniques – summary of imputation techniques tested 
using SMC dataset 
 
Objective 
To maximize the number of observations and sample size for both the individual and 
pooled analyses, imputation techniques were used to estimate entries for those 
observations that were affected by ‘not applicable’ or ‘not reported’ data.  In order to 
determine the method most adapted to the analyses, several approaches to imputation 
were tested including imputation by replacing missing values with the overall mean of 
the variable, generating regression estimates of the missing value, and multiple 
imputation techniques that take random variation into account.  This exercise was 
performed on one of the HTA datasets (SMC dataset) to test which imputation method 
would be most useful to extrapolate to the remaining HTA multivariate analyses.   
 
Analyses 
The results of this exercise are summarised in the tables provided below: 
• Table 1 provides the multinomial logistic regression results in which incomplete 
observations were imputed using mean imputation.  In this technique, the mean 
value of the variable is used to fill incomplete observations.  
• Table 2 provides the multinomial logistic regression results in which incomplete 
observations were imputed using regression driven imputation.  In this 
technique, regression from other available variables is used to generate a value 
to fill incomplete entries. To generate these values the ‘impute’ command from 
Stata was used.   
• Table 3 provides the multinomial logistic regression results in which incomplete 
observations were imputed using multiple imputation techniques.  In this 
technique, the statistical model to generate the imputed values is based on 
multiple imputed datasets are created each of which contain different imputed 
values (UCLA 2011).  This technique can also take into consideration whether 
the variable is categorical, and was therefore felt to be relevant for this analysis.  
In this particular test case, only one imputed dataset was generated.    
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Table 1.  SMC multinomial logistic regression results With mean imputation 
(decision==recommended is the base outcome)
                                                                              
       _cons     2.099526   .6853151     3.06   0.002     .7563334    3.442719
 alternative    -1.042411   .6076999    -1.72   0.086    -2.233481    .1486584
  prevalence    -.0000209   9.76e-06    -2.14   0.033      -.00004   -1.74e-06
       BNF13    -1.818445   .9247152    -1.97   0.049    -3.630854    -.006037
        BNF7    -1.965731   .5906051    -3.33   0.001    -3.123296   -.8081663
        ICER     .0000382   .0000133     2.88   0.004     .0000122    .0000643
     RCTfwup    -.0087137   .0036469    -2.39   0.017    -.0158615    -.001566
     RCTsize     -.000307   .0001717    -1.79   0.074    -.0006435    .0000295
not recomm~d  
                                                                              
       _cons     .8277638   .6830546     1.21   0.226    -.5109986    2.166526
 alternative    -.6010864   .6107646    -0.98   0.325    -1.798163    .5959902
  prevalence    -.0000124   8.44e-06    -1.47   0.141     -.000029    4.12e-06
       BNF13    -.3657278   .7352662    -0.50   0.619    -1.806823    1.075368
        BNF7    -.4321934   .4895508    -0.88   0.377    -1.391695    .5273085
        ICER     .0000353   .0000133     2.65   0.008     9.19e-06    .0000613
     RCTfwup    -.0030883   .0029582    -1.04   0.296    -.0088862    .0027096
     RCTsize      .000034   .0000643     0.53   0.596    -.0000919      .00016
restricted    
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -266.75563                       Pseudo R2       =     0.1086
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(14)     =      64.99
Multinomial logistic regression                   Number of obs   =        288
 
 
Table 2.  SMC multinomial logistic regression results With imputation driven by 
regression from other available variables (i.e. impute command in stata) 
(decision==recommended is the base outcome)
                                                                              
       _cons     2.178807   .6699368     3.25   0.001     .8657553    3.491859
 alternative    -.9756176   .6028344    -1.62   0.106    -2.157151    .2059161
IMPprevale~e     -.000015   8.75e-06    -1.71   0.087    -.0000321    2.15e-06
       BNF13    -1.721107       .918    -1.87   0.061    -3.520354    .0781396
        BNF7    -1.674223   .5820207    -2.88   0.004    -2.814962   -.5334832
    IMPICER2     .0000273   .0000115     2.37   0.018     4.75e-06    .0000498
  IMPRCTfwup    -.0095656   .0036281    -2.64   0.008    -.0166765   -.0024547
  IMPRCTsize    -.0002907   .0001589    -1.83   0.067    -.0006022    .0000208
not recomm~d  
                                                                              
       _cons     .9710208   .6719289     1.45   0.148    -.3459356    2.287977
 alternative    -.5311602   .6109776    -0.87   0.385    -1.728654    .6663339
IMPprevale~e    -.0000158   9.13e-06    -1.73   0.083    -.0000337    2.08e-06
       BNF13    -.3224628   .7241085    -0.45   0.656    -1.741689    1.096764
        BNF7    -.1610554   .4803539    -0.34   0.737    -1.102532    .7804211
    IMPICER2     .0000246   .0000115     2.13   0.033     2.00e-06    .0000472
  IMPRCTfwup    -.0039241   .0029853    -1.31   0.189    -.0097751    .0019269
  IMPRCTsize     .0000563   .0000696     0.81   0.418      -.00008    .0001926
restricted    
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -268.25905                       Pseudo R2       =     0.1036
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(14)     =      61.98
Multinomial logistic regression                   Number of obs   =        288
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Table 3.  SMC multinomial logistic regression results with multiple imputation 
using ICE command 
(decision==recommended is the base outcome)
                                                                              
       _cons     2.565645   .6132337     4.18   0.000     1.363729    3.767561
 alternative    -1.017091   .5988571    -1.70   0.089    -2.190829    .1566478
  prevalence    -4.91e-06   3.10e-06    -1.58   0.114     -.000011    1.17e-06
       BNF13    -1.894411   .9185067    -2.06   0.039    -3.694651   -.0941711
        BNF7    -1.942678   .5966816    -3.26   0.001    -3.112152   -.7732035
        ICER     9.70e-06   3.24e-06     2.99   0.003     3.35e-06    .0000161
     RCTfwup    -.0091805   .0033508    -2.74   0.006     -.015748    -.002613
     RCTsize     -.000246   .0001048    -2.35   0.019    -.0004515   -.0000405
not recomm~d  
                                                                              
       _cons      1.37813   .6212923     2.22   0.027       .16042    2.595841
 alternative    -.6032234   .6058133    -1.00   0.319    -1.790596    .5841489
  prevalence    -3.97e-06   3.03e-06    -1.31   0.190    -9.90e-06    1.96e-06
       BNF13    -.4085267   .7258759    -0.56   0.574    -1.831217    1.014164
        BNF7    -.4062836   .4904738    -0.83   0.407    -1.367595    .5550274
        ICER     8.23e-06   3.21e-06     2.57   0.010     1.95e-06    .0000145
     RCTfwup    -.0029613   .0028239    -1.05   0.294    -.0084961    .0025735
     RCTsize    -.0000179   .0000548    -0.33   0.744    -.0001252    .0000895
restricted    
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -269.35554                       Pseudo R2       =     0.0999
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(14)     =      59.79
Multinomial logistic regression                   Number of obs   =        288
 
 
Results 
The results suggest that the various imputation techniques provided similar pseudo R-
squared results across the models and similar pattern of size, direction and significance 
of effect.  It was therefore felt to be appropriate, for the remainder of the multivariate 
analyses to impute missing values by using regression estimates of the missing value. 
 
References 
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G. Implications of assuming ordinality of the outcome variable on 
multivariate analyses 
 
Overview 
In performing the multivariate analysis of coverage decisions issued by NICE, SMC, 
CFH and HAS, an important consideration from a methodological standpoint is whether 
ordinality should be assumed, as this has implications for the statistical methods that 
should be applied.  A categorical variable can be considered ordinal if there is a 
‘natural’ ordering in the outcome that can be identified.  Dakin et al (2006), in their 
econometric analysis of NICE decision-making, used a three-category approach, and 
argued that an assumption of ordinality was not appropriate as there was no consensus 
on the ‘direction’ of the ordering.  In other words, depending on whether the aim of the 
appraisal decision was to define volume (i.e. number of patients that can access the 
therapy), total drug cost for the technology (budget impact) or maximization of 
patient/healthcare system outcome can lead to different ordering and consideration of 
appraisal decisions.  For example, if the main objective of the coverage decision was to 
control cost, then it could be expected that those decisions which restrict or not 
recommend access may be considered as preferable to a recommendation. The opposite 
is true if we consider patient access to medications as the main objective of coverage 
decisions:  in this case, a coverage decision that covers 100% of the eligible population, 
less than 100% or 0% could be considered.  In the base case analysis, multinomial logit 
regression was assumed to be appropriate.  Here, multivariate models were run for each 
of the four HTA bodies in which ordinality of the outcome variable was assumed.  The 
results of these analyses are compared with the base-case analyses and are presented 
below.   
 
Ordinal Logistic Regression method 
A well known ordinal logistic regression model is the proportional odds model.  It 
assumes that the relationship between each pair of outcome groups is the same.  This is 
a significant assumption and is highly restrictive – in many cases the coefficient for a 
variable in one group may be different from that in the lower category group (Williams 
2006).    The proportional odds model can only  be applied if the assumption of 
proportional odds is not violated.  To assess whether this is the case, two tests were 
performed:  A likelihood ratio test (using the omodel command by Wolfe and Gould’s 
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(1998)) and a Brant test (Long and Freese) were performed to assess whether the 
proportional odds model applied was appropriate or not – i.e. whether the assumption of 
proportional odds was violated.  The Brant test provides both a global test of whether 
any variable violates the parallel-lines assumption, as well as tests of the assumption for 
each variable separately (Williams 2006).  
 
In the event that the assumption of proportional odds is violated, several options exist 
that provide alternative modelling options. The first would be to revert to a non-ordinal 
model, such as the multinomial logistic regression model.  This is the model that was 
used in the base case analyses of this thesis, and therefore will not be repeated in this 
sensitivity analysis.  Another option to the proportional odds model would be to use a 
generalized ordered logistic model.  Therefore, a generalized ordered logistic model was 
run.  To run such a model, the gologit2 command developed by Williams (2006) was 
used.  The advantage of gologit2 is that, rather than assuming that the proportional odds 
assumption is violated for all variables, it assesses those variables for which this is 
actually the case, and fits partial proportional odds models to those variables where the 
assumption holds, and generalized linear models where it does not hold – in other 
words, the restriction of the proportional odds assumption is relaxed for those variables 
that violate the assumption only (Williams 2006).    
 
 When interpreting the results of the generalized ordered logit model it is important to 
bear in mind that, while the output resembles that obtained from multinomial logistic 
regression, the reference case is not the same.  In the generalized ordered logit model, 
the reference case is a group of outcome variables. The first panel of output compares 
recommended technologies (category 1) with both restricted (cat. 2) and not-
recommended technologies (cat. 3), while the second panel compares restricted (cat. 2) 
and recommended (cat. 1) categories with not recommended technologies (cat. 3, 
reference) (Williams 2006).  Within the model output, positive coefficients signal that 
an increase in the unit of the explanatory variable increased the odds that the technology 
will be in a higher outcome category (category 3 is the highest category representing 
non recommendation).  The opposite is true for negative coefficients.  
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Results 
NICE 
When the proportional odds ordinal logistic regression model was fitted to the data, 
both the likelihood ratio test and the Brant test were significant (at the 0.05) level, 
meaning that the assumption of proportional odds between the outcome categories was 
violated.  Therefore, a generalized ordered logistic model was run.  Table 1 provides the 
base-case model for NICE coverage decisions.  
 
Table 1. Multivariate analysis of NICE coverage decisions 2004-2009:  base case 
model results (n=118) 
Restricted Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.567512 0.006 -2.678506 -0.456519 
ICER 0.0000484 0.009 0.0000123 0.0000846 
Number of technologies appraised simultaneously 0.4891155 0.005 1.44E-01 0.8338142 
Year of Appraisal 0.3579406 0.072 -0.0317402 0.7476213 
Constant -718.9729 0.071 -1500.761 62.81519 
Not Recommended Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -2.009114 0.016 -3.636783 -0.3814446 
ICER 0.0000865 0.000 0.0000419 0.0001311 
Number of technologies appraised simultaneously 0.1199482 0.645 -3.91E-01 0.630705 
Year of Appraisal 0.6721141 0.028 0.0733939 1.270834 
Constant -1351.138 0.028 -2552.896 -149.3792 
Note:  Recommended technologies are the reference case 
 
Table 2.  NICE dataset - Generalized Ordered Logit Model (proportional odds 
constraint relaxed for all variables) 
                                                                              
       _cons    -550.1457   508.9175    -1.08   0.280    -1547.606    447.3143
        year     .2726342   .2535441     1.08   0.282     -.224303    .7695715
    no_drugs    -.2336803   .2087955    -1.12   0.263     -.642912    .1755513
superior_yes    -1.136288    .727402    -1.56   0.118     -2.56197    .2893934
        ICER      .000071   .0000217     3.28   0.001     .0000286    .0001134
Restricted    
                                                                              
       _cons    -855.2074   406.0203    -2.11   0.035    -1650.993   -59.42216
        year     .4257265   .2023483     2.10   0.035     .0291311    .8223218
    no_drugs     .5187612    .181614     2.86   0.004     .1628043     .874718
superior_yes    -1.660658   .5602506    -2.96   0.003    -2.758729   -.5625873
        ICER     .0000663   .0000191     3.47   0.001     .0000288    .0001038
Recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -79.569463                       Pseudo R2       =     0.2878
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(8)      =      64.30
Generalized Ordered Logit Estimates               Number of obs   =        118
 
Generalized ordinal logit models were implemented – one model (Table 2) the 
proportional odds constraint relaxed was for all variables, while in the other model the 
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proportional odds assumption relaxed only for variables that violated the assumption 
(Table 3).   The results of the model are shown in Table 2 – and provide very similar 
results to the base case analyses run using a multinomial logistic regression model.  In 
the first panel, recommended technologies are compared with restricted and not 
recommended technologies.  An increase in the ICER increases the odds of restriction 
and non-recommendation, as does an increase in the year of appraisal and the number of 
technologies appraised simultaneously.  The demonstration of superiority within the 
RCT decreases the odds of restriction or non-recommendation.  These results are in line 
with those observed in the base case analysis.  In the second panel, recommended and 
restricted technologies were compared with non-recommended technologies (reference).  
In this panel, an increase in the ICER increased the odds of non-recommendation, as did 
the year of appraisal.  The demonstration of clinical superiority and an increase in the 
number of technologies appraised simultaneously decreased the odds of non-
recommendation, increasing the odds of either recommendation or restriction.   
 
Table 3.  NICE Generalized Ordered Logit Regression (proportional odds 
assumption relaxed only for variables that violate the assumption) 
  
             
       _cons  
                                                                
  -731.9488   330.9301    -2.21   0.027     -1380.56   -83.33773
        year      .363303   .1648912     2.20   0.028     .0401222    .6864838
    no_drugs    -.2428722   .2036811    -1.19   0.233    -.6420799    .1563355
superior_yes     -1.47203   .4768137    -3.09   0.002    -2.406568   -.5374923
        ICER     .0000691   .0000152     4.54   0.000     .0000393     .000099
Restricted    
                                                                              
       _cons    -730.0836   330.8916    -2.21   0.027    -1378.619   -81.54787
        year      .363303   .1648912     2.20   0.028     .0401222    .6864838
    no_drugs     .5114306   .1765594     2.90   0.004     .1653805    .8574806
superior_yes     -1.47203   .4768137    -3.09   0.002    -2.406568   -.5374923
        ICER     .0000691   .0000152     4.54   0.000     .0000393     .000099
Recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
 ( 3)  [Recommended]superior_yes - [Restricted]superior_yes = 0
 ( 2)  [Recommended]year - [Restricted]year = 0
 ( 1)  [Recommended]ICER - [Restricted]ICER = 0
Log likelihood = -79.867881                       Pseudo R2       =     0.2851
                                                  Prob > chi2     =     0.0000
                                                  Wald chi2(5)    =      34.37
Generalized Ordered Logit Estimates               Number of obs   =        118
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SMC 
When the proportional odds ordinal logistic regression model was fitted to the SMC 
data, both the likelihood ratio test and the Brant test were significant (at the 0.05) level, 
meaning that the assumption of proportional odds between the outcome categories was 
violated.  Therefore, a generalized ordered logistic model was run.   
 
Table 4 SMC Base case multinomial logistic regression 
Restricted Technologies Log Odds P value 95%  Conf. Interval 
RCT size 0.0000563 0.418 -0.00008 0.0001926 
RCT duration of follow-up -0.0039241 0.189 -0.0097751 0.0019269 
ICER 0.0000246 0.033 0.000002 0.0000472 
Infectious Diseases -0.1610554 0.737 -1.102532 0.7804211 
Skin Diseases -0.3224628 0.656 -1.741689 1.096764 
Disease prevalence -0.0000158 0.083 -0.0000337 2.08E-06 
Presence of alternative therapy -0.5311602 0.385 -1.728654 0.6663339 
Constant 0.9710208 0.148 -0.3459356 2.287977 
Restricted Technologies Log Odds P value 95%  Conf. Interval 
RCT size -0.0002907 0.067 -0.0006022 0.0000208 
RCT duration of follow-up -0.0095656 0.008 -0.0166765 -0.0024547 
ICER 0.0000273 0.018 4.75E-06 0.0000498 
Infectious Diseases -1.674223 0.004 -2.814962 -0.5334832 
Skin Diseases -1.721107 0.061 -3.520354 0.0781396 
Disease prevalence -0.000015 0.087 -0.0000321 2.15E-06 
Presence of alternative therapy -0.9756176 0.106 -2.157151 0.2059161 
Constant 2.178807 0.001 0.8657553 3.491859 
 
The resulting model for this sensitivity analysis is shown below.  The pseudo R squared 
for this model is similar to that of the base case model using multinomial logistic 
regression techniques (0.0981 vs. 0.1063). The results of the model are shown in Table 
5 – and provide generally similar results to the base case analyses run using a 
multinomial logistic regression model (Table 4).  In the first panel, recommended 
technologies are compared with restricted and not recommended technologies.  An 
increase in RCT size increases the odds of a recommendation, as does an increase in the 
duration of follow-up.  An increase in the ICER increases the odds of restriction or non 
recommendation, although in this sensitivity analysis the statistical significance of the 
effect of the ICER is borderline (p=0.102).   Technologies indicated for the treatment of 
infectious diseases or skin diseases increase the odds of recommendation, as was also 
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seen in the base-case analyses.  An increasing prevalence increased the odds of 
recommendation.  Its effect in the lower panel of results was not significant.   Table 6 
provides results for the generalized ordinal logit model in which proportional odds 
assumption relaxed only for variables that violate the assumption.  The resulting pseudo 
R-squared is 0.0811, lower than that observed in the base case model (0.1063), although 
the direction and size of effect observed in this model is similar to that observed in the 
previous generalized model.  .    
 
Table 5  SMC Generalized Ordered Logit Regression (proportional odds assumption 
relaxed for all variables) 
       _cons     .9601263   .3889691     2.47   0.014      .197761    1.722492
 alternative    -.5606204   .3587356    -1.56   0.118    -1.263729    .1424883
IMPprevale~e    -8.39e-06   6.73e-06    -1.25   0.213    -.0000216    4.81e-06
       BNF13    -1.391018   .8042916    -1.73   0.084    -2.967401    .1853643
        BNF7    -1.661123   .4849069    -3.43   0.001    -2.611523   -.7107234
    IMPICER2     4.95e-06   4.41e-06     1.12   0.261    -3.68e-06    .0000136
  IMPRCTfwup    -.0071538   .0028702    -2.49   0.013    -.0127794   -.0015283
  IMPRCTsize    -.0002936   .0001384    -2.12   0.034    -.0005648   -.0000224
restricted    
                                                                              
       _cons     2.509094   .6185565     4.06   0.000     1.296745    3.721442
 alternative    -.8496164   .5720232    -1.49   0.137    -1.970761    .2715285
IMPprevale~e    -.0000136   6.95e-06    -1.96   0.050    -.0000272    1.32e-08
       BNF13    -1.003322   .6718258    -1.49   0.135    -2.320076    .3134322
        BNF7    -.8027816   .4520825    -1.78   0.076    -1.688847    .0832838
    IMPICER2     .0000163   9.96e-06     1.63   0.102    -3.25e-06    .0000358
  IMPRCTfwup    -.0062476   .0026463    -2.36   0.018    -.0114342   -.0010609
  IMPRCTsize    -.0000316   .0000616    -0.51   0.608    -.0001524    .0000892
recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -269.88325                       Pseudo R2       =     0.0981
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(14)     =      58.73
Generalized Ordered Logit Estimates               Number of obs   =        288
 
Table 6.  SMC Generalized Ordered Logit Regression (proportional odds assumption 
relaxed only for variables that violate the assumption) 
   
                                                                              
       _cons     .7786995   .3621462     2.15   0.032      .068906    1.488493
 alternative    -.5743616   .3324418    -1.73   0.084    -1.225935    .0772123
IMPprevale~e    -.0000103   6.03e-06    -1.71   0.087    -.0000222    1.49e-06
       BNF13     -1.24658   .5908885    -2.11   0.035      -2.4047   -.0884596
        BNF7    -1.241631   .3584794    -3.46   0.001    -1.944238   -.5390246
    IMPICER2     6.98e-06   4.91e-06     1.42   0.155    -2.64e-06    .0000166
  IMPRCTfwup    -.0072192   .0022261    -3.24   0.001    -.0115823   -.0028561
  IMPRCTsize    -.0000961   .0000467    -2.06   0.040    -.0001877   -4.59e-06
restricted    
                                                                              
       _cons     2.642918   .3944229     6.70   0.000     1.869864    3.415973
 alternative    -.5743616   .3324418    -1.73   0.084    -1.225935    .0772123
IMPprevale~e    -.0000103   6.03e-06    -1.71   0.087    -.0000222    1.49e-06
       BNF13     -1.24658   .5908885    -2.11   0.035      -2.4047   -.0884596
        BNF7    -1.241631   .3584794    -3.46   0.001    -1.944238   -.5390246
    IMPICER2     6.98e-06   4.91e-06     1.42   0.155    -2.64e-06    .0000166
  IMPRCTfwup    -.0072192   .0022261    -3.24   0.001    -.0115823   -.0028561
  IMPRCTsize    -.0000961   .0000467    -2.06   0.040    -.0001877   -4.59e-06
recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
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CFH 
When the proportional odds ordinal logistic regression model was fitted to the data, 
both the likelihood ratio test and the Brant test were significant (at the 0.05) level, 
meaning that the assumption of proportional odds between the outcome categories was 
violated.  Therefore, a generalized ordered logistic model was run.   
 
Table 7.  Multivariate analysis of CFH coverage decisions 2004-2009:  base case 
model results   
Restricted Log Odds P value 95% Confidence Interval 
Use of active comparator in RCT -0.4926263 0.239 -1.312877 0.3276248 
Demonstrated clinical superiority in 
RCT -0.8223267 0.022 -1.52789 -0.1167636 
Budgetary Impact 0.0068947 0.051 -0.0000311 0.0138206 
Cancer therapy -1.593124 0.000 -2.467556 -0.7186923 
Therapies for cardiovascular diseases 1.401083 0.017 0.2532709 2.548895 
Therapies for obstetrics, gynaecology, 
and urinary-tract disorders 2.396135 0.032 0.2027481 4.589521 
Prevalence of target population -0.00000135 0.091 -0.0000029 2.15E-07 
Patient Submission -0.149162 0.879 -2.075549 1.777225 
Lack of data on duration of RCT 0.2441296 0.560 -0.5760478 1.064307 
Constant 0.2812028 0.459 -0.4628566 1.025262 
Not Recommended Log Odds P value 95% Confidence Interval  
Use of active comparator in RCT -2.541106 0.000 -3.839421 -1.242791 
Demonstrated clinical superiority in 
RCT -1.853915 0.000 -2.818847 -0.8889837 
Budgetary Impact 0.0047054 0.217 -0.0027627 0.0121735 
Cancer therapy -0.6968874 0.177 -1.70854 0.3147655 
Therapies for cardiovascular diseases 0.823405 0.338 -0.8608332 2.507643 
Therapies for obstetrics, gynaecology, 
and urinary-tract disorders 2.197455 0.141 -0.7261041 5.121014 
Prevalence of target population -1.64E-08 0.982 -1.42E-06 1.38E-06 
Patient Submission 1.786073 0.032 0.1576834 3.414462 
Lack of data on duration of RCT 1.775784 0.001 0.7376478 2.813921 
Constant 0.0663455 0.878 -0.7782347 0.9109256 
 
The results of the model are shown in Table 8 – and provide generally similar results to 
the base case analyses run using a multinomial logistic regression model (Table 7).  The 
model results for this sensitivity analysis yield a slightly higher pseudo R-squared than 
in the base case model (0.1929 vs. 0.1725).  In the first panel, recommended 
technologies are compared with restricted and not recommended technologies.  An 
increase in the proportion of trials with an active comparator, the demonstration of 
superiority, and cancer therapies increase the odds of recommendation, as was observed 
in the base-case analysis.  Technologies indicated for the treatment of cardiovascular 
disorders or for obstetrics/gynaecology disorders, as well as the presence of a patient 
submission and the lack of information on the trial duration increased the odds of 
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restriction or non-recommendation, also consistent with the base case analysis. Table 8 
provides results for the generalized ordinal logit model in which proportional odds 
assumption relaxed only for variables that violate the assumption.  The resulting pseudo 
R-squared is 0.1646, similar to that observed in the base case model (0.1725), and the 
direction and size of effect observed in this model is similar to that observed in the 
previous generalized model.    
 
Table 8.  CFH Generalized Ordered Logit Regression (proportional odds 
assumption relaxed for all variables) 
                                                                              
       _cons    -.6668427   .3801655    -1.75   0.079    -1.411953     .078268
 patient_sub     2.475603    .803122     3.08   0.002     .9015124    4.049693
IMPprevale~e     2.34e-06   1.02e-06     2.30   0.021     3.46e-07    4.34e-06
   RCTfwup_M     2.071838   .5372991     3.86   0.000     1.018752    3.124925
       BNF11     .9296203   1.163985     0.80   0.424    -1.351749     3.21099
        BNF1     .0195211   .7024361     0.03   0.978    -1.357228     1.39627
      CANCER    -.1113597   .5143169    -0.22   0.829    -1.119402    .8966828
      IMPBIM    -.0039186   .0040164    -0.98   0.329    -.0117905    .0039534
IMPsuperio~s    -1.710759   .4928227    -3.47   0.001    -2.676674   -.7448441
IMPActive_~p    -3.081604    .755256    -4.08   0.000    -4.561878   -1.601329
Restricted    
                                                                              
       _cons     .7044065   .3685162     1.91   0.056     -.017872    1.426685
 patient_sub     .7976289   .7711926     1.03   0.301    -.7138808    2.309139
IMPprevale~e    -8.71e-07   5.84e-07    -1.49   0.136    -2.02e-06    2.74e-07
   RCTfwup_M     .6866893   .3764034     1.82   0.068    -.0510478    1.424426
       BNF11     2.417799   1.112583     2.17   0.030     .2371766    4.598422
        BNF1     1.421132   .5903941     2.41   0.016     .2639811    2.578284
      CANCER     -1.21891   .3625657    -3.36   0.001    -1.929526   -.5082944
      IMPBIM     .0064387   .0036572     1.76   0.078    -.0007292    .0136066
IMPsuperio~s    -1.000851   .3566156    -2.81   0.005    -1.699805   -.3018978
IMPActive_~p    -.8984875   .4089198    -2.20   0.028    -1.699956   -.0970195
Recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -206.74479                       Pseudo R2       =     0.1929
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(18)     =      98.82
Generalized Ordered Logit Estimates               Number of obs   =        256
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Table 9. Generalized Ordered Logit Model(proporitional odds constraint relaxed 
only for variables where assumption is violated, using ‘autofit’ command) 
                                                                              
       _cons     -1.13452   .3773007    -3.01   0.003    -1.874016   -.3950244
 patient_sub     2.641552   .8020039     3.29   0.001     1.069653     4.21345
IMPprevale~e     1.46e-06   9.73e-07     1.50   0.134    -4.51e-07    3.36e-06
   RCTfwup_M     1.985576   .4832085     4.11   0.000     1.038505    2.932648
       BNF11     1.731503   .7360465     2.35   0.019     .2888784    3.174128
        BNF1     .8584665   .4500128     1.91   0.056    -.0235423    1.740475
      CANCER    -.1595909    .495196    -0.32   0.747    -1.130157    .8109754
      IMPBIM     .0012359    .001163     1.06   0.288    -.0010435    .0035153
IMPsuperio~s    -1.268082   .3186665    -3.98   0.000    -1.892657   -.6435067
IMPActive_~p    -2.839025   .7090808    -4.00   0.000    -4.228798   -1.449252
Restricted    
                                                                              
       _cons     1.146864   .3340843     3.43   0.001     .4920711    1.801657
 patient_sub     .4697717   .7652413     0.61   0.539    -1.030074    1.969617
IMPprevale~e    -6.64e-07   5.59e-07    -1.19   0.235    -1.76e-06    4.32e-07
   RCTfwup_M     .7963189   .3672564     2.17   0.030     .0765095    1.516128
       BNF11     1.731503   .7360465     2.35   0.019     .2888784    3.174128
        BNF1     .8584665   .4500128     1.91   0.056    -.0235423    1.740475
      CANCER    -1.251005   .3585961    -3.49   0.000     -1.95384   -.5481695
      IMPBIM     .0012359    .001163     1.06   0.288    -.0010435    .0035153
IMPsuperio~s    -1.268082   .3186665    -3.98   0.000    -1.892657   -.6435067
IMPActive_~p    -1.219262   .3878347    -3.14   0.002    -1.979404   -.4591198
Recommended   
                                                                              
    decision        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
 
 
 HAS 
When the proportional odds ordinal logistic regression model was fitted to the HAS 
data, the likelihood ratio test was found to be statistically significant at the 0.05 level,  
but the Brant test was not found to be statistically significant (p= 0.147).   Thus the 
diagnostic tests provided mixed feedback as to whether the ordinal logit regression 
model based on proportional odds was appropriate or not for the data set.  To this end, 
both the ordinal logit as well as the generalized ordered logistic model are presented.   
 
Table 10. HAS Base Case analysis – multinomial logistic regression 
ASMR III-IV Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -0.4204505 0.277 -1.178813 0.337912 
Disease prevalence 0.000000489 0.113 -1.15E-07 0.00000109 
Orphan designation status -1.271573 0.010 -2.24461 -0.2985352 
Central nervous system 2.870115 0.007 0.786877 4.953353 
Infections 2.311445 0.036 0.1485392 4.47435 
Musculoskeletal and joint diseases -1.58E+00 0.002 -2.61E+00 -5.57E-01 
Healthcare expenditure on pharmaceuticals 9.12E-03 0.273 -7.20E-03 2.54E-02 
Missing data on prevalence of disease -2.14573 0.001 -3.376858 -0.914602 
Constant -3.449974 0.419 -11.81306 4.913112 
ASMR V Log Odds P value 95%  Conf. Interval 
Clinical superiority demonstrated in RCT -1.349468 0.001 -2.167562 -0.5313733 
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Disease prevalence 0.000000875 0.005 0.000000265 0.00000149 
Orphan designation status -3.522852 0.000 -5.18217 -1.863535 
Central nervous system 3.170685 0.003 1.070034 5.271336 
Infections 2.213558 0.046 0.0441185 4.382997 
Musculoskeletal and joint diseases -2.58E+00 0.000 -3.87E+00 -1.28E+00 
Healthcare expenditure on pharmaceuticals 2.39E-02 0.008 6.33E-03 4.15E-02 
Missing data on prevalence of disease -2.746339 0.000 -3.980416 -1.512263 
Constant -10.67378 0.021 -19.72712 -1.620434 
 
The results of the model are shown in Table 10.  Having modelled HAS decision-
making using the five ASMR categories means that a straightforward comparison with 
the base case analysis is challenging.   The model results for this sensitivity analysis 
yield a slightly higher pseudo R-squared than in the base case model (0.1862 vs. 
0.1878).  Thus assuming the ordinality assumption and modelling using a five-category 
outcome variable does not increase the ability for the model to explain a larger 
percentage of HAS decision-making, suggesting that a multinomial approach using a 3-
category variable may be appropriate.  The results however, of this sensitivity analysis, 
reveal more detail in how the factors behave within the different comparisons, as 
highlighted by the four panels displayed in Table 11.  In the first panel, ASMR I 
technologies are compared with ASMR II-V technologies.  In this particular panel two 
variables demonstrate a statistically significant effect:  orphan designation increases the 
odds of an ASMR I.  Oddly, those technologies for which no information was available 
on the prevalence of the disease also increased the odds of an ASMR I relative to 
ASMR II-V.  In the second panel, technologies with ASMR I-II are compared with 
ASMR III-V technologies, similar to the sensitivity analysis in which binary category 
was used, although in that case, ordinality was not assumed.  In this particular panel, all 
variables have statistically significant effects with the exception of trial duration and 
technologies indicated for infectious diseases, which do not demonstrate statistical 
significance.  Consistent with results in the base case analysis, demonstration of 
superiority, a longer trial duration, orphan designation, and indication for the treatment 
of musculoskeletal diseases increases the odds of an ASMR I-II relative to technologies 
with an ASMR III-V.  The remaining panels (3 and 4) reflect closely the results 
obtained in the base case model, while providing a more detailed view on the behaviour 
of each explanatory variable within the various ASMR ratings.   The results obtained 
from the ordinal logit model, which assumes proportional odds, are very similar to those 
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obtained in the base case multinomial logistic regression model, although the pseudo R-
squared is lower than the base case model (0.1279 vs. 0.1878).   
 
Table 11 HAS Generalized Ordered Logit Regression (proportional odds assumption 
relaxed for all variables), using 5 ASMR categories 
                                                                              
       _cons    -7.787468   3.003142    -2.59   0.010    -13.67352   -1.901418
prevalence_M    -1.012878   .3944723    -2.57   0.010    -1.786029   -.2397263
    drug_exp     .0153856   .0058062     2.65   0.008     .0040057    .0267656
        BNF9    -1.038595    .591875    -1.75   0.079    -2.198649    .1214584
        BNF7     .2899447   .3934601     0.74   0.461    -.4812229    1.061112
        BNF2     .6311121   .3472323     1.82   0.069    -.0494507    1.311675
      orphan    -2.422181    .769751    -3.15   0.002    -3.930866   -.9134971
IMP_preval~e     5.33e-07   1.79e-07     2.98   0.003     1.83e-07    8.84e-07
IMP_fwup_RCT    -.0021929   .0026662    -0.82   0.411    -.0074185    .0030327
IMPsuperio~s    -.9607761   .2807114    -3.42   0.001     -1.51096   -.4105918
4             
                                                                              
       _cons    -11.87794    3.10484    -3.83   0.000    -17.96332   -5.792568
prevalence_M    -1.478545   .4197982    -3.52   0.000    -2.301334   -.6557555
    drug_exp     .0252388   .0060627     4.16   0.000     .0133561    .0371214
        BNF9    -1.656029   .5305292    -3.12   0.002    -2.695847   -.6162109
        BNF7     .4197093   .4375743     0.96   0.337    -.4379205    1.277339
        BNF2     2.214457   .5754387     3.85   0.000     1.086618    3.342296
      orphan    -1.806465   .5011118    -3.60   0.000    -2.788626   -.8243043
IMP_preval~e     4.63e-07   2.00e-07     2.31   0.021     7.08e-08    8.55e-07
IMP_fwup_RCT    -.0057788   .0028616    -2.02   0.043    -.0113874   -.0001701
IMPsuperio~s     -.826269    .289044    -2.86   0.004    -1.392785   -.2597532
3             
                                                                              
       _cons    -4.794615   4.025102    -1.19   0.234    -12.68367    3.094439
prevalence_M    -2.122849   .5699047    -3.72   0.000    -3.239842   -1.005857
    drug_exp     .0139212   .0077513     1.80   0.072     -.001271    .0291135
        BNF9    -1.937744   .4870652    -3.98   0.000    -2.892374   -.9831137
        BNF7     1.646184   1.057101     1.56   0.119    -.4256956    3.718063
        BNF2     2.784682   1.036082     2.69   0.007     .7539978    4.815365
      orphan    -1.864821   .4813334    -3.87   0.000    -2.808218   -.9214254
IMP_preval~e     5.90e-07   2.81e-07     2.10   0.036     3.98e-08    1.14e-06
IMP_fwup_RCT    -.0037046   .0028905    -1.28   0.200      -.00937    .0019607
IMPsuperio~s    -.7725188    .389363    -1.98   0.047    -1.535656   -.0093813
2             
                                                                              
       _cons     1.346192   8.845789     0.15   0.879    -15.99124    18.68362
prevalence_M    -2.313847   1.080178    -2.14   0.032    -4.430958   -.1967366
    drug_exp     .0044086   .0175877     0.25   0.802    -.0300627    .0388799
        BNF9     12.69895   550.5427     0.02   0.982    -1066.345    1091.743
        BNF7      15.6971   2537.926     0.01   0.995    -4958.547    4989.942
        BNF2      17.4004   2530.209     0.01   0.995    -4941.717    4976.518
      orphan     -1.77837   .7525145    -2.36   0.018    -3.253271   -.3034689
IMP_preval~e     5.04e-07   5.16e-07     0.98   0.329    -5.07e-07    1.51e-06
IMP_fwup_RCT      .004596   .0084366     0.54   0.586    -.0119393    .0211313
IMPsuperio~s    -.8675846   .8529147    -1.02   0.309    -2.539267    .8040976
1             
                                                                              
        asmr        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -355.76654                       Pseudo R2       =     0.1862
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(36)     =     162.81
Generalized Ordered Logit Estimates               Number of obs   =        315
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Table 12 Ordinal Logistic Regression, assuming proportional odds 
                                                                              
       _cut4     8.979997   2.568308 
       _cut3     7.958039   2.556279 
       _cut2     6.633968   2.542549 
       _cut1     4.581367   2.547416          (Ancillary parameters)
                                                                              
prevalence_M    -1.467968   .3750687    -3.91   0.000    -2.203089   -.7328468
    drug_exp     .0175786   .0049441     3.56   0.000     .0078882    .0272689
        BNF9    -1.467647   .3850269    -3.81   0.000    -2.222286   -.7130081
        BNF7     .5002555   .3625853     1.38   0.168    -.2103987     1.21091
        BNF2     1.033565   .3133411     3.30   0.001     .4194279    1.647702
      orphan    -1.864357   .3675365    -5.07   0.000    -2.584716   -1.143999
IMP_preval~e     5.11e-07   1.58e-07     3.24   0.001     2.02e-07    8.21e-07
IMP_fwup_RCT    -.0037254    .001996    -1.87   0.062    -.0076374    .0001867
IMPsuperio~s    -.8657282   .2335222    -3.71   0.000    -1.323423   -.4080332
                                                                              
        asmr        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -381.24898                       Pseudo R2       =     0.1279
                                                  Prob > chi2     =     0.0000
                                                  LR chi2(9)      =     111.84
Ordered logit estimates                           Number of obs   =        315
 
References 
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H. Chapter 8 appendices - Pooled analyses,  descriptive statistics 
 
Table 1.  Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CFH and HAS (n= 977) by coverage decision  
  
Recommended Restricted Not Recommended 
P 
value Test 
Variable Mean 95% CI   Mean 95% CI   Mean 95% CI       
NICE 12% 8% 16% 18% 14% 22% 5% 3% 8% <0.01 2 
SMC 20% 15% 25% 27% 22% 31% 40% 35% 45% <0.01 2 
CFH 49% 43% 55% 23% 18% 27% 12% 9% 16% <0.01 2 
HAS 19% 14% 24% 32% 27% 37% 43% 38% 48% <0.01 2 
Number of RCTs 
considered in 
decision 2.7 2.1 3.3 3.4 2.9 3.8 2.6 2.3 2.9 <0.05 3 
Size of population 
included in RCTs 967 687 1247 1251 914 1587 830 607 1053 NS 1 
Statistically 
Significant results -      
yes 49% 43% 55% 42% 37% 47% 39% 33% 44% <0.05 2 
no 15% 11% 20% 16% 13% 20% 18% 14% 23% <0.01 2 
inconsistent 20% 15% 25% 32% 27% 37% 29% 24% 34% NS 2 
Length/extent of 
follow-up in RCT 58.4 50.4 66.3 49.1 42.9 55.4 41.4 34.6 48.2 <0.01 1 
Use of active 
comparator 52% 46% 58% 45% 40% 49% 43% 38% 48% NS 1 
Number of 
observational studies 
considered in 
guidance 0.6 0.3 0.8 0.3 0.2 0.4 1.2 -0.3 2.7 <0.05 3 
Consideration of 
Cost Utility Analysis 
in guidance 31% 26% 37% 39% 34% 44% 37% 31% 42% NS 2 
Incremental Cost-
effectiveness ratio of £20,151 £12,203 £28,099 £25,358 £18,523 £32,193 £50,253 £29,179 £71,326 <0.05 1 
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technology vs. 
comparator in base 
case 
More than one CUA 
submitted 12% 7% 16% 17% 12% 21% 6% 3% 10% <0.01 2 
If More than one 
CUA submitted - low 
range £16,256 £4,175 £28,336 £13,141 £9,888 £16,393 £20,201 £10,459 £29,944 <0.01 3 
If More than one 
CUA submitted - 
high range £95,652 £6,764 £184,540 £125,859 £82,185 £169,533 £69,600 £28,140 £111,059 <0.01 3 
Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) £11,278 £6,677 £15,879 £14,881 £6,640 £23,123 £59,904 £17,958 £101,849 <0.05 1 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate)  Low £105,042 £29,268 £180,816 £42,049 £28,653 £55,445 £242,362 £75,624 £409,101 <0.05 1 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) High 65% 51% 78% 46% 36% 57% 23% 11% 35% <0.05 1 
Non-CUA analyses 
submitted 23% 17% 28% 21% 16% 26% 26% 20% 33% NS 2 
Anticipated 
budgetary impact of 
introduction of new 
technology in health 
care system £10.9 £6 £15.3 £274.6 £25.4 £523.8 £163.4 -£40 £366.7 <0.05 1 
Prevalence of 
disease/clinical 
condition 
           
105,118  
             
44,430  
           
165,805  
           
746,591  
           
363,878  
        
1,129,304  
           
561,944  
           
326,147  
           
797,741  <0.05 1 
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Societal Perspective 
adopted 1% 0% 3% 1% 0% 3% 0% 0% 0% NS 2 
Availability of 
alternative therapies 
in current treatment 
setting. 82% 77% 86% 86% 83% 90% 85% 81% 89% NS 2 
Inclusion of patient 
submission 17% 12% 22% 27% 22% 32% 22% 18% 27% <0.05 2 
Number of Decision 
Makers Accountable 24 23 25 27 26 27 27 27 28 <0.01 1 
Cost-effectiveness 
evaluation 
component in process 64% 58% 70% 60% 55% 65% 54% 49% 60% <0.05 2 
Budget impact as a 
component of 
decision-making 
process 81% 76% 86% 68% 63% 73% 57% 52% 62% <0.01 2 
Pricing known during 
appraisal 49% 43% 55% 23% 18% 27% 12% 9% 16% <0.01 2 
Number of drugs 
appraised in same 
appraisal 1.1 1.1 1.2 1.4 1.3 1.6 1.1 1.0 1.1 <0.05 3 
Accountability of 
drug budget 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a 2 
Independence of 
decision-making 
agency 80% 75% 85% 73% 69% 78% 60% 55% 65% <0.01 2 
Date guidance was 
issued 2006 2006 2006 2006 
               
2,006  2007 2007 2007 2007 <0.01 1 
Population size – 
Agency coverage 
(million) 
               
27.50  
               
24.80  
               
30.20  
               
35.30  
               
32.70  
               
37.90  
               
34.10  
               
31.10  
               
37.10  <0.01 1 
GDP-healthcare 
expenditure 10% 9% 10% 10% 9% 10% 10% 10% 10% <0.01 3 
Healthcare 
expenditure on £263 £252 £274 £280 £269 £291 £306 £293 £320 <0.01 1 
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pharmaceuticals 
Election year at time 
of decision 28% 22% 33% 31% 26% 35% 30% 25% 35% NS 2 
Priority disease area 64% 58% 70% 62% 57% 67% 63% 58% 68% NS 2 
Orphan Designated 11% 7% 15% 9% 6% 12% 8% 5% 11% NS 2 
cardiovascular 
system 10% 6% 13% 12% 9% 15% 11% 7% 14% NS 2 
central nervous 
system 12% 8% 15% 19% 15% 23% 23% 19% 28% <0.01 2 
ear, nose and 
oropharynx 1% 0% 3% 0% 0% 0% 0% 0% 1% <0.05 2 
endocrine system 4% 2% 7% 7% 5% 10% 6% 4% 9% NS 2 
eye 3% 1% 5% 1% 0% 2% 1% 0% 2% <0.05 2 
gastro-intestinal 
system 3% 1% 6% 2% 1% 4% 6% 3% 9% <0.05 2 
infections 9% 6% 12% 12% 9% 16% 10% 7% 13% NS 2 
malignant disease 
and 
immunosuppression 34% 29% 40% 22% 18% 26% 21% 17% 26% <0.01 2 
musculoskeletal and 
joint diseases 10% 7% 14% 12% 9% 15% 5% 2% 7% <0.01 2 
nutrition and blood 6% 3% 9% 4% 2% 6% 5% 3% 8% NS 2 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 0% 0% 1% 2% 1% 4% 1% 0% 2% <0.05 2 
respiratory system 1% 0% 2% 1% 0% 2% 6% 3% 9% <0.01 2 
skin 4% 2% 7% 5% 3% 7% 4% 2% 6% NS 2 
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Table 2.  Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CFH and HAS (n=977)  
  NICE Total (n=118) SMC Total (n=288) CFH Total (n=256) HAS Total (n=315) P value Test 
  mean 95% CI   mean 95% CI   mean 95% CI   mean 95% CI       
Number of RCTs 
considered in 
decision 
6.7 5.2 8.4 2.2 1.9 2.5 2.6 2.3 3.0 2.3 2.1 2.6 <0.01 1 
Size of population 
included in RCTs 1249 807 1691 991 689 1294 830 494 1165 1154 824 1484 <0.01 3 
Statistically 
Significant results -     
yes 
39% 29% 47% 58% 48% 60% 20% 33% 45% 47% 33% 43% <0.01 2 
no 16% 9% 22% 19% 13% 22% 46% 13% 22% 20% 12% 20% <0.01 2 
inconsistent 45% 34% 52% 23% 16% 26% 34% 23% 34% 33% 21% 31% NS 2 
Length/extent of 
follow-up in RCT 76.2 63.5 88.9 44.9 38.4 51.4 39.5 33.4 45.6 49.3 41.2 57.4 <0.01 1 
Relevance of RCT 
to payor decision 47% 39% 55% 52% 46% 57% 44% 38% 51% 42% 37% 48% <0.01 3 
Number of 
observational studies 
considered in 
guidance 
0.6 0.1 1.1 1.3 -0.4 2.9 0.6 0.4 0.7 0.3 0.2 0.4 <0.01 1 
Consideration of 
Cost Utility 
Analysis in guidance 
95% 91% 99% 74% 69% 79% 11% 7% 15% 0% 0% 0% <0.01 2 
Incremental Cost-
effectiveness ratio of 
technology vs. 
comparator in base 
case 
£31,266 £29,122 £42,410 £34,055 £21,630 £46,481 £30,977 £8,643 £53,312       <0.01 3 
More than one CUA 
submitted 63% 54% 72% 1% 0% 2% 1% 0% 2%       <0.01 1 
If More than one 
CUA submitted - 
low range 
£13,260 £10,409 £16,110 £10,399 -£9,782 £30,580 £85,091 -£198,747 £368,928       <0.10 3 
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If More than one 
CUA submitted - 
high range 
£107,421 £66,886 £147,956 £18,207 -£2,672 £39,086 £221,499 £201,610 £241,389       <0.05 3 
Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) 
43% 34% 52% 57% 42% 73% 66% 42% 90% 
      
<0.10 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate)  Low 
£25,417 £6,412 £44,422 £33,277 £8,916 £57,637 £15,187 £4,338 £26,036       <0.05 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) High 
£167,389 £56,865 £277,913 £77,927 £19,847 £43,448 £92,826 -£6,356 £192,008       <0.01 3 
Non-CUA analyses 
submitted 23% 15% 30% 30% 25% 36% 15% 11% 20%       <0.01 2 
Anticipated 
budgetary impact of 
introduction of new 
technology in health 
care system 
£701.3 £179.7 £1,223.0 £1.2 £0.9 £1.5 £31.0 £5.9 £56.2           
Prevalence of 
disease/clinical 
condition 
  
2,418,119  
 
1,256,514 
   
3,579,724 
       
11,277      1,647   20,908 
       
94,543  
      
31,394    157,693 
     
511,047 
 
314,122 
 
707,972 <0.01 1 
Social Perspective 
adopted 3% 0% 5% 0% 0% 1% 1% 0% 1% 0% 0% 0% <0.10 2 
Availability of 
alternative therapies 
in current treatment 
setting. 
89% 83% 95% 83% 79% 88% 79% 74% 84% 89% 85% 92% <0.01 2 
Inclusion of patient 
submission 87% 81% 93% 42% 36% 48% 4% 2% 6% 0% 0% 0% <0.01 2 
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Number of Decision 
Makers Accountable 30 28 32 25 24 25 20 20 20 31 31 31 <0.01 1 
Cost-effectiveness 
evaluation 
component in 
process 
100% 100% 100% 100% 100% 100% 67% 61% 73% 0% 0% 0% <0.01 2 
Budget impact as a 
component of 
decision-making 
process 
100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 0% <0.01 2 
Pricing and 
Reimbursement 
decided jointly 
0% 0% 0% 0% 0% 0% 100% 100% 100% 0% 0% 0% <0.01 2 
Number of drugs 
appraised in same 
appraisal 
2.8 2.5 3.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <0.01 1 
Accountability of 
drug budget 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a 2 
Independence of 
decision-making 
agency 
100% 100% 100% 0% 0% 0^% 100% 100% 100% 100% 100% 100% <0.01 2 
Date guidance was 
issued 
         
2,007  
        
2,006  
          
2,007  
         
2,006      2,006 2006 2006 2006 2006 2007 2006 2007 <0.01 1 
Population size – 
Agency coverage 
         
53.90  
        
53.80  
          
54.00  
           
5.13        5.12       5.13 
         
16.30  
        
16.30        16.40 
         
63.40  
     
63.30  
     
63.50  <0.01 3 
GDP-healthcare 
expenditure 8% 8% 8% 8% 8% 8% 10% 10% 10% 11% 11% 11% <0.01 1 
Healthcare 
expenditure on 
pharmaceuticals 
£175 £173 £176 £190 £189 £190 £249 £246 £251 £439 £437 £441 <0.01 3 
Election year at time 
of decision 7% 2% 11% 40% 35% 45% 20% 15% 24% 30% 25% 36% <0.01 2 
Priority disease area 56% 47% 65% 66% 61% 71% 55% 49% 61% 70% 65% 75% <0.01 2 
Orphan Designated 3% 0% 5% 11% 8% 15% 9% 5% 12% 9% 6% 12% <0.05 2 
cardiovascular 
system 10% 5% 16% 11% 7% 14% 9% 5% 12% 14% 10% 18% NS 2 
417 
 
central nervous 
system 15% 9% 22% 22% 16% 26% 16% 12% 21% 18% 14% 23% NS 2 
ear, nose and 
oropharynx 0% 0% 0% 0% 0% 1% 1% 0% 2% 0% 0% 1% NS 2 
endocrine system 1% -1% 3% 9% 5% 12% 6% 3% 9% 6% 4% 9% <0.05 2 
eye 2% -1% 4% 1% 0% 2% 2% 0% 3% 2% 0% 3% NS 2 
gastro-intestinal 
system 2% -1% 4% 4% 2% 6% 5% 2% 7% 3% 1% 6% NS 2 
infections 12% 6% 18% 10% 7% 14% 9% 5% 12% 12% 8% 15% NS 2 
malignant disease 
and 
immunosuppression 
31% 22% 39% 23% 20% 30% 25% 19% 30% 24% 19% 29% NS 2 
musculoskeletal and 
joint diseases 19% 12% 27% 3% 1% 6% 10% 6% 14% 9% 6% 12% <0.01 2 
nutrition and blood 3% 0% 5% 6% 3% 9% 7% 4% 10% 3% 1% 6% NS 2 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
0% 0% 0% 2% 0% 3% 3% 1% 5% 0% 0% 1% <0.05 2 
respiratory system 1% -1% 3% 3% 2% 6% 4% 1% 6% 2% 1% 4% NS 2 
skin 5% 1% 9% 3% 2% 6% 5% 2% 7% 4% 2% 7% NS 2 
 
Note:  1= Both ANOVA and Kruskal-Wallis test both indicate similar level of statistical significance.  2=Chi-squared test used, as categorical variable.  
3 = Either ANOVA or Kruskal-Wallis test indicate statistical significance.   
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Table 3.  Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CFH and HAS (n= 267) for Recommended 
Technologies 
 NICE SMC CFH HAS 
P 
value Test 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Number of RCTs 
considered in 
decision 
6.8 2.1 11.4 2.3 1.7 2.9 2.2 1.8 2.5 1.7 1.3 2.2 <0.01 1 
Size of population 
included in RCTs 1765 804 2727 1532 572 2492 525 366 684 836 192 1480 
<0.01 3 
Statistically 
Significant results -     
yes 
59% 41% 77% 48% 34% 62% 45% 37% 54% 53% 39% 67% NS 2 
Inconsistent 6% -3% 15% 24% 12% 36% 18% 11% 24% 6% -1% 13% NS 2 
No 31% 14% 48% 22% 11% 34% 20% 13% 27% 10% 1% 18% <0.05 2 
Length/extent of 
follow-up in RCT 95.9 65.9 125.8 59.7 41.7 77.7 44.0 34.5 53.5 67.7 50.6 84.8 
<0.01 3 
Use of active 
comparator 63% 46% 80% 67% 55% 79% 51% 42% 60% 25% 11% 38% 
<0.01 1 
Number of 
observational 
studies considered 
in guidance 
1.5 -0.4 3.4 0.0 0.0 0.0 0.6 0.3 0.8 0.6 0.0 1.2 <0.05 1 
Consideration of 
Cost Utility 
Analysis in 
guidance 
100% 100% 100% 67% 54% 80% 12% 7% 18% 0% 0% 0% <0.01 2 
Incremental Cost-
effectiveness ratio 
of technology vs. 
comparator in base 
case 
£17,782 £11,066 £24,498 £11,893 £8,645 £15,140 £43,864 £243,619 £673 . . . NS 1 
More than one CUA 69% 52% 86% 0% 0% 0% 2% 0% 5% . . . <0.01 2 
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submitted 
If More than one 
CUA submitted - 
low range 
£8,607 £4,551 £12,664 . . . £85,091 £107,429 £62,752 . . . <0.05 3 
If More than one 
CUA submitted - 
high range 
£83,666 -£12,619 £179,951 . . . £221,499 £223,064 £219,934 . . . <0.05 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate)  Low 
£7,881 £5,234 £10,527 £11,251 £5,017 £17,486 £26,614 £62,752 £5,075 . . . NS 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) High 
£113,286 £1,293 £225,279 £31,647 £19,847 £43,448 £163,012 £778,584 £11,639 . . . NS 1 
Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) 
61% 45% 77% 72% -164% 307% 79% 43% 115% . . . NS 1 
Non-CUA analyses 
submitted 22% 7% 37% 39% 25% 52% 16% 10% 23% . . . 
<0.01 2 
Anticipated 
budgetary impact of 
introduction of new 
technology in health 
care system 
(million) 
£35.9 £17.9 £53.9 £1.9 £1.0 £2.8 £5.8 £38.1 £0.0 . . . <0.01 1 
Prevalence of 
disease/clinical 
condition 
392,063 82,017 702,109 36,122 -     12,168 84,412 61,816 
-       
16,081 139,713 68,281 
-       
36,271 172,834 
<0.01 1 
Societal Perspective 
adopted 3% -3% 9% 0% 0% 0% 1% -1% 3% . . . 
NS 2 
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Availability of 
alternative therapies 
in current treatment 
setting. 
88% 75% 100% 93% 85% 100% 76% 68% 83% 81% 69% 93% <0.05 2 
Inclusion of patient 
submission 91% 80% 101% 27% 14% 41% 2% 0% 5% 0% 0% 0% 
<0.01 2 
Number of Decision 
Makers Accountable 28 25 31 25 24 26 20 20 20 31 31 31 
<0.01 1 
Cost-effectiveness 
evaluation 
component in 
process 
100% 100% 100% 100% 100% 100% 67% 61% 73% 0% 0% 0% <0.01 2 
Budget impact as a 
component of 
decision-making 
process 
100% 100% 100% 100% 100% 100% 65% 57% 74% 0% 0% 0% <0.01 2 
Pricing known 
during appraisal 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 0% 
<0.01 2 
Number of drugs 
appraised in same 
appraisal 
2.0 1.5 2.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <0.01 1 
Accountability of 
drug budget 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
n/a 2 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 0% 0% 0% 100% 100% 100% <0.01 2 
Date guidance was 
issued 2,006 2,006 2,007 2,007 2,006 2007 2006 2006 2006 2006 2006 2006 
<0.05 3 
Population size – 
Agency coverage 53.80 53.70 54.00 5.14 5.13 5.15 16.30 16.30 16.40 63.20 63.00 63.40 
<0.01 3 
GDP-healthcare 
expenditure 8% 8% 8% 8% 8% 8% 10% 10% 10% 11% 11% 11% 
<0.01 1 
Healthcare 
expenditure on 
pharmaceuticals 
£173 £171 £175 £191 £190 £193 £293 £289 £296 £209 £232 £188 <0.01 3 
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Election year at time 
of decision 6% -3% 15% 48% 34% 62% 23% 16% 30% 31% 18% 45% 
<0.01 2 
Priority disease area 59% 41% 77% 67% 54% 80% 61% 52% 69% 73% 60% 85% NS 2 
Orphan Designated 3% -3% 9% 6% -1% 12% 11% 5% 16% 24% 11% 36% <0.01 2 
cardiovascular 
system 13% 0% 25% 17% 6% 27% 4% 0% 7% 16% 5% 26% 
<0.05 2 
central nervous 
system 6% -3% 15% 15% 5% 25% 15% 9% 22% 2% -2% 6% 
<0.05 2 
ear, nose and 
oropharynx 0% 0% 0% 2% -2% 6% 2% 0% 5% 0% 0% 0% 
NS 2 
endocrine system 0% 0% 0% 9% 1% 17% 5% 1% 8% 2% -2% 6% NS 2 
eye 3% -3% 9% 4% -1% 9% 3% 0% 6% 2% -2% 6% NS 2 
gastro-intestinal 
system 0% 0% 0% 2% -2% 6% 5% 1% 9% 2% -2% 6% 
NS 2 
infections 19% 4% 33% 17% 6% 27% 6% 2% 10% 2% -2% 6% <0.01 2 
malignant disease 
and 
immunosuppression 
41% 23% 59% 20% 9% 31% 37% 29% 45% 39% 25% 53% NS 2 
musculoskeletal and 
joint diseases 16% 2% 29% 0% 0% 0% 7% 3% 11% 27% 15% 40% 
<0.01 2 
nutrition and blood 0% 0% 0% 6% -1% 12% 8% 3% 12% 8% 0% 15% NS 2 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
0% 0% 0% 0% 0% 0% 1% -1% 2% 0% 0% 0% NS 2 
respiratory system 0% 0% 0% 2% -2% 6% 2% -1% 4% 0% 0% 0% NS 2 
skin 3% -3% 9% 7% 0% 15% 5% 1% 9% 0% 0% 0% NS 2 
Note:  1= Both ANOVA and Kruskal-Wallis test both indicate similar level of statistical significance.  2=Chi-squared test used, as categorical variable.  
3 = Either ANOVA or Kruskal-Wallis test indicate statistical significance.   
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Table 4.  Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CFH and HAS (n=379 ) for Restricted Technologies 
  NICE recommended technologies  SMC recommended technologies 
CFH recommended 
technologies  
HAS Recommended 
Technologies 
P 
value Test 
  Mean 95% CI   Mean 95% CI   Mean 95% CI   Mean 95% CI       
Number of RCTs 
considered in 
decision 
7.6 5.9 9.2 2.3 1.7 2.8 2.8 2.2 3.5 2.3 1.9 2.7 <0.01 1 
Size of population 
included in RCTs 1044 442 1645 1360 691 2028 1364 447 2281 1206 663 1750 NS 1 
Statistically 
Significant results -   
yes 
29% 18% 40% 52% 42% 62% 35% 25% 45% 47% 38% 56% <0.01 2 
Inconsistent 17% 8% 27% 22% 13% 30% 17% 9% 26% 11% 5% 16% <0.01 2 
no 51% 39% 63% 23% 14% 31% 35% 25% 45% 27% 19% 35% NS 2 
Length/extent of 
follow-up in RCT 65.8 51.5 80.2 50.5 37.6 63.3 30.9 23.8 38.0 50.2 37.4 63.0 <0.01 3 
Use of active 
comparator 40% 30% 50% 53% 44% 62% 45% 35% 55% 40% 31% 48% NS 1 
Number of 
observational 
studies considered 
in guidance 
0.3 0.1 0.5 0.1 0.0 0.2 0.6 0.2 0.9 0.3 0.1 0.6 <0.05 3 
Consideration of 
Cost Utility 
Analysis in 
guidance 
94% 89% 100% 77% 69% 86% 7% 1% 12% 0% 0% 0% <0.01 2 
Incremental Cost-
effectiveness ratio 
of technology vs. 
comparator in base 
case 
£24,867 £21,002 £28,731 £26,316 £13,265 £39,367 £15,195 £9,592 £20,799 . . . <0.01 3 
More than one 
CUA submitted 63% 51% 75% 1% -1% 3% 0% 0% 0% . . . <0.01 2 
If More than one 
CUA submitted - £13,417 £10,119 £16,714 £3,194 . . . . . . . . NS 1 
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low range 
If More than one 
CUA submitted - 
high range 
£129,690 £85,202 £174,179 £10,920 . . . . . . . . <0.05 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate)  Low 
£19,747 £4,460 £35,035 £8,963 £5,794 £12,132 £11,336 -£14,217 £36,890 . . . NS 1 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) High 
£57,146 £29,962 £84,329 £27,112 £20,849 £33,375 £40,715 -£36,536 £117,965 . . . <0.01 3 
Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) 
41% 29% 53% 71% 53% 90% 52% -66% 170% . . . NS 1 
Non-CUA analyses 
submitted 28% 17% 38% 25% 16% 33% 10% 4% 17% . . . <0.05 2 
Anticipated 
budgetary impact of 
introduction of new 
technology in 
health care system 
£828.5 £51.3 £1,605.6 £1.3 £0.8 £1.8 £66.8 -£18 £151.1 . . . <0.01 1 
Prevalence of 
disease/clinical 
condition 
 
3,194,243   1,419,388   4,969,097      6,584     1,612   11,557   41,087  
     
8,932      73,242 
 
236,387 
 
113,270  359,503 <0.01 1 
Societal 
Perspective adopted 3% -1% 7% 1% -1% 3% 0% 0% 0% . . . NS 2 
Availability of 
alternative 
therapies in current 
treatment setting. 
90% 83% 97% 85% 78% 92% 85% 77% 93% 85% 79% 92% NS 2 
Inclusion of patient 84% 75% 93% 45% 34% 56% 2% -1% 6% 0% 0% 0% <0.01 2 
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submission 
Number of 
Decision Makers 
Accountable 
31 29 34 25 24 25 20 20 20 31 31 31 <0.01 1 
Cost-effectiveness 
evaluation 
component in 
process 
100% 100% 100% 100% 100% 100% 64% 54% 74% 0% 0% 0% <0.01 2 
Budget impact as a 
component of 
decision-making 
process 
100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 0% <0.01 2 
Pricing known 
during appraisal 0% 0% 0% 0% 0% 0% 100% 100% 100% 0% 0% 0% <0.01 2 
Number of drugs 
appraised in same 
appraisal 
3.4 2.9 3.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <0.01 1 
Accountability of 
drug budget 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a 2 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 0% 0% 0% 100% 100% 100% <0.01 2 
Date guidance was 
issued 2007 2006 2007 2007     2,006 2007 2006 2006 2006 2006 2006 2007 <0.01 3 
Population size – 
Agency coverage 
(million) 
        
53.90          53.80          54.10        5.13       5.13       5.14     16.30  
     
16.30        16.30 
     
63.30  
     
63.20       63.40 <0.01 3 
GDP-healthcare 
expenditure 8% 8% 8% 8% 8% 8% 10% 10% 10% 11% 11% 11% <0.01 1 
Healthcare 
expenditure on 
pharmaceuticals 
£174 £173 £176 £191 £190 £192 £247 £243 £251 £437 £434 £440 <0.01 3 
Election year at 
time of decision 7% 1% 14% 48% 38% 58% 20% 11% 28% 37% 28% 46% <0.01 2 
Priority disease 
area 57% 45% 69% 69% 59% 78% 43% 32% 54% 74% 66% 82% <0.01 2 
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Orphan Designated 3% -1% 7% 9% 3% 14% 9% 3% 16% 12% 6% 18% NS 2 
cardiovascular 
system 12% 4% 19% 9% 3% 14% 15% 7% 23% 13% 7% 19% NS 2 
central nervous 
system 22% 12% 32% 19% 11% 26% 15% 7% 23% 20% 13% 27% NS 2 
ear, nose and 
oropharynx 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a 2 
endocrine system 1% -1% 4% 10% 4% 16% 8% 2% 14% 7% 3% 12% NS 2 
eye 0% 0% 0% 1% -1% 3% 0% 0% 0% 2% -1% 4% NS 2 
gastro-intestinal 
system 1% -1% 4% 1% -1% 3% 5% 0% 9% 2% -1% 4% NS 2 
infections 7% 1% 14% 16% 9% 23% 12% 5% 19% 13% 7% 19% NS 2 
malignant disease 
and 
immunosuppression 
23% 13% 33% 26% 18% 35% 9% 3% 16% 27% 19% 35% <0.05 2 
musculoskeletal 
and joint diseases 22% 12% 32% 5% 1% 9% 19% 10% 27% 7% 3% 12% <0.01 2 
nutrition and blood 4% -1% 9% 3% 0% 6% 8% 2% 14% 2% 0% 5% NS 2 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
0% 0% 0% 3% 0% 6% 7% 1% 12% 0% 0% 0% <0.01 2 
respiratory system 1% -1% 4% 3% 0% 6% 0% 0% 0% 1% -1% 2% NS 2 
skin 6% 0% 11% 5% 1% 9% 2% -1% 6% 6% 2% 10% NS 2 
Note:  1= Both ANOVA and Kruskal-Wallis test both indicate similar level of statistical significance.  2=Chi-squared test used, as categorical variable.  
3 = Either ANOVA or Kruskal-Wallis test indicate statistical significance.   
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Table 5.  Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CFH and HAS (n= 267) for Recommended 
Technologies 
 NICE SMC CFH HAS 
P 
value Test 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Number of RCTs 
considered in 
decision 
6.8 2.1 11.4 2.3 1.7 2.9 2.2 1.8 2.5 1.7 1.3 2.2 <0.01 1 
Size of population 
included in RCTs 1765 804 2727 1532 572 2492 525 366 684 836 192 1480 
<0.01 3 
Statistically 
Significant results -     
yes 
59% 41% 77% 48% 34% 62% 45% 37% 54% 53% 39% 67% NS 2 
Inconsistent 6% -3% 15% 24% 12% 36% 18% 11% 24% 6% -1% 13% NS 2 
No 31% 14% 48% 22% 11% 34% 20% 13% 27% 10% 1% 18% <0.05 2 
Length/extent of 
follow-up in RCT 95.9 65.9 125.8 59.7 41.7 77.7 44.0 34.5 53.5 67.7 50.6 84.8 
<0.01 3 
Use of active 
comparator 63% 46% 80% 67% 55% 79% 51% 42% 60% 25% 11% 38% 
<0.01 1 
Number of 
observational 
studies considered 
in guidance 
1.5 -0.4 3.4 0.0 0.0 0.0 0.6 0.3 0.8 0.6 0.0 1.2 <0.05 1 
Consideration of 
Cost Utility 
Analysis in 
guidance 
100% 100% 100% 67% 54% 80% 12% 7% 18% 0% 0% 0% <0.01 2 
Incremental Cost-
effectiveness ratio 
of technology vs. 
comparator in base 
case 
£17,782 £11,066 £24,498 £11,893 £8,645 £15,140 £43,864 £243,619 £673 . . . NS 1 
More than one CUA 69% 52% 86% 0% 0% 0% 2% 0% 5% . . . <0.01 2 
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submitted 
If More than one 
CUA submitted - 
low range 
£8,607 £4,551 £12,664 . . . £85,091 £107,429 £62,752 . . . <0.05 3 
If More than one 
CUA submitted - 
high range 
£83,666 -£12,619 £179,951 . . . £221,499 £223,064 £219,934 . . . <0.05 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate)  Low 
£7,881 £5,234 £10,527 £11,251 £5,017 £17,486 £26,614 £62,752 £5,075 . . . NS 3 
Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) High 
£113,286 £1,293 £225,279 £31,647 £19,847 £43,448 £163,012 £778,584 £11,639 . . . NS 1 
Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) 
61% 45% 77% 72% -164% 307% 79% 43% 115% . . . NS 1 
Non-CUA analyses 
submitted 22% 7% 37% 39% 25% 52% 16% 10% 23% . . . 
<0.01 2 
Anticipated 
budgetary impact of 
introduction of new 
technology in health 
care system 
(million) 
£35.9 £17.9 £53.9 £1.9 £1.0 £2.8 £5.8 £38.1 £0.0 . . . <0.01 1 
Prevalence of 
disease/clinical 
condition 
392,063 82,017 702,109 36,122 -     12,168 84,412 61,816 
-       
16,081 139,713 68,281 
-       
36,271 172,834 
<0.01 1 
Societal Perspective 
adopted 3% -3% 9% 0% 0% 0% 1% -1% 3% . . . 
NS 2 
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Availability of 
alternative therapies 
in current treatment 
setting. 
88% 75% 100% 93% 85% 100% 76% 68% 83% 81% 69% 93% <0.05 2 
Inclusion of patient 
submission 91% 80% 101% 27% 14% 41% 2% 0% 5% 0% 0% 0% 
<0.01 2 
Number of Decision 
Makers Accountable 28 25 31 25 24 26 20 20 20 31 31 31 
<0.01 1 
Cost-effectiveness 
evaluation 
component in 
process 
100% 100% 100% 100% 100% 100% 67% 61% 73% 0% 0% 0% <0.01 2 
Budget impact as a 
component of 
decision-making 
process 
100% 100% 100% 100% 100% 100% 65% 57% 74% 0% 0% 0% <0.01 2 
Pricing known 
during appraisal 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 0% 
<0.01 2 
Number of drugs 
appraised in same 
appraisal 
2.0 1.5 2.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <0.01 1 
Accountability of 
drug budget 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
n/a 2 
Independence of 
decision-making 
agency 
100% 100% 100% 100% 100% 100% 0% 0% 0% 100% 100% 100% <0.01 2 
Date guidance was 
issued 2,006 2,006 2,007 2,007 2,006 2007 2006 2006 2006 2006 2006 2006 
<0.05 3 
Population size – 
Agency coverage 53.80 53.70 54.00 5.14 5.13 5.15 16.30 16.30 16.40 63.20 63.00 63.40 
<0.01 3 
GDP-healthcare 
expenditure 8% 8% 8% 8% 8% 8% 10% 10% 10% 11% 11% 11% 
<0.01 1 
Healthcare 
expenditure on 
pharmaceuticals 
£173 £171 £175 £191 £190 £193 £293 £289 £296 £209 £232 £188 <0.01 3 
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Election year at time 
of decision 6% -3% 15% 48% 34% 62% 23% 16% 30% 31% 18% 45% 
<0.01 2 
Priority disease area 59% 41% 77% 67% 54% 80% 61% 52% 69% 73% 60% 85% NS 2 
Orphan Designated 3% -3% 9% 6% -1% 12% 11% 5% 16% 24% 11% 36% <0.01 2 
cardiovascular 
system 13% 0% 25% 17% 6% 27% 4% 0% 7% 16% 5% 26% 
<0.05 2 
central nervous 
system 6% -3% 15% 15% 5% 25% 15% 9% 22% 2% -2% 6% 
<0.05 2 
ear, nose and 
oropharynx 0% 0% 0% 2% -2% 6% 2% 0% 5% 0% 0% 0% 
NS 2 
endocrine system 0% 0% 0% 9% 1% 17% 5% 1% 8% 2% -2% 6% NS 2 
eye 3% -3% 9% 4% -1% 9% 3% 0% 6% 2% -2% 6% NS 2 
gastro-intestinal 
system 0% 0% 0% 2% -2% 6% 5% 1% 9% 2% -2% 6% 
NS 2 
infections 19% 4% 33% 17% 6% 27% 6% 2% 10% 2% -2% 6% <0.01 2 
malignant disease 
and 
immunosuppression 
41% 23% 59% 20% 9% 31% 37% 29% 45% 39% 25% 53% NS 2 
musculoskeletal and 
joint diseases 16% 2% 29% 0% 0% 0% 7% 3% 11% 27% 15% 40% 
<0.01 2 
nutrition and blood 0% 0% 0% 6% -1% 12% 8% 3% 12% 8% 0% 15% NS 2 
obstetrics, 
gynaecology, and 
urinary-tract 
disorders 
0% 0% 0% 0% 0% 0% 1% -1% 2% 0% 0% 0% NS 2 
respiratory system 0% 0% 0% 2% -2% 6% 2% -1% 4% 0% 0% 0% NS 2 
skin 3% -3% 9% 7% 0% 15% 5% 1% 9% 0% 0% 0% NS 2 
Note:  1= Both ANOVA and Kruskal-Wallis test both indicate similar level of statistical significance.  2=Chi-squared test used, as categorical variable.  
3 = Either ANOVA or Kruskal-Wallis test indicate statistical significance.   
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Pooled analysis:  preliminary Multivariate Model 
The results of the multinomial regression yield a pseudo R-squared of 0.1604, 
suggesting that the model explains 16% of the variability in the pooled sample of 
coverage decisions.   
 
Table 8.1  Multivariate analysis of NICE, SMC, CFH and HAS coverage decisions 2004-2009:  preliminary 
model 
 Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of 
Trials 
-0.030 0.192 -0.08 0.02 -0.062 0.062 -0.13 0.00 
Clinical 
superiority 
demonstrated in 
RCT 
-0.088 0.918 -1.76 1.58 -1.777 0.021 -3.29 -0.27 
Lack of clinical 
superiority in 
RCT 
-0.105 0.904 -1.81 1.60 -1.370 0.083 -2.92 0.18 
Inconsistent 
clinical 
superiority 
demonstrated in 
RCT 
0.455 0.604 -1.27 2.17 -0.990 0.213 -2.55 0.57 
RCT duration 
of follow-up 
-0.002 0.265 -0.01 0.00 -0.003 0.122 -0.01 0.00 
CUA 0.245 0.416 -0.35 0.84 0.349 0.279 -0.28 0.98 
ICER 0.000 0.587 0.00 0.00 0.000 0.417 0.00 0.00 
Interaction term 
adjusting for no 
ICER within 
HAS decision-
making 
0.000 0.138 0.00 0.00 0.000 0.091 0.00 0.00 
Use of active 
comparator in 
RCT 
-0.596 0.008 -1.03 -0.16 -0.864 0.000 -1.35 -0.38 
Orphan 
designation 
status 
-0.117 0.709 -0.73 0.50 -0.856 0.019 -1.57 -0.14 
Patient 
submission 
included 
0.338 0.294 -0.29 0.97 0.793 0.017 0.14 1.44 
Size of 
appraisal 
committee 
0.004 0.897 -0.05 0.06 0.017 0.618 -0.05 0.08 
Cost 
Effectiveness 
part of process 
-0.291 0.512 -1.16 0.58 -0.438 0.444 -1.56 0.68 
Budgetary 
assessment part 
of process 
-4.550 0.058 -9.25 0.15 -4.822 0.065 -9.94 0.30 
Number of 
technologies 
appraised 
simultaneously 
0.526 0.002 0.19 0.86 0.169 0.488 -0.31 0.65 
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Year of 
Appraisal 
0.116 0.336 -0.12 0.35 0.196 0.140 -0.06 0.46 
National 
population size 
0.000 0.113 0.00 0.00 0.000 0.003 0.00 0.00 
% GDP 
expenditure on 
healthcare 
-66.848 0.288 -190.12 56.42 -135.869 0.058 -276.45 4.71 
Healthcare 
expenditure on 
pharmaceuticals 
0.004 0.739 -0.02 0.03 0.017 0.253 -0.01 0.05 
Cardiovascular 
disease 
17.933 0.941 -453.80 489.67 -1.656 0.000 -2.38 -0.94 
Central nervous 
system 
18.008 0.940 -453.75 489.76 2.302 0.090 -0.36 4.96 
Endocrine 
system 
18.531 0.939 -453.23 490.29 2.481 0.077 -0.27 5.23 
Eye 16.724 0.945 -455.08 488.53 1.240 0.414 -1.73 4.21 
Gastro-
intestinal 
system 
17.709 0.941 -454.03 489.44 2.678 0.060 -0.11 5.47 
Infections 18.415 0.939 -453.35 490.19 2.103 0.128 -0.61 4.81 
Cancer therapy 17.434 0.942 -454.28 489.15 1.444 0.290 -1.23 4.12 
Musculoskeletal 
and joint 
diseases 
17.932 0.941 -453.83 489.69 1.301 0.352 -1.44 4.04 
Nutrition and 
blood 
17.806 0.941 -453.96 489.57 2.115 0.133 -0.64 4.88 
Obstetrics, 
gynaecology, 
and urinary-
tract disorders 
20.318 0.933 -451.45 492.09 4.001 0.024 0.51 7.49 
Obstetrics, 
gynaecology, 
and urinary-
tract disorders 
18.033 0.940 -453.71 489.78 3.441 0.021 0.52 6.36 
Skin 18.046 0.940 -453.71 489.80 2.067 0.145 -0.71 4.85 
RCT follow-up 
not available 
0.154 0.743 -0.77 1.07 0.782 0.099 -0.15 1.71 
Use of active 
comparator not 
available 
-0.568 0.289 -1.62 0.48 -1.256 0.025 -2.35 -0.16 
Prevalence not 
available 
0.091 0.691 -0.36 0.54 -0.296 0.263 -0.81 0.22 
Use of patient 
submission not 
available 
0.186 0.689 -0.73 1.10 0.435 0.357 -0.49 1.36 
Constant -239.981 . . . -378.909 0.153 -899.20 141.38 
Note:  Recommended technologies are the reference case 
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Pooled analysis:  sensitivity analysis of Pooled data set including 4 HTA bodies and ICER 
Table 8.4  Multivariate analysis of pooled sample of NICE, SMC, CVZ and HAS coverage decisions 2004-2009:  base-case model results  (n=977) 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.021 0.340 -0.06 0.02 -0.055 0.085 -0.118 0.008 
RCT duration of follow-up -0.002 0.364 -0.0048 0.0017 -0.003 0.085 -0.0072 0.00046 
Use of active comparator in RCT -0.522 0.015 -0.94 -0.10 -0.895 <0.001 -1.353 -0.436 
Clinical superiority demonstrated in RCT -0.266 0.177 -0.65 0.12 -0.638 0.003 -1.065 -0.210 
ICER -0.0000035 0.148 -0.0000083 0.0000013 0.00000085 0.691 -0.0000033 0.0000050 
Interaction term (no ICER within HAS 
decision-making -0.000033 0.043 -0.000065 -0.000001 -0.000036 0.038 -0.000070 -0.0000020 
Eligible patient population 0.00000020 0.142 -0.000000066 0.00000046 0.00000028 0.040 0.00000001 0.00000055 
Orphan designation status -0.223 0.451 -0.80 0.36 -0.778 0.021 -1.437 -0.119 
Patient submission included 0.436 0.159 -0.17 1.04 0.769 0.016 0.141 1.396 
Number of technologies appraised 
simultaneously 0.506 0.003 0.17 0.84 -0.006 0.983 -0.558 0.547 
National population size 0.00000073 0.004 0.00000023 0.0000012 0.0000012 <0.001 0.00000068 0.0000018 
Central nervous system -0.086 0.789 -0.72 0.55 0.196 0.562 -0.468 0.860 
Eye -1.630 0.025 -3.06 -0.20 -1.279 0.073 -2.679 0.121 
Malignancy/immunosuppresion therapy -0.694 0.010 -1.22 -0.16 -0.533 0.069 -1.107 0.041 
Musculoskeletal and joint diseases -0.280 0.397 -0.93 0.37 -0.900 0.027 -1.697 -0.103 
Obstetrics, gynaecology, and urinary-tract 
disorders 2.329 0.032 0.20 4.46 1.681 0.150 -0.606 3.968 
Respiratory system 0.119 0.878 -1.40 1.63 1.585 0.030 0.157 3.013 
Cardiovascular disease -0.228 0.469 -0.85 0.39 -0.459 0.184 -1.137 0.218 
Skin -0.110 0.800 -0.96 0.74 -0.308 0.518 -1.243 0.627 
NICE -26.999 0.005 -45.67 -8.33 -46.133 <0.001 -66.803 -25.463 
SMC 9.282 0.001 3.71 14.86 15.745 <0.001 9.594 21.895 
HAS -29.062 0.009 -50.90 -7.23 -51.835 <0.001 -75.910 -27.760 
Constant -12.081 0.004 -20.23 -3.93 -20.094 <0.001 -29.113 -11.075 
Note:  Recommended technologies are the reference case. Multinomial logistic regression, pseudo R-squared: 0.26.   
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Table 8.5  Base case 2:  BASE CASE WITHOUT HAS, with ICER 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of Trials -0.024 0.304 -0.069 0.021 -0.057 0.116 -0.129 0.014 
RCT duration of follow-up -0.002 0.498 -0.006 0.003 -0.004 0.112 -0.010 0.001 
Use of active comparator in RCT -0.684 0.007 -1.184 -0.184 -1.382 0.000 -1.949 -0.815 
Clinical superiority demonstrated in RCT -0.596 0.010 -1.048 -0.143 -0.716 0.007 -1.233 -0.200 
ICER -0.0000028 0.275 -0.0000078 0.0000022 0.00000089 0.713 -0.0000039 0.0000056 
Size of eligible patient population -0.00000028 0.447 -0.0000010 0.0000004 -0.00000003 0.916 -0.0000005 0.0000004 
Orphan designation 0.075 0.846 -0.686 0.837 -0.038 0.927 -0.853 0.777 
Patient submission 0.410 0.188 -0.201 1.020 0.639 0.049 0.003 1.274 
Number of technologies appraised 
simultaneously 0.550 0.003 0.185 0.915 0.295 0.259 -0.217 0.806 
National population size 0.000 0.090 0.000 0.000 0.000 0.004 0.000 0.000 
Central nervous system -0.127 0.713 -0.804 0.550 0.323 0.380 -0.398 1.044 
Eye -1.992 0.077 -4.204 0.219 -1.656 0.191 -4.139 0.828 
Malignancy/immunosuppresion therapy -0.541 0.085 -1.157 0.075 0.012 0.973 -0.665 0.689 
musculoskeletal and joint diseases 0.510 0.223 -0.311 1.330 -0.059 0.912 -1.116 0.997 
obstetrics, gynaecology, and urinary-tract 
disorders 2.515 0.022 0.370 4.659 1.761 0.150 -0.634 4.156 
Respiratory system 0.082 0.921 -1.535 1.699 1.896 0.012 0.417 3.376 
Cardiovascular disease 0.227 0.560 -0.536 0.990 0.118 0.793 -0.766 1.002 
Skin -0.272 0.580 -1.236 0.692 -0.477 0.423 -1.643 0.689 
NICE -32.906 0.095 -71.548 5.736 -82.219 0.004 -138.557 -25.880 
SMC 11.116 0.058 -0.376 22.609 26.578 0.002 9.883 43.273 
Constant -14.623 0.090 -31.507 2.261 -36.103 0.004 -60.565 -11.641 
 
 
